<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.63, http://www.edgar-online.com -->
<TITLE> ACELRX PHARMACEUTICALS INC (Form: 10-K, Received: 03/07/2016 17:07:57) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_COMPENSATION **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES **FIS_AUDITORS_OPINION **FIS_AUDITORS_OPINION_2 **FIS_BALANCE_SHEET **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_EXHIBIT_INDEX FIS_EXHIBIT_21 FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_23_2 **FIS_EXPERTS_CONSENT_2 FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 ">
<META NAME="DETECTED PAGES" CONTENT="129">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="ACRX20151231_10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<HR STYLE="MARGIN-BOTTOM: 2PX; BORDER-TOP: MEDIUM NONE; HEIGHT: 3PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 100%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #000000">
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 100%; BORDER-BOTTOM: MEDIUM NONE; POSITION: RELATIVE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; MARGIN-TOP: 0PX; TOP: 0PX; BACKGROUND-COLOR: #000000">
<P ID=PARA7 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 12PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	UNITED STATES
</B>
</FONT>
</P>
<P ID=PARA8 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 12PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</FONT>
</P>
<P ID=PARA9 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	WASHINGTON, DC 20549
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 10%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="CENTER">
<P ID=PARA11 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 12PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	FORM 10-K
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 10%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="CENTER">
<TABLE ID=MTAB16 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 24PT; VERTICAL-ALIGN: TOP">
<P ID=PARA17 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9745;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA18 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA20 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	For the fiscal year ended December&nbsp;31, 2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA21 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	or
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<TABLE ID=MTAB25 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 24PT; VERTICAL-ALIGN: TOP">
<P ID=PARA26 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#9744;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA27 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
</B>
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA29 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>
</FONT>
</P>
<P ID=PARA30 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Commission File Number: 001-35068
</B>
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 10%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="CENTER">
<TABLE STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0>
<TR>
<TD STYLE="WIDTH: 100%">
<P ID=PARA6 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT">
	&nbsp;
<FONT STYLE="FONT-SIZE: 18PT; FONT-FAMILY: ">
<B>
	ACELRX PHARMACEUTICALS, INC.&nbsp;
</B>
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA34 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Exact name of registrant as specified in its charter)
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 10%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="CENTER">
<TABLE ID=TBL41 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA37 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Delaware
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA38 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	41-2193603
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA39 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(State or other jurisdiction of incorporation or organization)
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA40 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(IRS Employer Identification No.)
</B>
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA43 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	351 Galveston Drive
</B>
</FONT>
</P>
<P ID=PARA44 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Redwood City, CA 94063
</B>
</FONT>
</P>
<P ID=PARA45 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(650) 216-3500
</B>
</FONT>
</P>
<P ID=PARA46 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 10%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="CENTER">
<P ID=PARA48 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Securities registered pursuant to Section&nbsp;12(b) of the Act:
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE ID=TBL57 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA51 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Title of Each Class
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</U>
</P>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA53 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Name of Each Exchange on Which Registered
</B>
</FONT>
</U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA55 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Common Stock, $0.001 par value
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA56 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 0PT 0PT 5.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The NASDAQ Stock Market LLC
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA59 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Securities registered pursuant to Section&nbsp;12(g) of the Act:
</B>
</FONT>
</P>
<P ID=PARA60 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	None
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 10%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="CENTER">
<P ID=PARA62 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9745;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA64 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9745;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA66 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 18.35PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9745;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA68 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;-232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9745;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA70 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K (&#167;-229.405) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&nbsp;&#9744;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA73 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0PT; MARGIN-TOP: 0PT; TEXT-INDENT: 18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):
</FONT>
</P>
<TABLE ID=TBL80 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 16.2%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA74 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Large&nbsp;accelerated&nbsp;filer
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 60%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA75 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&#9744;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 23.8%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA76 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9745;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 16.2%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA77 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Non-accelerated filer
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 60%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA78 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&#9744;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Do not check if a smaller reporting company)
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 23.8%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA79 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;&#9744;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA82 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 18PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2)&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9745;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA84 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 0PT; MARGIN-TOP: 0PT; TEXT-INDENT: 18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The aggregate market value of the voting stock held by non-affiliates of the registrant on June&nbsp;30, 2015 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), based upon the last sale price reported on the NASDAQ Global Market on that date, was approximately $145,535,000. The calculation excludes 10,050,102 shares of the registrant&#8217;s common stock held by current executive officers, directors and stockholders that the registrant has concluded are affiliates of the registrant. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.
</FONT>
</P>
<P ID=PARA86 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-LEFT: 18PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of February&nbsp;24, 2016, the number of outstanding shares of the registrant&#8217;s common stock was 45,273,772.
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 10%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="CENTER">
<P ID=PARA87 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 223.9PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	DOCUMENTS INCORPORATED BY REFERENCE
</B>
</FONT>
</P>
<P ID=PARA91 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA90 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL95 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 89.6%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 0.4%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA92 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 9.9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 89.6%; VERTICAL-ALIGN: TOP">
<P ID=PARA93 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 8PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Portions of the Registrant&#39;s notice of annual meeting of stockholders and proxy statement to be filed pursuant to Regulation&nbsp;14A within 120&nbsp;days after Registrant&#39;s fiscal year end of December&nbsp;31, 2015, are incorporated by reference into Part&nbsp;III of this report.
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 0.4%; VERTICAL-ALIGN: TOP">
<P ID=PARA94 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 9.9%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
</TABLE>
<P ID=PARA96 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<HR STYLE="MARGIN-BOTTOM: 2PX; BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 100%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #000000">
<HR STYLE="MARGIN-BOTTOM: 0PX; BORDER-TOP: MEDIUM NONE; HEIGHT: 3PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 100%; BORDER-BOTTOM: MEDIUM NONE; POSITION: RELATIVE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; MARGIN-TOP: 0PX; TOP: 0PX; BACKGROUND-COLOR: #000000">
<DIV ID=PGBK3 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGNUM3 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	1
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage2"></A>
<DIV ID=PGHDR3 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA3.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA101 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ACELRX PHARMACEUTICALS, INC.
</B>
</FONT>
</P>
<P ID=PARA104 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA103 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015 ANNUAL REPORT ON FORM 10-K
</B>
</FONT>
</P>
<P ID=PARA106 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA105 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	TABLE OF CONTENTS
</B>
</FONT>
</P>
<P ID=PARA107 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL161 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA108 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID">
<P ID=PARA109 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Page
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA111 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PART I
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA112 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA113 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;1. Business
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA114 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	4
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA115 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;1A. Risk Factors
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA116 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	29
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA117 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;1B. Unresolved Staff Comments
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA118 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	58
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA119 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;2. Properties
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA120 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	58
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA121 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;3. Legal Proceedings
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA122 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	59
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA123 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;4. Mine Safety Disclosures
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA124 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	59
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA125 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PART II
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA126 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA127 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA128 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	60
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA129 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;6. Selected Financial Data
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA130 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	62
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA131 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA132 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	63
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA133 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;7A. Quantitative and Qualitative Disclosures About Market Risk
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA134 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	81
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA135 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;8. Financial Statements and Supplementary Data
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA136 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	81
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA137 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA138 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	81
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA139 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;9A. Controls and Procedures
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA140 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	81
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA141 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;9B. Other Information
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA142 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	84
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA143 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PART III
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA144 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA145 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;10. Directors, Executive Officers and Corporate Governance
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA146 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	85
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA147 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;11. Executive Compensation
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA148 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	85
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA149 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA150 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	85
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA151 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;13. Certain Relationships and Related Transactions, and Director Independence
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA152 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	86
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA153 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;14. Principal Accounting Fees and Services
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA154 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	86
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA155 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PART IV
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA156 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA157 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Item&nbsp;15. Exhibits, Financial Statement Schedules
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA158 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	86
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA159 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Signatures
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA160 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	87
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA163 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA162 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Unless the context indicates otherwise, the terms &#8220;AcelRx,&#8221; &#8220;AcelRx Pharmaceuticals,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to AcelRx Pharmaceuticals, Inc.
</FONT>
</P>
<P ID=PARA165 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA164 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ACELRX and &#8220;ACCELERATE.INNOVATE.ALLEVIATE.&#8221; are registered trademarks of AcelRx Pharmaceuticals, Inc. Other trademarks of AcelRx Pharmaceuticals, Inc., including ZALVISO&#8482;, appearing in this annual report on Form 10-K are the property of AcelRx Pharmaceuticals, Inc. This report also contains trademarks and trade names that are the property of their respective owners.
</FONT>
</P>
<P ID=PARA167 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<DIV ID=PGBK4 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGNUM4 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	2
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage3"></A>
<DIV ID=PGHDR4 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA4.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA168 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Forward-Looking Statements
</B>
</FONT>
</P>
<P ID=PARA170 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA169 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This Annual Report on Form&nbsp;10-K, or Form 10-K, contains &#8220;forward-looking statements&#8221; within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by that section. The forward-looking statements in this Form 10-K are contained principally under &#8220;Item 1. Business,&#8221; &#8220;Item 1A. Risk Factors&#8221; and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; In some cases, you can identify forward-looking statements by the following words: &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Form 10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Many important factors affect our ability to achieve our objectives, including:
</FONT>
</P>
<P ID=PARA172 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB173 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA174 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA175 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the success, cost and timing of our product development activities and clinical trials, including the SAP302 and SAP303 studies for ARX-04 (sufentanil sublingual tablet, 30 mcg) and the additional clinical study, IAP312, for Zalviso&#8482; (sufentanil sublingual tablet system);
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA177 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB178 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA179 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA180 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to fund the completion of our ARX-04 Phase 3 development&nbsp;with the proceeds&nbsp;from the contract with the Department of Defense, or DoD;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA182 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB183 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA184 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA185 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to resubmit the Zalviso New Drug Application, or NDA, including our ability to satisfactorily conduct the additional clinical study requested by the U.S. Food and Drug Administration, or FDA, and any additional studies that may be required by the FDA in order to resubmit the Zalviso NDA, and the time and resources required to do so;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA187 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB188 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA189 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA190 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to manufacture and supply Zalviso to Gr&#252;nenthal GmbH, or Gr&#252;nenthal, in accordance with their forecast and the Manufacture and Supply Agreement with Gr&#252;nenthal;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA192 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB193 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA194 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA195 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to successfully recruit a full-time Chief Executive Officer and retain our key scientific or management personnel;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA197 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB198 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA199 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA200 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to obtain and maintain regulatory approval of Zalviso and other product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA202 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB203 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA204 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA205 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the status of the Collaboration and License Agreement with Gr&#252;nenthal or any other future potential collaborations, including potential milestones and royalty payments under the Gr&#252;nenthal agreement and obligations under the Purchase and Sale Agreement with PDL BioPharma, Inc., or
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PDL;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA207 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB208 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA209 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA210 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the outcome of any potential FDA Advisory Committee meetings held for any of our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA212 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB213 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA214 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA215 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our plans to research, develop and commercialize our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA217 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB218 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA219 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA220 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to attract additional collaborators with development, regulatory and commercialization expertise;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA222 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB223 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA224 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA225 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA227 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB228 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA229 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA230 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our liquidity and capital resources;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA232 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB233 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA234 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA235 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to successfully commercialize our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA237 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB238 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA239 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA240 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the rate and degree of market acceptance of our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA242 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB243 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA244 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA245 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA247 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB248 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA249 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA250 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	regulatory developments in the United States and foreign countries;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA252 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB253 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA254 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA255 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the performance of our third party suppliers and manufacturers;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA257 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB258 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA259 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA260 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the success of competing therapies that are or become available;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA262 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB263 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA264 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA265 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA267 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB268 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA269 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA270 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to obtain and maintain intellectual property protection for our product candidates.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA272 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<DIV ID=PGBK5 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGNUM5 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	3
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage4"></A>
<DIV ID=PGHDR5 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA5.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA271 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, you should refer to &#8220;Item 1A. Risk Factors&#8221; in this Form 10-K for a discussion of these and other important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Form 10-K will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Also, forward-looking statements represent our estimates and assumptions only as of the date of this Form 10-K. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
</FONT>
</P>
<P ID=PARA274 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P ID=PARA273 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PART I
</B>
</FONT>
</P>
<P ID=PARA276 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P ID=PARA275 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;1. Business
</B>
</FONT>
</P>
<P ID=PARA278 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<P ID=PARA280 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA279 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Overview
</B>
</FONT>
</P>
<P ID=PARA282 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA281 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. Our lead product candidates, ARX-04 and Zalviso, utilize sublingual sufentanil, delivered via a non-invasive route of administration. We intend to commercialize our product candidates in the United States and license the development and commercialization rights to our product candidates for sale outside of the United States through strategic partnerships and collaborations. We may also consider the option to enter into strategic partnerships for our product candidates in the United States.
</FONT>
</P>
<P ID=PARA283 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA284 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have chosen sufentanil as the therapeutic ingredient for all of our product candidates. Opioids have been utilized for pain relief for centuries and are the standard of care for the treatment of moderate-to-severe acute pain. Sufentanil is available as an injectable in several markets around the world and is used by anesthesiologists for induction of sedation or as an epidural; however, the injectable formulation is not suitable for the treatment of acute pain. The Company has created a proprietary sublingual (under the tongue) formulation of sufentanil intended for the treatment of moderate-to-severe acute pain. The sublingual formulation retains the therapeutic value of sufentanil and novel delivery devices provide a non-invasive route of administration. Sufentanil is highly lipophilic which provides for rapid absorption in the mucosal tissue, or fatty cells, found under the tongue, and for rapid transit across the blood-brain barrier to reach the mu-opioid receptors in the brain. The sublingual delivery used by ARX-04 and Zalviso provides a recognized onset of analgesia. The sublingual delivery system also eliminates the risk of intravenous, or IV, complications, such as catheter-related infections. In addition, because patients do not require direct connection to an IV infusion pump, ARX-04 and Zalviso allow for ease of patient mobility.
</FONT>
</P>
<P ID=PARA285 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA286 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	ARX-04 (sufentanil sublingual tablet, 30 mcg)
</I>
</FONT>
</P>
<P ID=PARA287 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA288 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04 is an investigational product candidate consisting of a single 30 mcg sufentanil sublingual tablet delivered via a disposable, pre-filled, single-dose applicator, or SDA. We are developing ARX-04 for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. If approved, examples of potential patient populations and settings in which ARX-04 could be used include: emergency room patients; patients who are recovering from short-stay or ambulatory surgery and do not require more long-term patient-controlled analgesia; post-operative patients who are transitioning from the operating room to the recovery floor; patients being treated and transported by paramedics; and for battlefield casualties.
</FONT>
</P>
<P ID=PARA289 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA290 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In September 2015, we reported that SAP301, a pivotal Phase 3 multi-center, double-blind, placebo-controlled study of ARX-04, met the primary (summed pain intensity, or SPID, over 12 hours, or SPID-12) and secondary endpoints in the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
</FONT>
</P>
<P ID=PARA8 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA7 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In October 2015, we initiated SAP302, an open-label Phase 3 study of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. Based on discussions with the FDA, we have amended the protocol for SAP302 to allow for multiple dosing of ARX-04. We are planning to enroll up to an additional 60 patients in the extension phase of the SAP302 study. The SAP302 study is expected to be completed by the third quarter of 2016.
</FONT>
</P>
<P ID=PARA9 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA10 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In December 2015, we, along with representatives from our partner at the U.S. Department of Defense, or DoD, held a pre-NDA meeting with the FDA to review plans for an NDA for ARX-04. Based on discussions with the FDA, we intend to increase the safety database by expanding the clinical program for ARX-04 by approximately 160 additional patients to include individuals from specific populations and settings. Enrollment in the ongoing SAP302 open-label study in the emergency room will be increased, as described above, and a new study, known as SAP303, was initiated in March 2016 in post-operative patients with moderate-to-severe acute pain. SAP303 will focus on enrolling patients greater than 40 years of age and will allow for administration of ARX-04 for up to 12 hours. With these modifications, assuming successful completion of SAP302 and SAP303 by the third quarter of 2016, we anticipate submitting the NDA for ARX-04 in the fourth quarter of 2016.
</FONT>
</P>
<P ID=PARA11 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
	&nbsp;
</P>
<DIV ID=PGBK6 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGNUM6 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	4
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage5"></A>
<DIV ID=PGHDR6 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA6.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA296 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The FDA has also agreed to allow us to include as supporting safety information in the NDA for ARX-04, data from approximately 323 patients treated in the Zalviso clinical studies who had administered two 15 mcg tablets 20-to-25 minutes apart. AcelRx had previously completed and analyzed pharmacokinetic and modeling data, which demonstrated the equivalency of one ARX-04 sufentanil sublingual tablet, 30 mcg, to two sufentanil sublingual tablets, 15 mcg, taken 20-to-25 minutes apart.
</FONT>
</P>
<P ID=PARA297 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA298 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the fall of 2015, we had informal scientific advice meetings regarding the planned Marketing Authorization Application, or MAA, filing for ARX-04. Divergent advice was received regarding the need for an additional active comparator clinical study for product registration in the European Union, or EU. Accordingly, we plan to meet with three additional health authorities in April 2016 to further clarify the need for such a study.
</FONT>
</P>
<P ID=PARA15 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA14 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On May 11, 2015, we entered into an award contract supported by the United States Army Medical Research and Materiel Command, or USAMRMC, within the DoD, in which the DoD agreed to provide up to $17.0 million to support the development of ARX-04, referred to as the DoD Contract. Under the terms of the contract, the DoD will reimburse us for costs incurred for development, manufacturing, regulatory and clinical costs outlined in the contract in order to submit an NDA to the FDA, including reimbursement for certain personnel and overhead expenses. The period of performance under the DoD Contract began on May 11, 2015. The contract gives the DoD the option to extend the term of the contract and provide additional funding. On March 2, 2016, the DoD Contract was amended
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	to approve enrollment of additional patients in the SAP302 study, approve the addition of the SAP303 study, and extend the contract period of performance by four months from November 10, 2016 to March 9, 2017, to accommodate the increased SAP302 patient enrollment and the SAP303 study. The costs for these changes will be absorbed within the current contract value. If ARX-04 is approved by the FDA, the DoD has the option to purchase a certain number of units of commercial product pursuant to the terms of the contract.
</FONT>
</P>
<P ID=PARA16 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA302 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Zalviso&#8482; (sufentanil sublingual tablet system)
</I>
</FONT>
</P>
<P ID=PARA303 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA304 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our U.S. product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets, 15 mcg, delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system, or together, Zalviso. While still under development in the U.S., as discussed further below, Zalviso is approved in the EU.
</FONT>
</P>
<P ID=PARA305 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA306 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Zalviso is an investigational pre-programmed, non-invasive, secure system to allow hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets, 15 mcg, to manage their pain. Zalviso is designed to help address certain problems associated with post-operative intravenous patient-controlled analgesia, or IV PCA, such as the risk of programming errors and complications associated with IV delivery of pharmaceuticals.
</FONT>
</P>
<P ID=PARA307 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA308 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December 16, 2013, AcelRx and Gr&#252;nenthal entered into a Collaboration and License Agreement, which was amended effective July 17, 2015, or the Amended License Agreement, which grants Gr&#252;nenthal rights to commercialize Zalviso in the countries of the EU, Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory, for human use in pain treatment within or dispensed by hospitals, hospices, nursing homes and other medically-supervised settings, or the Field. We retain rights with respect to Zalviso in countries outside the Territory, including the United States, Asia and Latin America. In September 2015, the European Commission approved the MAA for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. The approval allows Gr&#252;nenthal to market Zalviso in the 28 EU member states as well as in the European Economic Area countries of Norway, Iceland and Liechtenstein, or EEA.
</FONT>
</P>
<P ID=PARA20 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA19 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the terms of the Amended License Agreement, we received an upfront cash payment of $30.0 million in December 2013, a milestone payment of $5.0 million related to the MAA submission to the European Medicines Agency, or EMA, in the third quarter of 2014, and an additional milestone payment of $15.0 million related to the EC approval of the MAA for Zalviso in the third quarter of 2015. In addition, we are eligible to receive approximately $194.5 million in additional milestone payments, based upon successful regulatory and product development efforts ($28.5 million) and net sales target achievements ($166.0 million). Gr&#252;nenthal will also make tiered royalty, supply and trademark fee payments in the mid-teens up to the mid-twenties percent range, depending on the sales level achieved, on net sales of Zalviso in the Territory. A portion of the tiered royalty payment, exclusive of the supply and trademark fee payments, will be paid to PDL in connection with the Royalty Monetization, as discussed below.
</FONT>
</P>
<P ID=PARA21 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA312 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Also on December 16, 2013, we entered into the related Manufacture and Supply Agreement with Gr&#252;nenthal, which was amended effective July 17, 2015, or the Amended MSA, and together with the Amended License Agreement, the Amended Agreements. Under the Amended MSA, we will exclusively manufacture and supply Zalviso to Gr&#252;nenthal for the Field in the Territory. For additional information on the Amended Agreements, see Note 6 &#8220;Collaboration Agreement&#8221; in the accompanying notes to the Consolidated Financial Statements.
</FONT>
</P>
<P ID=PARA313 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<DIV ID=PGBK3 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR3 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM3 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	5
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage6"></A>
<DIV ID=PGHDR3 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA3.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA314 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September 18, 2015, we sold a portion of the expected royalty stream and commercial milestones from the sales of Zalviso in the EU and EEA by Gr&#252;nenthal to PDL, or the Royalty Monetization. AcelRx received gross proceeds of $65.0 million in the Royalty Monetization. PDL will receive 75% of the European royalties under the Amended License Agreement with Gr&#252;nenthal, as well as 80% of the first four commercial milestones worth $35.6 million (or 80% of $44.5 million), subject to the capped amount of $195.0 million. For additional information on the Royalty Monetization with PDL, see Note 8 &#8220;Liability Related to Sale of Future Royalties&#8221; in the accompanying notes to the Consolidated Financial Statements.
</FONT>
</P>
<P ID=PARA315 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA316 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We submitted an NDA for Zalviso in September 2013, which the FDA accepted for filing in December 2013. On July 25, 2014, the FDA issued a Complete Response Letter, or CRL, for the Zalviso NDA. The CRL contains requests for additional information on the Zalviso System to ensure proper use of the device. The requests include submission of data demonstrating a reduction in the incidence of optical system errors, changes to address inadvertent dosing, among other items, and submission of additional data to support the shelf life of the product. Although there were no requests for additional clinical studies in the CRL, in March 2015, we received correspondence from the FDA stating that, in addition to the work we had performed to address the items in the CRL, a clinical study would be required to test the modifications to the Zalviso device.
</FONT>
</P>
<P ID=PARA317 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA318 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our IAP312 study is designed to evaluate the effectiveness of changes made to enhance performance of the Zalviso device and takes into account comments from the FDA on the protocol. The IAP312 study will include approximately 315 post-operative patients and collect information requested by the Division to supplement the three positive Phase 3 trials already completed.&nbsp;AcelRx plans to initiate the study in the first quarter of 2016.
</FONT>
</P>
<P ID=PARA319 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA320 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	IAP312 is an open-label Phase 3 study and will enroll adult post-operative patients who will self-administer sufentanil sublingual tablets, 15 mcg, using Zalviso for 24-to-72 hours. Patients will self-administer a tablet as often as once every 20 minutes to manage their moderate-to-severe acute pain. The study will measure the rate of device errors, including the failure to dispense medication, as well as the incidence of any misplaced or dropped tablets. Efficacy pain measurements and safety data will also be collected in the study. The results of the study, including the actual device failure rate and the number of misplaced or dropped tablets, will be subject to final review by the FDA. There can be no assurance that the results of the study will be sufficient to address the issues raised by the Division, or that the Zalviso NDA, once resubmitted, will be approved.
</FONT>
</P>
<P ID=PARA321 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA322 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The initial 505(b)(2) NDA submission for Zalviso was based on a development program that included data from seven Phase 1 clinical studies, three Phase 2 clinical trials, and three Phase 3 clinical trials. The Phase 3 trial program included two placebo-controlled efficacy and safety trials and one open-label active comparator trial, in which Zalviso was compared to IV PCA with morphine. To date, the Zalviso safety database includes more than 600 patients. Zalviso successfully achieved the primary efficacy endpoints for each of the Phase 2 and Phase 3 trials. A summary of the Phase 3 trials completed to-date, and the results, follows:
</FONT>
</P>
<P ID=PARA324 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB325 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA326 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
<I>
</I>
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA327 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Active comparator trial (IAP309)
</I>
	&#8212;in November 2012, we reported top-line data demonstrating that Zalviso met its primary endpoint of non-inferiority in a Phase 3 open-label active comparator trial designed to compare the efficacy and safety of Zalviso (15 mcg/dose, 20 minute lock-out) to IV PCA with morphine (1mg/dose, 6 minute lock-out)&nbsp;for the treatment of moderate-to-severe acute post-operative pain immediately following major abdominal or orthopedic surgery.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA329 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB330 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA331 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
<I>
</I>
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA332 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Double-blind, placebo-controlled, abdominal surgery trial (IAP310)
</I>
	&#8212;in March 2013, we reported top-line data demonstrating that Zalviso met its primary endpoint in a pivotal Phase 3 trial designed to compare the efficacy and safety of Zalviso to placebo in the management of moderate-to-severe acute post-operative pain after major open abdominal surgery. Adverse events reported in the trial were generally mild or moderate in nature and similar in both placebo and treatment groups. Utilizing a randomized, double-blind, placebo-controlled design, this pivotal Phase 3 trial enrolled 178 adult patients at 13 U.S. sites.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA334 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB335 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA336 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
<I>
</I>
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA337 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Double-blind, placebo-controlled, orthopedic surgery trial (IAP311)
</I>
	&#8212;in May 2013, we reported top-line data demonstrating that Zalviso met its primary endpoint in a pivotal Phase 3 trial designed to compare the efficacy and safety of Zalviso to placebo in the management of moderate-to-severe acute post-operative pain after major orthopedic surgery.&nbsp;Utilizing a randomized, double-blind, placebo-controlled design, this pivotal Phase 3 trial enrolled 426 adult patients at 34 U.S. sites. Treatment-emergent adverse events were generally mild-to-moderate in nature and similar for the majority of adverse events between Zalviso and placebo-treated patients, despite the shorter duration of exposure in the placebo-treated patients caused by early termination due to inadequate analgesia.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA339 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<DIV ID=PGBK4 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR4 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM4 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	6
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage7"></A>
<DIV ID=PGHDR4 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA4.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA338 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	ARX-03
</I>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<EM>
</EM>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA340 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition to ARX-04 and Zalviso, our product candidate pipeline consists of another sufentanil-based sublingual product candidate. The sufentanil/triazolam sublingual tablet, or ARX-03, is a single, fixed-dose, combination drug product designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician&#8217;s office. We have successfully completed Phase 2 clinical trials for ARX-03. Future development of ARX-03 is contingent on funding from a corporate partnership or other external funding source.
</FONT>
</P>
<P ID=PARA343 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA342 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	ARX-02
</I>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<EM>
</EM>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA344 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have made a strategic decision to focus our pipeline on products delivered in medically-supervised settings and since ARX-02 (Sufentanil Sublingual Tablet BTP Management System) would be used in a broader setting and was not actively being developed, the Investigational New Drug, or IND, application for ARX-02&nbsp;was withdrawn.
</FONT>
</P>
<P ID=PARA347 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA346 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Sufentanil
</B>
<B>
	Sublingual
</B>
<B>
	Tablets
</B>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<STRONG>
</STRONG>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA348 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Sufentanil, a high therapeutic index opioid, which has no active metabolites, is 5 to 10 times more potent than fentanyl and is used intravenously as a primary anesthetic to produce balanced general anesthesia for surgery, and for epidural administration during labor and delivery. Sufentanil has many pharmacological advantages over other opioids. Published studies demonstrate that sufentanil produces significantly less respiratory depressive effects relative to its analgesic effects compared to other opioids, including morphine and fentanyl. These third-party clinical results correlate well with preclinical trials demonstrating sufentanil&#8217;s high therapeutic index, or the ratio of the toxic dose to the therapeutic dose of a drug, used as a measure of the relative safety of the drug for a particular treatment. Accordingly, we believe that sufentanil can be developed to provide an effective and well-tolerated treatment for acute pain. The following table illustrates the difference between the therapeutic index of different opioids.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<TABLE ID=TBL366 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL366.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 81%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA350 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Opioid
</B>
</FONT>
</U>
</P>
</TD>
<TD ID=TBL366.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA352 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Therapeutic
<BR>
	Index
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL366.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR ID=TBL366.FINROW.2 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA354 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Meperidine
</FONT>
</P>
</TD>
<TD ID=TBL366.FINROW.2.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.2.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.2.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	5
</TD>
<TD ID=TBL366.FINROW.2.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL366.FINROW.3 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA356 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Methadone
</FONT>
</P>
</TD>
<TD ID=TBL366.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	12
</TD>
<TD ID=TBL366.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL366.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA358 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Morphine
</FONT>
</P>
</TD>
<TD ID=TBL366.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	71
</TD>
<TD ID=TBL366.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL366.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA360 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Hydromorphone
</FONT>
</P>
</TD>
<TD ID=TBL366.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	250
</TD>
<TD ID=TBL366.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL366.FINROW.6 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA362 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Fentanyl
</FONT>
</P>
</TD>
<TD ID=TBL366.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	277
</TD>
<TD ID=TBL366.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL366.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA364 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Sufentanil
</FONT>
</P>
</TD>
<TD ID=TBL366.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL366.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	26,716
</TD>
<TD ID=TBL366.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA368 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA367 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, the pharmaceutical attributes of sufentanil, including lipid solubility and ionization, result in rapid cell membrane penetration and onset of action, which we believe make sufentanil an optimal opioid for the treatment of acute pain.
</FONT>
</P>
<P ID=PARA370 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA369 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Although the analgesic efficacy and safety of sufentanil have been well established, the product&#8217;s use has been historically limited due to its short duration of action when delivered intravenously. Sublingual delivery of sufentanil avoids the high peak plasma levels and short duration of action of IV administration.
</FONT>
</P>
<P ID=PARA372 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P ID=PARA163 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our portfolio of product candidates leverages the above-mentioned advantages of sufentanil delivered via the sublingual route. We believe our non-invasive, proprietary sufentanil tablet sublingual dosage form potentially overcomes many of the limitations of current treatment options available for moderate-to-severe acute pain.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA372 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0>
<TR>
<TD STYLE="WIDTH: 100%">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/07/0001437749-16-026987_PENCIL.JPG" WIDTH=251 HEIGHT=211>
<P ID=PARA3 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA376 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None of our product candidates have been approved by the FDA.&nbsp;
</FONT>
</P>
<P ID=PARA377 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We&nbsp;have not generated any revenue from the sale of&nbsp;any&nbsp;of&nbsp;our&nbsp;product candidates.
</FONT>
</P>
<P ID=PARA378 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK5 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR5 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM5 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	7
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage8"></A>
<DIV ID=PGHDR5 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA5.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA379 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Our Product Candidates
</B>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<STRONG>
</STRONG>
	&nbsp;
</P>
<P ID=PARA381 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table summarizes key information about our existing product candidates.
</FONT>
</P>
<P ID=PARA383 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA382 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<TABLE ID=TBL409 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID" WIDTH=173>
<P ID=PARA384 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Product&nbsp;Candidate
</B>
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID" WIDTH=197>
<P ID=PARA386 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Description
</B>
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID" WIDTH=209>
<P ID=PARA388 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Target&nbsp;Indication
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID" WIDTH=553>
<P ID=PARA390 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Status
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=173>
<P ID=PARA392 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=197>
<P ID=PARA393 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Sufentanil sublingual tablet, 30 mcg
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=209>
<P ID=PARA394 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Moderate-to-severe acute pain in a medically supervised setting, administered by a healthcare professional
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=553>
<P ID=PARA395 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18.95PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Phase 3 development ongoing. Pending successful completion of Phase 3 studies, NDA submission planned for&nbsp;fourth quarter&nbsp;of 2016.
</FONT>
</P>
<P ID=PARA396 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=173>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=197>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=209>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=553>
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=173>
<P ID=PARA397 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Zalviso
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=197>
<P ID=PARA398 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 6PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Sufentanil sublingual tablet system, 15 mcg
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=209>
<P ID=PARA399 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 5.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Moderate-to-severe acute pain in the hospital setting, administered by the patient as needed
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=553>
<P ID=PARA400 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18.95PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Phase 3 development ongoing. Planning to initiate IAP312, open label study in post-operative patients. Pending successful completion of IAP312, NDA resubmission planned for&nbsp;by the end&nbsp;of 2016.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	European Commission approved MAA in September 2015 and Zalviso device is CE marked. Gr&#252;nenthal expects to launch Zalviso in the European Union in 2016.
</FONT>
</P>
<P ID=PARA402 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=173>
<P ID=PARA403 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-03
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=197>
<P ID=PARA404 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Sufentanil, 15 mcg/
<BR>
	triazolam, 200 mg sublingual tablet
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=209>
<P ID=PARA405 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Mild sedation and pain relief during painful procedures in a physician&#8217;s office
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=9>
	&nbsp;
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP" WIDTH=553>
<P ID=PARA406 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18.95PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Phase 2 clinical trial and End of Phase 2 meeting completed.
</FONT>
</P>
<P ID=PARA407 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18.95PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA408 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18.95PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Future development contingent upon identification of corporate partnership resources.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA410 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	&nbsp;
</B>
</I>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<DIV ID=PGBK412 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGNUM412 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	8
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage9"></A>
<DIV ID=PGHDR412 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA412.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
</B>
</I>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<P ID=PARA414 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	ARX-04 (sufentanil sublingual tablet, 30 mcg)
</B>
</I>
</FONT>
</P>
<P ID=PARA415 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL421 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 44.7%; VERTICAL-ALIGN: TOP">
<P STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/07/0001437749-16-026987_ARXPIC.JPG" WIDTH=275 HEIGHT=180>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This product candidate has not been approved by the
<BR>
	FDA. We have not generated any revenue from the
<BR>
	sale&nbsp;of any of our product candidates.
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 55.3%; VERTICAL-ALIGN: TOP">
<P ID=PARA418 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 10.8PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	The Market Opportunity for ARX-04
</B>
</I>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 10.8PT; LINE-HEIGHT: 1.25">
<STRONG>
<EM>
</EM>
</STRONG>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA420 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We believe that ARX-04&nbsp;could be useful in a variety of medically supervised settings, including emergency room patients; patients who are recovering from short-stay or ambulatory surgery and do not require more long-term patient-controlled analgesia; post-operative patients who are transitioning from the operating room to the recovery floor; patients being treated and transported by paramedics; and for battlefield casualties. According to the Nationwide Emergency Department Sample, or NEDS, there were more than 109 million adult emergency room visits in the United States during 2011, of which we estimate more than 51 million were associated with moderate-to-severe acute pain.&nbsp;Based on the National Survey of Ambulatory Surgery, in 2006, an estimated 30 million adult patients underwent outpatient surgical procedures in the United States, of which we estimate more than 12 million patients experienced moderate-to-severe acute pain. According to the National Inpatient Sample, in 2011, more than 16 million adult patients in the United States underwent surgical procedures in an inpatient setting, of which we estimate more than 8 million resulted in moderate-to-severe acute pain. In the EU, we estimate that there were more than 95 million adult emergency room visits, of which more than 36 million were associated with moderate-to-severe acute pain. Also in the EU, we estimate 13 million adult patients underwent outpatient surgical procedures, and of these, nearly 3 million patients experienced moderate-to-severe acute pain, while more than 18 million adult patients underwent surgical procedures in an inpatient setting in the EU, of which we estimate more than 9 million of these procedures resulted in moderate-to-severe acute pain. In the EU, the pricing of prescription drugs is subject to government control. In addition, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. If we are unable to achieve premium pricing for ARX-04 in the EU and/or the United States, the profitability of ARX04, if approved, may be negatively impacted.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA423 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA422 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	How ARX-04 Addresses the Unmet Medical Need for Moderate-to-Severe Acute Pain
</B>
</I>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<STRONG>
<EM>
</EM>
</STRONG>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA424 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04 is a proprietary, non-invasive, investigational product candidate consisting of a single 30 mcg sufentanil sublingual tablet delivered via a disposable, pre-filled SDA. We are developing ARX-04 for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional in medically supervised settings. Our proprietary sufentanil sublingual tablet technology enables rapid sublingual absorption when the tablet is placed under the tongue. As a result, sufentanil sublingual tablets can provide recognized onset of analgesia and display a consistent pharmacokinetic profile due to a high percentage of drug being absorbed sublingually instead of through the gastrointestinal tract. If approved, examples of potential patient populations and settings where ARX-04 could be used include: emergency room patients; patients who are recovering from short-stay or ambulatory surgery and do not require more long-term patient-controlled analgesia; post-operative patients who are transitioning from the operating room to the recovery floor; patients being transported by paramedics; and battlefield casualties. In the emergency room and in ambulatory care environments, patients often do not have immediate IV access available, or maintaining IV access can be an impediment to rapid discharge. Oral pills and liquids generally have slow and erratic onset of analgesia. Moreover, IV dosing results in high peak plasma levels, thereby limiting the opioid dose and requiring frequent redosing intervals to titrate to satisfactory analgesia. Based on internal market research conducted to date, we believe that additional treatment options are needed that can safely and rapidly treat acute trauma pain, in both civilian and military settings.
</FONT>
</P>
<P ID=PARA427 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK6 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR6 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM6 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	9
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage10"></A>
<DIV ID=PGHDR6 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA6.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA426 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Phase 3 Clinical Program for ARX-04
</I>
</FONT>
</P>
<P ID=PARA429 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA428 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In September 2015, we reported that SAP301, a pivotal Phase 3 multi-center, double-blind, placebo-controlled study of ARX-04 that evaluated the efficacy and safety of ARX-04 vs. placebo for the treatment of moderate-to-severe acute pain following ambulatory abdominal surgery, met its primary and secondary endpoints. Results demonstrated that patients receiving ARX-04 administered via a disposable, pre-filled SDA, experienced significantly greater pain reduction compared to placebo, as measured by the SPID-12 (p&lt;0.001). Adverse events reported in the study were typical of opioid therapy and were similar for patients treated with ARX-04 and placebo, the most common of which were nausea, headache and vomiting. SAP301 is considered the second of two pivotal placebo-controlled studies required to be included in the NDA submission.
</FONT>
</P>
<P ID=PARA430 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P ID=PARA166 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA178 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Phase 3 SAP301 trial enrolled adult patients undergoing outpatient abdominal surgery procedures at four clinical sites in the United States. Following surgery, 163 patients were randomized to receive either ARX-04, or placebo, in a 2:1 active to placebo ratio. ARX-04, or placebo, was administered by site staff as requested by the patient, but not more than once per hour. The intent-to-treat, or ITT, population in this study averaged 40.9 years of age with an average Body Mass Index of 27.5, and had a higher percent of females to males (68%:32%). Eighty-nine percent of patients entering the study completed the 24-hour study period.
</FONT>
</P>
<P ID=PARA180 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	&nbsp;
</FONT>
</P>
</FONT>
<P ID=PARA433 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The primary endpoint of the study was the difference in the SPID-12 score of patients receiving ARX-04 compared to those receiving placebo. SPID&#8209;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	12 scores were +25.8 for ARX-04-treated patients and +13.1 for placebo-treated patients; the difference between the two groups being highly statistically significant (p&lt;0.001). Notably, the difference in pain intensity from baseline was superior for ARX-04 over placebo at the earliest time point measured (15 minutes; p=0.002). Secondary efficacy endpoints were also superior for ARX-04 compared to placebo.
</FONT>
</P>
<P ID=PARA434 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA435 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There were two SAEs reported during the study period, both of which were in the placebo group and resulted in early termination of the affected patients. No patient in the ARX-04 group dropped out of the study prior to 24 hours due to an adverse event. A lower percent of patients treated with ARX-04 dropped out of the study prior to 24 hours due to lack of efficacy compared to the placebo group (3.7% and 18.5%, respectively; p=0.002).
</FONT>
</P>
<P ID=PARA25 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA24 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In October 2015, we announced the initiation of an open-label Phase 3 study, SAP302, of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. The primary efficacy endpoint is the summed pain intensity difference, or SPID, over 1-hour, or SPID-1. Safety endpoints, such as adverse events and vital signs will also be assessed, as will the patients&#8217; and healthcare providers&#8217; satisfaction with the method of pain control. Based on a pre-NDA meeting held with the FDA in December 2015, we have amended the protocol for SAP302 to allow for multiple dosing of ARX-04. We are planning to enroll an additional 60 patients in the extension phase of the SAP302 study. The SAP302 study is expected to be completed by the third quarter of 2016.
</FONT>
</P>
<P ID=PARA26 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA27 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As mentioned above, we met with the FDA in December 2015 to review plans for an NDA for ARX-04. Based on feedback from the FDA, we intend to increase the safety database by expanding the clinical program for ARX-04 by approximately 160 additional patients to include individuals from specific populations and settings. Enrollment in the ongoing SAP302 open-label study in the emergency room will continue, and a new study, known as SAP303, was initiated in March 2016 in post-operative patients with moderate-to-severe acute pain. SAP303 will focus on enrolling patients greater than 40 years of age and will allow for administration of ARX-04 for up to 12 hours. With these modifications, assuming successful completion of SAP302 and SAP303 by the third quarter of 2016, AcelRx anticipates submitting the NDA for ARX-04 in the fourth quarter of 2016.
</FONT>
</P>
<P ID=PARA28 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA441 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The FDA has also agreed to allow us to include as supporting safety information in the NDA for ARX-04, data from approximately 323 patients treated in the Zalviso clinical studies who had administered two sufentanil sublingual 15 mcg tablets 20-to-25 minutes apart. AcelRx had previously completed and analyzed pharmacokinetic and modeling data, which demonstrated the equivalency of one sufentanil sublingual tablet, 30 mcg, to two sufentanil sublingual tablets, 15 mcg, taken 20-to-25 minutes apart.
</FONT>
</P>
<P ID=PARA442 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA443 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In June 2014, we completed a pharmacokinetic study in support of the ARX-04 development program. In this study of healthy volunteers, it was shown that two sublingual administrations of a Zalviso sufentanil sublingual tablet, 15 mcg, dosed 20 minutes apart were comparable, in terms of AUC exposure and peak plasma concentration, to one sublingual administration of sufentanil sublingual tablet, 30 mcg.
</FONT>
</P>
<P ID=PARA444 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK7 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR7 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM7 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	10
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage11"></A>
<DIV ID=PGHDR7 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA7.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA445 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Phase 2 Clinical Trial for ARX-04
</I>
</FONT>
</P>
<P ID=PARA447 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA446 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In April 2013, we announced top-line results demonstrating that a placebo-controlled, dose-finding, Phase 2 trial of our investigational single-dose sufentanil sublingual tablet for acute pain, ARX-04, successfully met its primary endpoint. Results demonstrated that patients receiving ARX-04 administered by a healthcare professional, no more frequently than once per hour, had significantly greater pain reduction as measured by SPID-12 than placebo-treated patients (+6.53 for ARX-04-treated patients and -7.12 for placebo-treated patients; p=0.003).&nbsp;The sufentanil sublingual 20 mcg tablet-treated patients did not achieve SPID-12 scores that differentiated from placebo. Adverse events reported in the study were generally mild-to-moderate in nature, with two serious adverse events of post-surgical infection reported, both of which were determined by the investigator to be unrelated to study drug.&nbsp;This dose-ranging study randomized 101 patients following bunionectomy surgery in a 2:2:1 ratio to sufentanil sublingual tablet, 30 mcg, sufentanil sublingual tablet, 20 mcg, or placebo treatment arms.&nbsp;The intent-to-treat, or ITT, population in this study averaged 42.5 years of age and was evenly balanced for males and females (51%:49%). Ninety-one percent of patients entering the study completed the full 12-hour study period.
</FONT>
</P>
<P ID=PARA449 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA448 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A number of secondary endpoints were also achieved, as follows:
</FONT>
</P>
<P ID=PARA451 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA450 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For the time-weighted sum of pain relief scores over the 12-hour study period, or TOTPAR12, there was a statistically significant difference in favor of the 30 mcg group over placebo (9.73 vs. 4.37 p&nbsp;= 0.002). Patients treated with the 30 mcg dose of sufentanil sublingual tablet showed a rapid onset of action with a statistically significant beneficial difference in pain relief (p&lt;0.001) and pain intensity (p&lt;0.01) seen at 30 minutes after dosing compared to placebo.&nbsp;Dosing averaged every 2.4 hours over the duration of the 12-hour study.&nbsp;In addition, patient global assessment of the 30 mcg dose at 12 hours was superior to placebo (p=0.002) with 43.6% vs. 5.0% of the patients responding good or excellent for overall pain control. The 20 mcg dose was not significantly different from placebo for either endpoint.
</FONT>
</P>
<P ID=PARA453 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA452 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Two SAEs, both in the 20 mcg-dose group, occurred one week after the study (surgical infections) and were deemed unrelated to study drug. All but two adverse events reported in the study were mild-to-moderate in nature with 58 patients (58%)&nbsp;reporting a total of 135 adverse events. The most frequently reported adverse events for all patients were nausea (30%), vomiting (17%), dizziness (14%)&nbsp;and somnolence (11%).&nbsp;Two patients discontinued treatment, one unrelated to study drug (anxiety/chest pain) and the other probably related to study drug (somnolence/respiratory depression), however both patients recovered without medical intervention.
</FONT>
</P>
<P ID=PARA455 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<P ID=PARA454 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Zalviso&#8212; Sufentanil Sublingual Tablet System
</B>
</FONT>
</P>
<P ID=PARA456 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL466 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 34.7%; VERTICAL-ALIGN: TOP">
<P STYLE="TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/07/0001437749-16-026987_ZALPIC.JPG" WIDTH=234 HEIGHT=169>
</P>
<P ID=PARA458 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have not
</FONT>
</P>
<P ID=PARA459 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	generated&nbsp;any revenue from the sale of
</FONT>
</P>
<P ID=PARA460 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	any&nbsp;of&nbsp;our product candidates.
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 65.3%; VERTICAL-ALIGN: TOP">
<P ID=PARA461 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 7.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	The Market Opportunity for Zalviso
</B>
</I>
</FONT>
</P>
<P ID=PARA462 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 7.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA463 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 9.7PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	According to the 2014 Decision Resources Acute Pain Report, or 2014 DR Report, the acute pain market (represented by treatments for post-operative pain, acute musculoskeletal pain and cancer breakthrough pain) in the United States, Europe and Japan realized 2013 revenues of $12.7 billion, and is&nbsp;expected to reach approximately $13.3 billion by 2023.&nbsp;Opioid analgesic use remains a standard the management of acute pain, representing 44% of the 2013 market, and is projected to grow to 46% of the 2023 market.&nbsp;Post-operative acute pain treatment in the United States is projected to grow significantly in the 2013 to 2023 period, from management of 13.8 million procedures in 2011 to 16.0 million procedures in 2023, a 1.5% CAGR.&nbsp;Despite its size, this market remains underserved. Studies report that up to 75% of patients experience inadequate pain relief after surgery. Inadequate pain relief can lead to decreased mobility, which increases the risks of other medical complications, including deep vein thrombosis and partial lung collapse, and can result in extended hospital stays.
</FONT>
</P>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR>
<TD STYLE="WIDTH: 100%; VERTICAL-ALIGN: TOP" COLSPAN=2>
<P ID=PARA464 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA465 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the United States, we estimate that approximately one third of all procedures conducted are orthopedic in nature, one third are gastrointestinal, obstetric or gynecologic, and the remaining third are a mix of spinal, cardiothoracic and other procedures.&nbsp;Commissioned market research targeting surgeons and anesthesiologists has identified a consistent positive response to the attributes of Zalviso and indicates an interest in using Zalviso in at least 75% of their eligible patients. Additional market research indicated that physicians expressed interest in using Zalviso for patients who stay in the hospital for less than 24 hours and are not traditionally treated with IV PCA. Regardless of size or affiliation of hospitals, the majority of Pharmacy and Therapeutics, or P&amp;T, committees we surveyed were likely to review and approve Zalviso, subject to demonstration of satisfactory pharmacoeconomic value.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA468 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK8 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR8 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM8 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	11
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage12"></A>
<DIV ID=PGHDR8 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA8.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA469 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	How Zalviso Addresses the Unmet Medical Need in Moderate-To-Severe Acute Pain Management in a Hospital Setting
</B>
</I>
</FONT>
</P>
<P ID=PARA471 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA470 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	While IV PCA does allow patient control over their pain medication, it suffers from the following:
</FONT>
</P>
<P ID=PARA473 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB474 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA475 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA476 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	side effects associated with the most commonly used opioid, morphine, and its active metabolites;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA478 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB479 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA480 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA481 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	infection risk, analgesic gaps and decreased mobility associated with the invasive nature of IV delivery; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA483 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB484 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA485 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA486 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	medication errors, which in some instances may be fatal, due to the complexity of IV PCA pumps, many of which arise from programming errors.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA488 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA487 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Hospitalized patients in moderate-to-severe acute pain could significantly benefit from the following items:
</FONT>
</P>
<P ID=PARA490 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB491 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA492 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA493 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	recognized onset of analgesia;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA495 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB496 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA497 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA498 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	reduction in medication errors, especially relating to the use of opioids, such as wrong drug or wrong drug concentration programmed into PCA pumps which are not possible with Zalviso;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA500 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB501 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA502 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA503 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	fewer side effects, including infection and bleeding risks due to invasive routes of delivery such as IV route of administration of opioids;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA505 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB506 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA507 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA508 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	enhanced ability for patients to ambulate after surgery and avoid falls; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA510 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB511 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA512 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA513 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	patient control over their pain medication which has been shown to increase patient satisfaction.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA515 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA514 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For example, epidural catheters delivering local anesthetic are invasive and have a significant risk of lower extremity weakness and tethering the patient to a pump attached to an IV pole, creates multiple mobility impediments and fall risks; nerve blocks of the lower extremities (e.g., femoral nerve blocks) are also invasive and create weakness and fall risks; oral multimodal analgesia is not patient-controlled, is nurse-intensive and suffers from slow onset of action.
</FONT>
</P>
<P ID=PARA517 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA516 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In our clinical studies, Zalviso has demonstrated the following attributes:
</FONT>
</P>
<P ID=PARA519 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB520 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA521 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA522 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a rapid onset of effect in comparison to intravenous delivery of morphine, and an ability to control pain as a monotherapy after moderately to severely painful surgeries such as knee replacement or colectomies;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA524 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB525 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA526 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA527 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a rate of adverse events that is similar to a placebo-treated patient population, with the exception of opioid
<BR>
	induced itching;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA529 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB530 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA531 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA532 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a high level of Patient Satisfaction as a result of Zalviso usage under patient control to manage pain after surgery over 48 to 72 hours; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA534 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB535 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA536 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA537 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a high Nurse Ease of Care rating for ease of set-up and use of Zalviso by the health care professional.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA539 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA538 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	According to published literature, an estimated 407 errors occur per 10,000 people treated with IV PCA each year in the United States. The most common and serious types of errors involve human factors, such as mis-programming the PCA pump or administering the wrong dose. In 2009, approximately 6.5% of errors associated with PCA pumps were due to operator error and that nearly half of these events (~19,000) lead to patient harm. Between 2005 and 2009, errors associated with infusion pumps led to 70 Class II recalls of devices that could cause temporary or reversible adverse effects and 14 Class I recalls of devices that could cause serious injury or death. These issues have resulted in the issuance of new draft guidance by the FDA, significantly increasing the data required to be submitted by manufacturers to address safety problems.
</FONT>
</P>
<P ID=PARA541 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA540 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Zalviso has the potential to address many of the key disadvantages of IV PCA, including:
</FONT>
</P>
<P ID=PARA543 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB544 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA545 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA546 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	eliminating the risk of IV PCA related infections, and enhancing mobility; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA548 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB549 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA550 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA551 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	eliminating the risk of IV PCA programming errors.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA553 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA552 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA554 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We believe that Zalviso provides a favorable safety, efficacy and tolerability profile, potentially enabling Zalviso to become a new standard of care for moderate-to-severe acute pain control via patient-controlled analgesia.
</FONT>
</P>
<P ID=PARA556 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA555 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	Zalviso Description
</B>
</I>
</FONT>
</P>
<P ID=PARA558 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA557 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The benefits of Zalviso are the result of combining the following three elements:
</FONT>
</P>
<P ID=PARA560 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB561 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA562 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA563 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	sufentanil, a high therapeutic index opioid;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA565 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB566 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA567 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA568 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	sufentanil sublingual tablets, our proprietary, non-invasive sublingual dosage form; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA570 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB571 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA572 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA573 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our novel, pre-programmed, handheld PCA device that enables simple patient-controlled delivery of sufentanil sublingual tablets in the hospital setting and eliminates the risk of programming errors.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA575 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK9 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR9 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM9 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	12
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage13"></A>
<DIV ID=PGHDR9 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA9.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA574 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Zalviso allows patients to self-administer sufentanil sublingual tablets as needed to manage their moderate-to-severe acute pain in the hospital setting, and provides the record-keeping attributes of a conventional IV PCA pump while avoiding some of the key issues, such as programming errors, associated with conventional IV PCA use.
</FONT>
</P>
<P ID=PARA577 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA576 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Zalviso utilizes sufentanil, which has one of the highest therapeutic indices of all commercially available opioids, making it an attractive candidate for the management of post-operative pain. Formulated in our proprietary sublingual tablet dosage form, sufentanil provides for relatively high bioavailability, with lower peak drug levels and a longer duration of action compared to IV delivery.
</FONT>
</P>
<P ID=PARA579 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA578 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Zalviso System consists of the following components: a disposable dispenser tip (Figure A); a disposable dispenser cap (Figure B); an adhesive thumb tag (Figure C); a cartridge of 40 sufentanil sublingual 15 mcg tablets (approximately a two-day supply) in a disposable radio frequency identification and bar-coded cartridge (Figure D); a reusable, rechargeable handheld controller (as pictured, nurse-side view) (Figure E); a tether (Figure F); and an authorized access card (Figure G).
</FONT>
</P>
<P ID=PARA580 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0>
<TR>
<TD STYLE="WIDTH: 100%">
<P STYLE="TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/07/0001437749-16-026987_ZALPICB.JPG" WIDTH=485 HEIGHT=236>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA583 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA582 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	This product candidate has not been approved by the FDA. We have not generated any revenue
</FONT>
</P>
<P ID=PARA584 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	from the sale of any of our product candidates.
</FONT>
</P>
<P ID=PARA586 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA585 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Drugs are classified or scheduled by the Drug Enforcement Agency, or DEA, according to their potential for abuse and addiction. Sufentanil is scheduled as a class II opioid. Scheduled drugs, when they are under patient control in a hospital setting, must be secured and have adequate dose access control and tracking mechanisms. Our novel handheld PCA device has the following safety features:
</FONT>
</P>
<P ID=PARA588 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB589 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA590 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA591 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	an authorized access card, which is a wireless system access key for the healthcare professional;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA593 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB594 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA595 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA596 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a wireless, electronic, adhesive thumb tag that acts as a single-patient identification key;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA598 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB599 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA600 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA601 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	pre-programmed 20-minute lock-out to avoid overdosing;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA603 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE ID=MTAB605 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA606 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA607 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	tablet singulation, or dispensing, motion that eliminates runaway motor delivery risk;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA609 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB610 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA611 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA612 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a security tether that is designed to prevent theft and misuse; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA614 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB615 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA616 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA617 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	fully automated inventory record of sufentanil sublingual tablet usage.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA619 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA618 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To set up Zalviso, the nurse or healthcare professional turns on the controller and follows the simple step-by-step instructions on the color graphical user interface screen described below:
</FONT>
</P>
<P ID=PARA621 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB622 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA623 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA624 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	retrieve the sufentanil sublingual tablet cartridge from secure drug storage;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA626 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB627 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA628 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA629 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	insert the cartridge into the dispenser and lock the cartridge and dispenser into the controller; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA631 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB632 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA633 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA634 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	set up the secure patient access system, which is comprised of a security tether and a wireless, electronic, adhesive thumb tag that acts as a single-patient identification key.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA636 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA635 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To use Zalviso, the patient would:
</FONT>
</P>
<P ID=PARA638 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB639 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA640 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA641 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	confirm that the green indicator light is illuminated, meaning the device is available to dose;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA643 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB644 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA645 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA646 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	place dispenser tip under tongue and push the large button on the controller with the thumb to which the thumb tag has been applied, which in turn dispenses a single sufentanil sublingual tablet;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA648 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK10 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR10 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM10 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	13
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage14"></A>
<DIV ID=PGHDR10 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA10.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB649 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA650 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA651 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	remove the device from mouth upon hearing a tone confirming delivery of the sufentanil sublingual tablet; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA653 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB654 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA655 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA656 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	see the blue indicator light illuminate, indicating no new dose can be dispensed for the next 20 minutes.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA658 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA657 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	Zalviso&#8212;Development Status
</B>
</I>
</FONT>
</P>
<P ID=PARA660 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA659 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We submitted an NDA for Zalviso in September 2013 and, as mentioned above, the FDA issued a CRL for Zalviso on July 25, 2014. Based on interaction with the FDA we have agreed to complete an additional study, known as IAP312, in post-operative patients. This Phase 3 study is designed to measure the performance of the Zalviso device and to measure any misplaced or dropped tablets. IAP312 is expected to begin in the first quarter of 2016.
</FONT>
</P>
<P ID=PARA662 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA661 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The NDA resubmission for Zalviso will be based on a development program that includes data from seven Phase 1 studies, three Phase 2 clinical trials, and four Phase 3 clinical trials. The Phase 3 clinical trial program will have included two placebo-controlled efficacy and safety trials and one open-label active comparator trial, in which Zalviso was compared to IV PCA with morphine, and an additional open-label Phase 3 study in post-operative patients (IAP312), designed to measure the performance of the Zalviso device. To date, the Zalviso safety database includes more than 600 patients, and with the data from IAP312 included in the resubmission, will comprise over 900 total patients. Zalviso has successfully achieved the primary efficacy endpoints for each of the Phase 2 and Phase 3 trials performed to date.
</FONT>
</P>
<P ID=PARA664 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA663 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA665 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	Zalviso&#8212;Clinical Program
</B>
</I>
</FONT>
</P>
<P ID=PARA667 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA666 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Summary
</I>
</FONT>
</P>
<P ID=PARA669 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA668 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Phase 3 program for Zalviso to date has consisted of three Phase 3 clinical trials. We have reported positive top-line results from each of these three clinical trials. Prior to our Phase 3 program, we completed three successful Phase 2 clinical trials of sufentanil sublingual tablets in the post-operative setting.
</FONT>
</P>
<P ID=PARA671 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA670 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As mentioned above, in March 2015, we received correspondence from the FDA stating that an additional clinical study is needed. We have completed the protocol review with the FDA for IAP312 and we plan to initiate the study in the first quarter of 2016. IAP312 will be an open-label Phase 3 study conducted in post-operative patients. In the study, Zalviso will be used in patients requiring at least a one night hospital stay. IAP312 will allow for the utilization of additional post-operative treatments for moderate-to-severe acute pain and will not be limited to orthopedic or abdominal surgeries. The study is powered to rule out a device failure rate of 5%. Unlike our other Phase 3 clinical studies, IAP312 will not include a primary endpoint of efficacy. Rather, we will collect pain scores, device performance data and any misplaced or dropped tablets. The results of the study, including the actual failure rate and the number of misplaced or dropped tablets, will be subject to final review by the FDA.
</FONT>
</P>
<P ID=PARA673 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA672 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Phase 3 Clinical Trials for Zalviso
</I>
</FONT>
</P>
<P ID=PARA675 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA674 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
<I>
	Active comparator trial (IAP309)
</I>
</U>
</FONT>
</P>
<P ID=PARA677 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA676 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In November 2012, we reported top-line data showing that Zalviso had met its primary endpoint of non-inferiority in the Phase 3 open-label active comparator trial designed to compare the efficacy and safety of Zalviso (15 mcg/dose) to IV PCA with morphine (1mg/dose)&nbsp;for the treatment of moderate-to-severe acute post-operative pain. Utilizing a randomized, open-label, parallel group design, this trial enrolled 359 adult patients at 26 U.S. sites for the treatment of pain immediately following open-abdominal or major orthopedic surgery (hip and knee replacement). Patients were randomized 1:1 to treatment with Zalviso or IV PCA morphine and were treated for a minimum of 48 hours and up to 72 hours.
</FONT>
</P>
<P ID=PARA679 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA678 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
<I>
	Double-blind, placebo-controlled, abdominal surgery trial (IAP310)
</I>
</U>
</FONT>
</P>
<P ID=PARA681 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA680 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In March 2013, we reported top-line data results demonstrating that Zalviso met its primary endpoint in a pivotal Phase 3 trial designed to compare the efficacy and safety of Zalviso to placebo in the management of acute post-operative pain after major open abdominal surgery. Adverse events reported in the trial were generally mild or moderate in nature and similar in both placebo and treatment groups. Utilizing a randomized, double-blind, placebo-controlled design, this Phase 3 trial enrolled 178 adult patients at 13 U.S. sites. Patients were treated for post-operative pain for a minimum of 48 hours, and up to 72 hours. Patients were randomized 2:1, with 119 patients randomized to sufentanil sublingual tablet treatment and 59 to placebo treatment. Both treatments were delivered by the patient, as needed, using Zalviso with a 20-minute lock-out period. Patients in both groups could receive up to 2 mg morphine intravenously per hour as a rescue medication, the primary purpose of this rescue medication being to provide placebo-treated patients access to pain medication to enable them to stay in the trial as long as possible. Pre-rescue pain scores were imputed to minimize the impact of this rescue opioid on efficacy evaluations.
</FONT>
</P>
<P ID=PARA683 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA682 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The primary endpoint evaluated pain intensity over the 48-hour study period compared to baseline, or Summed Pain Intensity Difference, or SPID-48, in patients following major open abdominal surgery. Patients receiving sufentanil sublingual tablets demonstrated a significantly greater SPID-48 compared to placebo-treated patients during the study period (105.6 and 55.6, respectively; p=0.001).
</FONT>
</P>
<P ID=PARA685 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK11 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR11 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM11 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	14
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage15"></A>
<DIV ID=PGHDR11 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA11.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA684 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
<I>
	Double-blind, placebo-controlled, orthopedic surgery trial (IAP311)
</I>
</U>
</FONT>
</P>
<P ID=PARA687 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA686 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In May 2013, we reported top-line data results demonstrating that Zalviso met its primary endpoint in a pivotal Phase 3 trial designed to compare the efficacy and safety of Zalviso to placebo in the management of acute post-operative pain after major orthopedic surgery. Adverse events reported in the study were generally mild or moderate in nature and were similar in both placebo and treatment groups for the majority of adverse events. Utilizing a randomized, double-blind, placebo-controlled design, this pivotal Phase 3 study enrolled 426 adult patients at 34 U.S. sites for treatment of moderate-to-severe acute pain immediately following major orthopedic surgery.&nbsp;Seven patients did not receive study drug, resulting in 419 patients being included in the ITT population.&nbsp;Patients were treated for a minimum of 48 hours, and up to 72 hours.&nbsp;Patients were randomized 3:1, with 323 patients randomized to sufentanil sublingual tablet treatment and 104 to placebo treatment.&nbsp;Both treatments were delivered by the patient, as needed, using the Zalviso System with a 20-minute lock-out period.&nbsp;Patients in both groups could receive up to 2 mg morphine intravenously per hour as a rescue medication, the primary purpose of this rescue medication being to enable placebo-treated patients to stay in the study.&nbsp;Pain scores recorded just prior to the delivery of rescue medication were gathered and imputed forward to minimize the impact of this rescue opioid on efficacy evaluations.
</FONT>
</P>
<P ID=PARA689 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA688 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The primary endpoint evaluated SPID-48 in patients following major orthopedic surgery. Patients receiving Zalviso demonstrated a significantly greater SPID-48 compared to placebo-treated patients during the study period (+76.1 and -11.5, respectively; p &lt; 0.001). Two hundred fifteen (68.3%)&nbsp;sufentanil sublingual tablet-treated patients completed the 48-hour study period, compared to 43 (41.3%)&nbsp;placebo-treated patients.&nbsp;Primary reasons for drop-out in the sufentanil sublingual tablet- and placebo-treated groups were adverse events (7.0% and 6.7%, respectively) and lack of efficacy (14.3% and 48.1%, respectively).
</FONT>
</P>
<P ID=PARA691 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA690 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Two patients (one each in the sufentanil sublingual tablet group and placebo group) experienced a serious adverse event considered possibly or probably related to the study drug by the investigator.
</FONT>
</P>
<P ID=PARA693 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA692 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Combined related adverse events for the two placebo-controlled pivotal studies (IAP310 and IAP311) compared to placebo are shown below. Only pruritus (itching) was statistically different for Zalviso compared to placebo (p&nbsp;= 0.002).
</FONT>
</P>
<P ID=PARA695 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<P ID=PARA694 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Adverse Reactions Occurring in
</B>
<U>
<B>
	&gt;
</B>
</U>
<B>
	2% in Either Group
</B>
</FONT>
</P>
<P ID=PARA696 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL735 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL735.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 70%; VERTICAL-ALIGN: BOTTOM">
<P STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Poss
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ibly or Probably Related Adverse Reactions
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</U>
</P>
</TD>
<TD ID=TBL735.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA699 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Zalviso
<BR>
	n=429
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.1.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.1.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA701 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Placebo
<BR>
	n=162
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.1.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP">
<P ID=PARA703 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	At least 2% in either group
</B>
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT" COLSPAN=6>
<P ID=PARA704 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 28.8PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Two Placebo-
<BR>
	Controlled
<BR>
	Phase 3 Studies
</B>
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA705 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Nausea
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #CCEEFF">
	29.4%
</TD>
<TD ID=TBL735.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #CCEEFF">
	22.2%
</TD>
<TD ID=TBL735.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA708 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Vomiting
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #FFFFFF">
	8.9%
</TD>
<TD ID=TBL735.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #FFFFFF">
	4.9%
</TD>
<TD ID=TBL735.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA711 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Oxygen Saturation Decreased*
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #CCEEFF">
	6.1%
</TD>
<TD ID=TBL735.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #CCEEFF">
	2.5%
</TD>
<TD ID=TBL735.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA714 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pruritus
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #FFFFFF">
	4.7%
</TD>
<TD ID=TBL735.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #FFFFFF">
	0%
</TD>
<TD ID=TBL735.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA717 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dizziness
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #CCEEFF">
	4.4%
</TD>
<TD ID=TBL735.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #CCEEFF">
	1.2%
</TD>
<TD ID=TBL735.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.8 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA720 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Constipation
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #FFFFFF">
	3.7%
</TD>
<TD ID=TBL735.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #FFFFFF">
	0.6%
</TD>
<TD ID=TBL735.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.9 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA723 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Headache
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #CCEEFF">
	3.3%
</TD>
<TD ID=TBL735.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #CCEEFF">
	3.7%
</TD>
<TD ID=TBL735.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.10 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA726 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Insomnia
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #FFFFFF">
	3.3%
</TD>
<TD ID=TBL735.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #FFFFFF">
	1.9%
</TD>
<TD ID=TBL735.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.11 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA729 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Hypotension
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #CCEEFF">
	3.0%
</TD>
<TD ID=TBL735.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #CCEEFF">
	1.2%
</TD>
<TD ID=TBL735.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL735.FINROW.12 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA732 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Confusional state
</FONT>
</P>
</TD>
<TD ID=TBL735.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #FFFFFF">
	2.1%
</TD>
<TD ID=TBL735.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL735.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 28.8PT; BACKGROUND-COLOR: #FFFFFF">
	0.6%
</TD>
<TD ID=TBL735.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
<P ID=PARA736 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 89.6% 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 10%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="LEFT">
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA737 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	*3 patients (0.7%) in the Zalviso group had treatment-emergent respiratory events that required naloxone reversal.
</FONT>
</P>
<P ID=PARA740 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK741 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGNUM741 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	15
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage16"></A>
<DIV ID=PGHDR741 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA741.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA743 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ARX-03&#8212;Sufentanil/Triazolam S
</B>
<B>
	ublingual
</B>
<B>
	Tablet
</B>
</FONT>
</P>
<P ID=PARA745 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA746 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	The Market Opportunity for ARX-03
</B>
</I>
</FONT>
</P>
<P ID=PARA748 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA747 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Each year in the United States, more than 100 million procedures take place in a physician&#8217;s office that are known to be anxiety-inducing and painful, according to commissioned market research data that was completed in 2010. These include diagnostic procedures such as breast and prostate biopsies, cosmetic procedures such as liposuction and dermal abrasions, interventional radiology procedures, and therapeutic procedures such as vasectomies and endometrial ablation procedures. IV sedative medications are typically not offered to these patients because of the high cost of the specialized personnel and monitoring equipment. Despite the high potential for pain and anxiety, most patients currently undergo these procedures with only a local anesthetic, resulting in unnecessary discomfort during the procedure. We believe there is significant opportunity for a fast-acting, effective and safe product that can provide mild levels of sedation, anxiety reduction and analgesia for painful procedures conducted in a physician&#8217;s office without the need for specialized personnel to monitor the patient.
</FONT>
</P>
<P ID=PARA750 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA749 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	ARX-03 Description
</B>
</I>
</FONT>
</P>
<P ID=PARA752 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA751 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-03 sufentanil/triazolam sublingual tablet is a single, fixed-dose sublingual product candidate designed to be administered by a healthcare professional prior to a painful procedure in a physician&#8217;s office. An important attribute of sufentanil and triazolam compared to current therapies is the rapid uptake from the sublingual mucosa. Our Phase 2 clinical data showed that administering ARX-03 via sublingual route prior to a procedure results in a rapid onset of mild sedation and reduction in anxiety in 15 to 30 minutes. Sufentanil and triazolam have short half-lives compared to many other agents in the same class of compounds, enabling patients treated with ARX-03 to be discharged immediately following completion of the procedure. The sublingual route of administration avoids the high plasma concentrations associated with IV delivery, thereby obviating the need for specialized personnel and extensive monitoring.
</FONT>
</P>
<P ID=PARA754 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA753 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	ARX-03 Clinical Program Overview
</B>
</I>
</FONT>
</P>
<P ID=PARA756 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA755 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have completed a successful Phase 2 clinical trial of ARX-03 demonstrating rapid onset of mild sedation and anxiety reduction, with a low adverse event profile during an abdominal liposuction procedure. In addition, we participated in an End of Phase 2 meeting with the FDA in May 2010 to discuss the Phase 3 clinical program and requirements for an NDA submission. Based on these discussions, two four-arm factorial Phase 3 clinical trials will be required with a minimum of 700 patients exposed to active drug.
</FONT>
</P>
<P ID=PARA758 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA757 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Further development of the ARX-03 program is contingent on identification of corporate partnership resources. Currently we have no plans to advance the development of ARX-03.
</FONT>
</P>
<P ID=PARA760 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA759 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Our Strategy
</B>
</FONT>
</P>
<P ID=PARA762 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA761 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our strategy is to develop and commercialize our sufentanil sublingual tablet-based products in the United States. We have designed and are developing product candidates that meet clearly defined unmet medical needs, have clearly defined clinical development programs, target large commercial market opportunities and require modestly-sized commercial organizations in the United States. We selectively utilize third-party contractors in order to maximize the capital efficiency of our development and commercialization efforts. We plan to enter into partnerships to market our product candidates outside the United States. In December 2013, we announced a commercial collaboration with Gr&#252;nenthal, covering the territory of the European Union, certain other European countries and Australia for Zalviso for potential use in pain treatment within or dispensed by a hospital, hospice, nursing home or other medically supervised setting.&nbsp;We retain all rights in remaining countries, including the United States. We continue to seek partnerships to market Zalviso in markets outside of the Gr&#252;nenthal territory and the United States.
</FONT>
</P>
<P ID=PARA764 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA765 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
<I>
	ARX-04
</I>
</U>
</FONT>
</P>
<P ID=PARA768 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA31 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04 is a non-invasive investigational product candidate consisting of a single sufentanil sublingual tablet, 30 mcg, delivered via a disposable, pre-filled, single-dose applicator, or SDA. We are developing ARX-04 for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings of acute pain. If approved, examples of potential patient populations and settings in which ARX-04 could be used include: emergency room patients; patients who are recovering from short-stay or ambulatory surgery and do not require more long-term patient-controlled analgesia; post-operative patients who are transitioning from the operating room to the recovery floor; patients being treated and transported by paramedics; and for battlefield casualties. We plan to complete our Phase 3 development program for ARX-04 by the third quarter of 2016, and, pending successful completion, we anticipate submitting the NDA to the FDA for ARX-04 in the fourth quarter of 2016.
</FONT>
</P>
<P ID=PARA33 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
	&nbsp;
</P>
<DIV ID=PGBK12 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR12 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM12 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	16
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage17"></A>
<DIV ID=PGHDR12 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA12.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA770 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our specific strategy with respect to ARX-04 is to:
</FONT>
</P>
<P ID=PARA772 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB773 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA774 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA775 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	complete our Phase 3 clinical program and seek regulatory approval in the United States and in the EEA;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA777 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB778 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA779 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA780 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	further expand our relationship with our existing contract manufacturing organizations, or CMOs, for the manufacture and packaging of ARX-04;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA782 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB783 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA784 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA785 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	build a targeted sales force focused on the emergency room and corporate-owned ambulatory surgery centers in the United States;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA787 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB788 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA789 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA790 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	on our own, or with a partner, supply the DoD and other military organizations as requested and appropriate; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA792 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB793 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA794 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA795 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	seek commercial partnerships for ARX-04 in countries outside of the United States.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA797 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA796 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
<I>
	Zalviso
</I>
</U>
<U>
	&nbsp;
</U>
</FONT>
</P>
<P ID=PARA798 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are seeking FDA approval for the use of Zalviso to treat moderate-to-severe acute pain in the hospital setting. We submitted an NDA for Zalviso in September 2013 and, as mentioned above, the FDA issued a CRL for Zalviso on July 25, 2014. Based on interaction with the FDA we have agreed to conduct the IAP312 study in post-operative patients. We anticipate the initiation of the IAP312 study in the first quarter of 2016. Pending successful completion of IAP312, we plan to resubmit the NDA for Zalviso&nbsp;by the end&nbsp;of 2016.
</FONT>
</P>
<P ID=PARA800 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA801 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our specific strategy with respect to Zalviso is to:
</FONT>
</P>
<P ID=PARA803 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB804 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA805 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA806 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	collaborate with Gr&#252;nenthal to support the launch of Zalviso in their licensed territories;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA808 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB809 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA810 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA811 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	strengthen our commercial relationships for the manufacturing of the components and assembly of the Zalviso System;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA813 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB814 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA815 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA816 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	seek regulatory approval in the United States;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA818 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB819 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA820 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA821 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	build a targeted hospital-directed sales force in the United States; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA823 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB824 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA825 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA826 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	seek commercial partnerships for Zalviso in other unlicensed countries outside of the United States.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA828 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA827 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Sales and Marketing
</B>
</FONT>
</P>
<P ID=PARA830 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA829 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We anticipate developing a distribution capability and commercial organization in the United States to market and sell our product candidates alone or with partners, while out-licensing commercialization rights outside of the United&nbsp;States. In executing our strategy, our goal is to have significant control over the development process and commercial execution for our product candidates, while retaining meaningful economics.
</FONT>
</P>
<P ID=PARA832 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA831 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We plan to progressively build commercial capability to support introduction of ARX-04 and Zalviso to the United States market as we move toward potential NDA approval. We foresee two stages of commercial execution to support successful introduction of ARX-04 and Zalviso in the United States:
</FONT>
</P>
<P ID=PARA834 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA833 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Prior to FDA approval of ARX-04 and Zalviso, we plan to:
</FONT>
</P>
<P ID=PARA836 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB837 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA838 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA839 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	create and deploy a focused scientific support team to gather a detailed understanding of individual emergency room, ambulatory surgery center and hospital needs in order to be prepared to present ARX-04 and Zalviso effectively at the time of commercial launch;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA841 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB842 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA843 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA844 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	increase awareness of the clinical profile of sublingual administration of sufentanil through publication of our clinical data;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA846 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB847 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA848 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA849 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	establish advisory boards with emergency room physicians, anesthesiologists, surgeons, nurses and P&amp;T committees to provide us with input on appropriate commercial positioning for ARX-04 and Zalviso for each of these key audiences;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA851 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB852 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA853 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA854 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	build a sales and marketing organization that can define appropriate segmentation and positioning strategies and tactics for ARX-04 and Zalviso; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA856 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB857 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA858 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA859 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	present the clinical and health economic data identifying the limitations of IV PCA and other relevant treatments for moderate-to-severe acute pain in use today.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA861 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA860 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Assuming FDA approval, we plan to:
</FONT>
</P>
<P ID=PARA863 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB864 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA865 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA866 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	establish ARX-04 and Zalviso on formularies through deployment of an experienced team to explain the clinical and economic attributes of ARX-04 and Zalviso;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA868 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK13 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR13 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM13 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	17
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage18"></A>
<DIV ID=PGHDR13 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA13.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB869 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA870 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA871 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	create and progressively deploy a high-quality, customer-focused and experienced sales organization dedicated to bringing innovative, highly-valued healthcare solutions to patients, payors and healthcare providers, including progressively building a targeted sales force of approximately 65 people in the United States;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA873 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB874 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA875 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA876 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	conduct post-approval clinical trials for ARX-04 and Zalviso;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA878 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB879 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA880 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA881 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	undertake efforts to establish ARX-04 and Zalviso as the products of choice for moderate-to-severe acute pain; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA883 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB884 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA885 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA886 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expand the market through deployment of ARX-04 in medically-supervised settings outside of the hospital and ambulatory surgery centers and, for Zalviso, for 24-hour stay patients and other in-hospital moderate-to-severe acute pain conditions.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA887 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA888 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Collaborative Arrangements
</B>
</FONT>
</P>
<P ID=PARA891 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA890 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	Gr&#252;nenthal Collaboration
</B>
</I>
</FONT>
</P>
<P ID=PARA892 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA893 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December&nbsp;16, 2013, we and Gr&#252;nenthal entered into a Collaboration and License Agreement, or the License Agreement, and related Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. The License Agreement grants Gr&#252;nenthal rights to commercialize Zalviso, or the Product, in the Territory for human use in pain treatment within or dispensed by hospitals, hospices, nursing homes and other medically-supervised settings, or the Field. The Company retains rights with respect to the Product in countries outside the Territory, including the United States, Asia and Latin America. Under the MSA, we will exclusively manufacture and supply the Product to Gr&#252;nenthal for the Field in the Territory. On July 22, 2015, we entered into amendments to the License Agreement, or the License Amendment, and together with the License Agreement, the Amended License Agreement, and the MSA, or the MSA Amendment, and together with the MSA, the Amended MSA, between AcelRx and Gr&#252;nenthal, each effective as of July 17, 2015, and together, the Amended Agreements.
</FONT>
</P>
<P ID=PARA895 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA894 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the Amended Agreements, the parties amended the Product supply configurations and packaging of Product components and accessories, and associated pricing therefor, which we will manufacture and supply to Gr&#252;nenthal for the Territory. The parties agreed to increase the pricing of the Product components and accessories, while reducing the total milestone payments due from Gr&#252;nenthal contingent upon achieving specified net sales targets from a total of $171.5 million to $166.0 million. As a result of the Royalty Monetization, PDL will receive 75% of the European royalties under the Amended License Agreement with Gr&#252;nenthal, as well as 80% of the first four commercial milestones worth $35.6 million (or 80% of $44.5 million), subject to the capped amount of $195.0 million. The parties also updated the development plan for the Product in the Territory, providing for additional near-term development services to be rendered by AcelRx in exchange for payments of approximately $0.7 million, primarily in 2015. Simultaneously, we also received a binding Product forecast from Gr&#252;nenthal for approximately $3.7 million.
</FONT>
</P>
<P ID=PARA36 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA35 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the terms of the Amended Agreements with Gr&#252;nenthal, we received an upfront cash payment of $30.0 million in December 2013, and in the third quarter of 2014, we received a milestone payment of $5.0 million related to the MAA submission to EMA and an additional milestone payment of $15.0 million related to the EC approval of the MAA for Zalviso in the third quarter of 2015. Under the Amended License Agreement, we are eligible to receive approximately $194.5 million in additional milestone payments, based upon successful regulatory and product development efforts ($28.5 million) and net sales target achievements ($166.0 million). Gr&#252;nenthal will also make tiered royalty, supply and trademark fee payments in the mid-teens up to the mid-twenties percent range, depending on the sales level achieved, on net sales of Zalviso in the Territory. A portion of the tiered royalty payment, exclusive of the supply and trademark fee payments, will be paid to PDL in connection with the Royalty Monetization. For additional information on the Royalty Monetization with PDL, see Note 8 &#8220;Liability Related to Sale of Future Royalties&#8221; in the accompanying notes to the Consolidated Financial Statements.
</FONT>
</P>
<P ID=PARA37 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA898 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal will be responsible for all commercial activities for Zalviso, including obtaining and maintaining pharmaceutical product regulatory approval in the Territory.&nbsp;We will be responsible for obtaining and maintaining device regulatory approval in the Territory and manufacturing and supply of Zalviso to Gr&#252;nenthal for commercial sales.
</FONT>
</P>
<P ID=PARA901 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA900 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Intellectual Property
</B>
</FONT>
</P>
<P ID=PARA903 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA902 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We seek patent protection in the United States and internationally for our product candidates. Our policy is to pursue, maintain and defend patent rights developed internally and to protect the technology, inventions and improvements that are commercially important to the development of our business. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology. We also rely on trade secrets to protect our product candidates. Our commercial success also depends in part on our non-infringement of the patents or proprietary rights of third parties. For a more comprehensive discussion of the risks related to our intellectual property, please see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; appearing elsewhere in this Form&nbsp;10-K.
</FONT>
</P>
<P ID=PARA905 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK14 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR14 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM14 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	18
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage19"></A>
<DIV ID=PGHDR14 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA14.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA904 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our success will depend significantly on our ability to:
</FONT>
</P>
<P ID=PARA907 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB908 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA909 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA910 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtain and maintain patent and other proprietary protection for our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA912 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB913 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA914 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA915 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	defend our patents;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA917 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB918 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA919 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA920 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	preserve the confidentiality of our trade secrets; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA922 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB923 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 28PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 14PT; VERTICAL-ALIGN: TOP">
<P ID=PARA924 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA925 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	operate our business without infringing the patents and proprietary rights of third parties.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA927 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA926 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have established and continue to build proprietary positions for our product candidates and related technology in the United States and abroad.
</FONT>
</P>
<P ID=PARA929 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA928 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December&nbsp;31, 2015, we are the owner of record of 17 issued U.S. patents, which provide coverage for sufentanil sublingual tablets, the device components of Zalviso and the ARX-04 SDA. These patents provide coverage through at least 2027. We also hold four issued European patents, each valid in at least six countries in Europe. In addition, we own five patents in Japan, four in China and six in Korea, and a number of other international patents which provide coverage through at least 2027. We are also pursuing a number of U.S. and foreign patent applications. The patent applications that we have filed and have not yet been granted may fail to result in issued patents in the United States or in foreign countries. Even if the patents do successfully issue, third parties may challenge the patents.
</FONT>
</P>
<P ID=PARA931 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA930 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We continue to seek and expand our patent protection for both compositions of matter and delivery devices, as well as methods of treatment related to our product candidates. In particular, we are pursuing additional patent protection for our Zalviso and ARX-04 and formulations, our Zalviso device, the combination of drugs and our Zalviso device, our ARX-04 SDA, as well as to methods of treatment using such drug and device compositions.
</FONT>
</P>
<P ID=PARA933 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA932 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have filed for additional patent coverage in the United States, Europe as well as many other foreign jurisdictions including, Japan, China, India, Canada and Korea. If issued, and if the appropriate maintenance, renewal, annuity or other governmental fees are paid, we expect that these patents will expire between 2027 and 2030, excluding any additional term for patent term adjustments or patent term extensions in the United States. We note that the patent laws of foreign countries differ from those in United States, and the degree of protection afforded by foreign patents may be different from the protection offered by U.S. patents.
</FONT>
</P>
<P ID=PARA935 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA934 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Further, we seek trademark protection in the United States and internationally where available and when appropriate. We have registered our ACELRX mark in Class 5, &#8220;Pharmaceutical preparations for treating pain; pharmaceutical preparations for treating anxiety,&#8221; and Class 10, &#8220;Drug delivery systems; medical device, namely, a mechanical and electronic device used to administer medications, perform timed medication delivery, and to provide secure access to and delivery of medications,&#8221; in the United&nbsp;States.
</FONT>
</P>
<P ID=PARA937 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA936 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our ACELRX mark is also registered in the European Community, Canada, and India. We have also registered the mark ACCELERATE. INNOVATE. ALLEVIATE. in the United States.
</FONT>
</P>
<P ID=PARA939 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA940 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Competition
</B>
</FONT>
</P>
<P ID=PARA942 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA941 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, and medical technology companies. We believe the key competitive factors that will affect the development and commercial success of our product candidates are the safety, efficacy and tolerability profile, the patient and healthcare professional satisfaction with using our product candidates in relation to available alternatives and the reliability, convenience of dosing, price and reimbursement of our product candidates.
</FONT>
</P>
<P ID=PARA944 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA943 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Many of our potential competitors, including many of the organizations named below, have substantially greater financial, technical and human resources than we do and significantly greater experience in the development of product candidates, obtaining FDA and other regulatory approvals of products and the commercialization of those products. Accordingly, our competitors may be more successful than we may be in obtaining FDA approval for drugs and achieving widespread market acceptance. Our competitors&#8217; drugs may be more effective, or may be more effectively marketed and sold, than any drug we may commercialize, which may render our product candidates obsolete or non-competitive before we can recover our losses. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available.
</FONT>
</P>
<P ID=PARA945 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	&nbsp;
</B>
</I>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK15 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR15 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM15 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	19
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage20"></A>
<DIV ID=PGHDR15 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA15.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA946 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
<B>
	Potential Competition for ARX-04
</B>
</I>
</FONT>
</P>
<P ID=PARA948 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA181 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Within the civilian environment, there are a wide variety of approved injectable and oral opioid products to treat moderate-to-severe acute pain, including IV opioids such as morphine, fentanyl, hydromorphone and meperidine or oral opioids such as oxycodone and hydrocodone. More specifically, competitors for ARX-04 in the emergency department are likely to include generic injectable intravenous opioids such as morphine, hydromorphone and fentanyl. In this environment, ARX-04 may also compete with other branded non-invasive products or product candidates, such as Egalet Corporation&#8217;s SPRIX, Hospira Inc.&#8217;s DYLOJECT (Hospira, Inc. acquired by Pfizer, Inc. in September 2015), Acura Pharmaceuticals, Inc.&#8217;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	s OXAYDO, Depomed, Inc.&#8217;s NUCYNTA, Bristol-Myers Squibb Company&#8217;s COMBUNOX, Purdue Pharma, L.P.&#8217;s OXYFAST, Endo Pharmaceuticals, Inc.&#8217;s OPANA, Medical Developments International Limited&#8217;s
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PENTHROX (methoxyflurane) inhaler, CL-108, a bi-layered tablet
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	, in development by Charleston Laboratories Inc., in collaboration with Daiichi Sankyo, or generic oral opioids which have moderate-to-severe acute pain labeling. In the short-stay or ambulatory surgery segment, ARX-04 will likely compete with these products in addition to generic injectable local anesthetics such as bupivacaine, or branded formulations thereof, including Pacira Pharmaceuticals, Inc.&#8217;s EXPAREL. Within the military environment, and in certain civilian settings, ARX-04 competitors may also include intramuscular morphine injections that are marketed by a variety of generic manufacturers.
</FONT>
</FONT>
</P>
</FONT>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA953 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Potential Competition for Zalviso
</I>
</B>
</FONT>
</P>
<P ID=PARA956 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA955 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are developing Zalviso for the management of moderate-to-severe acute pain in adult patients during hospitalization. We believe that Zalviso would compete with a number of opioid-based and non-opioid based treatment options that are currently available, as well as some products that are in development.&nbsp;These products can be grouped into three classes &#8211; PCA-based systems, most commonly using an opioid as the pain control agent; non PCA-based systems that require nurse delivery of oral or parenteral opioids; and other non-opioid based treatment modalities.&nbsp;Due to the difficulty of managing moderate-to-severe acute pain, healthcare professionals will often use a combination of PCA opioids, parenteral or oral opioids and non-opioid based treatments to manage pain.
</FONT>
</P>
<P ID=PARA958 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA957 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The primary competition for Zalviso is the IV PCA pump, which is widely used in the moderate-to-severe acute pain in the hospital setting. Leading manufacturers of IV PCA pumps include Hospira, Inc. (acquired by Pfizer, Inc.), CareFusion Corporation (purchased by Becton, Dickinson and Company), Baxter International, Inc., Curlin Medical, Inc. and Smiths Medical. The most common opioids used to treat moderate-to-severe acute pain are morphine, hydromorphone and fentanyl, all of which are available as generics
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	both from generic product manufacturers as well as from compounding pharmacies. In addition, branded manufacturers (e.g., Hospira, Inc.) sell pre-filled glass syringes of morphine to fit their IV PCA pump systems.
</FONT>
</P>
<P ID=PARA960 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA959 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Also available on the market is the Avancen Medication on Demand, or MOD, Oral PCA Device developed by Avancen MOD Corporation. Oral opioids and other agents can be used in this system.&nbsp;In addition, oral and parenteral opioids administered by the nurse are used to manage moderate-to-severe acute pain in the hospital, available both as branded and generic products. These oral opioids, as well as IV PCA opioids, are often used as part of a multi-modal analgesia approach, which might include, in addition to the opioid, NSAIDs, acetaminophen, gabapentanoids and other pain management modalities, as well as local anesthetic blocks to provide temporary blockage of the pain signal, either as a wound infiltration agent or as a nerve block. These local anesthetic agents such as bupivacaine can also utilize controlled-release formulations such as Pacira Pharmaceuticals, Inc.&#8217;s EXPAREL. In addition, Halyard Health, Inc. has developed a medical device, the ON-Q* Pain Relief System, which is a non-narcotic elastomeric pump that automatically and continuously delivers a regulated flow of local anesthetic to a patient&#8217;s surgical site or in close proximity to nerves, providing targeted pain relief for up to five days.
</FONT>
</P>
<P ID=PARA961 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK16 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR16 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM16 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	20
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage21"></A>
<DIV ID=PGHDR16 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA16.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA962 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additional potential competitors for Zalviso include the fentanyl iontophoretic transdermal system, IONSYS, originally developed by Alza Corporation and Ortho-McNeil Pharmaceutical, Inc., both Johnson&nbsp;&amp; Johnson subsidiaries, and most recently by The Medicines Company. On April 30, 2015, IONSYS was approved for marketing in the U.S. by the FDA, providing a potential first-to-market advantage for IONSYS. Cara Therapeutics, Inc. is developing a kappa opioid agonist, CR845, as an IV agent for the management of post-operative moderate-to-severe pain.&nbsp;Trevena, Inc. is developing TRV130, an intravenous G protein biased ligand that targets the mu opioid receptor for the treatment of moderate-to-severe acute pain where intravenous therapy is preferred, with a clinical development focus in acute post-operative pain. Trevena, Inc. expects to initiate Phase 3 development of TRV130 in the first quarter of 2016. Recro Pharma, Inc. is developing an intranasal form of dexmedetomidine as a potential agent for the management of post-operative pain, for which it announced positive efficacy results in its Phase II clinical trial. Finally, Innocoll AG is developing XARACOLL a controlled-release resorbable implant containing bupivacaine, and Durect Corporation has been developing POSIDUR, a controlled-release bupivacaine product candidate utilizing Durect Corporation&#8217;s Saber technology.
</FONT>
</P>
<P ID=PARA963 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA964 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Potential Competition for ARX
</I>
</B>
<I>
	-
</I>
<B>
<I>
	03
</I>
</B>
<I>
</I>
</FONT>
</P>
<P ID=PARA966 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA183 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are developing ARX-03, the sufentanil/triazolam sublingual tablet, for use in diagnostic or therapeutic painful procedures of short duration in a physician&#8217;s office. For these procedures, many practitioners rely primarily on local anesthetics injected to the procedural area to reduce the pain of the procedure, and do not use IV sedatives to manage the anxiety of patients because of the cost of having additional trained staff to monitor the patients. Currently, we are not aware of any products on the market that combine an opioid with a benzodiazepine in a single dosage form to manage the anxiety and pain of procedures in a physician&#8217;s office. However, an anonymous third party filed an Opposition on October 7, 2015 against European patent EP2182902B1, which claims a dosage form related to ARX-03. Although the Opposition is currently pending, the European Patent Office has neither reviewed nor made any initial comments regarding the validity of the EP2182902B1 patent. We are not aware of any approved or development stage non-IV sedative/analgesic products that would present competition to ARX-03. In the future, there may be products developed or approved for this market that could directly compete with ARX-03.
</FONT>
</P>
<P ID=PARA968 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
	&nbsp;
</FONT>
</P>
<P ID=PARA967 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Pharmaceutical Manufacturing and Supply
</B>
</FONT>
</P>
<P ID=PARA970 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA969 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We currently rely on contract manufacturers to produce sufentanil sublingual tablets for commercial product and for our clinical trials under current Good Manufacturing Practices, or cGMP, with oversight by our internal managers. Equipment specific to the pharmaceutical manufacturing process was purchased and customized for us and is currently owned by us. We plan to continue to rely on contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our product candidates if and when approved for marketing by the FDA. We currently rely on a single manufacturer for the preclinical and clinical supplies of our drug product for each of our product candidates and do not currently have agreements in place for redundant supply or a second source for any of our product candidates. We have identified other manufacturers that could satisfy our commercial supply and packaging requirements and we continue to evaluate those manufacturers.
</FONT>
</P>
<P ID=PARA972 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA971 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In January 2013, we entered into a Manufacturing Services Agreement, or the Services Agreement, with Patheon Pharmaceuticals, Inc., or Patheon, relating to the manufacture of sufentanil sublingual tablets for use with the Zalviso device. Under the terms of the Services Agreement, Patheon has agreed to manufacture, supply, and provide certain validation and stability services with respect to Zalviso for sale in the United States, Canada, Mexico and other countries, subject to agreement by the parties to any additional fees for such other countries. The term of the Services Agreement extends until December&nbsp;31, 2017, or the Initial Term, and will automatically renew thereafter for periods of two years, unless terminated by either party upon eighteen months&#8217; prior written notice; provided, however, that the Services Agreement may not be terminated without cause prior to the end of the Initial Term. In addition, we entered into a related Amended and Restated Capital Expenditure and Equipment Agreement, or the Amended Capital Agreement, related to clinical and commercial production of our product candidates. Under the terms of the Amended Capital Agreement, we have made, and may make certain future modifications to Patheon&#8217;s Cincinnati facility.
</FONT>
</P>
<P ID=PARA974 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA973 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Device Manufacturing and Supply
</B>
</FONT>
</P>
<P ID=PARA976 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA975 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The device components of Zalviso are manufactured by contract manufacturers, component fabricators and secondary service providers. Suppliers of components, subassemblies and other materials are located in Korea, Japan, Germany, China, Taiwan, Canada and the United States. All contract manufacturers and component suppliers have been selected for their specific competencies in the manufacturing processes and materials that make up Zalviso. FDA regulations require that materials be produced under cGMPs or Quality System Regulation, or QSR. We outsource injection molding of all the plastic parts for the cartridge and device and product sub-assemblies; tablet cartridge filling and packaging; and assembly, packaging and labeling of the dispenser and controller.
</FONT>
</P>
<P ID=PARA978 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA977 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04 utilizes an SDA in the delivery of the tablets. FDA regulations require that materials be produced under cGMPs or QSR, as required for the respective unit operation within the manufacturing process. We outsource injection molding of all the plastic parts for the SDA, and product sub-assemblies; and filling, packaging and labeling of SDAs.
</FONT>
</P>
<P ID=PARA980 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK17 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR17 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM17 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	21
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage22"></A>
<DIV ID=PGHDR17 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA17.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA979 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Government Regulation
</B>
</FONT>
</P>
<P ID=PARA982 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA981 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Government authorities in the United States at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export and import of products such as those we are developing. Our product candidates must be approved by the FDA through the NDA process before they may legally be marketed in the United States.
</FONT>
</P>
<P ID=PARA44 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA983 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and complying with applicable laws and regulations requires the expenditure of substantial time and financial resources. Failure to comply at any time during the product development and approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. The process required by the FDA before a drug product may be marketed in the United States generally involves the following:
</FONT>
</P>
<P ID=PARA986 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB987 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA988 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA989 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	completion of non-clinical laboratory tests, animal trials and formulation studies according to Good Laboratory Practices regulations;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA991 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB992 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA993 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA994 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	submission to the FDA of an investigational new drug, or IND, application which must become effective before human clinical trials may begin;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA996 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB997 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA998 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA999 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	performance of adequate and well-controlled human clinical trials according to Good Clinical Practices, or GCP, to establish the clinical safety and efficacy of the proposed drug product for its intended use;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1001 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1003 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1004 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1005 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	submission to the FDA of an NDA for a new drug product;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1007 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1008 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1009 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1010 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug product and the drug substance(s) are produced to assess compliance with cGMP;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1012 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1013 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1014 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1015 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	payment of application, user and facility fees; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1017 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1018 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1019 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1020 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	FDA review and approval of the NDA.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1022 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1021 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all.
</FONT>
</P>
<P ID=PARA1024 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1023 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:
</FONT>
</P>
<P ID=PARA1026 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1027 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1028 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
<I>
</I>
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1029 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Phase 1.
</I>
	The product is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1031 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1032 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1033 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
<I>
</I>
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1034 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Phase 2.
</I>
	Involves trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted conditions and to determine dosage tolerance and optimal dosage and schedule.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1036 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1037 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1038 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
<I>
</I>
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1039 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Phase 3.
</I>
	Clinical trials are undertaken to further evaluate dosage, clinical safety and efficacy in an expanded patient population at geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1041 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1040 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an institutional review board, or IRB, can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biological product has been associated with unexpected serious harm to patients.
</FONT>
</P>
<P ID=PARA1043 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1042 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Concurrent with clinical trials, companies usually complete additional animal trials and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP and QSR for medical device requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.
</FONT>
</P>
<P ID=PARA1045 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK18 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR18 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM18 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	22
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage23"></A>
<DIV ID=PGHDR18 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA18.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1044 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our product candidates, Zalviso, ARX-04 and others, are regulated under IND applications for clinical development and in the case of Zalviso, all device related information is filed under the Chemistry, Manufacturing and Controls Section, or CMC, of an IND.
</FONT>
</P>
<P ID=PARA1047 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1046 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The results of product development, preclinical trials and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on our drug products, proposed labeling and other relevant information, will be submitted to the FDA as part of an NDA for a new drug product, requesting approval to market the product in the United States. The submission of an NDA is subject to the payment of a substantial user fee; a waiver of such fee may be obtained under certain limited circumstances. During its review of an NDA, FDA may inspect our manufacturers for GMP and QSR compliance, and our pivotal clinical trial sites for GCP compliance.
</FONT>
</P>
<P ID=PARA1049 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1048 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA must contain data to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers.
</FONT>
</P>
<P ID=PARA1051 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1050 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The approval process is lengthy and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. The FDA issues a Complete Response Letter at the conclusion of its review if the NDA is not yet deemed ready for approval. A Complete Response Letter generally outlines the deficiencies in the submission and may require substantial additional testing or information for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1053 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1052 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If one or more of our product candidates receive regulatory approval, the approval may be limited to specific conditions and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Our product candidates, if approved, will also require Risk Evaluations and Mitigation Strategies, or REMS, which can include a medication guide, patient package insert, a communication plan, elements to assure safe use and implementation system, and must include a timetable for assessment of the REMS. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. In addition, the FDA may require post-approval testing which involves clinical trials designed to further assess a drug product&#8217;s safety and effectiveness after the NDA.
</FONT>
</P>
<P ID=PARA1055 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1054 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Post-Approval Requirements
</B>
</FONT>
</P>
<P ID=PARA1057 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1056 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any drug products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated clinical safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements. Phase 4 clinical trials are conducted after approval to gain additional experience from the treatment of patients in the intended therapeutic indication or when otherwise requested by the FDA in the form of postmarketing requirements or commitments. Failure to promptly conduct any required Phase 4 clinical trials could result in withdrawal of NDA approval. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market. Drug products may be promoted only for the approved indications and in accordance with the provisions of the approved label. Further, manufacturers of drug products must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.
</FONT>
</P>
<P ID=PARA1059 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1058 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Drug product manufacturers and other entities involved in the manufacturing and distribution of approved drug products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, packaging, labeling, storage and shipment of the drug product. Manufacturers must establish validated systems to ensure that products meet specifications and regulatory standards, and test each product batch or lot prior to its release. In the case of Zalviso, the device component must comply with FDA&#8217;s Quality Systems Regulation.
</FONT>
</P>
<P ID=PARA1061 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1060 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products. Future FDA and state inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution or may require substantial resources to correct.
</FONT>
</P>
<P ID=PARA1063 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK19 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR19 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM19 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	23
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage24"></A>
<DIV ID=PGHDR19 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA19.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1062 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The FDA may withdraw a product approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Further, the failure to maintain compliance with regulatory requirements may result in administrative or judicial actions, such as fines, warning letters, holds on clinical trials, product recalls or seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing, injunctions or civil or criminal penalties.
</FONT>
</P>
<P ID=PARA1065 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1064 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Foreign Regulation
</B>
</FONT>
</P>
<P ID=PARA1067 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1066 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products to the extent we choose to sell any products outside of the United States.
</FONT>
</P>
<P ID=PARA1069 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1068 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In December 2015, the Committee for Medicinal Products for Human Use, or CHMP, at the European Medicines Agency, or EMA, confirmed that an MAA for ARX-04 may be submitted in the EU under the EMA&#39;s centralized procedure. This regulatory procedure, reserved for novel products, biotechnology products and new chemical entities, allows for commercialization across 31 EU and EFTA countries based on approval by EMA.
</FONT>
</P>
<P ID=PARA1071 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1070 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are responsible for maintaining Zalviso device regulatory approval in the EU in order to support the manufacturing and supply of Zalviso to Gr&#252;nenthal for commercial sales. We completed the Conformite Europeenne approval process for the Zalviso device, more commonly known as a CE Mark approval. We received CE Mark approval in December 2014, which permits the commercial sale of the Zalviso device in the European Union. In connection with the CE Mark approval, we were also granted International Standards Organization, or ISO, 13485:2003 certification of our quality management system. This is an internationally recognized quality standard for medical devices. Certification of our quality management system was issued by the British Standards Institution, or BSI, a Notified Body. ISO 13485:2003 certification recognizes that consistent quality policies and procedures are in place for the development, design and manufacturing of medical devices. The certification indicates that we have successfully implemented a quality system that conforms to ISO 13485 standards for medical devices. Certification to this standard is one of the key regulatory requirements for a CE Mark in the EU and EEA, as well as to meet equivalent requirements in other international markets. The certification applies to the Redwood City, California location which designs, manufactures and distributes finished medical devices, and includes critical suppliers. In November 2015, we underwent a successful surveillance audit by the Notified Body for the Zalviso CE mark and for our status as an ISO 13485 certified device manufacturer.
</FONT>
</P>
<P ID=PARA1073 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1072 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Controlled Substances Regulations
</B>
</FONT>
</P>
<P ID=PARA1075 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1074 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Sufentanil, a Schedule II controlled substance, is the active pharmaceutical ingredient in Zalviso and ARX-04. Controlled substances are governed by the Drug Enforcement Administration, or DEA, of the U.S. Department of Justice. The handling of controlled substances and/or drug product by us, our contract manufacturers, analytical laboratories, packagers and distributors, are regulated by the Controlled Substances Act and regulations thereunder.
</FONT>
</P>
<P ID=PARA1077 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1076 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As sufentanil is a controlled substance, until Zalviso is approved in the U.S., we are limited as to the countries we can export sufentanil cartridges to Europe, Japan, Australia, Israel, Switzerland, Canada and South Africa. Gr&#252;nenthal has the commercial rights to the European Union and Australia. As a result, we do not anticipate additional collaborations for Zalviso outside of the Gr&#252;nenthal territories until Zalviso is approved in the U.S.
</FONT>
</P>
<P ID=PARA1079 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1078 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Drug Supply Chain Security Act imposes obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements are that manufacturers will be required to provide certain information regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product. Further, manufacturers will have drug product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.
</FONT>
</P>
<P ID=PARA1081 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1080 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Unforeseen delays to the drug substance and drug product manufacture and supply chain may occur due to delays, errors or other unforeseen problems with the permitting and quota process. Also, any one of our suppliers, contract manufacturers, laboratories, packagers and/or distributors could be the subject of DEA violations and enforcement could lead to delays or even loss of DEA license by the contractors.
</FONT>
</P>
<P ID=PARA1083 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK20 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR20 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM20 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	24
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage25"></A>
<DIV ID=PGHDR20 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA20.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1082 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Federal and State Fraud and Abuse and Data Privacy and Security and Transparency Laws and Regulations
</B>
</FONT>
</P>
<P ID=PARA1085 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1084 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws restrict certain business practices in the pharmaceutical industry. These laws include, but are not limited to, anti-kickback, false claims, data privacy and security, and transparency statutes and regulations.
</FONT>
</P>
<P ID=PARA1087 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1086 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, facility, item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payment, ownership interests and providing anything at less than its fair market value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and/or formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and our practices may not in all cases meet all of the criteria for a statutory exception or safe harbor protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below).
</FONT>
</P>
<P ID=PARA1089 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1088 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The False Claims Act and related laws prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. Further, the Civil Monetary Penalties Law imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
</FONT>
</P>
<P ID=PARA1091 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1090 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates&#8212;independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
</FONT>
</P>
<P ID=PARA1093 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1092 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additionally, the federal Physician Payments Sunshine Act within the Patient Protection and Affordable Care Act, or PPACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biologicals and medical supplies, for which federal healthcare program payment is available, report information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.
</FONT>
</P>
<P ID=PARA1095 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1094 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Also, many states have similar healthcare statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. FDA and some states require the posting of information relating to clinical studies. In addition, California requires pharmaceutical companies to implement a comprehensive compliance program that includes a limit on expenditures for, or payments to, individual medical or health professionals. If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion of products from reimbursement under government programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products will be sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.
</FONT>
</P>
<P ID=PARA1097 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK21 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR21 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM21 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	25
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage26"></A>
<DIV ID=PGHDR21 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA21.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1096 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Pharmaceutical Coverage, Pricing and Reimbursement
</B>
</FONT>
</P>
<P ID=PARA1099 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1098 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In both domestic and foreign markets, our sales of any approved products will depend in part on the availability of coverage and adequate reimbursement from third-party payers. Third-party payers include government health administrative authorities, managed care providers, private health insurers and other organizations. Sales of our products will depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid by third-party payers. These third-party payers are increasingly focused on containing healthcare costs by challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the coverage and reimbursement status of newly approved healthcare product candidates. Third-party payers may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. Because each third-party payer individually approves coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a time-consuming, costly and sometimes unpredictable process. We may be required to provide scientific and clinical support for the use of any product to each third-party payer separately with no assurance that approval would be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. This process could delay the market acceptance of any product and could have a negative effect on our future revenues and operating results. We cannot be certain that our products and our product candidates will be considered cost-effective. Because coverage and reimbursement determinations are made on a payer-by-payer basis, obtaining acceptable coverage and reimbursement from one payer does not guarantee that we will obtain similar acceptable coverage or reimbursement from another payer. If we are unable to obtain coverage of, and adequate reimbursement and payment levels for, our product candidates from third-party payers, physicians may limit how much or under what circumstances they will prescribe or administer them. This in turn could affect our ability to successfully commercialize our products and impact our profitability, results of operations, financial condition and future success.
</FONT>
</P>
<P ID=PARA1101 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1100 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, in many foreign countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to government control. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. We may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of foreign products that compete with our own products, which could negatively impact our profitability.
</FONT>
</P>
<P ID=PARA1103 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1102 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Healthcare Reform
</B>
</FONT>
</P>
<P ID=PARA1105 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1104 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the United States and foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations as we begin to commercialize our products. In particular, there have been and continue to be a number of initiatives at the United States federal and state level that seek to reduce healthcare costs. Government payment for some of the costs of prescription drugs may increase demand for our products for which we receive marketing approval. However, any negotiated prices for our future products will likely be lower than the prices we might otherwise obtain from non-governmental payers. Moreover, private payers often follow federal healthcare coverage policy and payment limitations in setting their own payment rates.
</FONT>
</P>
<P ID=PARA1107 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1106 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Furthermore, political, economic and regulatory influences are subjecting the healthcare industry in the United States to fundamental change. Initiatives to reduce the federal deficit and to reform healthcare delivery are increasing cost-containment efforts. We anticipate that Congress, state legislatures and the private sector will continue to review and assess alternative benefits, controls on healthcare spending through limitations on the growth of private health insurance premiums and Medicare and Medicaid spending, the creation of large insurance purchasing groups, price controls on pharmaceuticals and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit or eliminate our spending on development projects and affect our ultimate profitability. In March 2010, PPACA was signed into law. Among other cost containment measures, PPACA established an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents. In the future, there may continue to be additional proposals relating to the reform of the U.S. healthcare system, some of which could further limit the prices we are able to charge for our products, or the amounts of reimbursement available for our products. If future legislation were to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business. Managed care organizations, as well as Medicaid and other government agencies, continue to seek price discounts. Some states have implemented, and other states are considering, price controls or patient access constraints under the Medicaid program, and some states are considering price-control regimes that would apply to broader segments of their populations that are not Medicaid-eligible. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, payer or policy actions, which may include cost containment and healthcare reform measures. Such policy actions could have a material adverse impact on our profitability.
</FONT>
</P>
<P ID=PARA1109 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK22 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR22 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM22 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	26
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage27"></A>
<DIV ID=PGHDR22 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA22.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1108 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Reimbursement and Health Reform
</I>
</B>
</FONT>
</P>
<P ID=PARA1111 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1110 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Significant uncertainty exists as to the coverage and reimbursement status of any product candidate that receives regulatory approval. In the United States and markets in other countries, sales of our product candidates, if approved for commercial sale, will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for product candidates.
</FONT>
</P>
<P ID=PARA47 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA46 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the United States, third-party payors include federal and state healthcare programs, government authorities, private managed care providers, private health insurers and other organizations. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Further, third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical drug products and medical services, in addition to questioning their safety and efficacy. Such payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication.&nbsp;We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our product candidates, in addition to the costs required to obtain the FDA approvals. Nonetheless, our product candidates may not be considered medically necessary or cost-effective.
</FONT>
</P>
<P ID=PARA1113 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA1114 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Moreover, the process for determining whether a third-party payor will provide coverage for a drug product may be separate from the process for setting the price of a drug product or for establishing the reimbursement rate that such a payor will pay for the drug product. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Adequate third-party reimbursement may not be available to maintain price levels sufficient to realize an appropriate return on our investment.
</FONT>
</P>
<P ID=PARA1117 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1116 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the United States, the PPACA, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Health Care Reform Law, was enacted in an effort to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, impose new taxes and fees on the health industry and impose additional health policy reforms. Aspects of the Health Care Reform Law that may impact our business include:
</FONT>
</P>
<P ID=PARA1119 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1120 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1121 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1122 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1124 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1125 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1126 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1127 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1129 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1130 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1131 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1132 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expansion of eligibility criteria for Medicaid programs, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1134 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1135 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1136 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1137 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1139 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1140 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1141 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1142 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a requirement to annually report drug samples that manufacturers and distributors provide to physicians;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1144 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1145 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1146 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1147 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1149 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1150 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1151 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1152 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	creation of the Independent Payment Advisory Board which has authority to recommend certain changes to the Medicare program that could result in reduced payments for prescription drugs.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1154 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1153 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Health Care Reform Law has the potential to substantially change health care financing and delivery by both governmental and private insurers, and may also increase our regulatory burdens and operating costs.
</FONT>
</P>
<P ID=PARA1156 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1155 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, other legislative changes have been proposed and adopted in the United States since the Health Care Reform Law was enacted. Aggregate reductions of Medicare payments to providers of 2% per fiscal year went into effect on April 1, 2013 and will stay in effect through 2024 unless Congressional action is taken. The American Tax Payer Relief Act further reduced Medicare payments to several providers, including hospitals.
</FONT>
</P>
<P ID=PARA1158 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK23 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR23 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM23 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	27
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage28"></A>
<DIV ID=PGHDR23 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA23.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1157 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Moreover, the Drug Supply Chain Security Act of 2013 imposes new obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this new legislation, manufacturers will be required to provide certain information regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product.
</FONT>
</P>
<P ID=PARA1160 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1159 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Legislative and regulatory proposals have been made to expand post-approval requirements and further restrict sales and promotional activities for pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be.
</FONT>
</P>
<P ID=PARA1162 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1161 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Research and Development
</B>
</FONT>
</P>
<P ID=PARA1164 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1163 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Conducting research and development is central to our business model. We have invested and expect to continue to invest significant time and capital in our research and development operations. Our research and development expenses were $22.5 million, $24.5 million and $26.3 million during the years ended December&nbsp;31, 2015, 2014 and 2013, respectively. We plan to incur significant expenditures for the foreseeable future as we seek to continue the development of ARX-04 and Zalviso and begin commercial preparations for ARX-04 and&nbsp;Zalviso.
</FONT>
</P>
<P ID=PARA1166 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1165 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Employees
</B>
</FONT>
</P>
<P ID=PARA1168 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1167 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December&nbsp;31, 2015, we employed 36 full-time employees. None of our employees are subject to a collective bargaining agreement. We consider our relationship with our employees to be good.
</FONT>
</P>
<P ID=PARA1170 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1169 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Corporate Information
</B>
</FONT>
</P>
<P ID=PARA1172 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1171 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We were originally incorporated as SuRx, Inc. in Delaware on July&nbsp;13, 2005. We subsequently changed our name to AcelRx Pharmaceuticals, Inc. on August&nbsp;13, 2006. We file electronically with the U.S. Securities and Exchange Commission, or SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We make available on our website at
<U>
	www.acelrx.com
</U>
	, free of charge, copies of these reports as soon as reasonably practicable after filing these reports with, or furnishing them to, the SEC.
</FONT>
</P>
<P ID=PARA1174 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK24 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR24 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM24 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	28
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage29"></A>
<DIV ID=PGHDR24 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_BUSINESS>
<P ID=PARA24.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<P ID=PARA1175 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;1A. Risk Factors
</B>
</FONT>
</P>
<P ID=PARA1177 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1176 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	This Form 10-K contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our actual future results, including, but not limited to, our revenues, expenses, net loss and loss per share. We believe the risks described below are the risks that are material to us as of the date of this Form 10-K. If any of the following risks comes to fruition, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected.
</I>
</FONT>
</P>
<P ID=PARA1179 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1178 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Risks Related to Clinical Development and Regulatory Approval
</B>
</FONT>
</P>
<P ID=PARA1181 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1180 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<B>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	We depend substantially on the success of ARX-04, which may not receive regulatory approval in the United States.
</I>
</FONT>
</B>
</P>
<P ID=PARA1183 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1182 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Since our inception in 2005, we have focused primarily on development of our product candidate, Zalviso&#8482;; however, given the delay in the potential approval of Zalviso in the United States, we believe the importance of ARX-04 (sufentanil sublingual tablet, 30 mcg) to our future success has increased. ARX-04 is a non-invasive investigational product candidate consisting of a single tablet delivered sublingually via a disposable, pre-filled, single-dose applicator, or SDA.
</FONT>
</P>
<P ID=PARA49 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA48 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As part of our development program, we met with the United States Food and Drug Administration, or FDA, in December 2015 to review plans for a New Drug Application, or NDA, for ARX-04. Based on feedback from the FDA, we intend to expand the clinical program for ARX-04 by approximately 160 additional patients to include individuals from specific populations and settings. Enrollment in the ongoing SAP302 open-label study in the emergency room will be increased, and a new study, known as SAP303, was initiated in March 2016 in post-operative patients with moderate-to-severe acute pain. SAP303 will focus on enrolling patients greater than 40 years of age and will allow for administration of ARX-04 for up to 12 hours. With these modifications, assuming successful completion of SAP302 and SAP303 by the third quarter of 2016, we anticipate submitting the NDA for ARX-04 in the fourth quarter of 2016. However, while we have announced positive top-line results from SAP301, SAP302 and SAP303 may not achieve positive results, or may not be completed by the third quarter of 2016 as anticipated. Even if we believe the results from SAP301, SAP302 and SAP303 support an NDA submission for ARX-04, the FDA may not agree, or may interpret the study results differently, which would delay the timing of our commercialization of ARX-04 and adversely affect our business operations. If ARX-04 is not approved for sale in the United States, it could have a significant impact on our ability to generate cash flows from product sales or to enter into a collaboration agreement. If we are not able to receive approval to commercialize ARX-04 in the United States, we would be required to find alternative sources of capital to continue operations. If ARX-04 is not approved for sale in the United States, and we are unsuccessful in finding alternative sources of capital, it will be difficult for us to continue under our current operating plan.
</FONT>
</P>
<P ID=PARA50 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA1186 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any disagreement with the FDA as to the results from SAP301, SAP302, and SAP303, and therefore any additional requirements imposed by the FDA prior to our ability to submit an NDA, as well as any delay in approval by the FDA of the ARX-04 NDA, if and when it is submitted, may negatively impact our stock price and harm our business operations. If and when the ARX-04 NDA is submitted, the FDA may hold an Advisory Committee meeting to obtain committee input on the safety and efficacy of ARX-04. Typically, Advisory Committees will provide responses to specific questions asked by the FDA, including the Committee&#8217;s view on the approvability of the drug under review. Advisory Committee decisions are not binding but an adverse decision at the Advisory Committee may have a negative impact on the regulatory review of ARX-04. Any delay in obtaining, or inability to obtain, regulatory approval would prevent us from commercializing ARX-04 in the United States, generating revenues and potentially achieving profitability. If any of these events occur, we may be forced to delay or abandon our development efforts for ARX-04, which would have a material adverse effect on our business and could potentially cause us to cease operations.
</FONT>
</P>
<P ID=PARA1189 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1188 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We depend substantially on the success of Zalviso, which may not receive regulatory approval in the United States.
</I>
</B>
</FONT>
</P>
<P ID=PARA1191 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1190 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Since our inception in 2005, we have focused primarily on development of our product candidate, Zalviso. While ARX-04&#8217;s importance has increased for our future success, Zalviso remains an important product candidate for us. Zalviso consists of sufentanil sublingual tablets, 15 mcg, delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system, or together, Zalviso. The success of our business depends primarily upon our ability to develop, receive regulatory approval in the United States for, and commercialize Zalviso for the management of moderate-to-severe acute pain in adult patients in the hospital setting. We have not marketed, distributed or sold any products to date anywhere in the world.
</FONT>
</P>
<P ID=PARA1193 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK25 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR25 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM25 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	29
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage30"></A>
<DIV ID=PGHDR25 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA25.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1192 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To date, our Phase 3 program for Zalviso has consisted of three Phase 3 clinical trials. We reported positive top-line data from each of these trials and submitted an NDA for Zalviso to the FDA in September 2013, which the FDA then accepted for filing in December 2013. On July 25, 2014, the FDA issued a Complete Response Letter, or CRL, for our NDA for Zalviso. The CRL contained requests for additional information on the Zalviso System to ensure proper use of the device. The requests included submission of data demonstrating a reduction in the incidence of optical system errors, changes to address inadvertent dosing, among other items, and submission of additional data to support the shelf life of the product. In the third quarter of 2014, we held a Type A meeting with the FDA to discuss the Zalviso CRL. During the meeting, we discussed the resubmission of the Zalviso NDA and the steps necessary for the resubmission. In advance of resubmitting our Zalviso NDA, we agreed with the FDA to submit protocols for the bench testing and Human Factors, or HF, studies for their review and comment. In addition, the FDA requested in the minutes of the meeting, that we provide a risk assessment that analyzes the risks associated with inadvertent dosing and the rationale that bench testing and HF studies would be sufficient to address the specific items included in the CRL. We submitted the protocols and this rationale in the fourth quarter of 2014. In January 2015, we received feedback from the FDA on the protocol and planned analysis of the results of the bench test. Based on the FDA feedback, no modifications to the conduct of the bench test were necessary; however, in response to the FDA&#8217;s request, we refined the planned analysis of the bench test results. In February 2015, we received feedback from the FDA on the HF protocols. In this feedback, the FDA confirmed that the HF studies as proposed were acceptable to evaluate the design changes related to inadvertent dispensing of tablets. In March 2015, we received additional correspondence from the FDA stating that in addition to the bench testing and two HF studies we had performed in response to the issues identified in the CRL, a clinical trial is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. On April 21, 2015, we submitted a request to the Division of Anesthesia, Analgesia, and Addiction Products, or the Division, of the FDA for a Type B meeting. On May 1, 2015, the Division notified us that the request for a meeting was denied and restated the Division&#8217;s view that a clinical study is required. Subsequently, we were granted a Type C meeting (previously identified as a General Advice meeting) with the FDA, which took place in early September 2015, to discuss their request for an additional clinical trial and our planned response to the CRL. In the Type C meeting minutes, the FDA provided some additional details about the type of clinical data they would like us to provide, as a complement to the other data we already have provided, to assess the overall performance of the Zalviso device. We have also received comments from the FDA on the protocol for the study, known as IAP312. In response to the comments, the protocol has been amended and will include approximately 315 post-operative patients and will collect information requested by the Division to supplement the three positive Phase 3 trials already completed.&nbsp;We expect to initiate the study in the first quarter of 2016.There is no guarantee that the additional work we perform related to Zalviso, including the IAP312 trial, will be supportive of, or guarantee, an NDA resubmission, or result in our successfully obtaining FDA approval of Zalviso in a timely fashion, if at all. For example, the trial might not meet its objectives or the FDA could still have concerns regarding the performance of the device, inadvertent dosing (dropped tablets), or other issues. At any future point in time, the FDA could require us to complete further clinical, Human Factors, pharmaceutical, reprocessing or other studies, which could delay or preclude any NDA submission or approval of the NDA and could require us to obtain significant additional funding. There is no guarantee such funding would be available to us on favorable terms, if at all. If the Zalviso NDA is resubmitted, the FDA may hold an Advisory Committee meeting to obtain committee input on the safety and efficacy of Zalviso. Typically, Advisory Committees will provide responses to specific questions asked by the FDA, including the Committee&#8217;s view on the approvability of the drug under review. Advisory Committee decisions are not binding but an adverse decision at the Advisory Committee may have a negative impact on the regulatory review of Zalviso. If the Zalviso NDA resubmission receives a second CRL, we may choose to engage in the dispute resolution process with the FDA.
</FONT>
</P>
<P ID=PARA1195 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1194 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our proposed trade name of Zalviso has been approved by the FDA, which must approve all drug trade names to avoid medication errors and misbranding. However, the FDA may withdraw this approval in which case any brand recognition or goodwill that we establish with the name Zalviso prior to commercialization may be worthless.
</FONT>
</P>
<P ID=PARA1197 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1196 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any delay in approval by the FDA of the Zalviso NDA, if, and when, it is resubmitted, may negatively impact our stock price and harm our business operations. Any delay in obtaining, or inability to obtain, regulatory approval would prevent us from commercializing Zalviso in the United States, generating revenues and potentially achieving profitability. If any of these events occur, we may be forced to delay or abandon our development efforts for Zalviso, which would have a material adverse effect on our business and could potentially cause us to cease operations.
</FONT>
</P>
<P ID=PARA1199 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1198 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Positive clinical results obtained to date for our product candidates may be disputed in FDA review, do not guarantee regulatory approval and may not be obtained from future clinical trials.
</I>
</B>
</FONT>
</P>
<P ID=PARA1201 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1200 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have reported positive top-line data from our first Phase 3 clinical trial for ARX-04, or SAP301, each of our three Zalviso Phase 3 clinical trials completed to date, in addition to all of our Phase 2 clinical trials for ARX-04 and Zalviso. However, even if we believe that the data from clinical trials is positive, the FDA has and in the future could determine that the data from our trials was negative or inconclusive or could reach a different conclusion than we did on that same data. Negative or inconclusive results of a clinical trial or difference of opinion could cause the FDA to require us to repeat the trial or conduct additional clinical trials prior to obtaining approval for commercialization, and there is no guarantee that additional trials would achieve positive results or that the FDA will agree with our interpretation of the results. Any such determination by the FDA would delay the timing of our commercialization plan for ARX-04 and Zalviso, or further development of our other product candidates, and adversely affect our business operations. For example, although we had achieved the primary endpoints in each of our three Phase 3 clinical trials for Zalviso which were included in our NDA filed in 2013, in March 2015, we received correspondence from the FDA stating that in addition to the bench testing and two Human Factors studies we had performed in response to the issues identified in the CRL, a clinical trial is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures.
</FONT>
</P>
<P ID=PARA1203 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK26 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR26 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM26 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	30
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage31"></A>
<DIV ID=PGHDR26 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA26.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1202 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales.
</I>
</B>
</FONT>
</P>
<P ID=PARA1205 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1204 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have experienced and may in the future experience delays in clinical trials of our product candidates. While we have completed one Phase 3 clinical trial for ARX-04, three Phase 3 clinical trials for Zalviso, and several Phase 2 clinical trials both for ARX-04 and Zalviso, current and potential future clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients or be completed on schedule, if at all. For example, in June 2014, we completed a pharmacokinetic study in support of the ARX-04 development program. In this study of healthy volunteers, it was shown that two sublingual administrations of a Zalviso sufentanil sublingual tablet, 15 mcg, dosed 20 minutes apart were equivalent to one sublingual administration of a sufentanil sublingual tablet, 30 mcg. Based on the pharmacokinetic equivalency of two Zalviso tablets to one ARX-04 tablet, the FDA has agreed to accept 323 Zalviso patients into the ARX-04 safety database, however, the FDA also required that the ARX-04 safety database comprise 350 patients dosed with at least one dose of ARX-04. Based on this feedback from the FDA, we intend to increase the safety database by expanding the clinical program for ARX-04 by approximately 160 additional patients to include individuals from specific populations and settings. Enrollment in the ongoing SAP302 open-label study in the emergency room will be increased, and a new study, known as SAP303,&nbsp;was initiated in&nbsp;March 2016 in post-operative patients with moderate-to-severe acute pain. Accordingly, the completion of the Phase 3 clinical program for ARX-04 has been extended and our clinical trial expenses will increase.
</FONT>
</P>
<P ID=PARA1207 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1206 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our clinical trials for any of our product candidates could be delayed for a variety of reasons, including:
</FONT>
</P>
<P ID=PARA1209 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1210 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1211 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1212 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	inability to raise funding necessary to initiate or continue a trial;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1214 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1215 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1216 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1217 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays in obtaining regulatory approval to commence a trial;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1219 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1220 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1221 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1222 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays in reaching agreement with the FDA on final trial design;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1224 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1225 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1226 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1227 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	imposition of a clinical hold by the FDA, IRBs or other regulatory authorities;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1229 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1230 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1231 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1232 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1234 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1235 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1236 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1237 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays in obtaining required institutional review board approval at each site;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1239 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1240 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1241 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1242 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays in recruiting suitable patients to participate in a trial;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1244 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1245 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1246 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1247 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays in the testing, validation, manufacturing and delivery of the tablets and device components of our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1249 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE ID=MTAB1251 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1252 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1253 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays in having patients complete participation in a trial or return for post-treatment follow-up;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1255 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1256 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1257 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1258 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	clinical sites dropping out of a trial to the detriment of enrollment or being delayed in entering data to allow for clinical trial database closure;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1260 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1261 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1262 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1263 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	time required to add new clinical sites; or
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1265 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1266 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1267 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1268 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1270 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1269 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If any future clinical trials are delayed for any of the above reasons, our development costs may increase, our approval process could be delayed and our ability to commercialize and commence sales of our product candidates could be materially harmed, which could have a material adverse effect on our business.
</FONT>
</P>
<P ID=PARA1272 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1271 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We have not yet responded to the Zalviso Complete Response Letter nor resubmitted the Zalviso NDA. Activities that we undertake to address issues raised in the CRL may be deemed insufficient by the FDA.
</I>
</B>
</FONT>
</P>
<P ID=PARA1274 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1273 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We completed bench testing and additional Human Factors studies that we believed addressed certain items contained in the CRL. However, before the results from these studies were submitted as a part of the proposed NDA resubmission, the FDA, in March 2015, notified us of the need for a clinical trial prior to the resubmission of the Zalviso NDA. In early September 2015, we had a Type C meeting with the FDA to discuss the FDA&#8217;s request for an additional clinical trial and our planned response to the CRL. In response to discussions with the FDA, we have agreed to complete an additional open label study with Zalviso in post-operative patients, known as IAP312. We have completed the protocol review for IAP312 and plan to initiate the study in the first quarter of 2016. There is no guarantee that the trial results, even if successful, will address the issues raised by the FDA. Any delay in obtaining, or inability to obtain, regulatory approval would prevent us from commercializing Zalviso in the United States, generating revenues and achieving profitability. If any of these events occur, we may be forced to delay or abandon our development and commercialization efforts for Zalviso in the United States, which would have a material adverse effect on our business and could potentially cause us to cease operations.
</FONT>
</P>
<P ID=PARA1276 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK27 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR27 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM27 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	31
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage32"></A>
<DIV ID=PGHDR27 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA27.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1275 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If we are able to resubmit an NDA for Zalviso with new clinical data, there is no guarantee that such data will be deemed sufficient by the FDA. While we designed the protocols for bench testing and the Human Factors studies to address the issues raised in the CRL, and designed the protocol for the additional Zalviso clinical trial to further address these issues, there is no guarantee that the FDA will deem such protocols and results sufficient to address those issues when they are formally reviewed as a part of an NDA resubmission.
</FONT>
</P>
<P ID=PARA1278 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1277 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Lastly, even if we believe that the test results from our bench testing and Human Factors studies are positive, and we are able to conduct and achieve positive results from the IAP312 study, the FDA may hold a different opinion and deem the results insufficient. The FDA may provide review commentary at any time during the resubmission and review process which could adversely affect or even prevent the approval of Zalviso, which would adversely affect our business. We may not be able to identify appropriate remediations to issues that the FDA may raise, and we may not have sufficient time or financial resources to conduct future activities to remediate issues raised by the FDA.
</FONT>
</P>
<P ID=PARA1280 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1279 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance.
</I>
</B>
</FONT>
</P>
<P ID=PARA1282 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1281 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Adverse events, or AEs, caused by our product candidates could cause us, other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. In our Phase 3 active comparator clinical trial (IAP309), 7.9% of Zalviso-treated patients dropped out of the trial prematurely due to an AE, and we observed one serious adverse event, or SAE, that was assessed as possibly or probably related to Zalviso. In our Phase 3, double-blind, placebo-controlled, abdominal surgery trial (IAP310), adverse events reported in the trial were generally mild or moderate in nature and similar in both placebo and treatment groups. In addition, one patient in the trial, who was in the sufentanil sublingual tablet group, experienced an SAE, which was determined to be unrelated to the trial drug. In our Phase 3, double-blind, placebo-controlled, orthopedic surgery trial (IAP311), treatment-emergent adverse events were generally mild-to-moderate in nature and similar for the majority of adverse events between sufentanil sublingual tablet- and placebo-treated patients. Two patients (one each in the sufentanil sublingual tablet group and placebo group) experienced a serious adverse event considered possibly or probably related to the trial drug by the investigator.
</FONT>
</P>
<P ID=PARA1284 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1283 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In our Phase 2 ARX-04 trial, two serious adverse events (SAEs), both in the 20 mcg dose group, occurred one week after the study (surgical infections) and were deemed unrelated to study drug. All but two adverse events reported in the study were mild-to-moderate in nature with 58 patients (58%)&nbsp;reporting a total of 135 adverse events. The most frequently reported adverse events for all patients were nausea (30%), vomiting (17%), dizziness (14%)&nbsp;and somnolence (11%).&nbsp;Two patients discontinued treatment, one unrelated to study drug (anxiety/chest pain) and the other probably related to study drug (somnolence/respiratory depression); however, both patients recovered without medical intervention.
</FONT>
</P>
<P ID=PARA1286 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1285 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Phase 2 clinical trials we have conducted with Zalviso did generate some AEs, but no SAEs, related to the trial drug.
</FONT>
</P>
<P ID=PARA1288 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1287 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Further, if any of our future products, including Zalviso or ARX-04 cause serious or unexpected side effects after receiving marketing approval, a number of potentially significant negative consequences could result, including:
</FONT>
</P>
<P ID=PARA1290 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1291 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1292 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1293 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a modified Risk Evaluation and Mitigation Strategy, or REMS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1295 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1296 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1297 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1298 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1300 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1301 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1302 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1303 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we may be required to change the way the product is administered or conduct additional clinical trials;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1305 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1306 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1307 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1308 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we could be sued and held liable for harm caused to patients; or
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1310 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1311 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1312 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1313 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our reputation may suffer.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1315 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1314 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing our product candidates.
</FONT>
</P>
<P ID=PARA1317 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1316 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Additional time may be required to obtain U.S. regulatory approval for ARX-04 and Zalviso because they are drug/device combination.
</I>
</B>
</FONT>
</P>
<P ID=PARA1319 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1318 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04 and Zalviso are combination product candidates with both drug and device components. The FDA requires both the drug and device components of combination product candidates to be reviewed as part of an NDA submission. There are very few examples of the FDA approval process for drug/device combination products such as ARX-04 and Zalviso. As a result, we have in the past, and may in the future, experience delays in the development and commercialization of Zalviso due to regulatory uncertainties in the product development and approval process, in particular as it relates to a drug/device combination product approval under an NDA, and we may experience similar delays and regulatory uncertainties when, and if, we submit the NDA for ARX-04. For example, the Zalviso CRL received from the FDA in July 2014 contains requests for additional information on the Zalviso System to ensure proper use of the device. The requests include submission of data demonstrating a reduction in the incidence of optical system errors, changes to address inadvertent dosing, among other items, and submission of additional data to support the shelf life of the product. Furthermore, in March 2015, we received correspondence from the FDA stating that in addition to the bench testing and two Human Factors studies we had performed in response to the issues identified in the CRL, a clinical trial is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. Based on the results of the Type C meeting with FDA, which took place in September 2015, we submitted a protocol to the FDA for a clinical study in post-operative patients designed to evaluate the effectiveness of changes made to enhance Zalviso device performance. We have completed the protocol review with the FDA and plan to initiate the study, IAP312, in the first quarter of 2016. Even if we are able to successfully complete IAP312, the FDA may deem the results of IAP312, as well as bench testing and/or the Human Factors studies inadequate, which could delay or preclude any approval of Zalviso.
</FONT>
</P>
<P ID=PARA1321 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK28 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR28 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM28 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	32
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage33"></A>
<DIV ID=PGHDR28 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA28.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1320 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We cannot predict when we will obtain regulatory approval to commercialize any of our product candidates, if at all, and we cannot, therefore, predict the timing of any future revenue.
</I>
</B>
</FONT>
</P>
<P ID=PARA1323 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1322 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We cannot commercialize any of our product candidates, including ARX-04 or Zalviso, until the appropriate regulatory authorities, such as the FDA or the European Medicines Agency, or EMA, have reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may be unable to obtain regulatory approval for our product candidates. In September 2015, the European Commission approved Gr&#252;nenthal GmbH, or Gr&#252;nenthal&#8217;s, Marketing Authorization Application, or MAA, for Zalviso for post-operative pain; however, we cannot predict the commercial success of Zalviso and thus its impact on us because commercial sales in Europe have not yet begun. We received a CRL for Zalviso on July 25, 2014, which contains requests for additional information on the Zalviso System. In addition, in March 2015, we received correspondence from the FDA stating that in addition to the bench testing and two Human Factors studies we had performed in response to the issues identified in the CRL, a clinical trial is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Based on our Type C meeting with the FDA in early September 2015 to discuss the FDA&#8217;s request for an additional clinical trial and our planned response to the CRL, we submitted a protocol to the FDA for a clinical study in post-operative patients designed to evaluate the effectiveness of changes made to enhance the Zalviso device. We have completed the protocol review and plan to initiate IAP312 in the first quarter of 2016. There is no guarantee that the IAP312 trial results will address the issues raised by the FDA. Additional delays may result if any of our product candidates is taken before an FDA Advisory Committee which may recommend restrictions on approval or recommend non-approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process.
</FONT>
</P>
<P ID=PARA1325 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1324 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The FDA and other foreign regulatory agencies, such as EMA, can delay, limit or deny marketing approval for many reasons, including:
</FONT>
</P>
<P ID=PARA1327 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1328 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1329 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1330 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a product candidate may not be considered safe or effective;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1332 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1333 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1334 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1335 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the manufacturing processes or facilities we have selected may not meet the applicable requirements; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1337 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1338 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1339 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1340 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes in their approval policies or adoption of new regulations may require additional work on our part.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1342 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1341 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Part of the regulatory approval process includes compliance inspections of manufacturing facilities to ensure adherence to applicable regulations and guidelines. The regulatory agency may delay, limit or deny marketing approval of our product candidates as a result of such inspections. In June 2014, the FDA completed an inspection at our corporate offices. We received a single observation on a Form 483 as a result of the inspection. In addition, in January 2015, EMA conducted a pre-approval inspection of our Zalviso contract manufacturer&#8217;s manufacturing and packaging site, and provided its observations. Although we believe we have adequately addressed these observations in revised standard operating procedures, we, our contract manufacturers, and their vendors, are all subject to preapproval and post-approval inspections at any time. The results of these inspections could impact our ability to obtain FDA approval for Zalviso and, if approved, our ability to launch and successfully commercialize Zalviso in the United States. In addition, results of EMA inspections could impact our ability to maintain EC approval of Zalviso, and Gr&#252;nenthal&#8217;s ability to commercially launch and sustain sales of Zalviso in the EU.
</FONT>
</P>
<P ID=PARA1344 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1343 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any delay in, or failure to receive or maintain, approval for any of our product candidates could prevent us from generating meaningful revenues or achieving profitability. Our product candidates may not be approved even if they achieve their endpoints in clinical trials. Regulatory agencies, including the FDA or EMA, or their advisors, may disagree with our trial design and our interpretations of data from preclinical studies and clinical trials. Regulatory agencies may change requirements for approval even after a clinical trial design has been approved. The FDA exercises significant discretion over the regulation of combination products, including the discretion to require separate marketing applications for the drug and device components in a combination product. To date, our product candidates are being regulated as drug products under the NDA process administered by the FDA. The FDA could in the future require additional regulation of our product candidates under the medical device provisions of the FDCA. We must comply with the Quality Systems Regulation, or QSR, which sets forth the FDA&#8217;s current good manufacturing practice, or cGMP, requirements for medical devices, and other applicable government regulations and corresponding foreign standards for drug cGMPs. If we fail to comply with these regulations, it could have a material adverse effect on our business and financial condition.
</FONT>
</P>
<P ID=PARA1346 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK29 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR29 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM29 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	33
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage34"></A>
<DIV ID=PGHDR29 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA29.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1345 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Regulatory agencies also may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing trials. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. For example, we intend to resubmit our NDA seeking approval of Zalviso for the management of moderate-to-severe acute pain in adult patients in the hospital setting; however, our clinical trial data was generated exclusively from the post-operative segment of this population, and the FDA may restrict any approval to post-operative patients only, which would reduce our commercial opportunity.
</FONT>
</P>
<P ID=PARA1348 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1347 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	The process for obtaining approval of an NDA is time consuming, subject to unanticipated delays and costs, and requires the commitment of substantial resources.
</I>
</B>
</FONT>
</P>
<P ID=PARA1350 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1349 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If the FDA determines that any of the clinical work submitted, including the clinical trials, Human Factors studies and bench testing submitted for a product candidate in support of an NDA were not conducted in full compliance with the applicable protocols for these trials, studies and testing as well as with applicable regulations and standards, or if the FDA does not agree with our interpretation of the results of such trials, studies and testing, the FDA may reject the data and results. The FDA may audit some or all of our clinical trial sites to determine the integrity of our clinical data. The FDA may audit some or all of our Human Factors study sites to determine the integrity of our data and may audit the data and results of bench testing. Any rejection of any of our data would negatively impact our ability to obtain marketing authorization for a product candidate and would have a material adverse effect on our business and financial condition. In addition, an NDA may not be approved, or approval may be delayed, as a result of changes in FDA policies for drug approval during the review period. For example, although many products have been approved by the FDA in recent years under Section&nbsp;505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA, objections have been raised to the FDA&#8217;s interpretation of Section&nbsp;505(b)(2). If challenges to the FDA&#8217;s interpretation of Section&nbsp;505(b)(2) are successful, the FDA may be required to change its interpretation, which could delay or prevent the approval of such an NDA. Any significant delay in the acceptance, review or approval of an NDA that we have submitted would have a material adverse effect on our business and financial condition and would require us to obtain significant additional funding.
</FONT>
</P>
<P ID=PARA1352 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1351 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Even if we obtain regulatory approval for ARX-04, Zalviso and our other product candidates in the United States, we and our collaborators face extensive regulatory requirements and our products may face future development and regulatory difficulties.
</I>
</B>
</FONT>
</P>
<P ID=PARA1354 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1353 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Even if we obtain regulatory approval in the United States, the FDA may impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval trials or post-market surveillance. Additionally, the labeling ultimately approved for ARX-04, Zalviso and our other product candidates, if approved, will likely include restrictions on use due to the opioid nature of sufentanil.
</FONT>
</P>
<P ID=PARA1356 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1355 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04, Zalviso and our other product candidates, if approved in the future, will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.
</FONT>
</P>
<P ID=PARA1358 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1357 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We must also register and obtain various state prescription drug distribution licenses and controlled substance permits, and any delay or failure to obtain or maintain these licenses or permits may limit our market and materially impact our business. In addition, manufacturers of drug products and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMPs and adherence to commitments made in the NDA. If we, or a regulatory agency, discover previously unknown problems with a product, such as AEs of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facilities, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.
</FONT>
</P>
<P ID=PARA1360 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA1361 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If we fail to comply with applicable regulatory requirements following approval of our product candidates, a regulatory agency may:
</FONT>
</P>
<P ID=PARA1364 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1365 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1366 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1367 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	issue a warning letter asserting that we are in violation of the law;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1369 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1370 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1371 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1372 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	seek an injunction or impose civil or criminal penalties or monetary fines;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1374 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1375 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1376 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1377 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	suspend or withdraw regulatory approval;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1379 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1380 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1381 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1382 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	suspend any ongoing clinical trials;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1384 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK30 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR30 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM30 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	34
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage35"></A>
<DIV ID=PGHDR30 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA30.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1385 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1386 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1387 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	refuse to approve a pending NDA or supplements to an NDA submitted by us;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1389 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1390 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1391 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1392 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	seize product; or
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1394 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1395 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1396 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1397 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	refuse to allow us to enter into supply contracts, including government contracts.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1399 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1398 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any future approved products and generate revenues.
</FONT>
</P>
<P ID=PARA1401 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1400 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Even if we obtain FDA approval for ARX-04, Zalviso or any of our product candidates in the United States, we may never obtain approval for or commercialize our products outside of the United States, which would limit our ability to realize their full market potential.
</I>
</B>
</FONT>
</P>
<P ID=PARA1403 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1402 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In order to market any products outside of the United States, we or our commercial partners, including Gr&#252;nenthal in Europe, must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. On September 22, 2015, we announced that the European Commission had approved Gr&#252;nenthal&#8217;s MAA for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients.
</FONT>
</P>
<P ID=PARA1405 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1404 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Outside of Europe, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional non-clinical trials or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country-to-country and could delay or prevent the introduction of our products in those countries. Our current clinical trial data may not be sufficient to support marketing approval in all territories. In addition, we lack the personnel, expertise and capabilities to gain regulatory approval of our product candidates on a global basis without a commercial partner. With Zalviso&#8217;s approval for sale in Europe, we will rely on Gr&#252;nenthal to commercialize it. While Gr&#252;nenthal does have products approved in international markets, we do not have any product candidates approved for sales in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. Gr&#252;nenthal&#8217;s experience in international markets does not guarantee regulatory approval or compliance with regulatory requirements in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.
</FONT>
</P>
<P ID=PARA1407 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1406 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	ARX-04, Zalviso and our other product candidates will require Risk Evaluation and Mitigation Strategies.
</I>
</B>
</FONT>
</P>
<P ID=PARA1409 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1408 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our product candidates, if approved in the United States, will require REMS. The REMS may include requirements for special labeling or medication guides for patients, special communication plans to health care professionals and restrictions on distribution and use. While we have received pre-clearance from the FDA regarding certain aspects of the proposed required REMS for Zalviso, we cannot predict the final REMS to be required as part of any FDA approval of Zalviso. Depending on the extent of the REMS requirements, any United States launch may be delayed, the costs to commercialize Zalviso may increase substantially and the potential commercial market could be restricted. ARX-04, if approved, will also require REMS programs that may significantly increase our costs to commercialize these product candidates. Furthermore, risks of sufentanil that are not adequately addressed through proposed REMS for our future product candidates, if approved, may also prevent or delay their approval for commercialization.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1411 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1410 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Existing and future legislation may increase the difficulty and cost for us to commercialize ARX-04, Zalviso and any of our product candidates that may obtain commercial approval in the future, and affect the prices we may obtain.
</I>
</B>
</FONT>
</P>
<P ID=PARA1413 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1412 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the United States and some foreign jurisdictions, the legislative landscape continues to evolve. There have been a number of legislative and regulatory changes and proposed changes regarding healthcare systems that could prevent or delay marketing approval of Zalviso outside the EU, or our other product candidates, including ARX-04, restrict or regulate post-approval activities for ARX-04 and Zalviso, and affect our ability to profitably sell any products for which we obtain marketing approval.
</FONT>
</P>
<P ID=PARA52 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA51 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the EU, the pricing of prescription drugs is subject to government control. In addition, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use.
</FONT>
</P>
<P ID=PARA1415 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1414 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the United States, the Health Care Reform Law (as defined below) was enacted in an effort to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, impose new taxes and fees on the health industry and impose additional health policy reforms. Aspects of the Health Care Reform Law that may impact our business include:
</FONT>
</P>
<P ID=PARA1417 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1418 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1419 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1420 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1422 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1423 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1424 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1425 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1427 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK31 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR31 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM31 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	35
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage36"></A>
<DIV ID=PGHDR31 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA31.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1428 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1429 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1430 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expansion of eligibility criteria for Medicaid programs, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1432 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1433 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1434 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1435 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1437 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1438 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1439 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1440 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a requirement to annually report drug samples that manufacturers and distributors provide to physicians;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1442 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1443 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1444 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1445 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1447 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1448 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1449 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1450 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	creation of the Independent Payment Advisory Board which has authority to recommend certain changes to the Medicare program that could result in reduced payments for prescription drugs.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1452 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1451 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Health Care Reform Law has the potential to substantially change health care financing and delivery by both governmental and private insurers, and may also increase our regulatory burdens and operating costs.
</FONT>
</P>
<P ID=PARA1454 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1453 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, other legislative changes have been proposed and adopted in the United States since the Health Care Reform Law was enacted. Aggregate reductions of Medicare payments to providers of 2% per fiscal year went into effect on April 1, 2013 and will stay in effect through 2024 unless Congressional action is taken. The American Tax Payer Relief Act further reduced Medicare payments to several providers, including hospitals.
</FONT>
</P>
<P ID=PARA1456 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1455 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Moreover, the Drug Supply Chain Security Act of 2013 imposes new obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this new legislation, manufacturers will be required to provide certain information regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product.
</FONT>
</P>
<P ID=PARA1458 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1457 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Legislative and regulatory proposals have been made to expand post-approval requirements and further restrict sales and promotional activities for pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be.
</FONT>
</P>
<P ID=PARA1460 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1459 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We expect that additional healthcare reform measures will be adopted within and outside the United States in the future, any of which could negatively impact our business. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.
</FONT>
</P>
<P ID=PARA1462 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1461 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Risks Related to Our Financial Condition and Need for Additional Capital
</B>
</FONT>
</P>
<P ID=PARA1464 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1463 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We have incurred significant losses since our inception, anticipate that we will continue to incur significant losses in 2016 and may continue to incur losses for the foreseeable future.
</I>
</B>
</FONT>
</P>
<P ID=PARA1466 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1465 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Since our inception in 2005, we have focused primarily on development of our product candidate, Zalviso. In September 2015, we announced that a pivotal Phase 3 study of ARX-04, SAP301, met all primary and secondary endpoints and in October 2015, we announced the initiation of SAP302, a Phase 3 study of ARX-04 in the emergency room, intended to complete the safety database requirements previously agreed to with the FDA. We have incurred significant net losses in each year since our inception in July 2005, and as of December 31, 2015, we had an accumulated deficit of $203.2 million.
</FONT>
</P>
<P ID=PARA1468 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1467 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have devoted most of our financial resources to research and development, including our non-clinical development activities and clinical trials. To date, we have financed our operations primarily through the sale of equity securities, debt, government contract funding, sale of royalty and milestones, and proceeds from our commercial partner, Gr&#252;nenthal. The size of our future net losses will depend, in part, on the rate of future expenditures and our ability to generate revenues. We expect to continue to incur substantial expenses as we continue our research and development activities for our product candidates, including addressing issues raised by the FDA related to regulatory review of Zalviso, as well as to support manufacturing and supply of Zalviso in Europe for Gr&#252;nenthal. To date, none of our product candidates have been commercialized, and if ARX-04, Zalviso, or our other product candidates are not successfully developed or commercialized, or if revenues are insufficient following marketing approval, we will not achieve profitability and our business may fail. Our success is also dependent on obtaining regulatory approval to market our product candidates outside of the United States through current and future collaborations which may not materialize or prove to be successful.
</FONT>
</P>
<P ID=PARA1470 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK32 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR32 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM32 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	36
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage37"></A>
<DIV ID=PGHDR32 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA32.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1469 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We are substantially dependent on our commercial partner, Gr&#252;nenthal, to successfully commercialize Zalviso in Europe.
</I>
</B>
</FONT>
</P>
<P ID=PARA1472 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1471 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December 16, 2013, we entered into a Collaboration and License Agreement, or the License Agreement, and related Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements, with Gr&#252;nenthal. On July 22, 2015, we entered into amendments to the License Agreement, or the License Amendment, and the MSA, or the MSA Amendment, with Gr&#252;nenthal, each effective as of July 17, 2015, and together with the License Agreement, and the MSA, the Amended Agreements. The Amended Agreements grant rights to commercialize Zalviso in the European Union, or EU, Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory, for human use in pain treatment within or dispensed by hospitals, hospices, nursing homes and other medically-supervised settings. In September 2015, the European Commission approved Gr&#252;nenthal&#8217;s MAA for Zalviso for post-operative pain. Gr&#252;nenthal has stated that it expects to initiate commercialization of Zalviso in Western Europe in the first half of 2016. In September 2015, we consummated a monetization transaction with PDL BioPharma, Inc., or PDL, pursuant to which we sold to PDL for $65.0 million 75% of the European royalties from sales of Zalviso and 80% of the first four commercial milestones under the License Agreement, subject to a capped amount, referred to as the Royalty Monetization. E
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ven if Gr&#252;nenthal is successful in the commercialization of Zalviso in the EU, we will receive only 25% of the royalties and 20% of the first four commercial milestones under the License Agreement, and 100% of the royalties after the capped amount is reached.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any failures in commercialization of Zalviso outside the United States could have a material adverse impact on our business, including an adverse impact on the development of ARX-04 or Zalviso in the United States, if related to issues underlying the sufentanil sublingual tablet technology, safety or efficacy. Additionally, we agreed to certain representations and covenants relating to the Amended Agreements under our agreements with PDL, and, if we breach those representations or covenants, we may become subject to indemnification claims by PDL and liable to PDL for its indemnifiable losses relating to such breaches. The amount of such losses could be material and could have a material adverse impact on our business.
</FONT>
</P>
<P ID=PARA1474 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1473 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We have never generated product revenue and may never be profitable.
</I>
</B>
</FONT>
</P>
<P ID=PARA1476 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1475 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our ability to generate revenue from commercial sales and achieve profitability depends on our ability, alone or with collaborators, to successfully complete the development of, obtain the necessary regulatory approvals for, and commercialize our product candidates. We may never generate revenues from sales of ARX-04, Zalviso or our other product candidates in the United States. While we have a collaboration with Gr&#252;nenthal for commercialization of Zalviso in Europe and Australia, we may not achieve all of the development milestones associated with the collaboration, and Gr&#252;nenthal may not recognize commercial sales of Zalviso, for which we would receive sales milestone payments and product royalties. Even if Gr&#252;nenthal is successful in commercialization of Zalviso, as a result of our sale to PDL of certain expected royalties from the sales of Zalviso by Gr&#252;nenthal and a portion of our first four commercial sales milestones, we will receive only 25% of the sales royalties and 20% of the first four commercial milestones under the Amended License Agreement.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, we do not anticipate generating revenues from our other product candidates for the foreseeable future, if ever. Our ability to generate future revenues from product sales depends heavily on our success in:
</FONT>
</P>
<P ID=PARA1478 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1479 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1480 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1481 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtaining and maintaining regulatory approval for ARX-04 and/or Zalviso in the United States and/or in Europe;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1483 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1484 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1485 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1486 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	launching and commercializing ARX-04 and/or Zalviso, including building internally or through entering a collaboration, a hospital-directed sales force in the United States and with third parties internationally, including Gr&#252;nenthal, which may require additional funding; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1488 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1489 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1490 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1491 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	completing the clinical development of, obtaining regulatory approval for, and launching and commercializing ARX-04 and Zalviso, which may require additional funding or corporate partnership resources.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1492 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA1493 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Because of the numerous risks and uncertainties associated with pharmaceutical product development and the regulatory environment, we are unable to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability. Our expenses could increase beyond expectations if we are delayed in receiving regulatory approval, or in launching ARX-04 and/or Zalviso in the United States, or if we are required by the FDA to complete activities in addition to those we currently anticipate or have already completed.
</FONT>
</P>
<P ID=PARA1496 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1495 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Even if we are able to generate revenues from the sale of any future approved products, we may not become profitable and may need to obtain additional funding to continue operations.
</FONT>
</P>
<P ID=PARA1498 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1497 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We have a limited operating history that may make it difficult to predict our future performance or evaluate our business and prospects.
</I>
</B>
</FONT>
</P>
<P ID=PARA1500 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1499 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We were incorporated in 2005. Since inception, our operations have been primarily limited to organizing and staffing our company, developing our technology and undertaking pharmaceutical development and clinical trials for our product candidates, understanding the market potential for our product candidates and preparing for the potential commercialization of ARX-04 and Zalviso in the United States. We have not yet obtained regulatory approval of any of our product candidates in the United States. Consequently, any predictions that are made about our future success, or viability, or evaluation of our business and prospects, may not be accurate.
</FONT>
</P>
<P ID=PARA1502 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK33 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR33 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM33 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	37
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage38"></A>
<DIV ID=PGHDR33 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA33.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1501 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We will require additional capital and may be unable to raise capital, which would force us to delay, reduce or eliminate our product development programs and could cause us to cease operations.
</I>
</B>
</FONT>
</P>
<P ID=PARA1504 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1503 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We expect to incur significant expenditures in connection with our ongoing activities, including conducting ARX-04 Phase 3 clinical trials, development activities associated with ARX-04, including regulatory costs in support of the potential NDA submission, and the remaining development activities associated with Zalviso, to respond to issues raised by the FDA. While we believe we have sufficient capital resources to continue planned operations through at least the first half of 2017, we may need additional capital to continue development and commercialization of ARX-04, and Zalviso will need additional capital to potentially pursue commercialization of any of our product candidates.
</FONT>
</P>
<P ID=PARA1506 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1505 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Future events and circumstances, including those beyond our control, may cause us to consume capital more rapidly than we currently anticipate. For example, in March 2015, we received correspondence from the FDA stating that we needed to complete an additional clinical trial of Zalviso. Any further development activities can be time consuming and costly. We submitted a protocol to the FDA for a clinical study in post-operative patients designed to evaluate the effectiveness of changes made to enhance Zalviso device performance. We received comments from the FDA on the protocol for the study, known as IAP312, and we plan to initiate IAP312 in the first quarter of 2016. Clinical trials, regulatory reviews, and a potential launch of a commercial product are expensive activities. In addition, commercialization costs for ARX-04 and Zalviso in the United States may be significantly higher than estimated. We may experience technical difficulties in our commercialization efforts or otherwise, which could substantially increase the costs of commercialization. Revenues may be lower than expected and accordingly costs to produce such revenues may exceed those revenues. We will need to seek additional capital to continue operations. Such capital demands could be substantial. To raise capital, we may seek to sell additional equity or debt securities, monetize or securitize certain assets including future royalty streams and milestones, obtain a credit facility, or enter into product development, license or distribution agreements with third parties, or divest one or more of our product candidates. Such arrangements may not be available on favorable terms, if at all. Furthermore, any product development, licensing, distribution or sale agreements that we enter into may require us to relinquish valuable rights. We may not be able to obtain sufficient additional funding or enter into a strategic transaction in a timely manner. If adequate funds are not available, we would be required to reduce our workforce, delay, reduce the scope of, or eliminate, one or more of our research and development programs in advance of the date on which we exhaust our cash resources to ensure that we have sufficient capital to meet our obligations and continue on a path designed to preserve stockholder value.
</FONT>
</P>
<P ID=PARA1507 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1508 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Securing additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:
</FONT>
</P>
<P ID=PARA1510 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1511 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1512 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1513 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	significantly delay, scale back or discontinue the development or commercialization of our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1515 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1516 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1517 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1518 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	seek additional corporate partners for Zalviso on terms that might be less favorable than might otherwise be available; or
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1520 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1522 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1523 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1524 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	relinquish, or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA34.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1525 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We may sell additional equity or debt securities to fund our operations, which may result in dilution to our stockholders and impose restrictions on our business.
</I>
</B>
</FONT>
</P>
<P ID=PARA1528 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1527 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In order to raise additional funds to support our operations, we may sell additional equity or debt securities which would result in dilution to our stockholders or impose restrictive covenants that may adversely impact our business. The sale of additional equity or convertible debt securities would result in the issuance of additional shares of our capital stock and dilution to all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions, such as minimum cash balances, that could adversely impact our ability to conduct our business. If we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of operations could be materially adversely affected and we may not be able to meet our debt service obligations.
</FONT>
</P>
<P ID=PARA6.1 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK6 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR6 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM6 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	38
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage39"></A>
<DIV ID=PGHDR6 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA6.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1529 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We might be unable to service our existing debt due to a lack of cash flow and might be subject to default.
</I>
</B>
</FONT>
</P>
<P ID=PARA1532 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1531 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In December 2013, we entered into an amended loan and security agreement, or the Amended Loan Agreement, with Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc., collectively referred to as Hercules, under which we could have borrowed up to $40.0 million in three tranches, represented by secured convertible promissory notes. We drew the first tranche of $15.0 million at the closing of the new credit facility and the second tranche of $10.0 million on June 16, 2014. We did not have access to the third tranche of up to $15.0 million, as it was conditioned upon FDA approval to market Zalviso in the United States by August 1, 2015, which we did not obtain. We began making principal payments in April 2015. On September 18, 2015, we amended the Amended Loan Agreement with Hercules to extend an interest only period from October 1, 2015 through March 31, 2016, with the potential for further extension to September 30, 2016 upon satisfaction of certain conditions, which have since been satisfied.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The scheduled maturity date is October&nbsp;31, 2017.
</FONT>
</P>
<P ID=PARA1534 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1533 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We granted Hercules a first priority security interest in substantially all of our assets, with the exception of our intellectual property and those assets sold under the Royalty Monetization
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	, where the security interest is limited to proceeds of intellectual property if it is licensed or sold.
</FONT>
</P>
<P ID=PARA1536 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1535 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If we do not make the required payments when due, either at maturity, or at applicable installment payment dates, or if we breach the agreement or become insolvent, Hercules could elect to declare all amounts outstanding, together with accrued and unpaid interest and penalty, to be immediately due and payable. Additional capital may not be available on terms acceptable to us, or at all. In addition, we recently sold a portion of the royalties and first four commercial sales milestone payments we are entitled to receive under the Amended Agreements with Gr&#252;nenthal to PDL, which will decrease future cash flows available to us to repay the Hercules debt
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	. Even if we were able to repay the full amount in cash, any such repayment could leave us with little or no working capital for our business. If we are unable to repay those amounts, Hercules will have a first claim on our assets pledged under the Amended Loan Agreement. If Hercules should attempt to foreclose on the collateral, it is unlikely that there would be any assets remaining after repayment in full of such secured indebtedness. Any default under the Amended Loan Agreement and resulting foreclosure would have a material adverse effect on our financial condition and our ability to continue our operations.
</FONT>
</P>
<P ID=PARA1538 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1537 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We may not receive all of the funding from the Department of Defense for the advancement of ARX-04.
</I>
</B>
</FONT>
</P>
<P ID=PARA1540 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA185 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On May 11, 2015, we entered into an award contract supported by the United States Army Medical Research and Materiel Command, or USAMRMC, within the U.S. Department of Defense, or the DoD, in which the DoD agreed to provide up to $17.0 million to support the development of ARX-04, referred to as the DoD Contract. Under the terms of the contract, the DoD will reimburse us for costs incurred for development, manufacturing, regulatory and clinical costs outlined in the contract in order to submit an NDA to the FDA, including reimbursement for certain personnel and overhead expenses. The period of performance under the contract began on May 11, 2015. The contract gives the DoD the option to extend the term of the contract and provide additional funding for the research. On March 2, 2016, the DoD Contract was amended
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	to approve enrollment of additional patients in the SAP302 study, approve the addition of the SAP303 study, and extend the contract period of performance by four months from November 10, 2016 to March 9, 2017, to accommodate the increased SAP302 patient enrollment and the SAP303 study. The costs for these changes will be absorbed within the current contract value. Funding under this contract will be subject to audit by the DoD to ensure adherence to specific guidance, policies and procedures. The DoD may find deficiencies during the course of an audit which could jeopardize, or even eliminate, continued funding from the DoD, as well as require repayment of any funds they had provided us since inception of the contract. The lack of ARX-04 supportive funding, may adversely affect our ability to continue to advance the development of ARX-04.
</FONT>
</P>
<P ID=PARA55 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<P ID=PARA1543 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Risks Related to Our Reliance on Third Parties
</B>
</FONT>
</P>
<P ID=PARA1545 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1544 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We rely on third party manufacturers to produce our preclinical and clinical drug supplies and intend to rely on third parties to produce commercial supplies of any approved product candidates.
</I>
</B>
</FONT>
</P>
<P ID=PARA1547 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1546 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Reliance on third party manufacturers entails many risks including:
</FONT>
</P>
<P ID=PARA1549 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1550 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1551 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1552 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the inability to meet our product specifications and quality requirements consistently;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1554 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1555 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1556 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1557 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a delay or inability to procure or expand sufficient manufacturing capacity;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1559 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1560 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1561 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1562 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	manufacturing and product quality issues related to scale-up of manufacturing;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1564 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1565 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1566 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1567 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	costs and validation of new equipment and facilities required for scale-up;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1569 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1570 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1571 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1572 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a failure to maintain in good order our production and manufacturing equipment for our products;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1574 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1575 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1576 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1577 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a failure to comply with cGMP and similar foreign standards;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1579 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1580 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1581 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1582 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1584 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1585 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1586 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1587 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1589 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1590 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1591 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1592 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell our product candidates in a timely fashion, in sufficient quantities or under acceptable terms;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1594 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1595 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1596 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1597 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1599 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK35 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR35 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM35 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	39
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage40"></A>
<DIV ID=PGHDR35 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA35.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1600 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1601 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1602 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	operations of our third party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1604 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1605 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1606 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1607 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	carrier disruptions or increased costs that are beyond our control; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1609 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1610 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1611 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1612 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the failure to deliver our products under specified storage conditions and in a timely manner.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1614 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1613 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Any of these events could lead to stock outs, inability to successfully commercialize our products, clinical trial delays, or failure to obtain regulatory approval. Some of these events could be the basis for FDA action, including injunction, recall, seizure, or total or partial suspension of production.
</FONT>
</P>
<P ID=PARA1616 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1615 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As mentioned above, we have entered into the Amended Agreements with Gr&#252;nenthal under which we are obligated to manufacture and supply Zalviso for use in the EU and their other licensed territories. If we are unable to establish a reliable commercial supply of Zalviso for Gr&#252;nenthal&#8217;s Territory, we may be unable to satisfy our obligations under the Amended Agreements in a timely manner or at all, and we may, as a result, be in breach of the Amended Agreements.
</FONT>
</P>
<P ID=PARA1618 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1617 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We rely on limited sources of supply for the drug component of our product candidates and any disruption in the chain of supply may cause delay in developing and commercializing our product candidates.
</I>
</B>
</FONT>
</P>
<P ID=PARA1620 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1619 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Currently, we use two established suppliers of sufentanil citrate for our tablets. We only have one supplier qualified for our manufacture of Zalviso. For each product candidate, only one of the two suppliers will be qualified as a vendor with the FDA. If supply from the approved vendor is interrupted, there could be a significant disruption in commercial supply. The alternative vendor would need to be qualified through an NDA supplement which could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional trials if a new sufentanil supplier is relied upon for commercial production.
</FONT>
</P>
<P ID=PARA1622 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1621 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Manufacture of sufentanil sublingual tablets requires specialized equipment and expertise.
</I>
</B>
</FONT>
</P>
<P ID=PARA1624 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1623 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Ethanol, which is used in the manufacturing process for our sufentanil sublingual tablets, is flammable, and sufentanil is a highly potent, Schedule II compound. These factors necessitate the use of specialized equipment and facilities for manufacture of sufentanil sublingual tablets. There are a limited number of facilities that can accommodate our manufacturing process and we need to use dedicated equipment throughout development and commercial manufacturing to avoid the possibility of cross-contamination. If our equipment breaks down or needs to be repaired or replaced, it may cause significant disruption in clinical or commercial supply, which could result in delay in the process of obtaining approval for or sale of our products. Furthermore, we are using one manufacturer to produce our sufentanil sublingual tablets and have not identified a back-up commercial facility to date. Any problems with our existing facility or equipment, including ongoing expansion, may delay or impair our ability to complete our clinical trials or commercialize our product candidates and increase our cost.
</FONT>
</P>
<P ID=PARA1626 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1625 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Manufacturing issues may arise that could delay or increase costs related to product and regulatory approval, and commercialization.
</I>
</B>
</FONT>
</P>
<P ID=PARA1628 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1627 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As we scale up manufacturing of our product candidates and conduct required stability testing, product, packaging, equipment and process-related issues may require refinement or resolution in order to obtain regulatory approval for commercial marketing. In the past we have identified impurities in our product candidates. In the future we may identify significant impurities, which could result in increased scrutiny by the regulatory agencies, delays in clinical program and regulatory approval, increases in our operating expenses, or failure to obtain or maintain approval for our products.
</FONT>
</P>
<P ID=PARA1630 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1629 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Early development and clinical trial manufacturing of Zalviso was conducted at Patheon in Toronto, Canada. Because the DEA requires that sufentanil be manufactured in the United States if our product candidates are marketed in the United States, we transferred our manufacturing capability in the third quarter of 2011 from Patheon in Toronto, Canada to Patheon&#8217;s production facility in Cincinnati, Ohio, where we have built out a suite within their existing buildings that will serve as a manufacturing facility for clinical and commercial supplies of sufentanil sublingual tablets. Late stage development and manufacture of registration stability lots, which were utilized in clinical trials, were manufactured at Patheon, Cincinnati. While we have successfully manufactured validation lots, we have not yet produced commercial supplies at this facility and we may encounter difficulties in production at the new facility, which may adversely affect our clinical and commercial plans and our ability to deliver product to Gr&#252;nenthal.
</FONT>
</P>
<P ID=PARA1632 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1631 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In January 2013, we entered into a Manufacturing Services Agreement, or the Services Agreement, with Patheon under which Patheon has agreed to manufacture, supply, and provide certain validation and stability services with respect to Zalviso for potential sales in the United States, Canada, Mexico and other countries, subject to agreement by the parties to any additional fees for such other countries. There is no guarantee that Patheon&#8217;s services will be satisfactory or that they will continue to meet the strict regulatory guidelines of the FDA or other foreign regulatory agencies. In addition, in January 2013, we entered into an Amended and Restated Capital Expenditure and Equipment Agreement, or the Amended Capital Agreement, with Patheon, relating to the manufacture of sufentanil sublingual tablets. Under the terms of the Amended Capital Agreement, we have made and may make certain future modifications to Patheon&#8217;s Cincinnati facility.
</FONT>
</P>
<P ID=PARA1634 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK36 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR36 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM36 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	40
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage41"></A>
<DIV ID=PGHDR36 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA36.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1633 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If Patheon cannot provide us with an adequate supply of sufentanil sublingual tablets, we may be required to pursue alternative sources of manufacturing capacity. Switching or adding commercial manufacturing capability can involve substantial cost and require extensive management time and focus, as well as additional regulatory filings which may result in significant delays. In addition, there is a natural transition period when a new manufacturing facility commences work. As a result, delays may occur, which can materially impact our ability to meet our desired commercial timelines, thereby increasing our costs and reducing our ability to generate revenue.
</FONT>
</P>
<P ID=PARA1636 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA187 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The facilities of any of our future manufacturers of sufentanil-containing sublingual tablets must be approved by the FDA or the relevant foreign regulatory agency, such as EMA, before commercial distribution from such manufacturers occurs. We do not fully control the manufacturing process of sufentanil sublingual tablets and are completely dependent on these third party manufacturing partners for compliance with the FDA or other foreign regulatory agency&#8217;s requirements for manufacture. In addition, although our third party manufacturers are well-established commercial manufacturers, we are dependent on their continued adherence to cGMP manufacturing and acceptable changes to their process. If our manufacturers do not meet the FDA or other foreign regulatory agency&#8217;s strict regulatory requirements, they will not be able to secure FDA or other foreign regulatory agency approval for their manufacturing facilities. Although European inspectors have approved our tablet manufacturing site, our third party manufacturing partner is responsible for maintaining compliance with the relevant foreign regulatory agency&#8217;s requirements. If the FDA or the relevant foreign regulatory agency does not approve these facilities for the commercial manufacture of sufentanil sublingual tablets, we will need to find alternative suppliers, which would result in significant delays in obtaining FDA or other foreign regulatory agency approval for ARX-04 and Zalviso outside the EU. These challenges may have a material adverse impact on our business, results of operations, financial condition and prospects.
</FONT>
</P>
<P ID=PARA1638 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
	&nbsp;
</FONT>
</P>
<P ID=PARA1637 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Related to the Zalviso device, we have conducted multiple Design Validation, Software Verification and Validation, Reprocessing and Human Factors studies, and have manufactured for and completed Phase 3 clinical trials using the intended commercial device. As mentioned above, the CRL from the FDA contains a request for additional information on the Zalviso System to ensure proper use of the device. In March 2015, we received correspondence from the FDA stating that in addition to the bench testing and two Human Factors studies we had performed in response to the issues identified in the CRL, a clinical trial is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. We have made modifications to the design of the Zalviso device subsequent to the original submission of the Zalviso NDA, which we plan to include as a part of any resubmitted NDA. In early September 2015, we met with the FDA to discuss their request for an additional clinical trial and our planned response to the CRL. In the Type C meeting minutes, the FDA provided some additional details about the type of clinical data they would like us to provide, as a complement to the other data we already have provided, to assess the overall performance of Zalviso. We submitted a protocol to the FDA for a clinical study in post-operative patients designed to evaluate the effectiveness of changes made to enhance Zalviso device performance. We received comments from the FDA on the protocol for the study, known as IAP312, and plan to initiate IAP312 in the first quarter of 2016. Furthermore, if any additional changes to the device are substantial, the FDA may require us to perform further clinical trials or studies in order to approve the device for commercial use.
</FONT>
</P>
<P ID=PARA1640 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1639 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have manufactured Zalviso devices and supplies on a small scale, including those needed for our Phase 3 clinical trials, and process validation for some of the device components has been completed. We, however, have not yet manufactured Zalviso devices and supplies on a large scale, for commercial purposes. We are completing the process validation for the device components and beginning to manufacture Zalviso devices and supplies for delivery to Gr&#252;nenthal. We will continue to rely on contract manufacturers, component fabricators and third party service providers to produce the necessary Zalviso devices for the commercial marketplace. We currently outsource manufacturing and packaging of the controller, dispenser and cartridge components of the Zalviso device to third parties and intend to continue to do so. Some of these purchases and components were made and will continue to be made utilizing short-term purchase agreements and we may not be able to enter into long-term agreements for commercial supply of ARX-04 or Zalviso devices with third-party manufacturers, or may be unable to do so on acceptable terms. In addition, we have encountered and may continue to encounter production issues with our current or future contract manufacturers and other third party service providers, including the reliability of the production equipment, quality of the components produced, their inability to meet demand or other unanticipated delays including the scale-up and automation process, which would adversely impact our ability to supply our customers with ARX-04, if approved, and Zalviso, in the EU, and if approved, in the U.S. and any other foreign territories.&nbsp;
</FONT>
</P>
<P ID=PARA1642 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1641 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We may not be able to establish additional sources of supply for sufentanil-containing sublingual tablets or device manufacture. Such suppliers are subject to FDA and other foreign regulatory agency&#8217;s regulations requiring that materials be produced under cGMPs or Quality System Regulations, or QSR, or in ISO 13485 accredited manufacturers, and subject to ongoing inspections by regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in delays and interruptions to our product candidate supply while we seek to secure another supplier that meets all regulatory requirements. In addition, if we are unable to establish a reliable commercial supply of Zalviso for Gr&#252;nenthal&#8217;s Territory, we may be unable to satisfy our obligations under the Amended Agreements in a timely manner or at all, and we may, as a result, be in breach of the Amended Agreements.
</FONT>
</P>
<P ID=PARA1644 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK37 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR37 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM37 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	41
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage42"></A>
<DIV ID=PGHDR37 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA37.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1643 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For ARX-04, we currently package the finished goods under a manual process at the Patheon facility. The capacity and cost to package the ARX-04 units under this manual process is not sufficient to support successful future sales of ARX-04. We will need to purchase, install and validate new equipment and processes to automate the ARX-04 manufacturing process. The purchase and subsequent installation of this equipment to automate the ARX-04 packaging process will require substantial resources and take several years. There is no assurance that we will be able to successfully purchase, install or validate the equipment necessary to automate the ARX-04 packaging process. If we are successful in the purchase, installation and validation of this equipment and process, there can be no assurance that we will be able to obtain the necessary regulatory approvals to manufacture product.
</FONT>
</P>
<P ID=PARA1646 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA1647 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Reliance on third party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including the possible breach of the manufacturing agreements by the third parties because of factors beyond our control; and the possibility of termination or nonrenewal of the agreements by the third parties because of our breach of the manufacturing agreement or based on their own business priorities.
</FONT>
</P>
<P ID=PARA1650 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1649 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.
</I>
</B>
</FONT>
</P>
<P ID=PARA1652 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1651 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We utilized contract research organizations, or CROs, for the conduct of our Phase 3 clinical trials of Zalviso, the Phase 2 clinical trial of ARX-04, and our ongoing Phase 3 clinical program for ARX-04. We rely on CROs, as well as clinical trial sites, to ensure the proper and timely conduct of our clinical trials and document preparation. While we have agreements governing their activities, we have limited influence over their actual performance. We have relied and plan to continue to rely upon CROs to monitor and manage data for our clinical programs for ARX-04, Zalviso, and our other product candidates, as well as the execution of nonclinical and clinical trials. We control only certain aspects of our CROs&#8217; activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.
</FONT>
</P>
<P ID=PARA1654 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1653 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We, and our CROs, are required to comply with the FDA&#8217;s current good clinical practices, or cGCPs, which are regulations and guidelines enforced by the FDA for all of our product candidates in clinical development. The FDA enforces these cGCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. Upon inspection, the FDA may determine that our clinical trials do not comply with cGCPs. Accordingly, if our CROs or clinical trial sites fail to comply with these regulations, we may be required to repeat clinical trials, which would delay the regulatory process.
</FONT>
</P>
<P ID=PARA1656 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1655 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may allow our potential competitors to access our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize ARX-04 and Zalviso, or our other product candidates. As a result, our financial results and the commercial prospects for ARX-04, Zalviso or any future product candidates for which we may obtain approval would be harmed, our costs could increase, and our ability to generate revenues could be delayed.
</FONT>
</P>
<P ID=PARA1658 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1657 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Risks Related to Commercialization of Our Product Candidates
</B>
</FONT>
</P>
<P ID=PARA1660 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1659 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	The commercial success of ARX-04, and Zalviso outside the EU, if approved, as well as Zalviso in the EU, will depend upon the acceptance of these products by the medical community, including physicians, nurses, patients, and pharmacy and therapeutics committees.
</I>
</B>
</FONT>
</P>
<P ID=PARA1662 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1661 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The degree of market acceptance of ARX-04, and Zalviso outside the EU, if approved, as well as Zalviso in the EU, will depend on a number of factors, including:
</FONT>
</P>
<P ID=PARA1664 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1665 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1666 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1667 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	demonstration of clinical safety and efficacy compared to other products;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1669 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1670 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1671 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1672 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the relative convenience, ease of administration and acceptance by physicians, patients and health care payors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1674 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK38 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR38 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM38 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	42
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage43"></A>
<DIV ID=PGHDR38 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA38.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1675 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1676 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1677 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the use of ARX-04 for the management of moderate-to-severe acute pain by a healthcare professional for patient types that were not specifically studied in our Phase 3 trials;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1679 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1680 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1681 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1682 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the use of Zalviso for the management of moderate-to-severe acute pain in the hospital setting for patient types that were not specifically studied in our Phase 3 trials;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1684 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1685 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1686 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1687 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the prevalence and severity of any AEs or SAEs;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1689 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<TABLE ID=MTAB1691 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1692 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1693 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	overcoming the perception of sufentanil as a potentially unsafe drug due to its high potency;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1695 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1696 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1697 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1698 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	limitations or warnings contained in the FDA-approved label for ARX-04 or Zalviso;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1700 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1701 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1702 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1703 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	restrictions or limitations placed on ARX-04 or Zalviso due to the REMS;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1705 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1706 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1707 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1708 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	availability of alternative treatments;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1710 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1711 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1712 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1713 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	existing capital investment by hospitals in IV PCA technology;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1715 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1716 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1717 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1718 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	pricing and cost-effectiveness;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1720 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1721 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1722 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1723 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the effectiveness of our or any future collaborators&#8217; sales and marketing strategies;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1725 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1726 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1727 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1728 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to obtain formulary approval; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1730 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1731 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 62PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1732 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1733 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to obtain and maintain sufficient third party coverage or reimbursement.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1735 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1734 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, nurses, patients and pharmacy and therapeutics committees, or P&amp;T Committees, we may not generate sufficient revenue and we may not become or remain profitable.
</FONT>
</P>
<P ID=PARA1736 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1737 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.
</I>
</B>
</FONT>
</P>
<P ID=PARA1739 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1738 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In order to commercialize any products that may be approved in the United States, including ARX-04 and Zalviso, we must build our internal sales, marketing, distribution, managerial and other capabilities or make arrangements with third parties to perform these services. In addition, we plan to enter into agreements with third parties for the distribution of approved product candidates, including ARX-04 and Zalviso; however, if there are delays in establishing such relationships or those third parties do not perform as expected, our ability to effectively distribute products would suffer.
</FONT>
</P>
<P ID=PARA1741 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1740 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As a result of delays in the resubmission of the Zalviso NDA and obtaining FDA approval, our Board of Directors implemented a cost reduction plan that reduced our workforce by 19 employees, approximately 36% of total headcount, in the first quarter of 2015. As a result, the build out of our commercial capabilities, including internal sales, marketing, supply chain and medical affairs departments is currently on hold. This delay in recruiting and hiring the appropriate individuals could adversely affect the potential success of any future approved product candidates, including ARX-04 and Zalviso in the United States.
</FONT>
</P>
<P ID=PARA1743 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1742 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have entered into a collaboration with Gr&#252;nenthal for the commercialization of Zalviso in Europe and Australia and intend to enter into additional strategic partnerships with third parties to commercialize our product candidates outside of the United States. We may also consider the option to enter into strategic partnerships for our product candidates in the United States. We face significant competition in seeking appropriate strategic partners, and these strategic partnerships can be intricate and time consuming to negotiate and document.
</FONT>
</P>
<P ID=PARA1745 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1744 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We may not be able to negotiate future strategic partnerships on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any strategic partnerships because of the numerous risks and uncertainties associated with establishing strategic partnerships. Our current or future collaboration partners, if any, may not dedicate sufficient resources to the commercialization of Zalviso or our other product candidates, if approved, or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective collaborations to enable the sale of our product candidates, if approved, to healthcare professionals and in geographical regions, including the United States, that will not be covered by our own marketing and sales force, or if our potential future collaboration partners do not successfully commercialize our product candidates, if approved, our ability to generate revenues from product sales will be adversely affected.
</FONT>
</P>
<P ID=PARA1747 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1746 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.
</FONT>
</P>
<P ID=PARA1749 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK39 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR39 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM39 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	43
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage44"></A>
<DIV ID=PGHDR39 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA39.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1750 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	A key part of our business strategy is to establish collaborative relationships to commercialize and fund development and approval of our product candidates, particularly outside of the United States. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize our products successfully, if at all.
</I>
</B>
</FONT>
</P>
<P ID=PARA1752 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1751 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We will need to establish and maintain successful collaborative relationships to obtain international sales, marketing and distribution capabilities for our product candidates. The process of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:
</FONT>
</P>
<P ID=PARA1754 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1755 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1756 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1757 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical or regulatory results, manufacturing issues, a change in business strategy, a change of control or other reasons;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1759 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1760 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1761 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1762 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our contracts for collaborative arrangements are terminable at will on written notice and may otherwise expire or terminate and we may not have alternatives available to achieve the potential for our products in those territories or markets;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1764 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1765 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1766 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1767 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our partners may choose to pursue alternative technologies, including those of our competitors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1769 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1770 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1771 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1772 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we may have disputes with a partner that could lead to litigation or arbitration;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1774 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1775 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1776 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1777 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we have limited control over the decisions of our partners and they may change the priority of our programs in a manner that would result in termination of the agreement or add significant delays to the partnered program;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1779 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1780 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1781 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1782 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our ability to generate future payments and royalties from our partners depends upon the abilities of our partners to establish the safety and efficacy of our drug candidates, obtain regulatory approvals and our ability to successfully manufacture and achieve market acceptance of products developed from our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1784 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1785 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1786 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1787 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may use our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1789 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1790 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1791 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1792 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our partners may not devote sufficient capital or resources towards our product candidates; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1794 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1795 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1796 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1797 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our partners may not comply with applicable government regulatory requirements necessary to successfully market and sell our products.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1799 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1798 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, any research, clinical development, manufacturing or commercialization efforts pursuant to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully and timely transition terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own expense or find alternative sources of capital.
</FONT>
</P>
<P ID=PARA1801 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1800 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Approval of Zalviso in the EU, and any future approvals of our product candidates outside of the United States, will result in a variety of risks associated with international operations and could materially adversely affect our business.
</I>
</B>
</FONT>
</P>
<P ID=PARA1803 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1802 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our existing collaboration with Gr&#252;nenthal for marketing Zalviso in European countries and Australia requires us to supply product to support the EU commercialization of Zalviso. In addition, if any of our currently unapproved product candidates are approved for commercialization outside the United States, we intend to enter into agreements with third parties to market our product candidates in those countries, which may also require us to supply products to the third party. We may be subject to additional risks related to entering into international business relationships, including:
</FONT>
</P>
<P ID=PARA1805 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1806 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1807 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1808 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	different regulatory requirements for drug approvals in foreign countries;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1810 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1811 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1812 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1813 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	reduced protection for intellectual property rights;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1815 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1817 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1818 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1819 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	unexpected changes in tariffs, trade barriers and regulatory requirements;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1821 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1822 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1823 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1824 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	economic weakness, including inflation, or political instability in particular foreign economies and markets;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1826 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1827 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1828 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1829 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1831 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1832 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1833 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1834 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	foreign taxes, including withholding of payroll taxes;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1836 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1837 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1838 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1839 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1841 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1842 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1843 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1844 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	workforce uncertainty in countries where labor unrest is more common than in the United States;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1846 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK40 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR40 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM40 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	44
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage45"></A>
<DIV ID=PGHDR40 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA40.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1847 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1848 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1849 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1851 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1852 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1853 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1854 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1856 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1855 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	If we, or current and potential partners, are unable to compete effectively, our product candidates may not reach their commercial potential.
</I>
</B>
</FONT>
</P>
<P ID=PARA1858 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1857 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The U.S. market for ARX-04, Zalviso, and our other product candidates is characterized by intense competition and cost pressure. If our product candidates obtain FDA approval, they will compete with a number of existing and future pharmaceuticals and drug delivery devices developed, manufactured and marketed by others. We or our current and potential partners will compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies.
</FONT>
</P>
<P ID=PARA1860 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA56 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There are a wide variety of approved injectable and oral opioid products to treat moderate-to-severe acute pain, including IV opioids such as morphine, fentanyl, hydromorphone and meperidine or oral opioids such as oxycodone and hydrocodone. More specifically, competitors for ARX-04 in the emergency department are likely to include generic injectable intravenous opioids such as morphine, hydromorphone and fentanyl. In this environment, ARX-04 may also compete with other branded non-invasive products or product candidates, such as Egalet Corporation&#8217;s SPRIX, Hospira, Inc.&#8217;s DYLOJECT (Hospira, Inc. acquired by Pfizer, Inc. in September 2015), Acura Pharmaceuticals, Inc.&#8217;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	s OXAYDO, Depomed, Inc.&#8217;s NUCYNTA, Bristol-Myers Squibb Company&#8217;s COMBUNOX, Purdue Pharma, L.P.&#8217;s OXYFAST, Endo Pharmaceuticals, Inc.&#8217;s OPANA, Medical Developments International Limited&#8217;s
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PENTHROX (methoxyflurane) inhaler, CL-108, a bi-layered tablet
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	, in development by Charleston Laboratories Inc., in collaboration with Daiichi Sankyo, or generic oral opioids which have moderate-to-severe acute pain labeling. In the short-stay or ambulatory surgery segment, ARX-04 will likely compete with these products in addition to generic injectable local anesthetics such as bupivacaine, or branded formulations thereof, including Pacira Pharmaceuticals, Inc.&#8217;s EXPAREL. Within the military environment, and in certain civilian settings, ARX-04 competitors may also include intramuscular morphine injections which are marketed by a variety of generic manufacturers.
</FONT>
</P>
<P STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
	&nbsp;
</P>
<P ID=PARA1865 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We believe that Zalviso would compete with a number of opioid-based and non-opioid based treatment options that are currently available, as well as some products that are in development. The hospital market for opioids for moderate-to-severe acute pain is large and competitive. The primary competition for Zalviso is the IV PCA pump, which is widely used in the moderate-to-severe acute pain in the hospital setting. Leading manufacturers of IV PCA pumps include Hospira, Inc. (acquired by Pfizer, Inc.), CareFusion Corporation (purchased by Becton, Dickinson and Company), Baxter International, Inc., Curlin Medical, Inc. and Smiths Medical. The most common opioids used to treat moderate-to-severe acute pain are morphine, hydromorphone and fentanyl, all of which are available as generics
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	both from generic product manufacturers as well as from compounding pharmacies. In addition, branded manufacturers (e.g., Hospira, Inc.) sell pre-filled glass syringes of morphine to fit their IV PCA pump systems.
</FONT>
</P>
<P ID=PARA1868 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK41 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR41 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM41 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	45
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage46"></A>
<DIV ID=PGHDR41 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA41.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1867 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Also available on the market is the Avancen Medication on Demand, or MOD, Oral PCA Device developed by Avancen MOD Corporation. Oral opioids and other agents can be used in this system.&nbsp;In addition, oral and parenteral opioids administered by the nurse are used to manage moderate-to-severe acute pain in the hospital, available both as branded and generic products. These oral opioids, as well as IV PCA opioids, are often used as part of a multi-modal analgesia approach, which might include, in addition to the opioid, NSAIDs, acetaminophen, gabapentanoids and other pain management modalities, as well as local anesthetic blocks to provide temporary blockage of the pain signal, either as a wound infiltration agent or as a nerve block. These local anesthetic agents such as bupivacaine can also utilize controlled-release formulations such as Pacira Pharmaceuticals, Inc.&#8217;s EXPAREL. In addition, Halyard Health, Inc. has developed a medical device, the ON-Q* Pain Relief System, which is a non-narcotic elastomeric pump that automatically and continuously delivers a regulated flow of local anesthetic to a patient&#8217;s surgical site or in close proximity to nerves, providing targeted pain relief for up to five days.
</FONT>
</P>
<P ID=PARA1869 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1870 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additional potential competitors for Zalviso include the fentanyl iontophoretic transdermal system, IONSYS, originally developed by Alza Corporation and Ortho-McNeil Pharmaceutical, Inc., both Johnson&nbsp;&amp; Johnson subsidiaries, and most recently by The Medicines Company. On April 30, 2015, IONSYS was approved for marketing in the U.S. by the FDA, providing a potential first-to-market advantage for IONSYS. Cara Therapeutics, Inc. is developing a kappa opioid agonist, CR845, as an IV agent for the management of post-operative moderate-to-severe pain.&nbsp;Trevena, Inc. is developing TRV130, an intravenous G protein biased ligand that targets the mu opioid receptor for the treatment of moderate-to-severe acute pain where intravenous therapy is preferred, with a clinical development focus in acute post-operative pain. Trevena, Inc. expects to initiate Phase 3 development of TRV130 in the first quarter of 2016. Recro Pharma, Inc. is developing an intranasal form of dexmedetomidine as a potential agent for the management of post-operative pain, for which it announced positive efficacy results in its Phase II clinical trial. Finally, Innocoll AG is developing XARACOLL a controlled-release resorbable implant containing bupivacaine, and Durect Corporation has been developing POSIDUR, a controlled-release bupivacaine product candidate utilizing Durect Corporation&#8217;s Saber technology.
</FONT>
</P>
<P ID=PARA1871 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1872 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	It is possible that any of these competitors could develop or improve technologies or products that would render our product candidates obsolete or non-competitive, which could adversely affect our revenue potential. Key competitive factors affecting the commercial success of our product candidates are likely to be efficacy, safety profile, reliability, convenience of dosing, price and reimbursement.
</FONT>
</P>
<P ID=PARA1873 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1874 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Many of our potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of drug candidates, obtaining FDA and other regulatory approval of products and the commercialization of those products. Accordingly, our competitors may be more successful than we are in obtaining FDA approval for drugs and achieving widespread market acceptance. Our competitors&#8217; drugs or drug delivery systems may be more effective, have fewer adverse effects, be less expensive to develop and manufacture, or be more effectively marketed and sold than any product candidate we may commercialize. This may render our product candidates obsolete or non-competitive before we can recover our losses. We anticipate that we will face intense and increasing competition as new drugs enter the market and additional technologies become available. These entities may also establish collaborative or licensing relationships with our competitors, which may adversely affect our competitive position. Finally, the development of different methods for the treatment of moderate-to-severe acute pain (ARX-04 and Zalviso) could render our products non-competitive or obsolete. These and other risks may materially adversely affect our ability to attain or sustain profitable operations.
</FONT>
</P>
<P ID=PARA1876 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1875 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Formulary approval may not be available, or could be subject to certain restrictions for ARX-04 or Zalviso in the United States and our other product candidates, which could make it difficult for us to sell our products profitably.
</I>
</B>
</FONT>
</P>
<P ID=PARA1878 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1877 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Obtaining formulary approval can be an expensive and time-consuming process. We cannot be certain if and when we will obtain formulary approval to allow us to sell our products into our target markets. Failure to obtain timely formulary approval will limit our commercial success. If we are successful in obtaining formulary approval, we may need to complete evaluation programs whereby ARX-04 or Zalviso is used on a limited basis for certain patient types. Hospitals may seek to obtain ARX-04 or Zalviso devices at little or no cost during this evaluation period. Revenue generated from these hospitals during the evaluation period would be minimal. The evaluation period may last several months and there can be no assurance that use during the evaluation period will lead to formulary approval of ARX-04 or Zalviso. Further, even successful formulary approval may be subject to certain restrictions based on patient type or hospital protocol. Failure to obtain timely formulary approval for ARX-04 and/or Zalviso would materially adversely affect our ability to attain or sustain profitable operations.
</FONT>
</P>
<P ID=PARA1880 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1879 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Coverage and adequate reimbursement may not be available for ARX-04 or Zalviso, if approved in the United States, or ARX-04 in the EU, if approved, or Zalviso in the EU, which could make it difficult for us, or our partners, to sell our products profitably.
</I>
</B>
	&nbsp;
</FONT>
</P>
<P ID=PARA1882 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1881 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our ability to commercialize
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04 or Zalviso, if approved in the United States, or ARX-04 in the EU, if approved, or Zalviso in the EU successfully will depend, in part, on the extent to which coverage and adequate reimbursement will be available from government payor programs at the federal and state levels, authorities, including Medicare and Medicaid, private health insurers, managed care plans and other third-party payors.
</FONT>
</P>
<P ID=PARA1884 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK42 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR42 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM42 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	46
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage47"></A>
<DIV ID=PGHDR42 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA42.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1883 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No uniform policy requirement for coverage and reimbursement for drug products exists among third-party payors in the United States or the EU. Therefore, coverage and reimbursement can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Our inability to promptly obtain coverage and adequate reimbursement rates from third party payors could significantly harm our operating results, our ability to raise capital needed to commercialize any future approved drugs and our overall financial condition.
</FONT>
</P>
<P ID=PARA1886 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1885 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. There have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions that could affect our ability to sell our products profitably. These legislative and/or regulatory changes may negatively impact the reimbursement for our products, following approval. The availability of numerous generic pain medications may also substantially reduce the likelihood of reimbursement for ARX-04, Zalviso or any of our other product candidates, if approved in the United States, and ARX-04 or any of our other product candidates, if approved outside the United States, as well as Zalviso in the EU and elsewhere. The application of user fees to generic drug products may expedite the approval of additional pain medication generic drugs. We expect to experience pricing pressures in connection with the sale of Zalviso in the EU, and ARX-04, Zalviso outside of the EU and any of our other product candidates, if approved, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. If we fail to successfully secure and maintain reimbursement coverage for our products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and our business will be harmed.
</FONT>
</P>
<P ID=PARA1888 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA189 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Furthermore, market acceptance and sales of our product candidates, if approved, will depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third party payors, such as private health insurers, hospitals and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. We cannot be sure that reimbursement will be available for ARX-04, Zalviso, or any of our other product candidates, if approved in the United States or ARX-04, or any of our other product candidates, if approved in the EU, or Zalviso in the EU. Also, reimbursement amounts may reduce the demand for, or the price of, our products. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize ARX-04, Zalviso, or any of product candidates, if approved in the United States, or ARX-04, or any of our other product candidates, if approved in the EU, or Zalviso in the EU.
</FONT>
</P>
<P ID=PARA1890 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
	&nbsp;
</FONT>
</P>
<P ID=PARA1889 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additionally, the regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues able to be generated from the sale of the product in that country. For example, although in September 2015 the European Commission approved the MAA for Gr&#252;nenthal
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	to market Zalviso in the 28 European Union member states as well as for the European Economic Area countries, Norway, Iceland and Liechtenstein, separate pricing and reimbursement approvals may delay or prevent their ability to successfully launch Zalviso. Adverse pricing limitations may hinder our ability to recoup our investment in ARX-04, Zalviso and/or our other drug candidates, even if/when those drug candidates obtain marketing approval.
</FONT>
</P>
<P ID=PARA1892 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P ID=PARA173 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA172 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Furthermore, even after initial price and reimbursement approvals, reductions in prices and changes in reimbursement levels can be triggered by multiple factors, including reference pricing systems and publication of discounts by third party payors or authorities in other countries. In the EU, prices can be reduced further by parallel distribution and parallel trade, i.e. arbitrage between low-priced and high-priced countries. If any of these events occur, Zalviso, and any future approved product candidates would be negatively affected.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1892 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
	&nbsp;
</FONT>
</P>
<P ID=PARA1894 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK43 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR43 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM43 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	47
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage48"></A>
<DIV ID=PGHDR43 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA43.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1893 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.
</I>
</B>
</FONT>
</P>
<P ID=PARA1896 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1895 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If we are found to have improperly promoted off-label uses of our product candidates, including ARX-04 and/or Zalviso, if approved in the United States, we may become subject to significant liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription drug products. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may nevertheless use our products for their patients in a manner that is inconsistent with the approved label, if the physicians personally believe in their professional medical judgment it could be used in such manner. However, if the FDA determines that our promotional materials or training constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an off-label use, which could result in significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, increased losses and diminished profits and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. The FDA or other regulatory authorities could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of our product candidates, including ARX-04 and Zalviso in the United States, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.
</FONT>
</P>
<P ID=PARA1898 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1897 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Guidelines and recommendations published by government agencies can reduce the use of our product candidates, including ARX-04 and Zalviso, if/when approved.
</I>
</B>
</FONT>
</P>
<P ID=PARA1900 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA191 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Government agencies promulgate regulations and guidelines applicable to certain drug classes that may include the product candidates that we are developing. Recommendations of government agencies may relate to such matters as usage, dosage, route of administration and use of concomitant therapies. Regulations or guidelines suggesting the reduced use of certain drug classes that may include the product candidates that we are developing or the use of competitive or alternative products as the standard of care to be followed by patients and healthcare providers could result in decreased use of our product candidates, or negatively impact our ability to gain market acceptance and market share.
</FONT>
</P>
<P ID=PARA1900 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	&nbsp;
</P>
</FONT>
<P ID=PARA1901 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	If we are unable to establish relationships with group purchasing organizations any future revenues or future profitability could be jeopardized.
</I>
</B>
</FONT>
</P>
<P ID=PARA1904 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1903 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Many end-users of pharmaceutical products have relationships with group purchasing organizations, or GPOs, whereby such GPOs provide such end-users access to a broad range of pharmaceutical products from multiple suppliers at competitive prices and, in certain cases, exercise considerable influence over the drug purchasing decisions of such end-users. Hospitals and other end-users contract with the GPO of their choice for their purchasing needs. We expect to derive revenue from end-user customers that are members of GPOs, if ARX-04 or Zalviso is approved by the FDA. Establishing and maintaining strong relationships with these GPOs will require us to be a reliable supplier, remain price competitive and comply with FDA regulations. The GPOs with whom we have relationships may have relationships with manufacturers that sell competing products, and such GPOs may earn higher margins from these products or combinations of competing products or may prefer products other than ours for other reasons. If we are unable to establish or maintain our GPO relationships, sales of our products and revenue could be negatively impacted.
</FONT>
</P>
<P ID=PARA1906 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1905 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We intend to rely on a limited number of pharmaceutical wholesalers to distribute our product candidates, including ARX-04 and Zalviso in the United States, if approved.
</I>
</B>
</FONT>
</P>
<P ID=PARA1908 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1907 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We intend to rely primarily upon pharmaceutical wholesalers in connection with the distribution of our product candidates, including ARX-04 and Zalviso in the United States, if approved. If we are unable to establish or maintain our business relationships with these pharmaceutical wholesalers on commercially acceptable terms, it could have a material adverse effect on our sales and may prevent us from achieving profitability.
</FONT>
</P>
<P ID=PARA1910 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1909 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Risks Related to Our Business Operations and Industry
</B>
</FONT>
</P>
<P ID=PARA1912 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1911 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Failure to receive required quotas of controlled substances or comply with the Drug Enforcement Administration regulations, or the cost of compliance with these regulations, may adversely affect our business.
</I>
</B>
</FONT>
</P>
<P ID=PARA1914 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1913 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Sufentanil is a Schedule II opioid, considered to present a high risk of abuse. The manufacture, shipment, storage, sale and use of controlled substances are subject to a high degree of regulation, including security, record-keeping and reporting obligations enforced by the DEA and also by comparable state agencies. This high degree of regulation can result in significant costs in order to comply with the required regulations, which may have an adverse effect on the development and commercialization of our product candidates.
</FONT>
</P>
<P ID=PARA1916 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK44 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR44 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM44 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	48
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage49"></A>
<DIV ID=PGHDR44 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA44.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1915 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The DEA limits the availability and production of all Schedule II substances, including sufentanil, through a quota system. The DEA requires substantial evidence and documentation of expected legitimate medical and scientific needs before assigning quotas to manufacturers. Our contract manufacturers have applied annually for a quota on our behalf. We will need significantly greater amounts of sufentanil to implement our commercialization plans for Zalviso in the EU, and any of our products that may be approved by the FDA in the future, including ARX-04 and Zalviso. Any delay or refusal by the DEA in establishing the procurement quota or a reduction in our quota for sufentanil or a failure to increase it over time to meet anticipated increases in demand could delay or stop the clinical development of any of our product candidates or the commercial sale of any approved products. This, in turn, could have a material adverse effect on our business, results of operations, financial condition and prospects.
</FONT>
</P>
<P ID=PARA1917 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P ID=PARA1918 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Our relationships with investigators, health care professionals, consultants, commercial partners, third-party payors, hospitals, and other customers are subject to applicable anti-kickback, fraud and abuse and other healthcare laws, which could expose us to penalties.
</I>
</B>
</FONT>
</P>
<P ID=PARA1920 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1919 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Healthcare providers, physicians and others play a primary role in the recommendation and prescribing of any products for which we may obtain marketing approval. Our business operations and arrangements with investigators, healthcare professionals, consultants, commercial partners, hospitals, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws. These laws may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute the products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws, include, but are not limited to, the following:
</FONT>
</P>
<P ID=PARA1922 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1923 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1924 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1925 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the federal healthcare Anti-Kickback Statute prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1927 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1928 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1929 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1930 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the federal civil and criminal false claims laws and civil monetary penalties, including civil whistleblower or qui tam actions, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1932 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1933 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1934 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1935 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, among other things, imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly or willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1937 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1938 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1939 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1940 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose certain obligations, including mandatory contractual terms, on covered healthcare providers, health plans and clearinghouses, as well as their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1942 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1943 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1944 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1945 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the federal transparency law, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the Health Care Reform Law), and its implementing regulations, requires certain manufacturers of drugs, devices, biologicals and medical supplies to report to the U.S. Department of Health and Human Services information related to payments and other transfers of value provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1947 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1948 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1949 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1950 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	analogous state laws that may apply to our business practices, including but not limited to, state laws that require pharmaceutical companies to implement compliance programs and/or comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines; state laws that impose restrictions on pharmaceutical companies&#8217; marketing practices and require manufacturers to track and file reports relating to pricing and marketing information, which requires tracking and reporting gifts, compensation and other remuneration and items of value provided to healthcare professionals and entities; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1952 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK45 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR45 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM45 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	49
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage50"></A>
<DIV ID=PGHDR45 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA45.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1953 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1954 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1955 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the federal Foreign Corrupt Practices Act of 1977 and other similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from providing money or anything of value to officials of foreign governments, foreign political parties, or international organizations with the intent to obtain or retain business or seek a business advantage. Recently, there has been a substantial increase in anti-bribery law enforcement activity by U.S. regulators, with more frequent and aggressive investigations and enforcement proceedings by both the Department of Justice and the U.S. Securities and Exchange Commission. A determination that our operations or activities are not, or were not, in compliance with United States or foreign laws or regulations could result in the imposition of substantial fines, interruptions of business, loss of supplier, vendor or other third-party relationships, termination of necessary licenses and permits, and other legal or equitable sanctions. Other internal or government investigations or legal or regulatory proceedings, including lawsuits brought by private litigants, may also follow as a consequence.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1957 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1956 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these or any other healthcare regulatory laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, increased losses and diminished profits and the curtailment or restructuring of our operations any of which could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses or divert our management&#8217;s attention from the operation of our business.
</FONT>
</P>
<P ID=PARA1959 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1958 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Business interruptions could delay us in the process of developing our products and could disrupt our sales.
</I>
</B>
</FONT>
</P>
<P ID=PARA1961 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1960 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our headquarters is located in the San Francisco Bay Area, near known earthquake fault zones and is vulnerable to significant damage from earthquakes. We are also vulnerable to other types of natural disasters and other events that could disrupt our operations. We do not carry insurance for earthquakes or other natural disasters and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our business operations.
</FONT>
</P>
<P ID=PARA1963 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1962 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
</I>
</B>
</FONT>
</P>
<P ID=PARA1965 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1964 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into offer letters with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#8220;at will&#8221; employees. Recruiting and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in clinical trials, or delays in the regulatory approval process, may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive or key employee might impede the progress of our research, development and commercialization objectives. On November 5, 2014, we announced that the Board of Directors has initiated a search to replace Richard King, our President and Chief Executive Officer. On March 31, 2015, Mr. King&#8217;s employment with AcelRx terminated. On March 19, 2015, the Board of Directors of AcelRx appointed Howard B. Rosen, a member of AcelRx&#8217;s Board of Directors, as interim Chief Executive Officer effective April 1, 2015. While Mr. Rosen has agreed to serve as our Chief Executive Officer and principal executive officer on an interim basis, there can be no assurance that a permanent replacement will be found on a timely basis, or at all. Our inability to find a suitable permanent replacement may have a detrimental impact on the organization and impede the progress of our research, development and commercialization objectives, as well as our ability to raise additional capital as needed.
</FONT>
</P>
<P ID=PARA1967 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA1968 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	In the future, we will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
</I>
</B>
</FONT>
</P>
<P ID=PARA1970 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1969 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December 31, 2015, we had 36 full-time employees. On March 19, 2015, our Board of Directors, in connection with our efforts to reduce operating costs, conserve capital, focus the Company&#39;s financial and development resources on working with the FDA to seek marketing approval for Zalviso, and continuing development of ARX-04, implemented a cost reduction plan. The cost reduction plan reduced our workforce by 19 employees, approximately 36% of total headcount, in the first quarter of 2015. As our product candidates mature and approach potential commercialization in the United States, we plan to expand our employee base to increase our managerial, sales, marketing, operational, quality, engineering, financial and other resources and to hire more consultants and contractors. Future growth will impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize ARX-04, Zalviso and our other product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.
</FONT>
</P>
<P ID=PARA1971 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK46 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR46 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM46 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	50
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage51"></A>
<DIV ID=PGHDR46 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA46.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA1972 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability.
</I>
</B>
</FONT>
</P>
<P ID=PARA1974 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA1973 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:
</FONT>
</P>
<P ID=PARA1976 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1977 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1978 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1979 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	impairment of our business reputation;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1981 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1982 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1983 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1984 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	withdrawal of clinical trial participants;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1986 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1987 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1988 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1989 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	costs due to related litigation;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1991 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1992 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1993 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1994 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	distraction of management&#8217;s attention from our primary business;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA1996 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB1997 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA1998 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA1999 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	substantial monetary awards to patients or other claimants;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2001 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2002 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2003 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2004 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the inability to commercialize our product candidates; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2006 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2007 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2008 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2009 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	decreased demand for our product candidates, if approved for commercial sale.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2011 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2010 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our current product liability insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for our product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. For example, with the recent approval of Zalviso in the EU, we have expanded our insurance coverage to include the sale of Zalviso to our commercial partner, Gr&#252;nenthal. There can be no assurance that such coverage will be adequate to protect us against any future losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.
</FONT>
</P>
<P ID=PARA2013 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2012 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
</I>
</B>
</FONT>
</P>
<P ID=PARA2015 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2014 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are exposed to the risk that our employees, independent contractors, investigators, consultants, commercial partners and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct that violates (1)&nbsp;the laws of the FDA and similar foreign regulatory bodies, including those laws requiring the reporting of true, complete and accurate information to such regulatory bodies; (2)&nbsp;healthcare fraud and abuse laws of the United States and similar foreign fraudulent misconduct laws; and (3)&nbsp;laws requiring the reporting of financial information or data accurately. Specifically, the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry are subject to extensive laws designed to prevent misconduct, including fraud, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. It is not always possible to identify and deter employee and other third-party misconduct. The precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws. If any such actions are instituted against us, and we are not successful in defending ourselves, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.
</FONT>
</P>
<P ID=PARA2017 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK47 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR47 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM47 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	51
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage52"></A>
<DIV ID=PGHDR47 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA47.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2016 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Risks Related to Our Intellectual Property
</B>
</FONT>
</P>
<P ID=PARA2019 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2018 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	If we cannot defend our issued patents from third party claims or if our pending patent applications fail to issue, our business could be adversely affected.
</I>
</B>
</FONT>
</P>
<P ID=PARA2021 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2020 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To protect our proprietary technology, we rely on patents as well as other intellectual property protections including trade secrets, nondisclosure agreements, and confidentiality provisions.&nbsp;As of December 31, 2015, we are the owner of record of 45 issued patents worldwide. These issued patents cover AcelRx&#8217;s sufentanil sublingual tablet, medication delivery devices, packaging and other platform technology. These issued patents are expected to provide coverage through 2027 &#8211; 2031.
</FONT>
</P>
<P ID=PARA2023 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2022 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, we are pursuing a number of U.S. non-provisional patent applications and foreign national applications directed to our product candidates. The patent applications that we have filed and have not yet been granted may fail to result in issued patents in the United States or in foreign countries. Even if the patents do successfully issue, third parties may challenge the patents.
</FONT>
</P>
<P ID=PARA2025 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2024 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our commercial success will depend in part on successfully defending our current patents against third party challenges and expanding our existing patent portfolio to provide additional layers of patent protection, as well as extending patent protection.&nbsp;There can be no assurance that we will be successful in defending our existing and future patents against third party challenges, or that our pending patent applications will result in additional issued patents.
</FONT>
</P>
<P ID=PARA2027 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2026 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The patent positions of pharmaceutical companies, including us, can be highly uncertain and involve complex and evolving legal and factual questions. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States. Legal developments may preclude or limit the scope of available patent protection.
</FONT>
</P>
<P ID=PARA2029 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2028 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There is also no assurance that any patents issued to us will not become the subject of adversarial proceedings such as opposition, inter partes review, post-grant review, reissue, supplemental examination, re-examination or other post-issuance proceedings. For example, an anonymous third party filed an Opposition on October 7, 2015 against European patent EP2182902B1, which claims a dosage form related to ARX-03. Although the Opposition is currently pending, the European Patent Office has neither reviewed nor made any initial comments regarding the validity of the EP2182902B1 patent. There is also no assurance that the respective court or agency in such adversarial proceedings would not make unfavorable decisions, such as reducing the scope of a patent of ours, or determining that a patent of ours is invalid or unenforceable. There is also no assurance that any patents issued to us will provide us with competitive advantages, will not be challenged by any third parties, or that the patents of others will not prevent the commercialization of products incorporating our technology. Furthermore, there can be no guarantee that others will not independently develop similar products, duplicate any of our products, or design around our patents.
</FONT>
</P>
<P ID=PARA2031 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA2032 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Litigation involving patents, patent applications and other proprietary rights is expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing our product candidates or approved products to market and interfere with our business.
</I>
</B>
</FONT>
</P>
<P ID=PARA2034 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2033 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our commercial success depends in part on not infringing patents and proprietary rights of third parties. Although we are not currently aware of litigation or other proceedings or third party claims of intellectual property infringement related to our product candidates, the pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights.
</FONT>
</P>
<P ID=PARA2036 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2035 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As we enter our target markets, it is possible that competitors or other third parties will claim that our products and/or processes infringe their intellectual property rights. These third parties may have obtained and may in the future obtain patents covering products or processes that are similar to, or may include compositions or methods that encompass our technology, allowing them to claim that the use of our technologies infringes these patents.
</FONT>
</P>
<P ID=PARA2038 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2037 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In a patent infringement claim against us, we may assert, as a defense, that we do not infringe the relevant patent claims, that the patent is invalid or both. The strength of our defenses will depend on the patents asserted, the interpretation of these patents, and our ability to invalidate the asserted patents. However, we could be unsuccessful in advancing non-infringement and/or invalidity arguments in our defense. In the United States, issued patents enjoy a presumption of validity, and the party challenging the validity of a patent claim must present clear and convincing evidence of invalidity, which is a high burden of proof. Conversely, the patent owner need only prove infringement by a preponderance of the evidence, which is a lower burden of proof.
</FONT>
</P>
<P ID=PARA2040 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2039 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If we were found by a court to have infringed a valid patent claim, we could be prevented from using the patented technology and/or be required to pay the owner of the patent for damages for past sales and for the right to license the patented technology for future sales. If we decide to pursue a license to one or more of these patents, we may not be able to obtain a license on commercially reasonable terms, if at all, or the license we obtain may require us to pay substantial royalties or grant cross licenses to our patent rights. For example, if the relevant patent is owned by a competitor, that competitor may choose not to license patent rights to us. If we decide to develop alternative technology, we may not be able to do so in a timely or cost-effective manner, if at all.
</FONT>
</P>
<P ID=PARA2042 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK48 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR48 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM48 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	52
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage53"></A>
<DIV ID=PGHDR48 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA48.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2041 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, because patent applications can take years to issue and are often afforded confidentiality for some period of time there may currently be pending applications, unknown to us, that later result in issued patents that could cover one or more of our products.
</FONT>
</P>
<P ID=PARA2044 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2043 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	It is possible that we may in the future receive, particularly as a public company, communications from competitors and other companies alleging that we may be infringing their patents, trade secrets or other intellectual property rights, offering licenses to such intellectual property or threatening litigation. In addition to patent infringement claims, third parties may assert copyright, trademark or other proprietary rights against us. We may need to expend considerable resources to counter such claims and may not be able to successful in our defense. Our business may suffer if a finding of infringement is established.
</FONT>
</P>
<P ID=PARA2046 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2045 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.
</I>
</B>
</FONT>
</P>
<P ID=PARA2048 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2047 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States. The pharmaceutical patent situation outside the United States is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. For example, on September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The United States Patent and Trademark Office has developed new regulations and procedures to govern the full implementation of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, that became effective March&nbsp;16, 2013. It is too early to tell what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.
</FONT>
</P>
<P ID=PARA2050 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2049 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in the patents that may be issued from the applications we currently or may in the future own or license from third parties. Claims could be brought regarding the validity of our patents by third parties and regulatory agencies. Further, if any patent license we obtain is deemed invalid and/or unenforceable, it could impact our ability to commercialize or partner our technology.
</FONT>
</P>
<P ID=PARA2052 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2051 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Competitors or third parties may infringe our patents. We may decide it is necessary to file patent infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or that the third party&#8217;s technology does not in fact infringe upon our patents. An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our related pending patent applications at risk of not issuing. Litigation may fail and, even if successful, may result in substantial costs and be a distraction to our management. We may not be able to prevent misappropriation of our proprietary rights, particularly in countries outside the United States where patent rights may be more difficult to enforce.&nbsp;Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course of litigation there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.
</FONT>
</P>
<P ID=PARA2054 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2053 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:
</FONT>
</P>
<P ID=PARA2056 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2057 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2058 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2059 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we were the first to make the inventions covered by each of our pending patent applications or issued patents;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2061 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2062 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2063 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2064 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	our patent applications were filed before the inventions covered by each patent or patent application was published by a third party;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2066 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2067 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2068 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2069 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we were the first to file patent applications for these inventions;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2071 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2072 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2073 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2074 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	others will not independently develop similar or alternative technologies or duplicate any of our technologies;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2076 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2077 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2078 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2079 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	any patents issued to us or our collaborators will provide a basis for commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties; or
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2081 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2082 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2083 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2084 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the patents of others will not have an adverse effect on our business.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2086 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2085 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If we do not adequately protect our proprietary rights, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could materially harm our business, negatively affect our position in the marketplace, limit our ability to commercialize our products and product candidates, and delay or render impossible our achievement of profitability.
</FONT>
</P>
<P ID=PARA2088 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK49 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR49 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM49 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	53
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage54"></A>
<DIV ID=PGHDR49 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA49.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2087 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
</I>
</B>
</FONT>
</P>
<P ID=PARA2090 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2089 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We rely on trade secrets to protect our proprietary know-how and technological advances, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights. Failure to obtain or maintain trade secret protection could enable competitors to use our proprietary information to develop products that compete with our products or cause additional, material adverse effects upon our competitive business position.
</FONT>
</P>
<P ID=PARA2092 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2091 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications will be due to be paid to the United States Patent and Trademark Office and various foreign governmental patent agencies in several stages over the lifetime of the patents and/or applications.
</I>
</B>
</FONT>
</P>
<P ID=PARA2094 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2093 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have systems in place, including use of third party vendors, to manage payment of periodic maintenance fees, renewal fees, annuity fees and various other patent and application fees. The United States Patent and Trademark Office, or the USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. There are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs, our competitors might be able to enter the market, which would have a material adverse effect on our business.
</FONT>
</P>
<P ID=PARA2096 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2095 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We may not be able to enforce our intellectual property rights throughout the world.
</I>
</B>
</FONT>
</P>
<P ID=PARA2098 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2097 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit.
</FONT>
</P>
<P ID=PARA2100 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2099 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. Additionally, claims may be brought regarding the validity of our patents by third parties and regulatory agencies in the United States and foreign countries. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of intellectual property.
</FONT>
</P>
<P ID=PARA2102 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2101 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.
</I>
</B>
</FONT>
</P>
<P ID=PARA2104 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2103 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have registered our ACELRX mark in the United States, Canada, the European Union and India. We have also registered the mark ACCELERATE. INNOVATE. ALLEVIATE. in the United States. We have additionally applied for registration of our ZALVISO mark in the United States on an intent-to-use basis and that application has been allowed. A statement of use was filed with the U.S. Patent and Trademark Office for the ZALVISO mark in January 2016 and we are currently awaiting a notice of registration. In early 2014, the FDA accepted the ZALVISO mark as part of the NDA review process. Although we are not currently aware of any oppositions to or cancellations of our registered trademarks or pending applications, it is possible that one or more of the applications could be subject to opposition or cancellation after the marks are registered. The registrations will be subject to use and maintenance requirements. It is also possible that we have not yet registered all of our trademarks in all of our potential markets, and that there are names or symbols other than &#8220;ACELRX&#8221; that may be protectable marks for which we have not sought registration, and failure to secure those registrations could adversely affect our business. Opposition or cancellation proceedings may be filed against our trademarks and our trademarks may not survive such proceedings.
</FONT>
</P>
<P ID=PARA2106 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK50 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR50 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM50 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	54
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage55"></A>
<DIV ID=PGHDR50 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA50.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2107 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Risks Related to Ownership of Our Common Stock
</B>
</FONT>
</P>
<P ID=PARA2109 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2108 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	The market price of our common stock may be highly volatile.
</I>
</B>
</FONT>
</P>
<P ID=PARA2111 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2110 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Since our initial public offering, or IPO, in February 2011, the trading price of our common stock has experienced significant volatility and is likely to be volatile in the future. For example, our stock price declined by more than 40% on July 28, 2014, the first trading day following the announcement of the receipt of the CRL from the FDA. In addition, our stock price dropped by 37% on March 9, 2015, the day we announced the correspondence we received from the FDA requesting a clinical trial to assess the risk of inadvertent dispensing and overall risk of dispensing failures for Zalviso. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:
</FONT>
</P>
<P ID=PARA2113 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2114 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2115 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2116 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	any delay in submitting the NDA for ARX-04 or resubmitting the NDA for Zalviso, and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of any NDA;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2118 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2119 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2120 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2121 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	adverse results or delays in current or future clinical trials, including the Phase 3 clinical development program for ARX-04 and Zalviso;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2123 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2124 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2125 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2126 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	inability to obtain additional funding, including funding necessary for the planned potential commercialization and manufacturing of ARX-04 and Zalviso in the United States;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2128 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2129 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2130 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2131 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	failure to successfully develop and commercialize our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2133 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2134 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2135 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2136 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes in laws or regulations applicable to our products;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2138 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2139 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2140 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2141 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	inability to obtain adequate product supply for our product candidates, or the inability to do so at acceptable prices;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2143 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2144 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2145 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2146 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	adverse regulatory decisions;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2148 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2149 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2150 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2151 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	introduction of new products, services or technologies by our competitors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2153 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2154 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2155 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2156 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	failure to meet or exceed financial projections we provide to the public;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2158 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2159 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2160 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2161 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	failure to meet or exceed the estimates and projections of the investment community;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2163 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2164 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2165 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2166 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2168 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2169 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2170 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2171 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	announcements of significant acquisitions, strategic partnerships, joint ventures,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	or other significant transactions, including disposition transactions, or capital commitments by us or our competitors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2173 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2174 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2175 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2176 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2178 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2179 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2180 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2181 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	additions or departures of key scientific or management personnel;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2183 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2184 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2185 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2186 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	significant lawsuits, including patent or stockholder litigation;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2188 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2189 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2190 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2191 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes in the market valuations of similar companies;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2193 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2194 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2195 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2196 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	sales of our common stock by us or our stockholders in the future; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2198 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2199 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2200 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2201 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	trading volume of our common stock.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2203 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2202 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, the stock market in general, and The NASDAQ Global Market, or NASDAQ, in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.
</FONT>
</P>
<P ID=PARA2205 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2204 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Historically, our common stock has thinly traded, and in the future may continue to be thinly traded, and our stockholders may be unable to sell at or near asking prices, or at all if they need to sell their shares to raise money or otherwise desire to liquidate such shares.
</I>
</B>
</FONT>
</P>
<P ID=PARA2207 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2206 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Historically, we have not had a high volume of daily trades in our common stock on NASDAQ. For example, the average daily trading volume in our common stock on NASDAQ during the years ended December 31, 2015 and 2014 was approximately 600,000 and 700,000 shares&nbsp;per day, respectively. A more active market for our stock has only recently developed and may not be sustained. Our stockholders may be unable to sell their common stock at or near their asking prices, which may result in substantial losses to our investors.
</FONT>
</P>
<P ID=PARA2209 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK51 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR51 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM51 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	55
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage56"></A>
<DIV ID=PGHDR51 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA51.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2208 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The market for our common stock may be characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will be more volatile than a seasoned issuer for the indefinite future. As noted above, our common stock may be sporadically and/or thinly traded. As a consequence of this lack of liquidity, the trading of relatively small quantities of shares by our stockholders may disproportionately influence the price of those shares in either direction. The price for our shares could, for example, decline significantly in the event that a large number of our common stock are sold on the market without commensurate demand, as compared to a seasoned issuer that could better absorb those sales without adverse impact on its share price.
</FONT>
</P>
<P ID=PARA2211 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2210 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.
</I>
</B>
</FONT>
</P>
<P ID=PARA2213 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2212 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our executive officers and directors, together with the stockholders with whom our executive officers and directors are affiliated or associated, beneficially own a significant percentage of our voting stock. Therefore, these stockholders have the ability to influence us through this ownership position. These stockholders are able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, are able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.
</FONT>
</P>
<P ID=PARA2215 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2214 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We incur significant increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives.
</I>
</B>
</FONT>
</P>
<P ID=PARA2217 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2216 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As a public company, we incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or Dodd-Frank Act, as well as the information and reporting requirements of the Exchange Act and other federal securities laws, and rules subsequently implemented by the SEC and NASDAQ, have imposed various requirements on public companies. The costs of compliance with the Sarbanes-Oxley Act and of preparing and filing annual and quarterly reports, proxy statements and other information with the SEC, the Dodd-Frank Act, and regulations promulgated under these statutes, are significant. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain our current levels of such coverage.
</FONT>
</P>
<P ID=PARA2218 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2219 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As a public company, we are subject to the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act. If we are unable to comply with Section&nbsp;404 in a timely manner, it may affect the reliability of our internal control over financial reporting. Assessing our staffing and training procedures to improve our internal control over financial reporting is an ongoing process.
</FONT>
</P>
<P ID=PARA2221 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA193 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have been and will continue to be involved in a substantial effort to implement appropriate processes, document the system of internal control over key processes, assess their design, remediate any deficiencies identified and test their operation. If we fail to comply with the requirements of Section&nbsp;404, it may affect the reliability of our internal control over financial reporting and negatively impact the quality of disclosure to our stockholders. If we, or our independent registered public accounting firm, identify and report a material weakness, it could adversely affect our stock price.
</FONT>
</P>
<P ID=PARA2221 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
</FONT>
	&nbsp;
</FONT>
</P>
<P ID=PARA2222 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Sales of a substantial number of shares of our common stock in the public market by our existing stockholders could cause our stock&nbsp;price to fall.
</I>
</B>
</FONT>
</P>
<P ID=PARA2225 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2224 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. A significant number of shares of our common stock are held by some of our original pre-IPO venture investors. These investors have previously distributed, and may in the future distribute their shares of AcelRx to their limited partners. Historically, these limited partners have subsequently sold those shares on the open market following the distribution. Sales of substantial number of shares of our common stock following such distributions may lead to a decline in the price of our common stock.
</FONT>
</P>
<P ID=PARA2227 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2226 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are unable to predict the effect that sales may have on the prevailing market price of our common stock. All of our shares of common stock outstanding are eligible for sale in the public market, subject in some cases to the volume limitations and manner of sale requirements of Rule&nbsp;144 under the Securities Act. Sales of stock by our stockholders could have a material adverse effect on the trading price of our common stock.
</FONT>
</P>
<P ID=PARA2229 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2228 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, certain holders of our securities are entitled to certain rights with respect to the registration of their shares of common stock under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.
</FONT>
</P>
<P ID=PARA2231 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK52 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR52 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM52 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	56
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage57"></A>
<DIV ID=PGHDR52 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA52.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2230 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
</I>
</B>
</FONT>
</P>
<P ID=PARA2233 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2232 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.
</FONT>
</P>
<P ID=PARA2235 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2234 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant to the 2011 Incentive Plan, our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under our 2011 Incentive Plan will automatically increase each year by 4% of all shares of our capital stock outstanding as of December&nbsp;31 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under our 2011 Incentive Plan each year. If our board of directors elects to increase the number of shares available for future grant by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall.
</FONT>
</P>
<P ID=PARA2237 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2236 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Our involvement in securities-related class action litigation could divert our resources and management&#39;s attention and harm our business.
</I>
</B>
</FONT>
</P>
<P ID=PARA2239 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2238 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for the common stock of pharmaceutical companies. These broad market fluctuations may cause the market price of our common stock to decline. In addition, the market price of our common stock may vary significantly based on AcelRx specific events, such as receipt of a CRL, negative clinical results, or other negative feedback from the FDA or other regulatory agencies. In the past, securities-related class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies often experience significant stock price volatility in connection with their investigational drug candidate development programs and the FDA&#39;s review of their NDAs.
</FONT>
</P>
<P ID=PARA2241 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
<P ID=PARA60 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For example, on October 1, 2014, a securities class action complaint was filed in the U.S. District Court for the Northern District of California against AcelRx and certain of our current and former officers. On April 17, 2015, lead plaintiff filed an amended complaint. The amended complaint alleged that between September 30, 2013 and July 25, 2014, AcelRx and certain of our current and former officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 in connection with statements related to our lead drug candidate, Zalviso. On November 25, 2015, the Court granted our Motion to Dismiss. Plaintiffs had the opportunity to file an amended complaint within 30 days&#8217; which they declined to do. On January 18, 2016, the Court issued an order dismissing the case with prejudice.
</FONT>
</P>
<P ID=PARA63 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA62 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If AcelRx experiences a decline in its stock price, we could face additional securities class action lawsuits. Securities class actions are often expensive and can divert management&#8217;s attention and our financial resources, which could adversely affect our business.
</FONT>
</P>
<P ID=PARA64 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</FONT>
<P ID=PARA2244 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
</I>
</B>
</FONT>
</P>
<P ID=PARA2247 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2246 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. The completion of the July 2013 public equity offering, together with our public equity offering in December 2012, our initial public offering, private placements and other transactions that have occurred, have triggered such an ownership change. In addition, since we will need to raise substantial additional funding to finance our operations, we may undergo further ownership changes in the future. In the year ended December 31, 2015, we used net operating losses to reduce our income tax liability. In the future, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset United States federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us.
</FONT>
</P>
<P ID=PARA2249 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2248 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK53 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR53 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM53 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	57
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage58"></A>
<DIV ID=PGHDR53 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA53.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2250 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
</I>
</B>
</FONT>
</P>
<P ID=PARA2252 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2251 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have never declared or paid any cash dividends on our capital stock, and we are prohibited from doing so under the terms of our Amended Loan Agreement with Hercules. Regardless of the restrictions in our Amended Loan Agreement with Hercules or the terms of any potential future indebtedness, we anticipate that we will retain all available funds and any future earnings to support our operations and finance the growth and development of our business and, therefore, we do not expect to pay cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.
</FONT>
</P>
<P ID=PARA2254 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2253 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<B>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.
</I>
</FONT>
</B>
</P>
<P ID=PARA2256 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2255 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:
</FONT>
</P>
<P ID=PARA2258 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2259 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2260 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2261 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	authorizing the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2263 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2264 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2265 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2266 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	limiting the removal of directors by the stockholders;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2268 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2269 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2270 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2271 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	a staggered board of directors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2273 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2274 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2275 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2276 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2278 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2279 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2280 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2281 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	eliminating the ability of stockholders to call a special meeting of stockholders; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2283 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2284 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2285 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2286 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	establishing advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon at stockholder meetings.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2288 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2287 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section&nbsp;203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our board of directors. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.
</FONT>
</P>
</EFX_RISK_FACTORS>
<P ID=PARA2290 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<P ID=PARA2289 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;1B. Unresolved Staff Comments
</B>
</FONT>
</P>
<P ID=PARA2292 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2291 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None.
</FONT>
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P ID=PARA2294 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<P ID=PARA2293 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;2. Properties
</B>
</FONT>
</P>
<P ID=PARA2296 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2295 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We lease approximately 25,893 square feet of office and laboratory space in Redwood City, California under an agreement that expires in January 2018. On October 2, 2015, we executed an agreement to sublease 11,871 square feet of this space for a term of 26 months commencing on December 1, 2015. Upon the completion of the sublease, we have the option to take back the subleased space. We believe that our facilities are adequate to meet our current needs.
</FONT>
</P>
<P ID=PARA2298 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK54 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR54 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM54 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	58
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage59"></A>
<DIV ID=PGHDR54 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_PROPERTIES>
<P ID=PARA54.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<P ID=PARA2299 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;3. Legal Proceedings
</B>
</FONT>
</P>
<P ID=PARA2300 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<P ID=PARA2301 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</P>
</FONT>
<P ID=PARA164 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
</P>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<P ID=PARA65 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On October 1, 2014, a securities class action complaint was filed in the U.S. District Court for the Northern District of California against AcelRx and certain of our current and former officers. On April 17, 2015, lead plaintiff filed an amended complaint. The amended complaint alleged that between September 30, 2013 and July 25, 2014, AcelRx and certain of our current and former officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 in connection with statements related to our lead drug candidate, Zalviso. On November 25, 2015, the Court granted our Motion to Dismiss. Plaintiffs had the opportunity to file an amended complaint within 30 days&#8217; which they declined to do. On January 18, 2016, the Court issued an order dismissing the case with prejudice.
</FONT>
</P>
<P ID=PARA68 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA67 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	From time to time we may be involved in additional legal proceedings arising in the ordinary course of business.
</FONT>
</P>
</EFX_LEGAL_PROCEEDINGS>
<P ID=PARA69 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</FONT>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<P ID=PARA2309 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;4. Mine Safety Disclosures
</B>
</FONT>
</P>
<P ID=PARA2312 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2311 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Not Applicable.
</FONT>
</P>
<P ID=PARA2314 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<DIV ID=PGBK55 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR55 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM55 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	59
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage60"></A>
<DIV ID=PGHDR55 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<P ID=PARA55.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P ID=PARA2315 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PART II
</B>
</FONT>
</P>
<P ID=PARA2317 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<P ID=PARA2316 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</B>
</FONT>
</P>
<P ID=PARA2319 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2318 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Market Information
</B>
</FONT>
</P>
<P ID=PARA2321 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2320 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our common stock has been trading on the NASDAQ Global Market under the symbol &#8220;ACRX&#8221; since our IPO on February&nbsp;11, 2011. Prior to this date, there was no public market for our common stock. The following table sets forth the high and low intraday sales prices of our common stock for the periods indicated as reported by the NASDAQ
<BR>
	Global Market:
</FONT>
</P>
<P ID=PARA2322 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL2361 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL2361.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2361.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2361.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=6>
<P ID=PARA2324 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Price
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<EFX_UNIDENTIFIED_TABLE>
<TR ID=TBL2361.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: BOTTOM">
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2361.FINROW.3.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2361.FINROW.3.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=2>
<P ID=PARA2327 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 8.65PT 0PT 10.1PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	High
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.3.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2361.FINROW.3.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2361.FINROW.3.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 8.65PT" COLSPAN=2>
<P ID=PARA2329 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 10.1PT 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Low
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.3.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2361.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2331 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Year ended 2015
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.4.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.4.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.4.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.4.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.4.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.4.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.4.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.4.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL2361.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2334 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Fourth Quarter
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2361.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	5.88
</TD>
<TD ID=TBL2361.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2361.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	2.97
</TD>
<TD ID=TBL2361.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2361.FINROW.6 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2337 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Third Quarter
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2361.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	5.10
</TD>
<TD ID=TBL2361.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2361.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	2.92
</TD>
<TD ID=TBL2361.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2361.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2340 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Second Quarter
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2361.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	4.99
</TD>
<TD ID=TBL2361.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2361.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	2.96
</TD>
<TD ID=TBL2361.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2361.FINROW.8 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2343 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	First Quarter
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2361.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	9.32
</TD>
<TD ID=TBL2361.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2361.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	3.58
</TD>
<TD ID=TBL2361.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2361.FINROW.9 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2346 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Year ended 2014
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.9.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.9.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.9.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.9.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.9.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.9.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.9.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.9.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL2361.FINROW.10 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2349 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Fourth Quarter
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2361.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	7.46
</TD>
<TD ID=TBL2361.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2361.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	5.22
</TD>
<TD ID=TBL2361.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2361.FINROW.11 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2352 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Third Quarter
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2361.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	11.65
</TD>
<TD ID=TBL2361.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2361.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	5.27
</TD>
<TD ID=TBL2361.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2361.FINROW.12 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2355 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Second Quarter
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2361.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	12.35
</TD>
<TD ID=TBL2361.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2361.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	8.13
</TD>
<TD ID=TBL2361.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2361.FINROW.13 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 62%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2358 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	First Quarter
</FONT>
</P>
</TD>
<TD ID=TBL2361.FINROW.13.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.13.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2361.FINROW.13.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	13.64
</TD>
<TD ID=TBL2361.FINROW.13.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.13.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2361.FINROW.13.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2361.FINROW.13.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	9.91
</TD>
<TD ID=TBL2361.FINROW.13.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
</TABLE>
<P ID=PARA2363 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2362 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2364 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Stock Price Performance Graph
</B>
</FONT>
</P>
<P ID=PARA2366 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2365 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following graph illustrates a comparison of the total cumulative stockholder return on our common stock since February&nbsp;11, 2011, which is the date our common stock first began trading on the NASDAQ Global Market, to two indices: the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The stockholder return shown in the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.&nbsp;
</FONT>
</P>
<P STYLE="TEXT-ALIGN: CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2016/03/07/0001437749-16-026987_GRAPH.JPG" WIDTH=645 HEIGHT=384>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA2372 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	The above Stock Price Performance Graph and related information shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing.
</I>
</FONT>
</P>
<P ID=PARA2375 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<DIV ID=PGBK56 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR56 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM56 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	60
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage61"></A>
<DIV ID=PGHDR56 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA56.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2374 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Holders of Record
</B>
</FONT>
</P>
<P ID=PARA2377 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2376 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of February 3, 2016, there were 16 holders of record of our common stock. This number does not include &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers, financial institutions and other nominees.
</FONT>
</P>
<P ID=PARA2379 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2378 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Dividend Policy
</B>
</FONT>
</P>
<P ID=PARA2381 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2380 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have never declared or paid any cash dividends on our capital stock, and we are prohibited from doing so under the terms of our loan and security agreement with Hercules. Regardless of the restrictions in our loan and security agreement with Hercules or the terms of any potential future indebtedness, we anticipate that we will retain all available funds and any future earnings to support our operations and finance the growth and development of our business and, therefore, we do not expect to pay cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.
</FONT>
</P>
<P ID=PARA2383 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA2384 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Recent Sales of Unregistered Securities
</B>
</FONT>
</P>
<P ID=PARA2385 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2386 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None.
</FONT>
</P>
<P ID=PARA2387 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<DIV ID=PGBK2388 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGNUM2388 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	61
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage62"></A>
<DIV ID=PGHDR2388 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</DIV>
</EFX_MARKET>
<P ID=PARA2389 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<P ID=PARA2390 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;6. Selected Financial Data
</B>
</FONT>
</P>
<P ID=PARA2392 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2391 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The selected financial data set forth below should be read together with the Consolidated Financial Statements and related notes, &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the other information contained in this Form 10-K. The selected financial data is not intended to replace our audited financial statements and the accompanying notes. Our historical results are not necessarily indicative of our future results.
</FONT>
</P>
<P ID=PARA2393 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE ID=TBL2602 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL2602.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.2.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.2.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=18>
<P ID=PARA2395 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.2.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2602.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.3.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.3.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=2>
<P ID=PARA2398 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 10.1PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.3.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.3.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.3.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=2>
<P ID=PARA2400 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 10.1PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.3.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.3.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.3.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=2>
<P ID=PARA2402 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 10.1PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.3.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.3.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.3.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=2>
<P ID=PARA2404 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 10.1PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2012
</B>
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.3.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.3.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.3.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=2>
<P ID=PARA2406 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 10.1PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2011
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.3.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2602.FINROW.4>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.4.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.4.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=18>
<P ID=PARA2409 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 10.1PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(in thousands, except share and per share data)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.4.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2602.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2410 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Consolidated Statements of Operations Data:
</B>
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.5.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.LEAD.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.SYMB.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.AMT.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2602.FINROW.5.TRAIL.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2602.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2416 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Revenue:
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.6.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.LEAD.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.SYMB.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.AMT.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.6.TRAIL.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2422 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Collaboration agreement
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	14,857
</TD>
<TD ID=TBL2602.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	5,217
</TD>
<TD ID=TBL2602.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	27,370
</TD>
<TD ID=TBL2602.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.7.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.7.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.7.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.7.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.7.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.7.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.7.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.7.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.8 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2428 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Contract and other
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	4,406
</TD>
<TD ID=TBL2602.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	2,132
</TD>
<TD ID=TBL2602.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	2,394
</TD>
<TD ID=TBL2602.FINROW.8.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.8.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	1,072
</TD>
<TD ID=TBL2602.FINROW.8.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.10 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 54PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2440 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total revenue
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	19,263
</TD>
<TD ID=TBL2602.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	5,217
</TD>
<TD ID=TBL2602.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	29,502
</TD>
<TD ID=TBL2602.FINROW.10.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	2,394
</TD>
<TD ID=TBL2602.FINROW.10.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.10.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	1,072
</TD>
<TD ID=TBL2602.FINROW.10.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.11 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2446 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Operating Expenses:
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.11.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.LEAD.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.SYMB.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.AMT.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.11.TRAIL.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.12 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2452 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cost of goods sold
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	1,770
</TD>
<TD ID=TBL2602.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.12.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.12.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.12.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.12.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.12.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.12.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.12.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.12.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.12.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.12.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.12.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.12.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.13 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2458 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Research and development
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.13.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	22,488
</TD>
<TD ID=TBL2602.FINROW.13.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	24,520
</TD>
<TD ID=TBL2602.FINROW.13.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	26,292
</TD>
<TD ID=TBL2602.FINROW.13.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	24,908
</TD>
<TD ID=TBL2602.FINROW.13.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.13.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	13,624
</TD>
<TD ID=TBL2602.FINROW.13.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.14 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2464 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	General and administrative
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.14.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	14,203
</TD>
<TD ID=TBL2602.FINROW.14.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	18,346
</TD>
<TD ID=TBL2602.FINROW.14.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	9,877
</TD>
<TD ID=TBL2602.FINROW.14.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	7,199
</TD>
<TD ID=TBL2602.FINROW.14.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.14.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	6,800
</TD>
<TD ID=TBL2602.FINROW.14.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.15 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2470 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Restructuring costs
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.15.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	756
</TD>
<TD ID=TBL2602.FINROW.15.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.15.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.15.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.15.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.15.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.15.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.17 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 54PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2482 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total operating expenses
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.17.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	39,217
</TD>
<TD ID=TBL2602.FINROW.17.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	42,866
</TD>
<TD ID=TBL2602.FINROW.17.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	36,169
</TD>
<TD ID=TBL2602.FINROW.17.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	32,107
</TD>
<TD ID=TBL2602.FINROW.17.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.17.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	20,424
</TD>
<TD ID=TBL2602.FINROW.17.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.19 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2494 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Loss from operations
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.19.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.19.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.19.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(19,954
</TD>
<TD ID=TBL2602.FINROW.19.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.19.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.19.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.19.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(37,649
</TD>
<TD ID=TBL2602.FINROW.19.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.19.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.19.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.19.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(6,667
</TD>
<TD ID=TBL2602.FINROW.19.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.19.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.19.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.19.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(29,713
</TD>
<TD ID=TBL2602.FINROW.19.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.19.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.19.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.19.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(19,352
</TD>
<TD ID=TBL2602.FINROW.19.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL2602.FINROW.20 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2500 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest expense
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.20.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.20.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.20.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(2,977
</TD>
<TD ID=TBL2602.FINROW.20.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.20.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.20.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.20.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(2,639
</TD>
<TD ID=TBL2602.FINROW.20.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.20.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.20.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.20.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(1,518
</TD>
<TD ID=TBL2602.FINROW.20.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.20.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.20.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.20.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(2,283
</TD>
<TD ID=TBL2602.FINROW.20.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.20.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.20.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.20.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(2,309
</TD>
<TD ID=TBL2602.FINROW.20.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL2602.FINROW.21 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2506 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest income and other income (expense), net
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.21.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	1,720
</TD>
<TD ID=TBL2602.FINROW.21.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	6,935
</TD>
<TD ID=TBL2602.FINROW.21.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(15,241
</TD>
<TD ID=TBL2602.FINROW.21.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.21.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(1,367
</TD>
<TD ID=TBL2602.FINROW.21.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.21.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.21.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	1,560
</TD>
<TD ID=TBL2602.FINROW.21.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.22 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -18PT">
<P ID=PARA2512 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Non-cash interest expense on liability related to sale of future royalties
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.22.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(2,428
</TD>
<TD ID=TBL2602.FINROW.22.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.22.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.22.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.22.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.22.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.22.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.22.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.24 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2524 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss before income taxes
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.24.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.24.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2602.FINROW.24.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(23,639
</TD>
<TD ID=TBL2602.FINROW.24.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.24.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.24.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2602.FINROW.24.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(33,353
</TD>
<TD ID=TBL2602.FINROW.24.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.24.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.24.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2602.FINROW.24.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(23,426
</TD>
<TD ID=TBL2602.FINROW.24.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.24.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.24.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2602.FINROW.24.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(33,363
</TD>
<TD ID=TBL2602.FINROW.24.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.24.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.24.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2602.FINROW.24.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(20,101
</TD>
<TD ID=TBL2602.FINROW.24.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL2602.FINROW.25 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2530 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Provision for income taxes
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.25.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(760
</TD>
<TD ID=TBL2602.FINROW.25.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.25.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.25.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.25.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.25.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.25.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2602.FINROW.25.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.27 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2542 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.27.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.27.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2602.FINROW.27.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(24,399
</TD>
<TD ID=TBL2602.FINROW.27.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.27.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.27.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2602.FINROW.27.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(33,353
</TD>
<TD ID=TBL2602.FINROW.27.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.27.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.27.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2602.FINROW.27.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(23,426
</TD>
<TD ID=TBL2602.FINROW.27.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.27.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.27.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2602.FINROW.27.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(33,363
</TD>
<TD ID=TBL2602.FINROW.27.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.27.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.27.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2602.FINROW.27.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(20,101
</TD>
<TD ID=TBL2602.FINROW.27.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL2602.FINROW.29 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2554 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss per share of common stock, basic
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.29.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.29.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.29.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(0.55
</TD>
<TD ID=TBL2602.FINROW.29.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.29.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.29.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.29.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(0.77
</TD>
<TD ID=TBL2602.FINROW.29.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.29.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.29.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.29.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(0.59
</TD>
<TD ID=TBL2602.FINROW.29.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.29.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.29.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.29.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(1.51
</TD>
<TD ID=TBL2602.FINROW.29.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.29.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.29.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.29.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(1.16
</TD>
<TD ID=TBL2602.FINROW.29.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL2602.FINROW.31 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -18PT">
<P ID=PARA2566 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Shares used in computing net loss per share of common stock, basic
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.31.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	44,300,099
</TD>
<TD ID=TBL2602.FINROW.31.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	43,427,111
</TD>
<TD ID=TBL2602.FINROW.31.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	39,746,678
</TD>
<TD ID=TBL2602.FINROW.31.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	22,124,637
</TD>
<TD ID=TBL2602.FINROW.31.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.31.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	17,344,727
</TD>
<TD ID=TBL2602.FINROW.31.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2602.FINROW.33 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA2578 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss per share of common stock, diluted &#8211; see Note 14
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.33.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.33.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.33.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(0.60
</TD>
<TD ID=TBL2602.FINROW.33.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.33.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.33.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.33.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(0.91
</TD>
<TD ID=TBL2602.FINROW.33.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.33.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.33.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.33.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(0.59
</TD>
<TD ID=TBL2602.FINROW.33.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.33.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.33.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.33.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(1.51
</TD>
<TD ID=TBL2602.FINROW.33.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2602.FINROW.33.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.33.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2602.FINROW.33.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(1.16
</TD>
<TD ID=TBL2602.FINROW.33.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL2602.FINROW.35 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -18PT">
<P ID=PARA2590 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Shares used in computing net loss per share of common stock, diluted
</FONT>
</P>
</TD>
<TD ID=TBL2602.FINROW.35.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	44,468,440
</TD>
<TD ID=TBL2602.FINROW.35.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	44,322,297
</TD>
<TD ID=TBL2602.FINROW.35.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	39,746,678
</TD>
<TD ID=TBL2602.FINROW.35.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	22,124,637
</TD>
<TD ID=TBL2602.FINROW.35.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2602.FINROW.35.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	17,344,727
</TD>
<TD ID=TBL2602.FINROW.35.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
<P ID=PARA2603 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL2670 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL2670.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.1.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.1.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 8.65PT" COLSPAN=18>
<P ID=PARA2605 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	As of December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.1.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2670.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 8.65PT" COLSPAN=2>
<P ID=PARA2608 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 8.65PT" COLSPAN=2>
<P ID=PARA2610 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 8.65PT" COLSPAN=2>
<P ID=PARA2612 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 8.65PT" COLSPAN=2>
<P ID=PARA2614 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2012
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.2.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.2.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 8.65PT" COLSPAN=2>
<P ID=PARA2616 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2011
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.2.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2670.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.3.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.3.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 8.65PT" COLSPAN=18>
<P ID=PARA2619 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(in thousands)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.3.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2670.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	Balance Sheet Data:
</B>
</TD>
<TD ID=TBL2670.FINROW.4.LEAD.B2 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.SYMB.B2 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.AMT.B2 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.TRAIL.B2 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.LEAD.B3 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.SYMB.B3 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.AMT.B3 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.TRAIL.B3 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.LEAD.B4 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.SYMB.B4 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.AMT.B4 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.TRAIL.B4 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.LEAD.B5 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.SYMB.B5 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.AMT.B5 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.TRAIL.B5 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.LEAD.B6 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.SYMB.B6 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.AMT.B6 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2670.FINROW.4.TRAIL.B6 STYLE="VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2670.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2622 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash, cash equivalents and short-term investments
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2670.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	113,464
</TD>
<TD ID=TBL2670.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2670.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	75,350
</TD>
<TD ID=TBL2670.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2670.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	103,663
</TD>
<TD ID=TBL2670.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2670.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	59,763
</TD>
<TD ID=TBL2670.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.5.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.5.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2670.FINROW.5.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	35,785
</TD>
<TD ID=TBL2670.FINROW.5.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2670.FINROW.6 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2628 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Working capital
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	106,167
</TD>
<TD ID=TBL2670.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	62,567
</TD>
<TD ID=TBL2670.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	97,692
</TD>
<TD ID=TBL2670.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	47,435
</TD>
<TD ID=TBL2670.FINROW.6.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.6.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	30,301
</TD>
<TD ID=TBL2670.FINROW.6.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2670.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2634 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total assets
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	127,785
</TD>
<TD ID=TBL2670.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	86,416
</TD>
<TD ID=TBL2670.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	110,031
</TD>
<TD ID=TBL2670.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	64,520
</TD>
<TD ID=TBL2670.FINROW.7.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.7.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	40,835
</TD>
<TD ID=TBL2670.FINROW.7.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2670.FINROW.8 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2640 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Long-term debt
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	20,922
</TD>
<TD ID=TBL2670.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	24,874
</TD>
<TD ID=TBL2670.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	14,364
</TD>
<TD ID=TBL2670.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	15,973
</TD>
<TD ID=TBL2670.FINROW.8.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.8.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	19,079
</TD>
<TD ID=TBL2670.FINROW.8.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2670.FINROW.9 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2646 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Liability related to sale of future royalties
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	63,612
</TD>
<TD ID=TBL2670.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL2670.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL2670.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL2670.FINROW.9.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.9.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL2670.FINROW.9.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2670.FINROW.10 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2652 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PIPE warrant liability
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	913
</TD>
<TD ID=TBL2670.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	5,577
</TD>
<TD ID=TBL2670.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	13,111
</TD>
<TD ID=TBL2670.FINROW.10.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	7,418
</TD>
<TD ID=TBL2670.FINROW.10.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.10.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL2670.FINROW.10.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2670.FINROW.11 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2658 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accumulated deficit
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	(203,205
</TD>
<TD ID=TBL2670.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2670.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	(178,806
</TD>
<TD ID=TBL2670.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2670.FINROW.11.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.11.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.11.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	(145,453
</TD>
<TD ID=TBL2670.FINROW.11.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2670.FINROW.11.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.11.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.11.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	(122,027
</TD>
<TD ID=TBL2670.FINROW.11.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL2670.FINROW.11.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.11.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.11.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #FFFFFF">
	(88,664
</TD>
<TD ID=TBL2670.FINROW.11.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL2670.FINROW.12 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2664 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total stockholders&#8217; equity
</FONT>
</P>
</TD>
<TD ID=TBL2670.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	33,113
</TD>
<TD ID=TBL2670.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	46,656
</TD>
<TD ID=TBL2670.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	73,159
</TD>
<TD ID=TBL2670.FINROW.12.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	33,847
</TD>
<TD ID=TBL2670.FINROW.12.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2670.FINROW.12.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 8.65PT; BACKGROUND-COLOR: #CCEEFF">
	17,468
</TD>
<TD ID=TBL2670.FINROW.12.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA2672 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK57 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR57 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM57 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	62
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage63"></A>
<DIV ID=PGHDR57 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_FINANCIAL_DATA>
<P ID=PARA57.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<P ID=PARA2673 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations
</B>
</FONT>
</P>
<P ID=PARA2675 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2674 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	The following discussion and analysis should be read in conjunction with our audited financial statements and the related notes that appear elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements within the meaning of Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements involve risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under &#8220;Item 1A. Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. Please refer to the section entitled &#8220;Forward-Looking Statements&#8221; in this Annual Report on Form 10-K.
</I>
</FONT>
</P>
<P ID=PARA2677 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2676 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Overview
</B>
</FONT>
</P>
<P ID=PARA2679 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2678 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. Our lead product candidates, ARX-04 and Zalviso, utilize sublingual sufentanil, delivered via a non-invasive route of administration. We intend to commercialize our product candidates in the United States and license the development and commercialization rights to our product candidates for sale outside of the United States through strategic partnerships and collaborations. We may also consider the option to enter into strategic partnerships for our product candidates in the United States.
</FONT>
</P>
<P ID=PARA2680 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2681 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	ARX-04 (sufentanil sublingual tablet, 30 mcg)
</I>
</FONT>
</P>
<P ID=PARA2682 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2683 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04 is an investigational product candidate consisting of a single tablet delivered via a disposable, pre-filled, single-dose applicator, or SDA. We are developing ARX-04 for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings of acute pain. If approved, examples of potential patient populations and settings in which ARX-04 could be used include: emergency room patients; patients who are recovering from short-stay or ambulatory surgery and do not require more long-term patient-controlled analgesia; post-operative patients who are transitioning from the operating room to the recovery floor; patients being treated and transported by paramedics; and for battlefield casualties.
</FONT>
</P>
<P ID=PARA2684 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2685 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In September 2015, we reported that SAP301, a pivotal Phase 3 multi-center, double-blind, placebo-controlled study of ARX-04, met primary and secondary endpoints in the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery. SAP301 is considered the second of two pivotal placebo-controlled studies required to be included in the NDA submission.
</FONT>
</P>
<P ID=PARA71 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA70 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In October 2015, we announced the initiation of an open-label Phase 3 study, SAP302, of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. The primary efficacy endpoint is the summed pain intensity difference, or SPID, over 1-hour, or SPID-1. Safety endpoints, such as adverse events and vital signs will also be assessed, as will the patients&#8217; and healthcare providers&#8217; satisfaction with the method of pain control. Based on discussions with the FDA, we have amended the protocol for SAP302 to allow for multiple dosing of ARX-04. We are planning to enroll an additional 60 patients in the extension phase of the SAP302 study. The SAP302 study is expected to be completed by the third quarter of 2016.
</FONT>
</P>
<P ID=PARA72 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA73 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We held a pre-NDA meeting with the FDA in December 2015 to review plans for an NDA for ARX-04. Based on discussions with the FDA, we intend to increase the safety database by expanding the clinical program for ARX-04 by approximately 160 additional patients to include individuals from specific populations and settings. Enrollment in the ongoing SAP302 open-label study in the emergency room will be increased as described above, and a new study, known as SAP303, was initiated in March 2016 in post-operative patients with moderate-to-severe acute pain. SAP303 will focus on enrolling patients greater than 40 years of age and will allow for administration of ARX-04 for up to 12 hours. With these modifications, assuming successful completion of SAP302 and SAP303 by the third quarter of 2016, AcelRx anticipates submitting the NDA for ARX-04 in the fourth quarter of 2016.
</FONT>
</P>
<P ID=PARA74 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA2691 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The FDA has also agreed to allow us to include as supporting safety information in the NDA for ARX-04, data from approximately 323 patients treated in the Zalviso clinical studies who had administered two 15 mcg tablets 20-to-25 minutes apart. AcelRx had previously completed and analyzed pharmacokinetic and modeling data, which demonstrated the equivalency of one sufentanil sublingual tablet, 30 mcg, to two sufentanil sublingual tablets, 15 mcg, taken 20-to-25 minutes apart.
</FONT>
</P>
<P ID=PARA2692 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK58 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR58 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM58 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	63
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage64"></A>
<DIV ID=PGHDR58 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA58.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA195 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On May 11, 2015, we entered into an award contract supported by the United States Army Medical Research and Materiel Command, or USAMRMC, within the U.S. Department of Defense, or the DoD, in which the DoD agreed to provide up to $17.0 million to support the development of ARX-04, referred to as the DoD Contract. Under the terms of the contract, the DoD will reimburse us for costs incurred for development, manufacturing, regulatory and clinical costs outlined in the contract in order to submit an NDA to the FDA, including reimbursement for certain personnel and overhead expenses. The period of performance under the DoD Contract began on May 11, 2015. The contract gives the DoD the option to extend the term of the contract and provide additional funding. On March 2, 2016, the DoD Contract was amended
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	to approve enrollment of additional patients in the SAP302 study, approve the addition of the SAP303 study, and extend the contract period of performance by four months from November 10, 2016 to March 9, 2017, to accommodate the increased SAP302 patient enrollment and the SAP303 study. The costs for these changes will be absorbed within the current contract value. If ARX-04 is approved by the FDA, the DoD has the option to purchase a certain number of units of commercial product pursuant to the terms of the contract.
</FONT>
</P>
<P ID=PARA197 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</FONT>
<P ID=PARA2695 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Zalviso&#8482; (sufentanil sublingual tablet system)
</I>
</FONT>
</P>
<P ID=PARA2696 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2697 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our product candidate, Zalviso, is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of sufentanil sublingual tablets, 15 mcg, delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system, or together, Zalviso.
</FONT>
</P>
<P ID=PARA2698 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2699 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Zalviso is a pre-programmed, non-invasive, system to allow hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets, 15 mcg, to manage their pain. Zalviso is designed to help address certain problems associated with post-operative intravenous patient-controlled analgesia. Zalviso allows patients to self-administer sufentanil sublingual tablets via a pre-programmed, secure system designed to eliminate the risk of programming errors.
</FONT>
</P>
<P ID=PARA2700 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2701 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December 16, 2013, AcelRx and Gr&#252;nenthal entered into a Collaboration and License Agreement, which was amended effective July 17, 2015, or the Amended License Agreement, which grants Gr&#252;nenthal rights to commercialize Zalviso in the countries of the European Union, or EU, Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory, for human use in pain treatment within or dispensed by hospitals, hospices, nursing homes and other medically-supervised settings, or the Field. We retain rights with respect to Zalviso in countries outside the Territory, including the United States, Asia and Latin America. In September 2015, the European Commission approved the Marketing Authorization Application, or MAA, previously submitted to the European Medicines Agency, or EMA, for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. The approval allows Gr&#252;nenthal to market Zalviso in the 28 EU member states as well as in the European Economic Area countries of Norway, Iceland and Liechtenstein, or EEA.
</FONT>
</P>
<P ID=PARA81 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA80 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the terms of the Amended License Agreement, we received an upfront cash payment of $30.0 million in December 2013, a milestone payment of $5.0 million related to the Marketing Authorization Application, or MAA, submission to the European Medicines Agency, or EMA, in the third quarter of 2014, and an additional milestone payment of $15.0 million upon EC approval of the MAA for Zalviso in the third quarter of 2015. In addition, we are eligible to receive approximately $194.5 million in additional milestone payments, based upon successful regulatory and product development efforts ($28.5 million) and net sales target achievements ($166.0 million). PDL BioPharma, Inc., or PDL, will receive 75% of the European royalties under the Amended License Agreement with Gr&#252;nenthal, as well as 80% of the first four commercial milestones worth $35.6 million (or 80% of $44.5 million), subject to a capped amount, as further described below. Gr&#252;nenthal will also make tiered royalty, supply and trademark fee payments in the mid-teens up to the mid-twenties percent range, depending on the sales level achieved, on net sales of Zalviso in the Territory. A portion of the tiered royalty payment, exclusive of the supply and trademark fee payments, will be paid to PDL in connection with the Royalty Monetization, as discussed below.
</FONT>
</P>
<P ID=PARA82 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA2705 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Also on December 16, 2013, we entered into the related Manufacture and Supply Agreement with Gr&#252;nenthal, which was amended effective July 17, 2015, or the Amended MSA, and together with the Amended License Agreement, the Amended Agreements. Under the Amended MSA, we will exclusively manufacture and supply Zalviso to Gr&#252;nenthal for the Field in the Territory. For additional information on the Amended Agreements, see Note 6 &#8220;Collaboration Agreement&#8221; in the accompanying notes to the Consolidated Financial Statements.
</FONT>
</P>
<P ID=PARA2706 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2707 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the Amended Agreements, the parties amended the Zalviso supply configurations and packaging of Zalviso components and accessories, and associated pricing therefor, which we will manufacture and supply to Gr&#252;nenthal for the Territory. The parties agreed to increase the pricing of the Zalviso components and accessories, while reducing the total milestone payments due from Gr&#252;nenthal, contingent upon achieving specified net sales targets, from a total of $171.5 million to $166.0 million. The parties also updated the development plan for Zalviso in the Territory, providing for additional near-term development services to be rendered by AcelRx in exchange for payments of approximately $0.7 million, primarily in 2015. Simultaneously, AcelRx also received a binding Zalviso product forecast from Gr&#252;nenthal for approximately $3.7 million.
</FONT>
</P>
<P ID=PARA2708 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK59 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR59 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM59 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	64
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage65"></A>
<DIV ID=PGHDR59 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA59.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2709 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September 18, 2015, we sold a portion of the expected royalty stream and commercial milestones from the sales of Zalviso in the EU by Gr&#252;nenthal to PDL, or the Royalty Monetization. AcelRx received gross proceeds of $65.0 million in the Royalty Monetization. PDL will receive 75% of the European royalties under the Amended License Agreement with Gr&#252;nenthal, as well as 80% of the first four commercial milestones worth $35.6 million (or 80% of $44.5 million), subject to the capped amount of $195.0 million. For additional information on the Royalty Monetization with PDL, see Note 8 &#8220;Liability Related to Sale of Future Royalties&#8221; in the accompanying notes to the Consolidated Financial Statements.
</FONT>
</P>
<P ID=PARA2710 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2711 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal will be responsible for all commercial activities for Zalviso, including obtaining and maintaining pharmaceutical product regulatory approval in the Territory. We will be responsible for obtaining and maintaining device regulatory approval in the Territory and the manufacturing and supply of Zalviso to Gr&#252;nenthal for commercial sales.
</FONT>
</P>
<P ID=PARA2712 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2713 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In association with the impending commercialization of Zalviso in the European Union, we completed the Conformite Europeenne approval process for the Zalviso device, more commonly known as a CE Mark approval process. We received CE Mark approval in December 2014, which permits the commercial sale of the Zalviso device in the European Union. In connection with the CE Mark approval, we were also granted International Standards Organization, or ISO, 13485:2003 certification of our quality management system in November 2014. This is an internationally recognized quality standard for medical devices. Certification of our quality management system was issued by the British Standards Institution, or BSI, a Notified Body. The certification applies to the Redwood City, California location which designs, manufactures and distributes finished medical devices, and includes critical suppliers.
</FONT>
</P>
<P ID=PARA2714 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2715 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We submitted an NDA for Zalviso in September 2013, which the FDA accepted for filing in December 2013. On July 25, 2014, the FDA issued a Complete Response Letter, or CRL, for the Zalviso NDA. The CRL contains requests for additional information on the Zalviso System to ensure proper use of the device. The requests include submission of data demonstrating a reduction in the incidence of optical system errors, changes to address inadvertent dosing, among other items, and submission of additional data to support the shelf life of the product. Although there were no requests for additional clinical studies in the CRL, in March 2015, we received correspondence from the FDA stating that, in addition to the work we had performed to address the items in the CRL, a clinical study would be required to test modifications to the Zalviso device.
</FONT>
</P>
<P ID=PARA2716 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2717 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our IAP312 study is designed to evaluate the effectiveness of changes made to enhance performance of the Zalviso device and takes into account comments from the FDA on the protocol. The IAP312 study will include approximately 315 post-operative patients and collect information requested by the Division to supplement the three positive Phase 3 trials already completed.&nbsp;AcelRx plans to initiate the study in the first quarter of 2016.
</FONT>
</P>
<P ID=PARA2718 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2719 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Financial Overview
</B>
</FONT>
</P>
<P ID=PARA2721 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2720 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have incurred net losses and generated negative cash flows from operations since inception and expect to incur losses in the future as we continue our research and development activities and pre-commercialization activities. As we pursue development of our product candidates, including regulatory review and potential commercial development, subject to FDA approval, of our product candidates, we expect the business aspects of our company to become more complex. In the future, we plan to add personnel and incur additional costs related to the maturation of our business and the potential commercialization of ARX-04 and Zalviso in the United States. In addition, we believe that continued investment in research and development is critical to attaining our strategic objectives. In order to develop our product candidates as commercially viable therapeutics, we expect to expend significant resources for expertise in manufacturing, regulatory affairs, clinical research and other aspects of pharmaceutical development.
</FONT>
</P>
<P ID=PARA2723 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2722 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To date, we have funded our operations primarily through the issuance of equity securities, borrowings, payments from our commercial partner, Gr&#252;nenthal, monetization of certain future royalties and commercial sales milestones from the sales of Zalviso by Gr&#252;nenthal, and funding from the DoD.
</FONT>
</P>
<P ID=PARA2725 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2724 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our revenues since inception have consisted primarily of revenues from our Amended License Agreement with Gr&#252;nenthal and our research contracts with the USAMRMC within the DoD. As mentioned above, in May 2015, the DoD agreed to provide us up to $17.0 million to support the development of ARX-04. Under the terms of the contract, the DoD will reimburse us for costs incurred for development, manufacturing, regulatory and clinical costs outlined in the contract in order to submit an NDA to the FDA, including reimbursement for certain personnel and overhead expenses.
</FONT>
</P>
<P ID=PARA2727 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2726 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There can be no assurance that we will enter into other collaborative agreements or receive research-related contract awards in the future. We expect revenues to continue to fluctuate from period-to-period. There can be no assurance that our relationship with our existing commercial partner, Gr&#252;nenthal, will continue beyond the initial term, or that we will be able to meet the milestones specified in the Amended License Agreement, or that the funding provided by the DoD Contract will be sufficient for an NDA submission for ARX-04, or that we will obtain marketing approval for any of our product candidates outside of Zalviso in the EU and EEA and subsequently generate revenue from those product candidates in excess of our operating expenses.
</FONT>
</P>
<P ID=PARA2729 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK60 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR60 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM60 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	65
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage66"></A>
<DIV ID=PGHDR60 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA60.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2728 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our net losses were $24.4 million and $33.4 million during the years ended December&nbsp;31, 2015 and 2014, respectively. As of December&nbsp;31, 2015, we had an accumulated deficit of $203.2 million. As of December&nbsp;31, 2015, we had cash, cash equivalents and investments totaling $113.5 million compared to $75.4 million as of December&nbsp;31, 2014.
</FONT>
</P>
<P ID=PARA2731 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2730 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As mentioned above, on September 18, 2015, we sold a portion of the expected royalty stream and commercial milestones from the sales of Zalviso in the EU by Gr&#252;nenthal to PDL under the Royalty Monetization. We received gross proceeds of $65.0 million from the Royalty Monetization.
</FONT>
</P>
<P ID=PARA2733 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2732 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the first step of the Royalty Monetization, we sold certain royalty and milestone payment rights to our newly formed wholly owned subsidiary, ARPI LLC, pursuant to a Purchase and Sale Agreement, or PSA. In the second step of the Royalty Monetization, ARPI LLC sold the royalty and milestone payment rights to PDL for an upfront cash purchase price of $65.0 million, subject to a capped amount of $195.0 million pursuant to the Subsequent Purchase and Sale Agreement, or SPSA. Under the SPSA, PDL will receive 75% of the European royalties under the Amended License Agreement with Gr&#252;nenthal, as well as 80% of the first four commercial milestones worth $35.6 million (or 80% of $44.5 million), subject to the capped amount of $195.0 million. We are entitled to receive all remaining amounts under the Amended License Agreement which include 25% of the European royalties, 20% of the first four commercial milestones, 100% of the remaining commercial milestones and all development milestones of $43.5 million, including the $15.0 million payment for the approval of the MAA for Zalviso, which the European Commission approved in September 2015.
</FONT>
</P>
<P ID=PARA2735 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2734 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The total liability related to sale of future royalties to PDL as of December 31, 2015 was $63.6 million.
</FONT>
</P>
<P ID=PARA2737 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2736 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December 16, 2013, we entered into an Amended and Restated Loan and Security Agreement with Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc., together, the Lenders, or the Amended Loan Agreement, under which we may borrow up to $40.0 million in three tranches. The loans are represented by secured convertible term promissory notes, collectively, the Notes. The Amended Loan Agreement amends and restates the Loan and Security Agreement between AcelRx and the Lenders dated as of June 29, 2011. We borrowed the first tranche of $15.0 million upon closing of the transaction on December 16, 2013, and the second tranche of $10.0 million on June 16, 2014. We used approximately $8.6 million of the proceeds from the first tranche to repay our obligations under the Loan and Security Agreement with the Lenders. We recorded the new debt at an estimated fair value of $24.9 million as of December 31, 2014.
</FONT>
</P>
<P ID=PARA2738 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2739 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September 24, 2014, we entered into Amendment No. 1 to the Amended Loan Agreement with Hercules. Amendment No. 1 extended the time period under which we could draw down the third tranche, of up to $15.0 million, from March 15, 2015 to August 1, 2015, subject to AcelRx obtaining approval for Zalviso from the FDA. We did not receive FDA approval of Zalviso by August 1, 2015 and as such, did not have access to the third tranche.
</FONT>
</P>
<P ID=PARA84 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA83 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September 18, 2015, concurrently with the closing of the Royalty Monetization, we entered into a Consent and Amendment No. 2, or Amendment No. 2, to the Amended Loan Agreement with the Lenders. Amendment No. 2 includes an interest only period from October 1, 2015 through March 31, 2016, with the potential for further extension to September 30, 2016 upon satisfaction of certain conditions, which have since been satisfied. After the expiration of the interest only period, we will make 13 monthly payments of $1.7 million beginning in October 2016 through October 2017. In addition, a final payment equal to $1.7 million will be due in October 2017. Loans under the Amended Loan Agreement mature on October 31, 2017. In consideration for the modifications made in Amendment No. 2, we reduced the exercise price of the warrants already held by the Lenders, which are exercisable for an aggregate of 176,730 shares of Common Stock, from the previous exercise price of $6.79 per share to $3.88 per share, or the Warrant Amendments. These warrants expire on the earlier to occur of five years from the date of issuance, or December 16, 2018, or the consummation of certain acquisitions of AcelRx, as set forth in the warrants.
</FONT>
</P>
<P ID=PARA85 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA2743 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The interest rate for each tranche will be calculated at a rate equal to the greater of either (i)&nbsp;9.10% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii)&nbsp;9.10%. Payments under the Amended Loan Agreement were interest only until April 1, 2015, followed by equal monthly payments of principal and interest through September 30, 2015, to be followed by an interest only period from October 1, 2015 through September 30, 2016, and by equal monthly payments of principal and interest from October 1, 2016 through the scheduled maturity date on October 1, 2017, or the Loan Maturity Date.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, a final payment equal to $1.7 million will be due on the Loan Maturity Date, or such earlier date specified in the Amended Loan Agreement. Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, other than our intellectual property and those assets sold under the Royalty Monetization
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	.
</FONT>
</P>
<P ID=PARA2744 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK61 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR61 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM61 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	66
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage67"></A>
<DIV ID=PGHDR61 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA61.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2745 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December 31, 2015, the outstanding principal owed to Hercules was $20.9 million.
</FONT>
</P>
<P ID=PARA2746 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2747 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December&nbsp;16, 2013, we and Gr&#252;nenthal entered into a Collaboration and License Agreement, or the License Agreement, and related Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. The License Agreement grants Gr&#252;nenthal rights to commercialize Zalviso, or the Product, in the Territory for human use in pain treatment in the Field. We retain rights with respect to the Product in countries outside the Territory, including the United States, Asia and Latin America. Under the MSA, we will exclusively manufacture and supply the Product to Gr&#252;nenthal for the Field in the Territory. On July 22, 2015, we entered into amendments to the License Agreement, or the License Amendment, and together with the License Agreement, the Amended License Agreement, and the MSA, or the MSA Amendment, and together with the MSA, the Amended MSA, between AcelRx and Gr&#252;nenthal, each effective as of July 17, 2015, and together, the Amended Agreements.
</FONT>
</P>
<P ID=PARA2749 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2748 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the Amended Agreements, the parties amended the Product supply configurations and packaging of Product components and accessories, and associated pricing therefor, which we will manufacture and supply to Gr&#252;nenthal for the Territory. The parties agreed to increase the pricing of the Product components and accessories, while reducing the total milestone payments due from Gr&#252;nenthal contingent upon achieving specified net sales targets from a total of $171.5 million to $166.0 million. As mentioned above, PDL will receive 75% of the European royalties under the Amended License Agreement with Gr&#252;nenthal, as well as 80% of the first four commercial milestones worth $35.6 million (or 80% of $44.5 million), subject to the capped amount of $195.0 million. The parties also updated the development plan for the Product in the Territory, providing for additional near-term development services to be rendered by AcelRx in exchange for payments of approximately $0.7 million, primarily in 2015. Simultaneously, AcelRx also received a binding Product forecast from Gr&#252;nenthal for approximately $3.7 million.
</FONT>
</P>
<P ID=PARA88 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA87 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the terms of the Amended Agreements with Gr&#252;nenthal, we received an upfront cash payment of $30.0 million in December 2013, and in the third quarter of 2014, we received a milestone payment of $5.0 million related to the MAA submission to EMA and an additional milestone payment of $15.0 million related to the EC approval of the MAA for Zalviso in the third quarter of 2015. Under the Amended License Agreement, we are eligible to receive approximately $194.5 million in additional milestone payments, based upon successful regulatory and product development efforts ($28.5 million) and net sales target achievements ($166.0 million). Gr&#252;nenthal will also make tiered royalty, supply and trademark fee payments in the mid-teens up to the mid-twenties percent range, depending on the level of sales achieved, on net sales of Zalviso in the Territory. A portion of the tiered royalty payment, exclusive of the supply and trademark fee payments, will be paid to PDL in connection with the Royalty Monetization. For additional information on the Royalty Monetization with PDL, see Note 8 &#8220;Liability Related to Sale of Future Royalties&#8221; in the accompanying notes to the Consolidated Financial Statements.
</FONT>
</P>
<P ID=PARA89 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA2752 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal will be responsible for all commercial activities for Zalviso, including obtaining and maintaining pharmaceutical product regulatory approval in the Territory.&nbsp;We will be responsible for obtaining and maintaining device regulatory approval in the Territory and manufacturing and supply of Zalviso to Gr&#252;nenthal for commercial sales.
</FONT>
</P>
<P ID=PARA2755 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2754 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Critical Accounting Estimates
</B>
</FONT>
</P>
<P ID=PARA2757 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2756 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Based on a critical assessment of our accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that our Consolidated Financial Statements are fairly stated in accordance with accounting principles generally accepted in the United States, and meaningfully present our financial condition and results of operations.
</FONT>
</P>
<P ID=PARA2759 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2758 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The accompanying discussion and analysis of our financial condition and results of operations are based upon our Consolidated Financial Statements and the related disclosures, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our Consolidated Financial Statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected. Note&nbsp;1 &#8220;Organization and Summary of Significant Accounting Policies&#8221;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	in the accompanying Notes to Consolidated Financial Statements describes the significant accounting policies used in the preparation of the financial statements. Certain of these significant accounting policies are considered to be critical accounting policies, as defined below.
</FONT>
</P>
<P ID=PARA2761 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK62 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR62 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM62 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	67
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage68"></A>
<DIV ID=PGHDR62 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA62.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2760 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: (i)&nbsp;we are required to make assumptions about matters that are highly uncertain at the time of the estimate; and (ii)&nbsp;different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.
</FONT>
</P>
<P ID=PARA2763 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2762 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We believe the following policies to be the most critical to an understanding of our financial condition and results of operations because they require us to make estimates, assumptions and judgments about matters that are inherently uncertain. Management has discussed the development, selection and disclosure of the following estimates with the Audit Committee.
</FONT>
</P>
<P ID=PARA2765 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2764 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Revenue Recognition
</I>
</B>
</FONT>
</P>
<P ID=PARA2767 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2766 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We recognize revenue when all of the following four basic revenue recognition criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured.
</FONT>
</P>
<P ID=PARA2769 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2768 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Revenue generated from collaboration agreements typically includes upfront signing or license fees, cost reimbursements, development and manufacturing services, milestone payments and royalties on future licensee&#8217;s product sales.
</FONT>
</P>
<P ID=PARA2771 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2770 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Revenue from non-refundable license, technology access or other payments under license and collaborative agreements where we have a continuing obligation to perform is recognized as revenue over the expected period of the continuing performance obligation. We estimate the performance period at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which the remaining revenue is recognized. Changes to these estimates are recorded on a prospective basis.
</FONT>
</P>
<P ID=PARA2773 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2772 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We account for multiple-element arrangements, such as license and commercialization agreements in which a customer may purchase several deliverables, in accordance with ASC Topic 605-25,
<I>
	Revenue Recognition&#8212;Multiple-Element Arrangements
</I>
	, or ASC 605-25. We evaluate if the deliverables in the arrangement represent separate units of accounting. In determining the units of accounting, we evaluate certain criteria, including whether the deliverables have value to our customers on a stand-alone basis. Factors considered in this determination include whether the deliverable is proprietary to us, whether the customer can use the license or other deliverables for their intended purpose without the receipt of the remaining elements, whether the value of the deliverable is dependent on the undelivered items, and whether there are other vendors that can provide the undelivered items. Deliverables that meet these criteria are considered a separate unit of accounting. Deliverables that do not meet these criteria are combined and accounted for as a single unit of accounting.
</FONT>
</P>
<P ID=PARA2774 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2775 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For revenue agreements with multiple-element arrangements, such as the collaboration and license agreement with Gr&#252;nenthal, we allocate revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, we determine the selling price for each deliverable using vendor-specific objective evidence, or
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	VSOE, of selling price or third-party evidence, or
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	TPE, of selling price. If neither exists we use best estimated selling price, or
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	BESP, for that deliverable. Revenue allocated is then recognized when the four basic revenue recognition criteria, mentioned above, are met for each element.
</FONT>
</P>
<P ID=PARA2777 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2776 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additionally, we recognize milestone payments, which are subject to substantive contingencies, upon completion of specified milestones, which represents the culmination of an earnings process, according to contract terms. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured.
</FONT>
</P>
<P ID=PARA2778 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2779 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In May 2015, we entered into an award contract with the USAMRMC to support the development of ARX-04. The contract provides for the reimbursement of qualified expenses for research and development activities as defined under the terms of the contract. Revenue under the contract is recognized when the related qualified research expenses are incurred. We are entitled to reimbursement of overhead costs associated with the study costs incurred under the DoD Contract. We estimate this overhead rate by utilizing forecasted expenditures. Final reimbursable overhead expenses are dependent on direct labor and direct reimbursable expenses throughout the life of the contract, which may increase or decrease based on actual expenses incurred.
</FONT>
</P>
<P ID=PARA2781 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2780 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Deferred revenue represents the portion of research or license payments received which have not been earned.
</FONT>
</P>
<P ID=PARA2783 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2782 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Inventories
</I>
</B>
</FONT>
</P>
<P ID=PARA2785 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2784 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Inventories are valued at the lower of cost or market. Cost is determined using the first-in, first-out method for all inventories. Inventory includes the cost of active pharmaceutical ingredients, or API, raw materials and third-party contract manufacturing and packaging services. Indirect overhead costs associated with production and distribution are allocated to the appropriate cost pool and then absorbed into inventory based on the units produced or distributed, assuming normal capacity, in the applicable period. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.
</FONT>
</P>
<P ID=PARA2787 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK63 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR63 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM63 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	68
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage69"></A>
<DIV ID=PGHDR63 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA63.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2786 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. We periodically evaluate the carrying value of inventory on hand for potential excess amount over demand using the same lower of cost or market approach as that used to value the inventory.
<B>
<I>
</I>
</B>
	Because selling prices to Gr&#252;nenthal
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	are set to recover only direct costs with minimal markup, all inventories are carried at net realizable value.
<B>
<I>
</I>
</B>
</FONT>
</P>
<P ID=PARA2789 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2788 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 10PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Cost of Goods Sold
</I>
</B>
</FONT>
</P>
<P ID=PARA2790 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2791 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cost of goods sold for Zalviso shipped to
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal includes the inventory costs of API, third-party contract manufacturing costs, packaging and distribution costs, shipping, handling and storage costs, depreciation and costs of the employees involved with production.
</FONT>
</P>
<P ID=PARA2792 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2793 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Research and Development Expenses
</I>
</B>
</FONT>
</P>
<P ID=PARA2795 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2794 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We expense research and development expenses as incurred. Research and development expenses consist primarily of direct and research-related allocated overhead costs such as facilities costs, salaries and related personnel costs, and material and supply costs. In addition, research and development expenses include costs related to clinical trials to validate our testing processes and procedures and related overhead expenses. Expenses resulting from clinical trials are recorded when incurred based in part on factors such as estimates of work performed, patient enrollment, progress of patient studies and other events. We make good faith estimates that we believe to be accurate, but the actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan.
</FONT>
</P>
<P ID=PARA2797 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2796 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Share-Based Compensation
</I>
</B>
</FONT>
</P>
<P ID=PARA2799 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2798 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We measure and recognize compensation expense for all share-based payment awards made to our employees and directors, including employee stock options and employee stock purchases related to the Employee Share Purchase Plan, or ESPP, on estimated fair values. The fair value of equity-based awards is amortized over the vesting period of the award using a straight-line method.
</FONT>
</P>
<P ID=PARA2801 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2800 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To estimate the value of an award, we use the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. Estimates of expected life are primarily determined using the simplified method in accordance with guidance provided by the Securities and Exchange Commission, or SEC. Volatility is derived from historical volatilities of several public companies within our industry that are deemed to be comparable to our business because we do not have sufficient history on the volatility of our common stock relative to our expected life assumptions. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. We review our valuation assumptions quarterly and, as a result, it is likely we will change our valuation assumptions used to value share based awards granted in future periods. Further, we are required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. If factors change and different assumptions are employed in determining the fair value of stock based awards, the stock based compensation expense recorded in future periods may differ significantly from what was recorded in the current period.
</FONT>
</P>
<P ID=PARA2803 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2802 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Liabilities Associated with Warrants
</I>
</B>
</FONT>
</P>
<P ID=PARA2805 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2804 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Warrants to Purchase Common Stock
</I>
</FONT>
</P>
<P ID=PARA2807 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2806 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In connection with the private placement equity financing in June 2012, or PIPE, we issued PIPE warrants to purchase up to 2,630,103 shares of common stock. Under the terms of the PIPE warrants, upon certain transactions, including a merger, tender offer, sale of all or substantially all of the assets of AcelRx or if a person or group shall become the owner of 50% of our issued and outstanding common stock, which is outside of our control, each PIPE warrant holder may elect to receive a cash payment in exchange for the warrant, in an amount determined by application of the Black-Scholes option-pricing model. Accordingly, the PIPE warrants are recorded as a liability at fair value at the end of each reporting period, as determined by the Black-Scholes option-pricing model and changes to the fair value are recorded in interest income and other income (expense), net. The inputs for the Black-Scholes option-pricing model include exercise price of the PIPE warrants, market price of the underlying common shares, expected term, volatility based on a group of our peers and the risk-free rate corresponding to the expected term of the PIPE warrants. These inputs are subjective and generally require significant analysis and judgment to develop. Changes to the inputs could significantly impact the estimated fair value of the PIPE warrants, and since issuance of the PIPE warrants through December&nbsp;31, 2015, changes in our stock price have had a significant impact to the estimated fair value of the PIPE warrants.
</FONT>
</P>
<P ID=PARA2809 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK64 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR64 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM64 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	69
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage70"></A>
<DIV ID=PGHDR64 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA64.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2808 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
</I>
</B>
</FONT>
</P>
<P ID=PARA2810 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2811 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In September 2015,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by our commercial partner, Gr&#252;nenthal, pursuant to the Collaboration and License Agreement, dated as of December 16, 2013, as amended, to PDL for an upfront cash purchase price of $65.0 million. We continue to have significant continuing involvement in the Royalty Monetization primarily due to our obligation to act as the intermediary for the supply of Zalviso to
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal. Under the relevant accounting guidance, because of our significant continuing involvement, the Royalty Monetization has been accounted for as a liability that will be amortized using the interest method over the life of the arrangement. In order to determine the amortization of the liability, we are required to estimate the total amount of future royalty and milestone payments to be received by PDL and payments we are required to make to PDL, up to a capped amount of $195.0 million, over the life of the arrangement. The sum of the capped amount of $195.0 million, less the $61.2 million of net proceeds we received will be recorded as interest expense over the life of the liability. Consequently, we impute interest on the unamortized portion of the liability and record interest expense using an estimated interest rate for an arms-length debt transaction. Our estimate of the interest rate under the arrangement is based on the amount of royalty and milestone payments expected to be received by PDL over the life of the arrangement. Our estimate of this total interest expense resulted in an effective annual interest rate of approximately 14%. We will periodically assess the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the liability and the interest rate.
</FONT>
</P>
<P ID=PARA2813 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2812 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We will record non-cash royalty revenues and non-cash interest expense within our Consolidated Statements of Comprehensive Loss over the term of the PDL agreement.
</FONT>
</P>
<P ID=PARA2814 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P ID=PARA2815 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Results of Operations
</B>
</FONT>
</P>
<P ID=PARA2817 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2816 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our results of operations have fluctuated from period to period and may continue to fluctuate in the future, based upon the progress of our research and development efforts and variations in the level of expenses related to developmental efforts during any given period. Results of operations for any period may be unrelated to results of operations for any other period. In addition, historical results should not be viewed as indicative of future operating results. We are subject to risks common to companies in our industry and at our stage of development, including risks inherent in our research and development efforts, reliance upon our collaborator, enforcement of our patent and proprietary rights, need for future capital, potential competition and uncertainty of clinical trial results or regulatory approvals or clearances. In order for a product candidate to be commercialized based on our research, we and our collaborators must conduct preclinical tests and clinical trials, demonstrate the efficacy and safety of our product candidates, obtain regulatory approvals or clearances and enter into manufacturing, distribution and marketing arrangements, as well as obtain market acceptance.
</FONT>
</P>
<P ID=PARA2818 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P ID=PARA2819 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Years Ended December&nbsp;31, 2015, 2014 and 2013
</I>
</B>
</FONT>
</P>
<P ID=PARA2821 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2820 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Revenue
</I>
</FONT>
</P>
<P ID=PARA2823 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA90 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To date, we have not generated any commercial product revenue. In September 2015, the European Commission, or EC, granted marketing approval for Zalviso in the European Union to our commercial partner, Gr&#252;nenthal. We do not expect to receive any commercial sales revenue until after we ship commercial product to Gr&#252;nenthal, who anticipates launching Zalviso in the European Union in the first half of 2016.
</FONT>
</P>
<P ID=PARA92 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2825 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Revenue during the year ended December 31, 2015, was $19.3 million, including $14.9 million recognized under our Amended License Agreement with Gr&#252;nenthal. In addition, we recognized $4.4 million in revenue under the DoD Contract.
</FONT>
</P>
<P ID=PARA2826 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2827 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Revenue for the year ended December&nbsp;31, 2014 was $5.2 million, related to our collaboration agreement with Gr&#252;nenthal.
</FONT>
</P>
<P ID=PARA2829 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2828 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Revenue for the year ended December 31, 2013 was $29.5 million, $27.4 million of which related to our collaboration with Gr&#252;nenthal and $2.1 million related to our grant with the USAMRMC.
</FONT>
</P>
<P ID=PARA2831 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK65 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR65 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM65 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	70
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage71"></A>
<DIV ID=PGHDR65 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA65.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<P ID=PARA2830 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Collaboration Agreement Revenue
</U>
</FONT>
</P>
<P ID=PARA2832 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2833 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Below is a summary of revenue recognized under the Amended Agreements during the years ended December 31, 2015, 2014 and 2013 (in thousands):
</FONT>
</P>
<P ID=PARA2834 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL2865 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; MARGIN-LEFT: 5%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL2865.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2865.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2865.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 35%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=10>
<P ID=PARA2836 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 0PT 0PT 0.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Years Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2865.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2865.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2865.FINROW.3.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2865.FINROW.3.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA2839 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2865.FINROW.3.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2865.FINROW.3.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2865.FINROW.3.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA2841 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2865.FINROW.3.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2865.FINROW.3.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2865.FINROW.3.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA2843 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2865.FINROW.3.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2865.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2845 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	License
</FONT>
</P>
</TD>
<TD ID=TBL2865.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2865.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	13,167
</TD>
<TD ID=TBL2865.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2865.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	4,560
</TD>
<TD ID=TBL2865.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2865.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	27,370
</TD>
<TD ID=TBL2865.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2865.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA2849 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Joint steering committee, research and development services and demonstration devices
</FONT>
</P>
</TD>
<TD ID=TBL2865.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	1,690
</TD>
<TD ID=TBL2865.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	657
</TD>
<TD ID=TBL2865.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL2865.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2865.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2865.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2857 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total
</FONT>
</P>
</TD>
<TD ID=TBL2865.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2865.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	14,857
</TD>
<TD ID=TBL2865.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2865.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	5,217
</TD>
<TD ID=TBL2865.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2865.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL2865.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	27,370
</TD>
<TD ID=TBL2865.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA2867 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA94 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the terms of the Amended Agreements with Gr&#252;nenthal, we received an upfront cash payment of $30.0 million, and a milestone payment of $5.0 million related to the MAA submission, which occurred in July 2014, and a $15.0 million milestone payment due to the EC approval of the MAA for Zalviso in September 2015. We are eligible to receive approximately $194.5 million in additional milestone payments, based upon successful regulatory and product development efforts ($28.5 million) and net sales target achievements ($166.0 million). As a result of the Royalty Monetization (described below), PDL will receive 75% of the European royalties under the Amended License Agreement with Gr&#252;nenthal, as well as 80% of the first four commercial milestones worth $35.6 million (or 80% of $44.5 million), subject to the capped amount of $195.0 million. Gr&#252;nenthal will also make tiered royalty and supply and trademark fee payments in the mid-teens up to the mid-twenties percent range, depending on the sales level achieved, on net sales of Zalviso. Refer to Note 6 &#8220;Collaboration Agreement&#8221; for additional information.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A portion of the tiered royalty payment, exclusive of the supply and trademark fee payments, will be paid to PDL in connection with the Royalty Monetization, as discussed below. In September 2015,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by Gr&#252;nenthal, pursuant to the Amended Agreements, to PDL for an upfront cash purchase price of $65.0 million. Due to our significant continuing involvement in the Royalty Monetization, primarily due to an obligation to act as the intermediary for the supply of Zalviso to
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal, the Royalty Monetization has been accounted for as a liability that will be amortized using the interest method over the life of the arrangement. As the portion of the royalties and milestone payments sold to PDL are remitted by
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal, the balance of the liability related to the Royalty Monetization will be effectively reduced over the life of the agreement. As such, we will record non-cash royalty revenues and non-cash interest expense within our Consolidated Statements of Comprehensive Loss over the term of the PDL agreement. There was no such non-cash royalty revenue in the year ended December 31, 2015.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We do not expect to receive any non-cash royalty revenue, or other commercial sales revenue, until after Gr&#252;nenthal launches Zalviso in the European Union. Refer to Note 8 &#8220;Liability Related to Sale of Future Royalties&#8221; for additional information.
</FONT>
</P>
<P ID=PARA96 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA97 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Contract and Other Revenue
</U>
</FONT>
</P>
<P ID=PARA99 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA98 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In May 2011, we received a grant award of $5.6 million from the USAMRMC for the development of ARX-04. Revenue related to this grant award was recognized as the related research and development expenses were incurred. As of December 31, 2013, we had completed all grant-supported research and development activities and the $5.6 million grant had been recognized in full. Refer to Note 5 &#8220;U.S. Department of Defense Funding&#8221; for additional information.
</FONT>
</P>
<P ID=PARA101 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA198 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On May 11, 2015, we entered into a new award contract supported by the USAMRMC within the DoD, in which the DoD agreed to provide up to $17.0 million to support the development of our product candidate ARX-04, a proprietary, non-invasive, single-use tablet in a disposable, pre-filled, single-dose applicator for the treatment of moderate-to-severe acute pain. The DoD Contract will support development of ARX-04. Under the terms of the contract, the DoD will reimburse us for costs incurred for development, manufacturing, regulatory and clinical costs outlined in the contract in order to submit an NDA to the FDA, including reimbursement for certain personnel and overhead expenses. The period of performance under the contract began on May 11, 2015. The contract gives the DoD the option to extend the term of the contract and provide additional funding for the research. On March 2, 2016, the DoD Contract was amended
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	to approve enrollment of additional patients in the SAP302 study, approve the addition of the SAP303 study, and extend the contract period of performance by four months from November 10, 2016 to March 9, 2017, to accommodate the increased SAP302 patient enrollment and the SAP303 study. The costs for these changes will be absorbed within the current contract value. If ARX-04 is approved by the FDA, the DoD has the option to purchase a certain number of units of commercial product pursuant to the terms of the contract. Refer to Note 5 &#8220;U.S. Department of Defense Funding&#8221; for additional information.
</FONT>
</P>
<P ID=PARA102 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<P ID=PARA2876 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Cost of goods sold
</I>
</FONT>
</P>
<P ID=PARA2878 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2879 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total cost of goods sold was $1.8 million for the year ended December 31, 2015. As mentioned above, the EC approved Zalviso in late September 2015. We have commenced commercial production in preparation for Gr&#252;nenthal&#8217;s European launch. Under the Amended Agreements with Gr&#252;nenthal, we will sell Zalviso to Gr&#252;nenthal at our cost with minimal markup and will not recover indirect costs through product sales. Cost of goods sold for Zalviso shipped to
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal includes the inventory costs of API, third-party contract manufacturing costs, packaging and distribution costs, shipping, handling and storage costs, depreciation and costs of the employees involved with production.
</FONT>
</P>
<P ID=PARA2880 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK66 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR66 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM66 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	71
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage72"></A>
<DIV ID=PGHDR66 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA66.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2881 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Research and Development Expenses
</I>
</FONT>
</P>
<P ID=PARA2882 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2883 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Conducting research and development is central to our business model. The majority of our operating expenses to date have been for research and development activities related to Zalviso. Research and development expenses included the following:
</FONT>
</P>
<P ID=PARA2885 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2886 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2887 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2888 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expenses incurred under agreements with contract research organizations and clinical trial sites;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2890 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2891 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2892 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2893 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	employee-related expenses, which include salaries, benefits and stock-based compensation;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2895 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2896 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2897 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2898 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	payments to third party pharmaceutical and engineering development contractors;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2900 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2901 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2902 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2903 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	payments to third party manufacturers;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2905 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2906 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2907 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2908 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities and equipment, and equipment and laboratory and other supply costs; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2910 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB2911 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA2912 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA2913 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	costs for equipment and laboratory and other supplies.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA2915 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA2916 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Product candidates in late stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of late stage clinical trials. We will incur substantial future expenditures as we seek to continue development of Zalviso, including activities to address issues raised by the FDA during their regulatory review process, as well as activities associated with potential preparation for commercialization of Zalviso, should we receive approval from the FDA. In addition, we plan to continue to incur significant research and development expenses, including the expenses associated with the continued development of ARX-04 and the additional clinical trial for Zalviso, IAP312. We do not plan to continue development of ARX-03 unless additional funding or corporate partnership resources are available to support this program.
</FONT>
</P>
<P ID=PARA2918 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2917 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We track external development expenses on a program-by-program basis. Our development resources are shared among all of our programs. Compensation and benefits, facilities, depreciation, stock-based compensation, and development support services are not allocated specifically to projects and are considered research and development overhead. Below is a summary of our research and development expenses during the years ended December&nbsp;31, 2015, 2014 and 2013 (in thousands):
</FONT>
</P>
<P ID=PARA2919 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<TABLE ID=TBL2954 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; MARGIN-LEFT: 5%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL2954.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2954.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2954.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 35%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=10>
<P ID=PARA2921 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 0PT 0PT 0.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Years Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2954.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2954.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2954.FINROW.3.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2954.FINROW.3.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA2924 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2954.FINROW.3.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2954.FINROW.3.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2954.FINROW.3.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA2926 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2954.FINROW.3.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2954.FINROW.3.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2954.FINROW.3.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA2928 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2954.FINROW.3.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2954.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2930 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Zalviso
</FONT>
</P>
</TD>
<TD ID=TBL2954.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2954.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	4,950
</TD>
<TD ID=TBL2954.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2954.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	10,638
</TD>
<TD ID=TBL2954.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2954.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	16,009
</TD>
<TD ID=TBL2954.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2954.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA2934 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04
</FONT>
</P>
</TD>
<TD ID=TBL2954.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	5,848
</TD>
<TD ID=TBL2954.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	3,068
</TD>
<TD ID=TBL2954.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	1,957
</TD>
<TD ID=TBL2954.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2954.FINROW.6 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2938 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Overhead
</FONT>
</P>
</TD>
<TD ID=TBL2954.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	11,690
</TD>
<TD ID=TBL2954.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	10,814
</TD>
<TD ID=TBL2954.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	8,326
</TD>
<TD ID=TBL2954.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL2954.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 49%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.LEAD.B2 STYLE="WIDTH: 1%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.SYMB.B2 STYLE="WIDTH: 1%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.AMT.B2 STYLE="WIDTH: 14%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.TRAIL.B2 STYLE="WIDTH: 1%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.LEAD.B3 STYLE="WIDTH: 1%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.SYMB.B3 STYLE="WIDTH: 1%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.AMT.B3 STYLE="WIDTH: 14%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.TRAIL.B3 STYLE="WIDTH: 1%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.LEAD.B4 STYLE="WIDTH: 1%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.SYMB.B4 STYLE="WIDTH: 1%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.AMT.B4 STYLE="WIDTH: 14%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.7.TRAIL.B4 STYLE="WIDTH: 1%; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL2954.FINROW.8 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2946 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total research and development expenses
</FONT>
</P>
</TD>
<TD ID=TBL2954.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2954.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	22,488
</TD>
<TD ID=TBL2954.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2954.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	24,520
</TD>
<TD ID=TBL2954.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2954.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2954.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	26,292
</TD>
<TD ID=TBL2954.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA2956 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2955 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Due to the inherently unpredictable nature of product development, development timelines and the probability of success, development costs can differ materially from expectations. While we are currently focused on advancing Zalviso and the continued development of ARX-04, our future research and development expenses will depend on the clinical success of each product candidate as well as ongoing assessments of the commercial potential of our product candidates. In addition, we cannot predict which product candidates may be subject to future collaborations, when these arrangements will be secured, if at all, and to what degree these arrangements would affect our development plans and capital requirements.
</FONT>
</P>
<P ID=PARA2958 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2957 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total research and development expenses for years ended December&nbsp;31, 2015, 2014 and 2013 were as follows (in thousands, except percentages):
</FONT>
</P>
<P ID=PARA2959 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL2986 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<EFX_UNIDENTIFIED_TABLE>
<TR ID=TBL2986.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 22%; VERTICAL-ALIGN: BOTTOM">
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 21%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=10>
<P ID=PARA2961 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Years Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2986.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 1.8PT" COLSPAN=2>
<P ID=PARA2963 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 0PT 0PT 1.8PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL2986.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.1.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.1.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA2965 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL2986.FINROW.1.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.1.LEAD.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.1.AMT.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA2967 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Percentage
<BR>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL2986.FINROW.1.TRAIL.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.1.LEAD.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.1.AMT.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.7PT" COLSPAN=2>
<P ID=PARA2969 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 0PT 0PT 2.7PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Percentage
<BR>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL2986.FINROW.1.TRAIL.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
</EFX_UNIDENTIFIED_TABLE>
<TR ID=TBL2986.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 22%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA2972 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2986.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA2974 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2986.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA2976 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL2986.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
<B>
<B>
	2015
</B>
	vs. 2014
</B>
</B>
</TD>
<TD ID=TBL2986.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
<B>
<B>
	2014
</B>
	&nbsp; vs. 2013
</B>
</B>
</TD>
<TD ID=TBL2986.FINROW.2.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.LEAD.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.AMT.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
<B>
	2015
</B>
	&nbsp; vs. 2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</B>
</TD>
<TD ID=TBL2986.FINROW.2.TRAIL.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.LEAD.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL2986.FINROW.2.AMT.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
<B>
<B>
	2014
</B>
	vs. 2013
</B>
</B>
</TD>
<TD ID=TBL2986.FINROW.2.TRAIL.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL2986.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 22%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA2978 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Research and development expenses
</FONT>
</P>
</TD>
<TD ID=TBL2986.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2986.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	22,488
</TD>
<TD ID=TBL2986.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2986.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	24,520
</TD>
<TD ID=TBL2986.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2986.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	26,292
</TD>
<TD ID=TBL2986.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2986.FINROW.3.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	(2,032
</TD>
<TD ID=TBL2986.FINROW.3.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2986.FINROW.3.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 6.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL2986.FINROW.3.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 6.75PT; BACKGROUND-COLOR: #CCEEFF">
	(1,772
</TD>
<TD ID=TBL2986.FINROW.3.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL2986.FINROW.3.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	(8
</TD>
<TD ID=TBL2986.FINROW.3.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)%
</TD>
<TD ID=TBL2986.FINROW.3.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL2986.FINROW.3.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	(7
</TD>
<TD ID=TBL2986.FINROW.3.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)%
</TD>
</TR>
</TABLE>
<P ID=PARA2987 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2988 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The $2.0 million decrease in research and development expenses during the year ended December 31, 2015, as compared to the year ended December 31, 2014, was primarily attributable to a $5.7 million decrease related to the Zalviso development program in response to the CRL received from the FDA in March 2015, partially offset by a $2.8 million increase related to ARX-04 as we advanced development into Phase 3 clinical trials, and a $0.9 million increase in overhead-related costs, primarily facilities expense, and personnel-related expenses, including stock-based compensation.
</FONT>
</P>
<P ID=PARA2989 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK3 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR3 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM3 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	72
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage73"></A>
<DIV ID=PGHDR3 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA3.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA2990 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The $1.8 million decrease in research and development expenses during the year ended December 31, 2014, as compared to the year ended December 31, 2013, was primarily attributable to a $5.4 million decrease related to our Zalviso Phase 3 clinical program conducted primarily in 2013, partially offset by an increase of $1.1 million related to our ARX-04 development program as we prepared for the Phase 3 clinical program and an increase of $2.5 million in overhead expenses, primarily due to increased personnel-related expenses, including stock-based compensation, primarily related to an increase in headcount to support continued development of Zalviso and ARX-04.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA2991 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2993 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	General and Administrative Expenses
</I>
</FONT>
</P>
<P ID=PARA2995 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2994 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	General and administrative expenses consisted primarily of salaries, benefits and stock-based compensation for personnel in administration, finance, marketing and business development activities. Other significant expenses included legal expenses related to litigation and patent protection of our intellectual property, allocated facility costs and professional fees for general legal, audit and consulting services. We expect general and administrative expenses to continue to decrease in the first quarter of 2016 as compared to the first quarter of 2015, as a result of the cost reduction plan, and then for the remainder of 2016 to remain comparable to 2015 expenses, as we focus our efforts on further development and seeking marketing approval for Zalviso, and the continued development of ARX-04.
</FONT>
</P>
<P ID=PARA2997 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2996 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total general and administrative expenses for the years ended December&nbsp;31, 2015, 2014 and 2013 were as follows (in thousands, except percentages):
</FONT>
</P>
<P ID=PARA2999 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA2998 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE ID=TBL3026 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 22%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 21%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.35PT" COLSPAN=10>
<P ID=PARA3002 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Years Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3026.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.15PT" COLSPAN=2>
<P ID=PARA3004 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 2.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3026.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.1.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.1.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.15PT" COLSPAN=2>
<P ID=PARA3006 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 4.3PT 0PT 2.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3026.FINROW.1.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.1.LEAD.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.1.AMT.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.15PT" COLSPAN=2>
<P ID=PARA3008 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 2.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Percentage
<BR>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD ID=TBL3026.FINROW.1.TRAIL.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.1.LEAD.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.1.AMT.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.15PT" COLSPAN=2>
<P ID=PARA3010 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 2.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Percentage
<BR>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3026.FINROW.1.TRAIL.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 22%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<P ID=PARA3012 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3026.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<P ID=PARA3014 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3026.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA3016 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3026.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
	2015 vs. 2014
</B>
</TD>
<TD ID=TBL3026.FINROW.2.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.LEAD.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.SYMB.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
	2014 vs. 2013
</B>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD ID=TBL3026.FINROW.2.TRAIL.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.LEAD.B7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.SYMB.B7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
	2015 vs. 2014
</B>
</TD>
<TD ID=TBL3026.FINROW.2.TRAIL.B7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.LEAD.B8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3026.FINROW.2.SYMB.B8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
	2014 vs. 2013
</B>
<B>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</B>
</TD>
<TD ID=TBL3026.FINROW.2.TRAIL.B8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 22%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3018 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	General and administrative expenses
</FONT>
</P>
</TD>
<TD ID=TBL3026.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3026.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	14,203
</TD>
<TD ID=TBL3026.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3026.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	18,346
</TD>
<TD ID=TBL3026.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3026.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	9,877
</TD>
<TD ID=TBL3026.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 12.15PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3026.FINROW.3.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.15PT; BACKGROUND-COLOR: #CCEEFF">
	(4,143
</TD>
<TD ID=TBL3026.FINROW.3.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3026.FINROW.3.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.85PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3026.FINROW.3.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.85PT; BACKGROUND-COLOR: #CCEEFF">
	8,469
</TD>
<TD ID=TBL3026.FINROW.3.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	(23
</TD>
<TD ID=TBL3026.FINROW.3.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)%
</TD>
<TD ID=TBL3026.FINROW.3.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3026.FINROW.3.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	86
</TD>
<TD ID=TBL3026.FINROW.3.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA3028 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3027 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The $4.1 million decrease in general and administrative expenses during the year ended December 31, 2015, as compared to the year ended December 31, 2014, was primarily due to a $3.9 million decrease in market research and outside services, primarily related to market research activities for Zalviso, and a $0.2 million decrease in headcount-related expenses, primarily due to the March 2015 restructuring.
</FONT>
</P>
<P ID=PARA3030 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3029 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The $8.5 million increase in general and administrative expenses during the year ended December 31, 2014, as compared to the year ended December 31, 2013, was primarily due to a $3.7 million increase in market research and use of outside services, primarily related to market research activities for Zalviso, and an increase of $4.8 million, primarily in headcount-related expenses, including recruiting efforts, to support organizational growth for the potential commercialization of Zalviso, and consulting and other professional services fees.
</FONT>
</P>
<P ID=PARA3032 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3031 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Restructuring Costs
</I>
</FONT>
</P>
<P ID=PARA3034 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3033 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In March 2015, we received correspondence from the FDA stating that in addition to the bench testing and two Human Factors studies we had performed in response to the issues identified in the CRL, a clinical trial is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. On March 19, 2015, our Board of Directors, in connection with our efforts to reduce operating costs, conserve capital, focus the Company&#39;s financial and development resources on working with the FDA to seek marketing approval for Zalviso, and continuing development of ARX-04, implemented a cost reduction plan. The cost reduction plan reduced our workforce by 19 employees, approximately 36% of total headcount, in the first quarter of 2015.
</FONT>
</P>
<P ID=PARA4.1 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK4 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR4 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM4 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	73
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage74"></A>
<DIV ID=PGHDR4 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA4.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE ID=TBL3051 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.35PT" COLSPAN=10>
<P ID=PARA3036 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Years Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3051.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.15PT" COLSPAN=2>
<P ID=PARA3038 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 2.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3051.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<P ID=PARA3040 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3051.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<P ID=PARA3042 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3051.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA3044 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3051.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.2.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3051.FINROW.2.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
</B>
<B>
	2015 vs. 2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</B>
</TD>
<TD ID=TBL3051.FINROW.2.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 36%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3046 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Restructuring costs
</FONT>
</P>
</TD>
<TD ID=TBL3051.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3051.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3051.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	756
</TD>
<TD ID=TBL3051.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3051.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3051.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3051.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3051.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3051.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3051.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3051.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3051.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3051.FINROW.3.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3051.FINROW.3.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 12.15PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3051.FINROW.3.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.15PT; BACKGROUND-COLOR: #CCEEFF">
	756
</TD>
<TD ID=TBL3051.FINROW.3.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA3053 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3052 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Restructuring cost in the year ended December 31, 2015 consists of employee termination benefit costs of $0.8 million. The restructuring liability has been fully disbursed as of December 31, 2015.
</FONT>
</P>
<P ID=PARA3054 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<P ID=PARA3055 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Other (Expense) Income
</I>
</FONT>
</P>
<P ID=PARA3057 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3056 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total other (expense) income for the years ended December&nbsp;31, 2015, 2014 and 2013 was as follows (in thousands, except percentages):
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<TABLE ID=TBL3109 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 23%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 23%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=10>
<P ID=PARA3059 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Years Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 1.8PT" COLSPAN=2>
<P ID=PARA3061 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 0PT 0PT 1.8PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.1.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.1.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3063 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.1.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.1.LEAD.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.1.AMT.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3065 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Percentage
<BR>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.1.TRAIL.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.1.LEAD.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.1.AMT.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.7PT" COLSPAN=2>
<P ID=PARA3067 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 0PT 0PT 2.7PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Percentage
<BR>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.1.TRAIL.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 23%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA3070 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA3072 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA3074 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
</B>
<B>
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	vs. 2014
</B>
</B>
</TD>
<TD ID=TBL3109.FINROW.2.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.LEAD.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.SYMB.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
</B>
<B>
<B>
	2014
</B>
	vs. 2013
</B>
</FONT>
</TD>
<TD ID=TBL3109.FINROW.2.TRAIL.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.LEAD.B7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.SYMB.B7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
</B>
<B>
<B>
<B>
	2015
</B>
	vs. 2014
</B>
</B>
</TD>
<TD ID=TBL3109.FINROW.2.TRAIL.B7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.LEAD.B8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3109.FINROW.2.SYMB.B8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<B>
</B>
<B>
<B>
	2014&nbsp;
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;vs. 2013
</B>
</B>
</TD>
<TD ID=TBL3109.FINROW.2.TRAIL.B8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 23%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3076 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest expense
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3109.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	(2,977
</TD>
<TD ID=TBL3109.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3109.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	(2,639
</TD>
<TD ID=TBL3109.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3109.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	(1,518
</TD>
<TD ID=TBL3109.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.3.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.3.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3109.FINROW.3.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	(338
</TD>
<TD ID=TBL3109.FINROW.3.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.3.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.3.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 6.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3109.FINROW.3.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 6.75PT; BACKGROUND-COLOR: #CCEEFF">
	(1,121
</TD>
<TD ID=TBL3109.FINROW.3.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.3.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.3.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.3.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	13
</TD>
<TD ID=TBL3109.FINROW.3.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	%
</TD>
<TD ID=TBL3109.FINROW.3.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.3.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.3.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	74
</TD>
<TD ID=TBL3109.FINROW.3.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	%
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 23%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3084 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest income and other income (expense), net
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	1,720
</TD>
<TD ID=TBL3109.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	6,935
</TD>
<TD ID=TBL3109.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	(15,241
</TD>
<TD ID=TBL3109.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.4.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	(5,215
</TD>
<TD ID=TBL3109.FINROW.4.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.4.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 6.75PT; BACKGROUND-COLOR: #FFFFFF">
	22,176
</TD>
<TD ID=TBL3109.FINROW.4.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	(75
</TD>
<TD ID=TBL3109.FINROW.4.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)%
</TD>
<TD ID=TBL3109.FINROW.4.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.4.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	(146
</TD>
<TD ID=TBL3109.FINROW.4.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)%
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 23%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA3093 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Non-cash interest expense on liability related to sale of future royalties
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	(2,428
</TD>
<TD ID=TBL3109.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3109.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3109.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	(2,428
</TD>
<TD ID=TBL3109.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.5.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 6.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3109.FINROW.5.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3109.FINROW.5.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	%
</TD>
<TD ID=TBL3109.FINROW.5.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.5.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3109.FINROW.5.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	%
</TD>
</TR>
<TR>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 23%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3101 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total other (expense) income
</FONT>
</P>
</TD>
<TD ID=TBL3109.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3109.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	(3,685
</TD>
<TD ID=TBL3109.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3109.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	4,296
</TD>
<TD ID=TBL3109.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3109.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	(16,759
</TD>
<TD ID=TBL3109.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.6.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3109.FINROW.6.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	(7,981
</TD>
<TD ID=TBL3109.FINROW.6.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL3109.FINROW.6.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 6.75PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3109.FINROW.6.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 6.75PT; BACKGROUND-COLOR: #FFFFFF">
	21,055
</TD>
<TD ID=TBL3109.FINROW.6.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	(186
</TD>
<TD ID=TBL3109.FINROW.6.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)%
</TD>
<TD ID=TBL3109.FINROW.6.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3109.FINROW.6.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	(126
</TD>
<TD ID=TBL3109.FINROW.6.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)%
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA3111 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3110 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest expense consisted primarily of interest accrued or paid on our debt obligation agreements and amortization of debt discounts. Interest expense for all periods pertains to interest on our Loan and Security Agreement with Hercules. In December 2013, we entered into the Amended Loan Agreement with Hercules, which amends and restates the Loan and Security Agreement. The overall debt facility was increased to $40.0 million, and the maturity was extended to October&nbsp;1, 2017. As of December 31, 2015, the outstanding principal owed to Hercules was $20.9 million. On June 16, 2014, we borrowed the second tranche of $10.0 million. We did not have access to the third tranche, of up to $15.0 million, as we did not receive FDA approval of Zalviso by August 1, 2015. As a result of the higher average principal balance in the year ended December 31, 2015 as compared to the year ended December 31, 2014, and in the year ended December 31, 2014 as compared to the year ended December 31, 2013, the amount of interest expense incurred increased in each consecutive year.
</FONT>
</P>
<P ID=PARA3113 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3112 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September 18, 2015, concurrently with the closing of the Royalty Monetization, the Company entered into a Consent and Amendment No. 2, or Amendment No. 2, to the Amended Loan Agreement. Amendment No. 2 provided for an interest only period from October 1, 2015 through March 31, 2016, with the potential for further extension to September 30, 2016 upon satisfaction of certain conditions, which have since been satisfied.
</FONT>
</P>
<P ID=PARA3115 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3114 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest income and other income (expense), net, during the years ended December 31, 2015, 2014 and 2013 consisted primarily of the change in the fair value of our warrants, or PIPE warrants, issued in connection with our private placement of our common stock, which was completed in June 2012. During the year ended December 31, 2013, we also recorded a loss of $1.2 million associated with extinguishment of our original loan agreement with Hercules, which we entered into in 2011, and amended in December 2013.
</FONT>
</P>
<P ID=PARA3117 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3116 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The decrease in interest income and other income (expense), net, during the year ended December 31, 2015 as compared to the year ended December 31, 2014, was primarily attributable to fewer PIPE warrants outstanding at December 31, 2015, as compared to December 31, 2014, and a smaller decrease in our stock price during the year ended December 31, 2015, as compared to the year ended December 31, 2014, which is a primary driver in the Black-Scholes valuation model used to estimate the fair value of the PIPE warrants. Interest income and other income (expense), net, during the year ended December 31, 2015 also included $0.5 million in impairment charges related to leasehold improvements in our corporate offices.
</FONT>
</P>
<P ID=PARA3119 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3118 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The decrease in interest income and other income (expense), net, during the year ended December 31, 2014, as compared to the year ended December 31, 2013, of $22.2 million was primarily attributable to fewer PIPE warrants outstanding at December 31, 2014, compared to December 31, 2013, and a decrease in our stock price during the year ended December 31, 2014 as compared to a significant increase in our stock price during the year ended December 31, 2013, which is the primary driver in the Black-Scholes valuation model used to estimate the fair value of the PIPE warrants. This decrease was partially offset by the $1.2 million loss we recorded in 2013 related to the extinguishment of the original Hercules debt arrangement.
</FONT>
</P>
<P ID=PARA3121 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK5 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR5 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM5 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	74
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage75"></A>
<DIV ID=PGHDR5 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA5.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA3120 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The increase in non-cash interest expense on liability related to the Royalty Monetization during the year ended December 31, 2015 as compared to the year ended December 31, 2014, is attributable to the royalty sale transaction that we completed in September 2015. As described above, the Royalty Monetization has been recorded as debt under the applicable accounting guidance. We impute interest on the liability and record interest expense based on the amount and timing of royalty and milestone payments expected to be received by PDL over the life of the arrangement. There are a number of factors that could materially affect the estimated interest rate and we will assess this estimate on a periodic basis. As a result, future interest rates could differ significantly and any such change in interest rate will be adjusted prospectively.
</FONT>
</P>
<P ID=PARA3122 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3123 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Provision for Income Taxes
</I>
</FONT>
</P>
<P ID=PARA3125 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3124 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Royalty Monetization results in a taxable gain of more than $60.0 million, the majority of which is expected to be offset with net operating loss carryforwards; however, we are expected to be subject to U.S. federal alternative minimum taxes in 2015, as reflected in our provision for income taxes in the third quarter of 2015.
</FONT>
</P>
<P ID=PARA3127 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3126 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total provision for income taxes for the years ended December&nbsp;31, 2015, 2014 and 2013 was as follows (in thousands, except percentages):
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE ID=TBL3144 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; MARGIN-RIGHT: 20%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL3144.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.35PT" COLSPAN=10>
<P ID=PARA3129 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Years Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3144.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.15PT" COLSPAN=2>
<P ID=PARA3131 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 2.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Increase/
<BR>
	(Decrease)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3144.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3144.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<P ID=PARA3133 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3144.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA3135 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3144.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.05PT" COLSPAN=2>
<P ID=PARA3137 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.05PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3144.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.2.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.2.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.2.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
<B>
	2015 vs. 2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	&nbsp;
</B>
</TD>
<TD ID=TBL3144.FINROW.2.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3144.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 36%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3139 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Provision for income taxes
</FONT>
</P>
</TD>
<TD ID=TBL3144.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3144.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3144.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	760
</TD>
<TD ID=TBL3144.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3144.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3144.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3144.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3144.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3144.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3144.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3144.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3144.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3144.FINROW.3.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3144.FINROW.3.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3144.FINROW.3.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	760
</TD>
<TD ID=TBL3144.FINROW.3.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
</EFX_RESULTS_OF_OPERATIONS>
<P ID=PARA3145 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P ID=PARA3150 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Liquidity and Capital Resources
</B>
</FONT>
</P>
<P ID=PARA3153 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3152 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Liquidity
</I>
</B>
</FONT>
</P>
<P ID=PARA3155 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3154 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have incurred losses and generated negative cash flows from operations since inception. We expect to continue to incur significant losses in 2016 and may incur significant losses and negative cash flows from operations for the foreseeable future. We have funded our operations primarily through issuance of equity securities, borrowings, payments from our commercial partner, Gr&#252;nenthal, monetization of certain future royalties and commercial sales milestones from the sales of Zalviso by Gr&#252;nenthal, and our contracts with the DoD.
</FONT>
</P>
<P ID=PARA3157 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3156 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December 31, 2015, we had cash, cash equivalents and investments totaling $113.5 million compared to $75.4&nbsp;million as of December&nbsp;31, 2014. The increase was primarily attributable to the $61.2 million in net proceeds in connection with the Royalty Monetization, partially offset by cash required to fund our continuing operations, as we continue our research and development activities. We anticipate that our existing capital resources will permit us to meet our capital and operational requirements through at least the first half of 2017. While we believe we have sufficient capital to meet our operational requirements through at least the first half of 2017, our expectations may change depending on a number of factors. For example, based on their review of the protocol we have submitted for the requested clinical trial for Zalviso, the FDA may require a scope or design change that is beyond what our current and estimated future capital resources can support. We believe that together with the support from the DoD Contract, we have sufficient resources to complete the Phase 3 development program for ARX-04 through submission of the NDA to the FDA. However, our existing capital resources will not be sufficient to fund our operations until such time as we may be able to generate sufficient revenues to sustain our operations.
</FONT>
</P>
<P ID=PARA3159 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3158 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September 18, 2015, we sold a portion of the expected royalty stream and commercial milestone payments from the sales of Zalviso in the EU by Gr&#252;nenthal to PDL. As mentioned above, we received net proceeds of $61.2 million in the Royalty Monetization. PDL will receive 75% of the European royalties under the Amended License Agreement with Gr&#252;nenthal, as well as 80% of the first four commercial milestones worth $35.6 million (or 80% of $44.5 million), subject to the capped amount of $195.0 million. We are entitled to receive all remaining amounts under the Amended License Agreement which include 25% of the European royalties, 20% of the first four commercial milestones, 100% of the remaining commercial milestones and all development milestones of $43.5 million, including the $15.0 million payment for the EC approval of the MAA for Zalviso, which we received in the fourth quarter of 2015. The total liability related to sale of future royalties to PDL as of December 31, 2015 was $63.6 million.
</FONT>
</P>
<P ID=PARA3161 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3160 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December&nbsp;16, 2013, AcelRx and Gr&#252;nenthal entered into the License Agreement, and related Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. The License Agreement grants Gr&#252;nenthal rights to commercialize Zalviso, or the Product, in the Territory for human use in pain treatment within or dispensed by hospitals, hospices, nursing homes and other medically-supervised settings. We retain rights with respect to the Product in countries outside the Territory, including the United States, Asia and Latin America. On July 22, 2015, the Company entered into amendments to the License Agreement, or the License Amendment, and together with the License Agreement, the Amended License Agreement, and the MSA, or the MSA Amendment, and together with the MSA, the Amended MSA, between the Company and Gr&#252;nenthal, each effective as of July 17, 2015, and together, the Amended Agreements.
</FONT>
</P>
<P ID=PARA3163 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK6 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR6 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM6 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	75
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage76"></A>
<DIV ID=PGHDR6 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA6.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA103 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the terms of the Amended Agreements, we received an upfront cash payment of $30.0 million, a milestone payment of $5.0 million related to the MAA submission in the third quarter of 2014 and an additional $15.0 million milestone payment related to the EC approval of the MAA for Zalviso in September 2015. In addition, under the terms of the Amended Agreements, we are eligible to receive approximately $194.5 million in additional milestone payments, based upon successful regulatory and product development efforts ($28.5 million) and net sales target achievements ($166.0 million).&nbsp; Gr&#252;nenthal will also make tiered royalty, supply and trademark fee payments in the mid-teens up to the mid-twenties percent range, depending on the level of sales achieved, on net sales of Zalviso in the Territory. A portion of the tiered royalty payment, exclusive of the supply and trademark fee payments, will be paid to PDL in connection with the Royalty Monetization, as discussed above.
</FONT>
</P>
<P ID=PARA105 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3164 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December 16, 2013, AcelRx entered into an Amended and Restated Loan and Security Agreement with Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc., together, the Lenders, or the Amended Loan Agreement, under which AcelRx may borrow up to $40.0 million in three tranches. The loans are represented by secured convertible term promissory notes, collectively, the Notes. The Amended Loan Agreement amends and restates the Loan and Security Agreement between AcelRx and the Lenders dated as of June 29, 2011. We borrowed the first tranche of $15.0 million upon closing of the transaction on December 16, 2013, and the second tranche of $10.0 million on June 16, 2014. We used approximately $8.6 million of the proceeds from the first tranche to repay our obligations under the Loan and Security Agreement with the Lenders. We recorded the new debt at an estimated fair value of $24.9 million as of December 31, 2014.
</FONT>
</P>
<P ID=PARA3167 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3166 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September 24, 2014, we entered into Amendment No. 1 to the Amended Loan Agreement with Hercules. Amendment No. 1 extended the time period under which we could draw down the third tranche, of up to $15.0 million, from March 15, 2015 to August 1, 2015, subject to AcelRx obtaining approval for Zalviso from the FDA. We did not receive FDA approval of Zalviso by August 1, 2015 and as such, did not have access to the third tranche.
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<P ID=PARA106 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September 18, 2015, concurrently with the closing of the Royalty Monetization, we entered into a Consent and Amendment No. 2, or Amendment No. 2, to the Amended Loan Agreement with the Lenders. Amendment No. 2 includes an interest only period from October 1, 2015 through March 31, 2016, with the potential for further extension to September 30, 2016 upon satisfaction of certain conditions, which have since been satisfied. Loans under the Amended Loan Agreement mature on October 31, 2017. As of December 31, 2015, the outstanding principal owed to Hercules was $20.9 million.
</FONT>
</P>
<P ID=PARA3168 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA3170 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our cash and investment balances are held in a variety of interest bearing instruments, including obligations of U.S. government agencies, money market funds and time deposits. Cash in excess of immediate requirements is invested with a view toward capital preservation and liquidity.
</FONT>
</P>
<P ID=PARA3173 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3172 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<P ID=PARA3174 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Cash Flows
</I>
</B>
</FONT>
</P>
<P ID=PARA3176 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL3201 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; MARGIN-LEFT: 5%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL3201.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3201.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3201.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=10>
<P ID=PARA3178 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Years Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3201.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3201.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3201.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3201.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 12.25PT" COLSPAN=2>
<P ID=PARA3181 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 12.25PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3201.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3201.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3201.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 11.5PT" COLSPAN=2>
<P ID=PARA3183 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 11.5PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3201.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3201.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3201.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 12.25PT" COLSPAN=2>
<P ID=PARA3185 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT 0PT 12.25PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3201.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3201.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3201.FINROW.3.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3201.FINROW.3.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 12.25PT" COLSPAN=10>
<P ID=PARA3188 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 12.25PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(in thousands)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3201.FINROW.3.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3201.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3189 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net cash used in operating activities
</FONT>
</P>
</TD>
<TD ID=TBL3201.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3201.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(19,953
</TD>
<TD ID=TBL3201.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3201.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3201.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(34,456
</TD>
<TD ID=TBL3201.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3201.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 12.25PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3201.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.25PT; BACKGROUND-COLOR: #CCEEFF">
	(487
</TD>
<TD ID=TBL3201.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL3201.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3193 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net cash provided by (used in) investing activities
</FONT>
</P>
</TD>
<TD ID=TBL3201.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	8,203
</TD>
<TD ID=TBL3201.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(5,776
</TD>
<TD ID=TBL3201.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL3201.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.25PT; BACKGROUND-COLOR: #FFFFFF">
	(6,920
</TD>
<TD ID=TBL3201.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL3201.FINROW.6 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3197 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net cash provided by financing activities
</FONT>
</P>
</TD>
<TD ID=TBL3201.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	59,634
</TD>
<TD ID=TBL3201.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	11,869
</TD>
<TD ID=TBL3201.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3201.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.25PT; BACKGROUND-COLOR: #CCEEFF">
	47,876
</TD>
<TD ID=TBL3201.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA3203 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3202 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Cash Flows from Operating Activities
</I>
</FONT>
</P>
<P ID=PARA3205 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3204 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The primary use of cash for our operating activities during these periods was to fund the development of our product candidates, including commercial readiness activities for our product candidate, Zalviso. Our cash used for operating activities also reflected changes in our working capital, net of adjustments for non-cash charges, such as depreciation and amortization of our fixed assets, stock-based compensation, non-cash interest expense related to the sale of future royalties, interest expense related to our debt financings and the revaluation of our PIPE warrant liability and the contingent put option liability.
</FONT>
</P>
<P ID=PARA3207 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK7 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR7 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM7 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	76
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage77"></A>
<DIV ID=PGHDR7 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA7.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA3206 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash used in operating activities of $20.0 million during the year ended December 31, 2015, reflected a net loss of $24.4 million, partially offset by aggregate non-cash charges of $8.8 million, and a net change of $4.4 million in our net operating assets and liabilities. Non-cash charges included $5.0 million for stock-based compensation, $2.0 million for depreciation and amortization of our fixed assets, and $2.4 million of non-cash interest expense related to the Royalty Monetization, partially offset by a $2.1 million for the change in fair value of our PIPE warrant liability and contingent put liability. The net change in our operating assets and liabilities included a $3.3 million increase in accounts receivable.
</FONT>
</P>
<P ID=PARA3209 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3208 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash used in operating activities of $34.5 million during the year ended December 31, 2014, reflected a net loss of $33.4 million, partially offset by aggregate non-cash charges of $1.1 million. Non-cash charges included $4.4 million for stock-based compensation, partially offset by $7.0 million for the change in fair value of our PIPE warrant liability and contingent put liability.
</FONT>
</P>
<P ID=PARA3211 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3210 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net cash used in operating activities of $0.5 million during the year ended December&nbsp;31, 2013 reflected a net loss of $23.4 million, partially offset by aggregate non-cash charges of $20.0 million and a net change of $2.9 million in our net operating assets and liabilities. Non-cash charges primarily included $14.1 million for the revaluation of the PIPE warrant liability and the contingent put option liability, $3.5 million in stock-based compensation and $1.2 million for the loss on extinguishment of debt associated with our original loan agreement with Hercules, which was amended in December 2013. The net change in our operating assets and liabilities was primarily a result of an increase in deferred revenue of $2.6 million associated with our collaboration agreement with Gr&#252;nenthal and a decrease in prepaid expenses of $1.1 million due to completion of our Phase 3 clinical trials for Zalviso in 2013.
</FONT>
</P>
<P ID=PARA3213 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3212 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Cash Flows from Investing Activities
</I>
</FONT>
</P>
<P ID=PARA3215 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3214 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our investing activities have consisted primarily of our capital expenditures and purchases and sales and maturities of our available-for-sale investments.
</FONT>
</P>
<P ID=PARA3217 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3216 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During the year ended December 31, 2015, cash provided by investing activities of $8.2 million was primarily as a result of $16.9 million in proceeds from maturity of investments, partially offset by $7.2 million for purchases of investments and $1.5 million for purchases of property and equipment.
</FONT>
</P>
<P ID=PARA3219 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3218 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During the year ended December 31, 2014, cash used in investing activities of $5.8 million was primarily as a result of $17.4 million for purchases of investments and $5.5 million for purchases of property and equipment, partially offset by $17.2 million in proceeds from maturity of investments.
</FONT>
</P>
<P ID=PARA3221 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3220 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During the year ended December&nbsp;31, 2013, cash used in investing activities of $6.9 million was primarily a result of $28.0 million in purchases of investments and $3.3 million in purchases of property and equipment, partially offset by $24.4 million in maturities of investments.
</FONT>
</P>
<P ID=PARA3223 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3222 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Cash Flows from Financing Activities
</I>
</FONT>
</P>
<P ID=PARA3225 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3224 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash flows from financing activities primarily reflect proceeds from the sale of future royalties, proceeds from the sale of our securities, proceeds from our debt financings and payments made on such debt financings. As of December 31, 2015, the total liability related to the sale of future royalties was $63.6 million and the balance of the outstanding debt with Hercules was $20.9 million.
</FONT>
</P>
<P ID=PARA3227 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3226 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During the year ended December 31, 2015, cash provided by financing activities of $59.6 million was primarily due to net proceeds from the Royalty Monetization of $61.2 million, proceeds from the issuance of common stock upon the exercise of common stock options and ESPP issuances of $3.2 million, partially offset by payments of long-term debt of $4.5 million under the Amended Loan Agreement with Hercules.
</FONT>
</P>
<P ID=PARA3229 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3228 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During the year ended December 31, 2014, cash provided by financing activities of $11.9 million was primarily due to the drawdown of the second tranche of the Hercules debt of $10.0 million.
</FONT>
</P>
<P ID=PARA3231 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3230 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During the year ended December&nbsp;31, 2013, cash provided by financing activities was primarily a result of the receipt of $47.9 million in proceeds from an underwritten public offering in July 2013, net of offering costs and underwriting discounts, and proceeds of $15.0 million from the Amended Loan Agreement with Hercules in December 2013, partially offset by payments of long-term debt of $16.3 million, including payment of the remaining principal of $8.5 million at the time of the amendment, and $7.8 million in principal payments made prior to the amendment.
</FONT>
</P>
<P ID=PARA3233 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK3 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR3 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM3 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	77
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage78"></A>
<DIV ID=PGHDR3 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA3.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA3232 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Operating Capital and Capital Expenditure Requirements
</I>
</FONT>
</P>
<P ID=PARA3235 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3234 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We expect our rate of cash usage to increase in the future, in particular to support our product development activities, including continued development of Zalviso, ARX-04 and the potential commercialization of our product candidates, if approved outside of the Gr&#252;nenthal Territory. Our future cash needs anticipate the receipt of reimbursement for qualified expenses under the DoD Contract. We anticipate that our existing capital resources will permit us to meet our capital and operational requirements through at least the first half of 2017. Our current operating plan includes the continued development of ARX-04, specifically the filing of the NDA in 2016. These assumptions may change as a result of many factors. For example, although the FDA has reviewed the protocol for the additional clinical trial for Zalviso and we&#8217;ve incorporated their comments into the trial design, pending the results of this additional clinical trial, the FDA may require us to complete additional work to resubmit the NDA for Zalviso. We will continue to evaluate the work necessary to gain approval of Zalviso in the U.S. The final pathway forward for Zalviso could have a material impact on our operating spend. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms underlying potential funding sources are unfavorable, our business and our ability to develop our product candidates would be harmed.
</FONT>
</P>
<P ID=PARA3237 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3236 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our future capital requirements may vary materially from our expectations based on numerous forward looking factors, including but not limited to the following:
</FONT>
</P>
<P ID=PARA3239 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3240 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3241 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3242 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the outcome, timing and cost of regulatory approvals;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3244 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3245 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3246 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3247 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expenditures related to the activities required in support of our resubmission of the Zalviso NDA, including an additional clinical trial for Zalviso, as requested by the FDA;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3249 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3250 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3251 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3252 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	expenditures related to our commercialization preparation of Zalviso;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3254 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3255 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3256 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3257 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	future manufacturing, selling and marketing costs related to Zalviso, including our contractual obligations to Gr&#252;nenthal;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3259 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3260 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3261 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3262 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the initiation, progress, timing and completion of clinical trials for our product candidates, including ARX-04;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3264 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3265 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3266 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3267 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	changes in the focus and direction of our business strategy and/or research and development programs;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3269 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3270 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3271 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3272 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	milestone and royalty revenue we receive under our collaborative development and commercialization arrangements;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3274 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3275 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3276 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3277 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delays that may be caused by changing regulatory requirements;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3279 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3280 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3281 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3282 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the number of product candidates that we pursue;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3284 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3285 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3286 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3287 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3289 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3290 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3291 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3292 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3294 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3295 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3296 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3297 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the timing and terms of future in-licensing and out-licensing transactions;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3299 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3300 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3301 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3302 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3304 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3305 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3306 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3307 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the cost of procuring clinical and commercial supplies of our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3309 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3308 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3311 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3312 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3313 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the extent to which we acquire or invest in businesses, products or technologies; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3315 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3316 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3317 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3318 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	the expenses associated with the pending securities lawsuit, as well as any other litigation.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3320 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3319 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We will need substantial funds to:
</FONT>
</P>
<P ID=PARA3322 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3323 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3324 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3325 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	commercialize any products we market, including ARX-04 and Zalviso, if approved outside of the Gr&#252;nenthal Territory;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3327 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3328 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3329 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3330 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	manufacture and market our product candidates;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3332 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3333 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3334 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3335 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	conduct preclinical and clinical testing of our product candidates; and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3337 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3338 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3339 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3340 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	conduct research and development programs.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3342 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3341 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our existing capital resources may not be sufficient to fund our operations until such time as we may be able to generate sufficient revenues to sustain our operations. To the extent that our capital resources are insufficient to meet our future capital requirements, we will have to raise additional funds through the sale of our equity securities, monetization of current and future assets, issuance of debt or debt-like securities or from development and licensing arrangements to continue our development programs. We may be unable to raise such additional capital on favorable terms, or at all. If we raise additional capital by selling our equity or convertible debt securities, the issuance of such securities could result in dilution of our shareholders&#8217; equity positions. If adequate funds are not available we may have to:
</FONT>
</P>
<P ID=PARA3344 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK4 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR4 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM4 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	78
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage79"></A>
<DIV ID=PGHDR4 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA4.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3345 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3346 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3347 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	significantly curtail or put on hold commercialization or development efforts of our product candidates or other operations;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3349 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3350 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3351 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3352 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	obtain funds through entering into collaboration agreements on unattractive terms; and/or
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3354 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3355 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3356 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8226;
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3357 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	delay, postpone or terminate planned clinical trials.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3359 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3358 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<P ID=PARA3360 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Contractual Obligations
</B>
</FONT>
</P>
<P ID=PARA3363 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3362 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table summarizes our long-term contractual obligations at December&nbsp;31, 2015:
</FONT>
</P>
<P ID=PARA3364 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL3453 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL3453.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.1.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.1.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=18>
<P ID=PARA3365 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Payments Due by Period
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.1.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3453.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: MIDDLE">
<P ID=PARA3366 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Contractual obligations
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3367 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Total
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3368 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2016
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<B>
	2017-2019
</B>
</TD>
<TD ID=TBL3453.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<B>
	2020-2021
</B>
</TD>
<TD ID=TBL3453.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.2.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.2.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3371 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Thereafter
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.2.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3453.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.3.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3453.FINROW.3.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=18>
<P ID=PARA3372 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(in thousands)
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.3.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3453.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3373 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Operating leases
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
	(1)
</SUP>
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3453.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	1,516
</TD>
<TD ID=TBL3453.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3453.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	717
</TD>
<TD ID=TBL3453.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3453.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	799
</TD>
<TD ID=TBL3453.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.4.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.4.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3453.FINROW.4.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3453.FINROW.4.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.4.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.4.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3453.FINROW.4.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3453.FINROW.4.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3453.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: MIDDLE; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3384 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Purchase obligations
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
	(2)
</SUP>
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	400
</TD>
<TD ID=TBL3453.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	200
</TD>
<TD ID=TBL3453.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	200
</TD>
<TD ID=TBL3453.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL3453.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.5.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL3453.FINROW.5.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3453.FINROW.6 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3390 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Principal payments on long-term debt
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
	(3)
</SUP>
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	22,166
</TD>
<TD ID=TBL3453.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	4,541
</TD>
<TD ID=TBL3453.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	17,625
</TD>
<TD ID=TBL3453.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3453.FINROW.6.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.6.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3453.FINROW.6.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3453.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3397 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest payments on long-term debt
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	2,539
</TD>
<TD ID=TBL3453.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	1,859
</TD>
<TD ID=TBL3453.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	680
</TD>
<TD ID=TBL3453.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL3453.FINROW.7.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.7.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL3453.FINROW.7.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3453.FINROW.8 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3404 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Repayment of liability related to the sale of future royalties
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	195,000
</TD>
<TD ID=TBL3453.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	118
</TD>
<TD ID=TBL3453.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	11,709
</TD>
<TD ID=TBL3453.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	29,798
</TD>
<TD ID=TBL3453.FINROW.8.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.8.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	153,375
</TD>
<TD ID=TBL3453.FINROW.8.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3453.FINROW.9 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3425 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total contractual obligations
</FONT>
</P>
</TD>
<TD ID=TBL3453.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3453.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	221,621
</TD>
<TD ID=TBL3453.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3453.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	7,435
</TD>
<TD ID=TBL3453.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3453.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	31,013
</TD>
<TD ID=TBL3453.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.9.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.9.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3453.FINROW.9.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	29,798
</TD>
<TD ID=TBL3453.FINROW.9.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.9.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3453.FINROW.9.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3453.FINROW.9.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	153,375
</TD>
<TD ID=TBL3453.FINROW.9.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
<P ID=PARA3454 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 89.6% 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 10%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="LEFT">
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 89.6% 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA3456 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
	(1)
</SUP>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease includes base rent for facilities we occupy in Redwood City, California.
</FONT>
</P>
<P ID=PARA3457 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
	(2)
</SUP>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We issue inventory and research and development program related purchase orders in the normal course of business. We do not consider purchase orders to be firm inventory or research and development program related commitments; therefore, they are excluded from the table above. If we choose to cancel a purchase order, we may be obligated to reimburse the vendor for unrecoverable outlays incurred prior to cancellation.
</FONT>
</P>
<P ID=PARA3458 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
	(3)
</SUP>
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The loan and security agreement with Hercules includes a $1.7&nbsp;million balloon payment due on maturity of the loan, October&nbsp;1, 2017, and is included in the table above.
</FONT>
</P>
<P ID=PARA3459 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18.35PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -18.35PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P ID=PARA3460 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Operating leases
</I>
</B>
</FONT>
</P>
<P ID=PARA3462 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3461 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In December 2011, we entered into a non-cancelable lease agreement, or the Existing Lease, for approximately 13,787 square feet of office and laboratory facilities in Redwood City, California, or the Current Premises, which serve as the Company headquarters, effective April 2012. The lease agreement expires in May 2016. Rent expense from the facility lease is recognized on a straight-line basis from the inception of the lease in December 2011, the early access date, through the end of the lease.
</FONT>
</P>
<P ID=PARA3463 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3464 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In May 2014, we entered into an amendment, or the Lease Amendment, to the Existing Lease. Pursuant to the Lease Amendment, the term of the Existing Lease has been extended for a period of twenty (20) months and twenty-two (22) days and expiring January 31, 2018, or the Expiration Date, unless sooner terminated pursuant to the terms of the Existing Lease. In addition, the Lease Amendment included a new lease on an additional 12,106 square feet of office space, or the Expansion Space, which is adjacent to the Current Premises.&nbsp;The new lease for the Expansion Space has a term of 42 months commencing on August 1, 2014, and expiring on the Expiration Date. We have an option to extend the term of the Lease Amendment for an additional five years, which would commence upon the Expiration Date, at a market rate determined according to the Existing Lease.
</FONT>
</P>
<P ID=PARA3466 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3465 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In October 2015, we executed an agreement to sublease 11,871 square feet of the Expansion Space for a term of 26 months commencing on December 1, 2015. The sublessee is entitled to abatement of the first two monthly installments of rent. Subsequent monthly installments of rent start at a rental rate of $2.05 per square foot (subject to agreed nominal increases). Upon the completion of the sublease, we have the option to take back the subleased space.
</FONT>
</P>
<P ID=PARA3467 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK3 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR3 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM3 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	79
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage80"></A>
<DIV ID=PGHDR3 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA3.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA3468 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Purchase obligations
</I>
</B>
</FONT>
</P>
<P ID=PARA3469 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3470 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Patheon
</I>
</FONT>
</P>
<P ID=PARA3472 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3471 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In January 2013, we entered into a Manufacturing Services Agreement, or the
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Services Agreement, with Patheon Pharmaceuticals, Inc., or Patheon, relating to the manufacture of sufentanil sublingual tablets, for use with Zalviso.
</FONT>
</P>
<P ID=PARA3474 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3473 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the terms of the Services Agreement, we have agreed to purchase, subject to Patheon&#8217;s continued material compliance with the terms of the Services Agreement, all of our sufentanil sublingual tablet requirements for the United States, Canada and Mexico from Patheon during the Initial Term of the Services Agreement (as defined below), and at least eighty percent (80%)&nbsp;of its sufentanil sublingual tablet requirements for such territories after the Initial Term. The term of the Services Agreement extends until December&nbsp;31, 2017, or the Initial Term, and will automatically renew thereafter for periods of two years, unless terminated by either party upon eighteen months&#8217; prior written notice; provided, however, that the Services Agreement may not be terminated without cause prior to the end of the Initial Term.
</FONT>
</P>
<P ID=PARA3476 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3475 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We also entered into a Capital Expenditure and Equipment Agreement, or the Capital Agreement, with Patheon. Under the terms of the Capital Agreement, as amended in January 2014, or the Amended Capital Agreement,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we have made and have the option to make certain future modifications to Patheon&#8217;s Cincinnati facility and which would be our responsibility. If additional equipment and facility modifications are required to meet our Product needs, we may be required to contribute to the cost of such additional equipment and facility modifications. Under the Amended Capital Agreement, we made payments in 2012 and 2013 totaling $480,000 to Patheon to partially offset taxes incurred and paid by Patheon in connection with facility modifications already completed by Patheon. We can seek reimbursement from Patheon for these payments if we receive approval from the U.S. Food and Drug Administration for Zalviso. The Amended Capital Agreement further requires that we pay a maximum &#8220;overhead fee&#8221; of $200,000 annually during the term of the Services Agreement, which amount may be reduced to $0 based on the amount of annual revenues earned by Patheon under the Services Agreement and pre-existing development agreements with Patheon. No fee was due in 2014 or 2015 based on the amount of revenues earned by Patheon from AcelRx in 2014 and 2015.
</FONT>
</P>
<P ID=PARA3478 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3477 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Long-term debt
</I>
</B>
</FONT>
</P>
<P ID=PARA3479 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P ID=PARA3480 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Hercules Loan
</I>
</FONT>
</P>
<P ID=PARA3482 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA107 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December 16, 2013, we entered into an Amended and Restated Loan and Security Agreement with Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc., together, the Lenders, or the Amended Loan Agreement, under which we may borrow up to $40.0 million in three tranches. On September 24, 2014, we entered into Amendment No. 1 to the Amended Loan Agreement with Hercules. Amendment No. 1 extended the time period under which we could draw down the third tranche, of up to $15.0 million, from March 15, 2015 to August 1, 2015, subject to AcelRx obtaining approval for Zalviso from the FDA. We did not receive FDA approval of Zalviso by August 1, 2015 and as such, did not have access to the third tranche. On September 18, 2015, concurrently with the closing of the Royalty Monetization, we entered into a Consent and Amendment No. 2, or Amendment No. 2, to the Amended Loan Agreement with the Lenders. Amendment No. 2 includes an interest only period from October 1, 2015 through March 31, 2016, with the potential for further extension to September 30, 2016 upon satisfaction of certain conditions, which have since been satisfied. After the expiration of the interest only period, we will make 13 monthly payments of $1.7 million beginning in October 2016 through October 2017. In addition, a final payment equal to $1.7 million will be due in October 2017. Loans under the Amended Loan Agreement mature on October 31, 2017.
</FONT>
</P>
<P ID=PARA109 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA3484 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The interest rate for each tranche will be calculated at a rate equal to the greater of either (i)&nbsp;9.10% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii)&nbsp;9.10%. Our obligations under the Amended Loan Agreement are secured by a security interest in substantially all of our assets, other than our intellectual property and those assets sold under the Royalty Monetization
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	.
</FONT>
</P>
<P ID=PARA3486 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK4 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR4 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM4 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	80
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage81"></A>
<DIV ID=PGHDR4 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA4.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA3485 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Liability related to the sale of future royalties
</I>
</B>
</FONT>
</P>
<P ID=PARA3487 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P ID=PARA3488 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 18PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -18PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Royalty Monetization with PDL
</I>
</FONT>
</P>
<P ID=PARA3490 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3489 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In September 2015,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	we sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by our commercial partner, Gr&#252;nenthal, pursuant to the Collaboration and License Agreement, dated as of December 16, 2013, as amended, to PDL for an upfront cash purchase price of $65.0 million. PDL will receive 75% of the European royalties under the Amended License Agreement with Gr&#252;nenthal, as well as 80% of the first four commercial milestones worth $35.6 million (or 80% of $44.5 million), subject to the capped amount of $195.0 million. The Royalty Monetization has been accounted for as a liability that will be amortized using the interest method over the life of the arrangement. The timing and the amount of the repayment of this liability is contingent upon the receipt of the related royalty and milestone payments from Gr&#252;nenthal. Upon receipt of these royalty and milestone payments from Gr&#252;nenthal, we will remit the applicable portion to PDL.
</FONT>
</P>
<P ID=PARA3492 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3491 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Off-Balance Sheet Arrangements
</B>
</FONT>
</P>
<P ID=PARA3494 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3493 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Through December&nbsp;31, 2015, we have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P ID=PARA3495 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<P ID=PARA3497 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;7A. Quantitative and Qualitative Disclosures About Market Risk
</B>
</FONT>
</P>
<P ID=PARA3498 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3499 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our cash, cash equivalents and short-term investments as of December 31, 2015, consisted primarily of money market funds and U.S. government agency securities. We do not have any auction rate securities on our Consolidated Balance Sheet, as they are not permitted by our investment policy. Our cash is invested in accordance with an investment policy approved by our board of directors which specifies the categories, allocations, and ratings of securities we may consider for investment. We do not believe our cash, cash equivalents and short-term investments have significant risk of default or illiquidity.
</FONT>
</P>
<P ID=PARA3500 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3501 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because the majority of our investments are in short-term marketable debt securities. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive from our investments without significantly increasing risk. In an attempt to limit interest rate risk, we follow guidelines to limit the average and longest single maturity dates, place our investments with high quality issuers and follow internally developed guidelines to limit the amount of credit exposure to any one issuer. Some of the securities that we invest in may be subject to market risk. This means that a change in prevailing interest rates may cause the value of the investment to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing interest rate later rises, the value of our investment may decline. If a 10 percent change in interest rates were to have occurred on December 31, 2015, this change would not have had a material effect on the fair value of our investment portfolio as of that date. In general, money market funds are not subject to market risk because the interest paid on such funds fluctuates with the prevailing interest rate.
</FONT>
</P>
<P ID=PARA3503 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3502 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, domestic and international equity markets have experienced and may continue to experience heightened volatility and turmoil based on domestic and international economic conditions and concerns. In the event these economic conditions and concerns continue and the markets continue to remain volatile, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary and our stock price may further decline. In addition, we maintain significant amounts of cash and cash equivalents that are not federally insured. If economic instability continues, we cannot provide assurance that we will not experience losses on these investments.
</FONT>
</P>
</EFX_MARKET_RISK>
<P ID=PARA3505 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<P ID=PARA3506 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;8. Financial Statements and Supplementary Data
</B>
</FONT>
</P>
<P ID=PARA3508 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3507 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The financial statements required by this item are attached to this Form 10-K beginning with page F-1.
</FONT>
</P>
</EFX_FINANCIAL_STATEMENTS>
<P ID=PARA3510 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<P ID=PARA3511 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
</B>
</FONT>
</P>
<P ID=PARA3513 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3512 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None.
</FONT>
</P>
</EFX_ACCOUNTING_CHANGES>
<P ID=PARA3515 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<P ID=PARA3514 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;9A. Controls and Procedures
</B>
</FONT>
</P>
<P ID=PARA3517 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3516 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Evaluation of Disclosure Controls and Procedures
</B>
</FONT>
</P>
<P ID=PARA3519 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3518 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have carried out an evaluation, under the supervision, and with the participation, of management including our principal executive officer and principal financial officer, of our disclosure controls and procedures (as defined in Rule 13a-15(e)) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Annual Report on Form 10&#8211;K. Based on their evaluation, our principal executive officer and principal financial officer concluded that, subject to the limitations described below, our disclosure controls and procedures were effective as of December&nbsp;31, 2015.
</FONT>
</P>
<P ID=PARA3521 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK5 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR5 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM5 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	81
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage82"></A>
<DIV ID=PGHDR5 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA5.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA3520 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Limitations on the Effectiveness of Controls.
</I>
	&nbsp;A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were sufficiently effective to provide reasonable assurance that the objectives of our disclosure control system were met. We continue to implement, improve and refine our disclosure controls and procedures and our internal control over financial reporting.
</FONT>
</P>
<P ID=PARA3523 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3522 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Changes in Internal Control over Financial Reporting
</B>
</FONT>
</P>
<P ID=PARA3525 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3524 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	There have been no significant changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting during the fiscal quarter ended December&nbsp;31, 2015.
</FONT>
</P>
<P ID=PARA3527 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3526 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Management&#8217;s Annual Report on Internal Control over Financial Reporting
</B>
</FONT>
</P>
<P ID=PARA3529 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3528 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following report is provided by management in respect of AcelRx Pharmaceuticals&#8217; internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act):
</FONT>
</P>
<P ID=PARA3531 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3530 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1. AcelRx Pharmaceuticals&#8217; management is responsible for establishing and maintaining adequate internal control over financial reporting.
</FONT>
</P>
<P ID=PARA3533 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3532 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2. AcelRx Pharmaceuticals management has used the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework (2013 framework) to evaluate the effectiveness of internal control over financial reporting. Management believes that the COSO framework is a suitable framework for its evaluation of financial reporting because it is free from bias, permits reasonably consistent qualitative and quantitative measurements of AcelRx Pharmaceuticals&#8217; internal control over financial reporting, is sufficiently complete so that those relevant factors that would alter a conclusion about the effectiveness of AcelRx Pharmaceuticals&#8217; internal control over financial reporting are not omitted and is relevant to an evaluation of internal control over financial reporting.
</FONT>
</P>
<P ID=PARA3535 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3534 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3. Management has assessed the effectiveness of AcelRx Pharmaceuticals&#8217; internal control over financial reporting as of December&nbsp;31, 2015 and has concluded that such internal control over financial reporting was effective.
</FONT>
</P>
<P ID=PARA3537 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3536 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	OUM&nbsp;&amp; Co. LLP, our independent registered public accounting firm, has attested to and issued a report on the effectiveness of our internal control over financial reporting, which is included herein.
</FONT>
</P>
<P ID=PARA222.1 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK222 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR222 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM222 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	82&nbsp;
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage83"></A>
<DIV ID=PGHDR222 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA222.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<P ID=PARA3539 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Board of Directors and Stockholders of
</FONT>
</P>
<P STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	AcelRx Pharmaceuticals, Inc.
</FONT>
</P>
<P STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<P ID=PARA203 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have audited AcelRx Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of December&nbsp;31, 2015, based on criteria established in
<I>
	Internal Control &#8211; Integrated Framework (2013)
</I>
	&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). AcelRx Pharmaceuticals, Inc.&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying
<I>
	Management&#8217;s
</I>
<I>
	Annual
</I>
<I>
	Report on Internal Control
</I>
<I>
	o
</I>
<I>
	ver Financial Reporting
</I>
	included in Item&nbsp;9A. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit.
</FONT>
</P>
<P ID=PARA206 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA205 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
</FONT>
</P>
<P ID=PARA208 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA207 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.
</FONT>
</P>
<P ID=PARA209 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA210 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
</FONT>
</P>
<P ID=PARA212 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA211 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In our opinion, AcelRx Pharmaceuticals, Inc. maintained, in all material respects, effective internal control over financial reporting as of December&nbsp;31, 2015, based on the COSO criteria.
</FONT>
</P>
<P ID=PARA214 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA213 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of AcelRx Pharmaceuticals, Inc. as of December&nbsp;31, 2015, and the related
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	consolidated statements of comprehensive loss, stockholders&#8217; equity, and cash flows for the year then ended, and our report dated March 7, 2016 expressed an unqualified opinion thereon.
</FONT>
</P>
<P ID=PARA216 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA215 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 6.1PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -6.1PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ OUM&nbsp;&amp; CO. LLP
</FONT>
</P>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</FONT>
<P ID=PARA223.1 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK223 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR223 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM223 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	83&nbsp;
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage84"></A>
<DIV ID=PGHDR223 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_CONTROL_AND_PROCEDURES>
<P ID=PARA223.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<P ID=PARA3540 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;9B. Other Information
</B>
</FONT>
</P>
<P ID=PARA3543 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3542 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None.
</FONT>
</P>
<P ID=PARA3545 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK6 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR6 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM6 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	84
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage85"></A>
<DIV ID=PGHDR6 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<P ID=PARA6.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P ID=PARA3548 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PART III
</B>
</FONT>
</P>
<P ID=PARA3550 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<P ID=PARA3549 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;10. Directors, Executive Officers and Corporate Governance
</B>
</FONT>
</P>
<P ID=PARA3552 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3551 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The information required by this item is hereby incorporated by reference from the information under the captions "Election of Directors," "Board of Directors Meetings and Committees&#8212;Board Committees" and "Executive Officers" contained in the Company&#39;s definitive Proxy Statement, to be filed with the Securities and Exchange Commission no later than 120&nbsp;days from the end of the Company&#39;s last fiscal year in connection with the solicitation of proxies for its 2016 Annual Meeting of Stockholders. The information required by Section&nbsp;16(a) is incorporated by reference from the information under the caption "Security Ownership of Certain Beneficial Owners and Management&#8212;Section&nbsp;16(a) Beneficial Ownership Reporting Compliance" in the Proxy Statement.
</FONT>
</P>
<P ID=PARA3554 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3553 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company has adopted a code of ethics that applies to its Chief Executive Officer, Chief Financial Officer, and to all of its other officers, directors, employees and agents. The code of ethics is available at the Corporate Governance section of the Investor Relations page on the Company&#39;s website at
<I>
	www.acelrx.com
</I>
	. The Company intends to disclose future amendments to, or waivers from, certain provisions of its code of ethics on the above website within five business days following the date of such amendment or waiver.
</FONT>
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P ID=PARA3556 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<P ID=PARA3555 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;11. Executive Compensation
</B>
</FONT>
</P>
<P ID=PARA3558 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3557 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The information required by this item is incorporated by reference from the information under the caption "Board of Directors Meetings and Committees&#8212;Compensation Committee Interlocks and Insider Participation," "Executive Compensation" and "Executive Compensation&#8212;Compensation Committee Report" in the Company&#39;s Proxy Statement referred to in Item&nbsp;10 above.
</FONT>
</P>
</EFX_COMPENSATION>
<P ID=PARA3560 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<P ID=PARA3559 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</B>
</FONT>
</P>
<P ID=PARA3562 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<P ID=PARA3561 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Equity Compensation Plan Information
</B>
</FONT>
</P>
<P ID=PARA3564 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3563 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table provides certain information with respect to our equity compensation plans in effect as of December&nbsp;31, 2015.
</FONT>
</P>
<P ID=PARA3565 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL3640 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL3640.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 31%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3568 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Column A
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3640.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.1.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.1.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3571 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Column B
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3640.FINROW.1.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3574 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Column C
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3640.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3640.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 31%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA3576 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Plan Category
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3640.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3578 STYLE="MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Number of securities&nbsp;to be
<BR>
	issued upon exercise
<BR>
	of outstanding options,
<BR>
	warrants and rights
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3640.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3581 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Weighted-average exercise
<BR>
	price of outstanding options,
<BR>
	warrants and rights
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3640.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3640.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3584 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Number of securities remaining available
</B>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	for future issuance under equity
</B>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	compensation plans (excluding securities
</B>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	reflected in column A)
<BR>
</B>
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
<B>
	(3)
</B>
</SUP>
</FONT>
</P>
</TD>
<TD ID=TBL3640.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3640.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 31%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA3586 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Equity compensation plans approved by security holders
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
	(1)
</SUP>
</FONT>
</P>
</TD>
<TD ID=TBL3640.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	4,618,949
</TD>
<TD ID=TBL3640.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3640.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	5.77
</TD>
<TD ID=TBL3640.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	2,945,509
</TD>
<TD ID=TBL3640.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3640.FINROW.4>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 31%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA3599 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Equity compensation plans not approved by security holders
</FONT>
</P>
</TD>
<TD ID=TBL3640.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL3640.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3640.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL3640.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL3640.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3640.FINROW.5>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 31%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3621 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total
</FONT>
</P>
</TD>
<TD ID=TBL3640.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	4,618,949
</TD>
<TD ID=TBL3640.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.5.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.5.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.5.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.5.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3640.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	2,945,509
</TD>
<TD ID=TBL3640.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
<P ID=PARA3641 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 100%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="LEFT">
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA3642 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<TABLE ID=TBL3645 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 3%; VERTICAL-ALIGN: TOP">
<P ID=PARA3643 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
	(1)
</SUP>
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 97%; VERTICAL-ALIGN: TOP">
<P ID=PARA3644 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Consists of the 2006 Plan, the 2011 Plan and the ESPP.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE ID=TBL3648 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 3%; VERTICAL-ALIGN: TOP">
<P ID=PARA3646 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
	(2)
</SUP>
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 97%; VERTICAL-ALIGN: TOP">
<P ID=PARA3647 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Consists of shares available for future issuance under the 2011 Incentive Plan, including shares that were previously available for future issuance under the 2006 Plan at the time of the execution and delivery of the underwriting agreement for our IPO, and the ESPP. As of December&nbsp;31, 2015, 2,654,302 shares of common stock were available for issuance under the 2011 Incentive Plan and 291,207 shares of common stock were available for issuance under the ESPP.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE ID=TBL3651 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 3%; VERTICAL-ALIGN: TOP">
<P ID=PARA3649 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<SUP STYLE="VERTICAL-ALIGN: BASELINE; POSITION: RELATIVE; BOTTOM:.33EM;">
	(3)
</SUP>
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 97%; VERTICAL-ALIGN: TOP">
<P ID=PARA3650 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The initial aggregate number of shares of our common stock that may be issued pursuant to stock awards under the 2011 Incentive Plan was 1,875,000 shares, which number was the sum of (i)&nbsp;51,693 shares remaining available for future grant under the 2006 Plan at the time of the execution and delivery of the underwriting agreement for our IPO, and (ii)&nbsp;an additional 1,823,307 new shares. The number of shares of our common stock reserved for issuance under the 2011 Incentive Plan will automatically increase on January&nbsp;1st each year, starting on January&nbsp;1, 2012 and continuing through January&nbsp;1, 2020, by 4% of the total number of shares of our common stock outstanding on December&nbsp;31 of the preceding calendar year, or such lesser number of shares of common stock as determined by our board of directors. The initial aggregate number of shares of common stock that may be issued pursuant to purchase rights granted to our employees or to employees of any of our designated affiliates under the ESPP was 250,000 shares. The number of shares of our common stock reserved for issuance will automatically increase on January&nbsp;1st each year, starting January&nbsp;1, 2012 and continuing through January&nbsp;1, 2020, in an amount equal to the lower of (i)&nbsp;2% of the total number of shares of our common stock outstanding on December&nbsp;31 of the preceding calendar year, and (ii)&nbsp;a number of shares of common stock as determined by our board of directors.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3653 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3652 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The information required by this item is incorporated by reference from the information under the caption "Security Ownership of Certain Beneficial Owners and Management" in the Company&#39;s Proxy Statement referred to in Item&nbsp;10 above.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<P ID=PARA3656.1 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK3656 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGNUM3656 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	85
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage86"></A>
<DIV ID=PGHDR3656 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_SECURITY_OWNERS>
<P ID=PARA3656.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<P ID=PARA3658 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;13. Certain Relationships and Related Transactions and Director Independence
</B>
</FONT>
</P>
<P ID=PARA3661 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3660 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The information required by this item is incorporated by reference from the information under the caption "Certain Relationships and Related Transactions" and "Board of Directors Meetings and Committees&#8212;Board Independence" in the Company&#39;s Proxy Statement referred to in Item&nbsp;10 above.
</FONT>
</P>
</EFX_OFFICER_TRANSACTIONS>
<P ID=PARA3663 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<P ID=PARA3662 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;14. Principal Accounting Fees and Services
</B>
<B>
<I>
</I>
</B>
</FONT>
</P>
<P ID=PARA3665 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3664 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The information required by this item is incorporated by reference from the information under the caption "Ratification of Appointment of Independent Registered Public Accounting Firm" in the Company&#39;s Proxy Statement referred to in Item&nbsp;10 above.
</FONT>
</P>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<P ID=PARA3667 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3666 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P ID=PARA3668 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	PART IV
</B>
</FONT>
</P>
<P ID=PARA3671 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<P ID=PARA3670 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Item&nbsp;15. Exhibits, Financial Statement Schedules
</B>
</FONT>
</P>
<P ID=PARA3673 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3672 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(a) The following documents are filed as part of this Form 10-K:
</FONT>
</P>
<P ID=PARA3675 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3676 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 24PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3677 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1.
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3678 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Financial Statements:
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3680 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3679 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	See Index to Financial Statements in Item&nbsp;8 of this Form 10-K.
</FONT>
</P>
<P ID=PARA3682 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB3683 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 24PT; VERTICAL-ALIGN: TOP">
<P ID=PARA3684 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA3685 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Financial Statement Schedules:
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3687 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3686 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	No schedules are provided because they are not applicable, not required under the instructions, or the requested information is shown in the financial statements or related notes thereto.
</FONT>
</P>
<P ID=PARA3689 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3688 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(b) Exhibits &#8211; The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Annual Report on Form 10-K
</FONT>
</P>
<P ID=PARA3691 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK7 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR7 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM7 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	86
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage87"></A>
<DIV ID=PGHDR7 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_EXHIBITS>
</EFX_PART_IV>
<P ID=PARA7.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P ID=PARA3692 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	SIGNATURES
</B>
</FONT>
</P>
<P ID=PARA3694 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3693 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant to the requirements of Section&nbsp;13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</FONT>
</P>
<P ID=PARA3695 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL3712 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA3696 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date: March&nbsp;7, 2016
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA3697 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA3698 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA3699 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(Registrant)
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA3700 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID">
<P ID=PARA3701 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;Howard B. Rosen&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA3702 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA3703 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Howard B. Rosen
</B>
</FONT>
</P>
<P ID=PARA3704 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Interim Chief Executive Officer and Director
</B>
</FONT>
</P>
<P ID=PARA3705 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Principal Executive Officer)
</B>
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA3706 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID">
<P ID=PARA3707 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;Timothy E. Morris&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: TOP">
<P ID=PARA3708 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 50%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA3709 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Timothy E. Morris
</B>
</FONT>
</P>
<P ID=PARA3710 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Chief Financial Officer and Head of Business Development
</B>
</FONT>
</P>
<P ID=PARA3711 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(Principal Financial and Accounting Officer)
</B>
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3714 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3713 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	POWER OF ATTORNEY
</B>
</FONT>
</P>
<P ID=PARA3716 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3715 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Howard B. Rosen and Timothy E. Morris, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
</FONT>
</P>
<P ID=PARA3718 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3717 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 24.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
</FONT>
</P>
<P ID=PARA3719 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL3768 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA3720 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Signature
</B>
</FONT>
</U>
</P>
<P STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<STRONG>
<U>
</U>
</STRONG>
	&nbsp;
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA3722 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Title
</B>
</FONT>
</U>
</P>
<P ID=PARA3723 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 91.45PT 0PT 91.25PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA3724 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Date
</B>
</FONT>
</U>
</P>
<P ID=PARA3725 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 28.8PT 0PT 28.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
	&nbsp; /s/&nbsp;&nbsp;&nbsp;&nbsp;Howard B. Rosen&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	Interim Chief&nbsp;Executive&nbsp;Officer and Director
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp; March&nbsp;7, 2016
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<P ID=PARA3726 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Howard B. Rosen
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="MARGIN-BOTTOM: 0PX; WIDTH: 41%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA3729 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	(Principal Executive Officer)
</I>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: TOP">
<P ID=PARA3731 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;Timothy E. Morris&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: TOP">
	Chief Financial Officer
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	March&nbsp;7, 2016
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<P ID=PARA3732 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Timothy E. Morris
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="MARGIN-BOTTOM: 0PX; WIDTH: 41%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA3735 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	(Principal&nbsp;Financial&nbsp;and&nbsp;Accounting&nbsp;Officer)
</I>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: TOP">
<P ID=PARA3737 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
	&nbsp; /s/&nbsp;&nbsp;&nbsp;&nbsp;Adrian Adams&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	Chairman
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp; March&nbsp;7, 2016
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<P ID=PARA3738 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Adrian Adams
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: TOP">
<P ID=PARA3741 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 6.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: TOP">
<P ID=PARA3742 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
	&nbsp; /s/&nbsp;&nbsp;&nbsp;&nbsp;Pamela P. Palmer, M.D., Ph.D.&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	Chief Medical Officer and Director
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp; March&nbsp;7, 2016
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<P ID=PARA3743 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Pamela P. Palmer, M.D., Ph.D.
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: TOP">
<P ID=PARA3746 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 6.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: TOP">
<P ID=PARA3747 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
	&nbsp; /s/&nbsp;&nbsp;&nbsp;&nbsp;Mark G. Edwards&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	Director
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp; March&nbsp;7, 2016
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<P ID=PARA3748 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Mark G. Edwards
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: TOP">
<P ID=PARA3751 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 6.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: TOP">
<P ID=PARA3752 STYLE="MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
	&nbsp; /s/&nbsp;&nbsp;&nbsp;&nbsp;Stephen J. Hoffman, Ph.D., M.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	Director
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp; March&nbsp;7, 2016
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<P ID=PARA3753 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Stephen J. Hoffman, Ph.D., M.D.
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: TOP">
<P ID=PARA3756 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 6.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: TOP">
<P ID=PARA3757 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
	&nbsp; /s/&nbsp;&nbsp;&nbsp;&nbsp;Richard Afable, M.D.&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="MARGIN-BOTTOM: 0PX; WIDTH: 41%; VERTICAL-ALIGN: MIDDLE; MARGIN-TOP: 0PX">
	Director
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp; March&nbsp;7, 2016
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<P ID=PARA3758 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Richard Afable, M.D.
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="MARGIN-BOTTOM: 0PX; WIDTH: 41%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA3761 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: TOP">
<P ID=PARA3762 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
	&nbsp; /s/&nbsp;&nbsp;&nbsp;&nbsp;Mark Wan&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 41%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp; March&nbsp;7, 2016
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 43%; VERTICAL-ALIGN: TOP">
<P ID=PARA3763 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Mark Wan
</B>
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="MARGIN-BOTTOM: 0PX; WIDTH: 41%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA3766 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Director
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 15%; VERTICAL-ALIGN: TOP">
<P ID=PARA3767 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3770 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK8 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR8 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM8 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	87
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage88"></A>
<DIV ID=PGHDR8 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA8.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA3769 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	ACELRX PHARMACEUTICALS, INC.
</B>
</FONT>
</P>
<P ID=PARA3772 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3771 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</FONT>
</P>
<P ID=PARA3773 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL3789 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA3774 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA3775 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Page
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3776 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3777 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Reports of Independent Registered Public Accounting Firms
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3778 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	F-2
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3779 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Balance Sheets at December&nbsp;31, 2015 and 2014
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3780 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	F-3
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3781 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Statements of Comprehensive Loss for each of the three years in the period ended December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3782 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	F-4
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3783 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3784 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	F-5
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3785 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Consolidated Statements of Cash Flows for each of the three years in the period ended December&nbsp;31, 2015
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3786 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	F-7
</FONT>
</P>
</TD>
</TR>
<TR STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="WIDTH: 93%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3787 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notes to Consolidated Financial Statements
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3788 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	F-8
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA3791 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<DIV ID=PGBK3792 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGNUM3792 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-1
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage89"></A>
<DIV ID=PGHDR3792 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_SIGNATURES>
<P ID=PARA3792.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE">
<B>
</B>
</FONT>
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P ID=PARA3794 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; TEXT-TRANSFORM: UPPERCASE">
<B>
	Report of Independent Registered Public Accounting Firm
</B>
</FONT>
</P>
<P ID=PARA3795 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA110 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Board of Directors and Stockholders
</FONT>
</P>
<P ID=PARA111 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	AcelRx Pharmaceuticals, Inc.
</FONT>
</P>
<P ID=PARA112 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA113 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have audited the accompanying consolidated balance sheet of AcelRx Pharmaceuticals, Inc. as of December 31, 2015, and the related consolidated statements of comprehensive loss, stockholders&#8217; equity, and cash flows for the year then ended. These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audit.
</FONT>
</P>
<P ID=PARA114 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA115 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
</FONT>
</P>
<P ID=PARA116 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA117 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of AcelRx Pharmaceuticals, Inc. at December 31, 2015, and the consolidated results of its operations and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.
</FONT>
</P>
<P ID=PARA118 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA119 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As discussed in Note 1 to the consolidated financial statements, in 2015 the Company changed the manner in which it accounts for the classification of debt issuance cost in the consolidated balance sheets due to the adoption of ASU 2015-03, Interest-Imputation of Interest.
</FONT>
</P>
<P ID=PARA120 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA121 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), AcelRx Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of December 31, 2015, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and our report dated March 7, 2016 expressed an unqualified opinion thereon.
</FONT>
</P>
<P ID=PARA122 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA123 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA124 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ OUM &amp; CO. LLP
</FONT>
</P>
<P ID=PARA125 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA126 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	San Francisco, California
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA3810 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 7, 2016
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA3812.1 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK3812 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGNUM3812 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-2
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage90"></A>
<DIV ID=PGHDR3812 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_AUDITORS_OPINION>
<P ID=PARA3812.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
</B>
</FONT>
</P>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION_2"></A>
<P ID=PARA3814 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Report of Independent Registered Public Accounting Firm&nbsp;
</B>
</FONT>
</P>
<P ID=PARA3815 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA128 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Board of Directors and Stockholders of AcelRx Pharmaceuticals, Inc.
</FONT>
</P>
<P ID=PARA130 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA131 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We have audited the accompanying consolidated balance sheet of AcelRx Pharmaceuticals, Inc. as of December 31, 2014, and the related consolidated statements of operations, comprehensive income, stockholders&#8216; equity, and cash flows for each of the two years in the period ended December 31, 2014. These financial statements are the responsibility of the Company&#39;s management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits.
</FONT>
</P>
<P ID=PARA132 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA133 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
</FONT>
</P>
<P ID=PARA134 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA135 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of AcelRx Pharmaceuticals, Inc. at December 31, 2014, and the consolidated results of its operations and its cash flows for each of the two years in the period ended December 31, 2014, in conformity with U.S. generally accepted accounting principles.
</FONT>
</P>
<P ID=PARA136 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA137 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Ernst &amp; Young LLP
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA139 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	San Jose, California
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA141 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 12, 2015
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA143 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	except for Note 1 and 7, as to which the date is
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA145 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 7, 2016
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
	&nbsp;
</P>
<DIV ID=PGBK10 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR10 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM10 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-3
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage91"></A>
<DIV ID=PGHDR10 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_AUDITORS_OPINION>
<P ID=PARA10.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P ID=PARA3834 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA3836 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3835 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Consolidated Balance Sheets
</B>
</FONT>
</P>
<P ID=PARA3837 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(in thousands, except share data)
</B>
</FONT>
</P>
<P ID=PARA3838 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL3974 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL3974.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3840 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	December 31,
<BR>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA3842 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	December 31,
<BR>
	2014
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3974.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 70%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3844 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Assets
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.3.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.3.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.3.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.3.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.3.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.3.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.3.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.3.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3974.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3847 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Current Assets:
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.4.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.4.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.4.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.4.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.4.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.4.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.4.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.4.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3850 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash and cash equivalents
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3974.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	107,922
</TD>
<TD ID=TBL3974.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3974.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	60,038
</TD>
<TD ID=TBL3974.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3853 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Short-term investments
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	5,542
</TD>
<TD ID=TBL3974.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	15,312
</TD>
<TD ID=TBL3974.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3856 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accounts receivable, net
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	3,286
</TD>
<TD ID=TBL3974.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3974.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.8 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3859 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Inventories
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	466
</TD>
<TD ID=TBL3974.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL3974.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.9 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3862 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Prepaid expenses and other current assets
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	1,731
</TD>
<TD ID=TBL3974.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	948
</TD>
<TD ID=TBL3974.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.11 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 45PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3868 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total current assets
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	118,947
</TD>
<TD ID=TBL3974.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	76,298
</TD>
<TD ID=TBL3974.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.12 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3871 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Property and equipment, net
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	8,610
</TD>
<TD ID=TBL3974.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	9,818
</TD>
<TD ID=TBL3974.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.13 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3874 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Restricted cash
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.13.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.13.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.13.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	178
</TD>
<TD ID=TBL3974.FINROW.13.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.13.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.13.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.13.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	250
</TD>
<TD ID=TBL3974.FINROW.13.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.14 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3877 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Other assets
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.14.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.14.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.14.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	50
</TD>
<TD ID=TBL3974.FINROW.14.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.14.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.14.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.14.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	50
</TD>
<TD ID=TBL3974.FINROW.14.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.16 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3883 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total Assets
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.16.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.16.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3974.FINROW.16.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	127,785
</TD>
<TD ID=TBL3974.FINROW.16.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.16.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.16.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL3974.FINROW.16.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	86,416
</TD>
<TD ID=TBL3974.FINROW.16.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.18 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3889 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Liabilities and Stockholders&#8217; Equity
</B>
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.18.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.18.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.18.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.18.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.18.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.18.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.18.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL3974.FINROW.18.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL3974.FINROW.19 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3892 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Current Liabilities:
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.19.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.19.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.19.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.19.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.19.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.19.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.19.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.19.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.20 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3895 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accounts payable
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.20.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.20.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3974.FINROW.20.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	1,561
</TD>
<TD ID=TBL3974.FINROW.20.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.20.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.20.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3974.FINROW.20.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	2,431
</TD>
<TD ID=TBL3974.FINROW.20.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.21 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3898 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accrued liabilities
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.21.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.21.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.21.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	3,956
</TD>
<TD ID=TBL3974.FINROW.21.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.21.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.21.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.21.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	3,654
</TD>
<TD ID=TBL3974.FINROW.21.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.22 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3901 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Long-term debt, current portion
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.22.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.22.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.22.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	4,541
</TD>
<TD ID=TBL3974.FINROW.22.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.22.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.22.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.22.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	6,859
</TD>
<TD ID=TBL3974.FINROW.22.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.23 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3904 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Deferred revenue, current portion
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.23.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.23.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.23.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	2,604
</TD>
<TD ID=TBL3974.FINROW.23.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.23.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.23.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.23.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	787
</TD>
<TD ID=TBL3974.FINROW.23.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.24 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3907 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Liability related to the sale of future royalties, current portion
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.24.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.24.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.24.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	118
</TD>
<TD ID=TBL3974.FINROW.24.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.24.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.24.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.24.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL3974.FINROW.24.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.26 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 45PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3913 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total current liabilities
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.26.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.26.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.26.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	12,780
</TD>
<TD ID=TBL3974.FINROW.26.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.26.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.26.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.26.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	13,731
</TD>
<TD ID=TBL3974.FINROW.26.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.27 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3916 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Deferred rent, net of current portion
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.27.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.27.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.27.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	245
</TD>
<TD ID=TBL3974.FINROW.27.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.27.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.27.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.27.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	529
</TD>
<TD ID=TBL3974.FINROW.27.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.28 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3919 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Long-term debt, net of current portion
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.28.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.28.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.28.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	16,381
</TD>
<TD ID=TBL3974.FINROW.28.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.28.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.28.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.28.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	18,015
</TD>
<TD ID=TBL3974.FINROW.28.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.29 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3922 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Deferred revenue, net of current portion
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.29.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.29.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.29.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	593
</TD>
<TD ID=TBL3974.FINROW.29.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.29.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.29.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.29.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	1,626
</TD>
<TD ID=TBL3974.FINROW.29.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.30 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3925 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Liability related to the sale of future royalties
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	, net of current portion
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.30.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.30.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.30.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	63,494
</TD>
<TD ID=TBL3974.FINROW.30.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.30.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.30.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.30.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL3974.FINROW.30.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.31 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3928 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Contingent put option liability
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.31.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.31.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.31.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	266
</TD>
<TD ID=TBL3974.FINROW.31.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.31.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.31.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.31.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	282
</TD>
<TD ID=TBL3974.FINROW.31.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.32 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3931 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Warrant liability
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.32.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.32.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.32.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	913
</TD>
<TD ID=TBL3974.FINROW.32.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.32.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.32.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.32.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	5,577
</TD>
<TD ID=TBL3974.FINROW.32.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.34 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 45PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3937 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total liabilities
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.34.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.34.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.34.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	94,672
</TD>
<TD ID=TBL3974.FINROW.34.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.34.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.34.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.34.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	39,760
</TD>
<TD ID=TBL3974.FINROW.34.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.36 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3943 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Commitments and Contingencies
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.36.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.36.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.36.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.36.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.36.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.36.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.36.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.36.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.37 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3944 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Stockholders&#8217; Equity:
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.37.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.37.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.37.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.37.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.37.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.37.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.37.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.37.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.38 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA3947 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Common stock, $0.001 par value&#8212;100,000,000 shares authorized as of December 31, 2015 and December 31, 2014; 45,273,772 and 43,712,363 shares issued and outstanding as of December 31, 2015 and December 31, 2014
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.38.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.38.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.38.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	45
</TD>
<TD ID=TBL3974.FINROW.38.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.38.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.38.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.38.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	43
</TD>
<TD ID=TBL3974.FINROW.38.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.39 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3950 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additional paid-in capital
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.39.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.39.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.39.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	236,274
</TD>
<TD ID=TBL3974.FINROW.39.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.39.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.39.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.39.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	225,423
</TD>
<TD ID=TBL3974.FINROW.39.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.40 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3953 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accumulated deficit
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.40.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.40.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.40.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(203,205
</TD>
<TD ID=TBL3974.FINROW.40.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL3974.FINROW.40.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.40.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.40.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(178,806
</TD>
<TD ID=TBL3974.FINROW.40.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL3974.FINROW.41 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3956 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accumulated other comprehensive loss
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.41.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.41.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.41.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(1
</TD>
<TD ID=TBL3974.FINROW.41.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL3974.FINROW.41.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.41.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.41.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(4
</TD>
<TD ID=TBL3974.FINROW.41.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL3974.FINROW.43 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 45PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3962 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total stockholders&#8217; equity
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.43.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.43.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.43.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	33,113
</TD>
<TD ID=TBL3974.FINROW.43.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.43.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.43.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.43.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	46,656
</TD>
<TD ID=TBL3974.FINROW.43.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL3974.FINROW.45 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3968 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total Liabilities and Stockholders&#8217; Equity
</FONT>
</P>
</TD>
<TD ID=TBL3974.FINROW.45.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.45.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3974.FINROW.45.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	127,785
</TD>
<TD ID=TBL3974.FINROW.45.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.45.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL3974.FINROW.45.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL3974.FINROW.45.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	86,416
</TD>
<TD ID=TBL3974.FINROW.45.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P ID=PARA3976 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3975 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	See notes to consolidated financial statements.
</FONT>
</P>
<P ID=PARA12.1 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK12 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR12 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM12 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-4
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage92"></A>
<DIV ID=PGHDR12 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA12.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<P ID=PARA3977 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA3979 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3978 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Consolidated Statements of Comprehensive Loss
</B>
</FONT>
</P>
<P ID=PARA3980 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(in thousands, except share and per share data)
</B>
</FONT>
</P>
<P ID=PARA3981 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL4137 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL4137.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4137.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4137.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=10>
<P ID=PARA3983 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL4137.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4137.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4137.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=2>
<P ID=PARA3986 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 10.1PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4137.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4137.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=2>
<P ID=PARA3988 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 10.1PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4137.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4137.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.1PT" COLSPAN=2>
<P ID=PARA3990 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 10.1PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL4137.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 55%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA3992 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Revenue:
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.3.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.3.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA3996 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Collaboration agreement
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4137.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	14,857
</TD>
<TD ID=TBL4137.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4137.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	5,217
</TD>
<TD ID=TBL4137.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4137.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	27,370
</TD>
<TD ID=TBL4137.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4000 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Contract and other
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	4,406
</TD>
<TD ID=TBL4137.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4137.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	2,132
</TD>
<TD ID=TBL4137.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4008 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total revenue
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	19,263
</TD>
<TD ID=TBL4137.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	5,217
</TD>
<TD ID=TBL4137.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	29,502
</TD>
<TD ID=TBL4137.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.9 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4016 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Operating costs and expenses:
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.9.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.9.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.10 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4020 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cost of goods sold
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	1,770
</TD>
<TD ID=TBL4137.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4137.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.10.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.10.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.10.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4137.FINROW.10.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.11 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4024 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Research and development
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	22,488
</TD>
<TD ID=TBL4137.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	24,520
</TD>
<TD ID=TBL4137.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.11.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.11.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.11.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	26,292
</TD>
<TD ID=TBL4137.FINROW.11.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.12 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4028 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	General and administrative
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	14,203
</TD>
<TD ID=TBL4137.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	18,346
</TD>
<TD ID=TBL4137.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.12.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.12.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.12.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	9,877
</TD>
<TD ID=TBL4137.FINROW.12.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.13 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4032 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Restructuring costs
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.13.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.13.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.13.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	756
</TD>
<TD ID=TBL4137.FINROW.13.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.13.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.13.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.13.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4137.FINROW.13.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.13.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.13.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.13.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4137.FINROW.13.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.15 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4040 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total operating costs and expenses
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.15.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.15.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.15.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	39,217
</TD>
<TD ID=TBL4137.FINROW.15.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.15.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.15.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.15.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	42,866
</TD>
<TD ID=TBL4137.FINROW.15.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.15.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.15.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.15.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	36,169
</TD>
<TD ID=TBL4137.FINROW.15.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.17 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4048 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Loss from operations
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.17.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.17.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.17.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(19,954
</TD>
<TD ID=TBL4137.FINROW.17.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.17.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.17.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.17.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(37,649
</TD>
<TD ID=TBL4137.FINROW.17.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.17.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.17.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.17.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(6,667
</TD>
<TD ID=TBL4137.FINROW.17.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4137.FINROW.18 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4052 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Other (expense) income:
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.18.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.18.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.19 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4053 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 10.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest expense
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.19.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.19.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.19.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(2,977
</TD>
<TD ID=TBL4137.FINROW.19.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.19.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.19.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.19.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(2,639
</TD>
<TD ID=TBL4137.FINROW.19.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.19.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.19.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.19.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(1,518
</TD>
<TD ID=TBL4137.FINROW.19.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4137.FINROW.20 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4057 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 10.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest income and other income (expense), net
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.20.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.20.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.20.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	1,720
</TD>
<TD ID=TBL4137.FINROW.20.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.20.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.20.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.20.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	6,935
</TD>
<TD ID=TBL4137.FINROW.20.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.20.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.20.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.20.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(15,241
</TD>
<TD ID=TBL4137.FINROW.20.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4137.FINROW.21 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4061 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 10.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Non-cash interest expense on liability related to sale of future royalties
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.21.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.21.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.21.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(2,428
</TD>
<TD ID=TBL4137.FINROW.21.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.21.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.21.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.21.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4137.FINROW.21.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.21.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.21.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.21.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4137.FINROW.21.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.23 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4069 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 37.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total other (expense) income
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.23.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.23.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.23.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(3,685
</TD>
<TD ID=TBL4137.FINROW.23.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.23.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.23.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.23.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	4,296
</TD>
<TD ID=TBL4137.FINROW.23.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.23.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.23.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.23.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(16,759
</TD>
<TD ID=TBL4137.FINROW.23.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4137.FINROW.24 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4073 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss before income taxes
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.24.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.24.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.24.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(23,639
</TD>
<TD ID=TBL4137.FINROW.24.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.24.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.24.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.24.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(33,353
</TD>
<TD ID=TBL4137.FINROW.24.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.24.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.24.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.24.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(23,426
</TD>
<TD ID=TBL4137.FINROW.24.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4137.FINROW.25 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4077 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Provision for income taxes
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.25.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.25.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.25.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(760
</TD>
<TD ID=TBL4137.FINROW.25.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.25.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.25.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.25.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4137.FINROW.25.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.25.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.25.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.25.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4137.FINROW.25.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.26 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4081 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.26.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.26.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.26.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(24,399
</TD>
<TD ID=TBL4137.FINROW.26.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.26.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.26.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.26.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(33,353
</TD>
<TD ID=TBL4137.FINROW.26.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.26.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.26.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.26.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(23,426
</TD>
<TD ID=TBL4137.FINROW.26.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4137.FINROW.27 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4085 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Other comprehensive income (loss):
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.27.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.27.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.28 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4089 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 10.5PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Unrealized gains (losses) on available for sale securities
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.28.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.28.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.28.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	3
</TD>
<TD ID=TBL4137.FINROW.28.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.28.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.28.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.28.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(5
</TD>
<TD ID=TBL4137.FINROW.28.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.28.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.28.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.28.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4137.FINROW.28.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.30 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4097 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Comprehensive loss
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.30.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.30.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4137.FINROW.30.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(24,396
</TD>
<TD ID=TBL4137.FINROW.30.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.30.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.30.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4137.FINROW.30.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(33,358
</TD>
<TD ID=TBL4137.FINROW.30.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.30.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.30.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4137.FINROW.30.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(23,426
</TD>
<TD ID=TBL4137.FINROW.30.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4137.FINROW.32 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4105 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss per share of common stock, basic
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.32.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.32.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4137.FINROW.32.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(0.55
</TD>
<TD ID=TBL4137.FINROW.32.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.32.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.32.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4137.FINROW.32.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(0.77
</TD>
<TD ID=TBL4137.FINROW.32.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.32.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.32.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4137.FINROW.32.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	(0.59
</TD>
<TD ID=TBL4137.FINROW.32.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4137.FINROW.34 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4113 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss per share of common stock, diluted
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.34.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.34.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4137.FINROW.34.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(0.60
</TD>
<TD ID=TBL4137.FINROW.34.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.34.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.34.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4137.FINROW.34.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(0.91
</TD>
<TD ID=TBL4137.FINROW.34.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4137.FINROW.34.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.34.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4137.FINROW.34.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #FFFFFF">
	(0.59
</TD>
<TD ID=TBL4137.FINROW.34.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4137.FINROW.36 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4121 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Shares used in computing net loss per share of common stock, basic
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.36.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.36.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.36.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	44,300,099
</TD>
<TD ID=TBL4137.FINROW.36.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.36.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.36.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.36.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	43,427,111
</TD>
<TD ID=TBL4137.FINROW.36.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.36.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.36.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.36.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	39,746,678
</TD>
<TD ID=TBL4137.FINROW.36.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.37 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.LEAD.B2 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.SYMB.B2 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.AMT.B2 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.TRAIL.B2 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.LEAD.B3 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.SYMB.B3 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.AMT.B3 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.TRAIL.B3 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.LEAD.B4 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.SYMB.B4 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.AMT.B4 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.37.TRAIL.B4 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4137.FINROW.38 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4129 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Shares used in computing net loss per share of common stock, diluted &#8211;see Note 14
</FONT>
</P>
</TD>
<TD ID=TBL4137.FINROW.38.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.38.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.38.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	44,468,440
</TD>
<TD ID=TBL4137.FINROW.38.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.38.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.38.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.38.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	44,322,297
</TD>
<TD ID=TBL4137.FINROW.38.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.38.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.38.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4137.FINROW.38.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.1PT; BACKGROUND-COLOR: #CCEEFF">
	39,746,678
</TD>
<TD ID=TBL4137.FINROW.38.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA4139 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4138 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	See notes to consolidated financial statements.
</FONT>
</P>
<P STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<DIV ID=PGBK15 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR15 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM15 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-5
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage93"></A>
<DIV ID=PGHDR15 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA15.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P ID=PARA4140 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA4143 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4142 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Consolidated Statements of Stockholders&#8217; Equity
</B>
</FONT>
</P>
<P ID=PARA4144 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(in thousands, except share data)
</B>
</FONT>
</P>
<P ID=PARA4145 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL4362 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL4362.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.1.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.1.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 6.9PT" COLSPAN=6>
<P ID=PARA4148 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Common Stock
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.1.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA4150 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Additional
<BR>
	Paid-in
<BR>
	Capital
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA4152 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Accumulated
<BR>
	Deficit
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.1.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.1.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA4154 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Other
<BR>
	Comprehensive
<BR>
	Income (loss)
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.1.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.1.LEAD.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.1.AMT.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.75PT" COLSPAN=2>
<P ID=PARA4156 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<BR>
	Total
<BR>
	Stockholders&#8217;
<BR>
	Equity
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.1.TRAIL.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL4362.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA4160 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Shares
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<P ID=PARA4162 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amount
</B>
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.LEAD.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.SYMB.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.AMT.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.TRAIL.B6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.LEAD.B7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.SYMB.B7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.AMT.B7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4362.FINROW.2.TRAIL.B7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL4362.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 28%; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4164 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Balance as of December 31, 2012
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	37,055,027
</TD>
<TD ID=TBL4362.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4362.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	37
</TD>
<TD ID=TBL4362.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4362.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	155,836
</TD>
<TD ID=TBL4362.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4362.FINROW.3.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	(122,027
</TD>
<TD ID=TBL4362.FINROW.3.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4362.FINROW.3.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4362.FINROW.3.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	1
</TD>
<TD ID=TBL4362.FINROW.3.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.3.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4362.FINROW.3.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	33,847
</TD>
<TD ID=TBL4362.FINROW.3.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4172 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of Warrants
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	1,130
</TD>
<TD ID=TBL4362.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.4.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.4.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.4.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	1,130
</TD>
<TD ID=TBL4362.FINROW.4.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4180 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Stock-based compensation
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	3,479
</TD>
<TD ID=TBL4362.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.5.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.5.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	3,479
</TD>
<TD ID=TBL4362.FINROW.5.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4188 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon exercise of stock options and in connection with restricted stock units
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	520,365
</TD>
<TD ID=TBL4362.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	1
</TD>
<TD ID=TBL4362.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	1,276
</TD>
<TD ID=TBL4362.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.6.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.6.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.6.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	1,277
</TD>
<TD ID=TBL4362.FINROW.6.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4196 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon exercise of stock warrants
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	1,050,062
</TD>
<TD ID=TBL4362.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	1
</TD>
<TD ID=TBL4362.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	8,689
</TD>
<TD ID=TBL4362.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.7.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.7.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.7.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	8,690
</TD>
<TD ID=TBL4362.FINROW.7.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.8 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4203 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon ESPP purchase
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	55,126
</TD>
<TD ID=TBL4362.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	219
</TD>
<TD ID=TBL4362.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.8.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.8.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.8.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	219
</TD>
<TD ID=TBL4362.FINROW.8.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.9 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4210 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon underwritten public offering, net of offering-related costs
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	4,370,000
</TD>
<TD ID=TBL4362.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	4
</TD>
<TD ID=TBL4362.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	47,939
</TD>
<TD ID=TBL4362.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.9.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.9.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.9.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	47,943
</TD>
<TD ID=TBL4362.FINROW.9.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.10 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4217 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Change in unrealized gains and losses on investments
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 6.5PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.10 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 6.5PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.10.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.11 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4224 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 6.5PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.11.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	(23,426
</TD>
<TD ID=TBL4362.FINROW.11.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4362.FINROW.11.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.11.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.11.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #FFFFFF">
	(23,426
</TD>
<TD ID=TBL4362.FINROW.11.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4362.FINROW.12 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.12 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4231 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Balance as of December 31, 2013
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	43,050,580
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	43
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	218,568
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	(145,453
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	1
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.12.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	73,159
</TD>
<TD ID=TBL4362.FINROW.12.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.13 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4239 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Stock-based compensation
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.13.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.13.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.13.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	4,440
</TD>
<TD ID=TBL4362.FINROW.13.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.13.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.13.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.13.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	4,440
</TD>
<TD ID=TBL4362.FINROW.13.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.14 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4247 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon exercise of stock options and in connection with restricted stock units
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.14.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	487,124
</TD>
<TD ID=TBL4362.FINROW.14.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.14.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	1,507
</TD>
<TD ID=TBL4362.FINROW.14.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.14.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.14.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.14.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	1,507
</TD>
<TD ID=TBL4362.FINROW.14.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.15 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4255 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon exercise of stock warrants
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.15.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	91,488
</TD>
<TD ID=TBL4362.FINROW.15.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.15.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	546
</TD>
<TD ID=TBL4362.FINROW.15.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.15.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.15.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.15.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	546
</TD>
<TD ID=TBL4362.FINROW.15.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.16 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4262 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon ESPP purchase
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.16.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	83,171
</TD>
<TD ID=TBL4362.FINROW.16.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.16.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	362
</TD>
<TD ID=TBL4362.FINROW.16.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.16.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.16.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.16.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	362
</TD>
<TD ID=TBL4362.FINROW.16.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.17 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4269 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Change in unrealized gains and losses on investments
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.17.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.17.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.17.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.17.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.17.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	(5
</TD>
<TD ID=TBL4362.FINROW.17.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4362.FINROW.17.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.17.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	(5
</TD>
<TD ID=TBL4362.FINROW.17.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4362.FINROW.18 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4276 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.18.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.18.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.18.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.18.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	(33,353
</TD>
<TD ID=TBL4362.FINROW.18.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4362.FINROW.18.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.18.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.18.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	(33,353
</TD>
<TD ID=TBL4362.FINROW.18.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4362.FINROW.19 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4283 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Balance as of December 31, 2014
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.19.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	43,712,363
</TD>
<TD ID=TBL4362.FINROW.19.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	43
</TD>
<TD ID=TBL4362.FINROW.19.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	225,423
</TD>
<TD ID=TBL4362.FINROW.19.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	(178,806
</TD>
<TD ID=TBL4362.FINROW.19.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4362.FINROW.19.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	(4
</TD>
<TD ID=TBL4362.FINROW.19.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4362.FINROW.19.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.19.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	46,656
</TD>
<TD ID=TBL4362.FINROW.19.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.20 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4291 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Stock-based compensation
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.20.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.20.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.20.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	5,010
</TD>
<TD ID=TBL4362.FINROW.20.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.20.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.20.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.20.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	5,010
</TD>
<TD ID=TBL4362.FINROW.20.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.21 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4299 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon exercise of stock options
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.21.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	938,497
</TD>
<TD ID=TBL4362.FINROW.21.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	1
</TD>
<TD ID=TBL4362.FINROW.21.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	2,769
</TD>
<TD ID=TBL4362.FINROW.21.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.21.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.21.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.21.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	2,770
</TD>
<TD ID=TBL4362.FINROW.21.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.22 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4307 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon exercise of stock warrants
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.22.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	527,101
</TD>
<TD ID=TBL4362.FINROW.22.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	1
</TD>
<TD ID=TBL4362.FINROW.22.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	2,543
</TD>
<TD ID=TBL4362.FINROW.22.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.22.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.22.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.22.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	2,544
</TD>
<TD ID=TBL4362.FINROW.22.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.23 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4314 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Modification of warrants
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.23.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.23.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.23.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	100
</TD>
<TD ID=TBL4362.FINROW.23.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.23.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.23.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.23.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	100
</TD>
<TD ID=TBL4362.FINROW.23.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.24 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4322 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon ESPP purchase
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.24.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	95,811
</TD>
<TD ID=TBL4362.FINROW.24.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.24.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	429
</TD>
<TD ID=TBL4362.FINROW.24.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.24.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.24.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.24.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	429
</TD>
<TD ID=TBL4362.FINROW.24.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.25 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4330 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Change in unrealized gains and losses on investments
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.25.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.25.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.25.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.25.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.25.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	3
</TD>
<TD ID=TBL4362.FINROW.25.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.25.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	3
</TD>
<TD ID=TBL4362.FINROW.25.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4362.FINROW.26 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA4338 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.26.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.26.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.26.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.26.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #FFFFFF">
	(24,399
</TD>
<TD ID=TBL4362.FINROW.26.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4362.FINROW.26.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4362.FINROW.26.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.26.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	(24,399
</TD>
<TD ID=TBL4362.FINROW.26.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4362.FINROW.28 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA4354 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Balance as of December 31, 2015
</FONT>
</P>
</TD>
<TD ID=TBL4362.FINROW.28.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.28.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.28.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	45,273,772
</TD>
<TD ID=TBL4362.FINROW.28.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.28.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.28.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4362.FINROW.28.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.6PT; BACKGROUND-COLOR: #CCEEFF">
	45
</TD>
<TD ID=TBL4362.FINROW.28.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.28.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.28.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4362.FINROW.28.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	236,274
</TD>
<TD ID=TBL4362.FINROW.28.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.28.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.28.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4362.FINROW.28.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 5.75PT; BACKGROUND-COLOR: #CCEEFF">
	(203,205
</TD>
<TD ID=TBL4362.FINROW.28.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4362.FINROW.28.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.28.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4362.FINROW.28.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 21.6PT; BACKGROUND-COLOR: #CCEEFF">
	(1
</TD>
<TD ID=TBL4362.FINROW.28.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4362.FINROW.28.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4362.FINROW.28.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4362.FINROW.28.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	33,113
</TD>
<TD ID=TBL4362.FINROW.28.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P ID=PARA4364 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4363 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	See notes to consolidated financial statements.
</FONT>
</P>
<P ID=PARA4366 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK14 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR14 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM14 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-6
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage94"></A>
<DIV ID=PGHDR14 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA14.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P ID=PARA4367 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA4369 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4368 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Consolidated Statements of Cash Flows
</B>
</FONT>
</P>
<P ID=PARA4370 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	(in thousands)
</B>
</FONT>
</P>
<P ID=PARA4371 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL4618 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL4618.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4618.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4618.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.55PT" COLSPAN=10>
<P ID=PARA4373 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL4618.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4618.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4618.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.1PT" COLSPAN=2>
<P ID=PARA4376 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4618.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4618.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.1PT" COLSPAN=2>
<P ID=PARA4378 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4618.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4618.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 5.1PT" COLSPAN=2>
<P ID=PARA4380 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 3.6PT 0PT 8.65PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL4618.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 55%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4382 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	CASH FLOWS FROM OPERATING ACTIVITIES:
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.3.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.3.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4386 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(24,399
</TD>
<TD ID=TBL4618.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(33,353
</TD>
<TD ID=TBL4618.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(23,426
</TD>
<TD ID=TBL4618.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4618.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4390 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Adjustments to reconcile net loss to net cash used in operating activities:
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.5.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.5.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4394 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Non-cash interest expense on liability related to royalty monetization
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	2,428
</TD>
<TD ID=TBL4618.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4398 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Depreciation and amortization
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	1,984
</TD>
<TD ID=TBL4618.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	866
</TD>
<TD ID=TBL4618.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	593
</TD>
<TD ID=TBL4618.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.8 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4402 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amortization of premium/discount on investments, net
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	114
</TD>
<TD ID=TBL4618.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	216
</TD>
<TD ID=TBL4618.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	202
</TD>
<TD ID=TBL4618.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.9 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4406 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interest expense related to debt financing
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	897
</TD>
<TD ID=TBL4618.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	553
</TD>
<TD ID=TBL4618.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	442
</TD>
<TD ID=TBL4618.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.10 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4410 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Stock-based compensation
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	5,010
</TD>
<TD ID=TBL4618.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	4,440
</TD>
<TD ID=TBL4618.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.10.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.10.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.10.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	3,479
</TD>
<TD ID=TBL4618.FINROW.10.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.11 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4414 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Revaluation of put option and PIPE warrant liabilities
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(2,136
</TD>
<TD ID=TBL4618.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(7,040
</TD>
<TD ID=TBL4618.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.11.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.11.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.11.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	14,071
</TD>
<TD ID=TBL4618.FINROW.11.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.12 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4418 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Loss on extinguishment of debt
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.12.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.12.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.12.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	1,202
</TD>
<TD ID=TBL4618.FINROW.12.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.13 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4422 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Loss on disposal and impairment of property and equipment
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.13.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.13.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.13.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	573
</TD>
<TD ID=TBL4618.FINROW.13.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.13.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.13.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.13.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.13.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.13.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.13.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.13.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.13.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.14 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 60PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4426 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 60PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Changes in operating assets and liabilities:
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.14.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.14.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.15 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 84PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4430 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 84PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accounts receivable
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.15.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.15.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.15.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(3,286
</TD>
<TD ID=TBL4618.FINROW.15.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.15.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.15.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.15.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.15.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.15.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.15.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.15.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.15.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.16 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 84PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4434 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 84PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Inventories
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.16.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.16.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.16.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(466
</TD>
<TD ID=TBL4618.FINROW.16.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.16.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.16.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.16.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.16.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.16.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.16.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.16.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.16.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.17 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 84PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4438 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 84PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Prepaid expenses and other assets
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.17.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.17.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.17.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(783
</TD>
<TD ID=TBL4618.FINROW.17.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.17.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.17.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.17.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	137
</TD>
<TD ID=TBL4618.FINROW.17.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.17.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.17.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.17.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	1,132
</TD>
<TD ID=TBL4618.FINROW.17.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.18 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 84PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4442 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 84PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Restricted cash
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.18.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.18.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.18.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	72
</TD>
<TD ID=TBL4618.FINROW.18.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.18.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.18.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.18.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.18.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.18.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.18.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.18.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(45
</TD>
<TD ID=TBL4618.FINROW.18.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4618.FINROW.19 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 84PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4446 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 84PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accounts payable
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.19.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.19.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.19.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(786
</TD>
<TD ID=TBL4618.FINROW.19.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.19.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.19.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.19.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	90
</TD>
<TD ID=TBL4618.FINROW.19.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.19.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.19.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.19.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	106
</TD>
<TD ID=TBL4618.FINROW.19.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.20 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 84PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4450 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 84PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accrued liabilities
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.20.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.20.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.20.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	325
</TD>
<TD ID=TBL4618.FINROW.20.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.20.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.20.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.20.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(126
</TD>
<TD ID=TBL4618.FINROW.20.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.20.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.20.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.20.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(760
</TD>
<TD ID=TBL4618.FINROW.20.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4618.FINROW.21 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 84PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4454 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 84PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Deferred revenue
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.21.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.21.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.21.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	784
</TD>
<TD ID=TBL4618.FINROW.21.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.21.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.21.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.21.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(217
</TD>
<TD ID=TBL4618.FINROW.21.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.21.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.21.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.21.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	2,630
</TD>
<TD ID=TBL4618.FINROW.21.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.22 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 84PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4458 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 84PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Deferred rent
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.22.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.22.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.22.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(284
</TD>
<TD ID=TBL4618.FINROW.22.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.22.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.22.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.22.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(22
</TD>
<TD ID=TBL4618.FINROW.22.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.22.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.22.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.22.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(113
</TD>
<TD ID=TBL4618.FINROW.22.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4618.FINROW.24 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 108PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4466 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 108PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net cash used in operating activities
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.24.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.24.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.24.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(19,953
</TD>
<TD ID=TBL4618.FINROW.24.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.24.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.24.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.24.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(34,456
</TD>
<TD ID=TBL4618.FINROW.24.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.24.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.24.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.24.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(487
</TD>
<TD ID=TBL4618.FINROW.24.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4618.FINROW.26 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4474 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	CASH FLOWS FROM INVESTING ACTIVITIES:
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.26.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.26.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.27 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4478 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Purchase of property and equipment
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.27.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.27.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.27.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(1,456
</TD>
<TD ID=TBL4618.FINROW.27.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.27.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.27.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.27.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(5,505
</TD>
<TD ID=TBL4618.FINROW.27.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.27.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.27.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.27.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(3,287
</TD>
<TD ID=TBL4618.FINROW.27.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4618.FINROW.28 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4482 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Purchase of investments
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.28.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.28.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.28.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(7,266
</TD>
<TD ID=TBL4618.FINROW.28.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.28.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.28.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.28.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(17,430
</TD>
<TD ID=TBL4618.FINROW.28.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.28.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.28.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.28.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(28,009
</TD>
<TD ID=TBL4618.FINROW.28.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4618.FINROW.29 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4486 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Proceeds from maturities of investments
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.29.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.29.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.29.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	16,925
</TD>
<TD ID=TBL4618.FINROW.29.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.29.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.29.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.29.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	17,159
</TD>
<TD ID=TBL4618.FINROW.29.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.29.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.29.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.29.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	24,376
</TD>
<TD ID=TBL4618.FINROW.29.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.31 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 108PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4494 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 108PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net cash provided by (used in) investing activities
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.31.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.31.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.31.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	8,203
</TD>
<TD ID=TBL4618.FINROW.31.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.31.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.31.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.31.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(5,776
</TD>
<TD ID=TBL4618.FINROW.31.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.31.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.31.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.31.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(6,920
</TD>
<TD ID=TBL4618.FINROW.31.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4618.FINROW.33 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4502 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	CASH FLOWS FROM FINANCING ACTIVITIES:
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.33.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.33.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.34 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4506 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net proceeds from sale of future royalties
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.34.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.34.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.34.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	61,184
</TD>
<TD ID=TBL4618.FINROW.34.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.34.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.34.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.34.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.34.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.34.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.34.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.34.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.34.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.35 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4510 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Proceeds from issuance of common stock in equity offerings, net of offering costs
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.35.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.35.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.35.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.35.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.35.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.35.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.35.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.35.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.35.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.35.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.35.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	47,943
</TD>
<TD ID=TBL4618.FINROW.35.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.36 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4514 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Proceeds from the issuance of long-term debt
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.36.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.36.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.36.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.36.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.36.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.36.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.36.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	10,000
</TD>
<TD ID=TBL4618.FINROW.36.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.36.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.36.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.36.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	14,958
</TD>
<TD ID=TBL4618.FINROW.36.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.37 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4518 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Payment of long-term debt
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.37.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.37.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.37.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(4,534
</TD>
<TD ID=TBL4618.FINROW.37.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.37.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.37.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.37.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.37.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.37.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.37.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.37.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(16,345
</TD>
<TD ID=TBL4618.FINROW.37.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4618.FINROW.38 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4522 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Payment of debt modification transaction costs
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.38.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.38.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.38.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(215
</TD>
<TD ID=TBL4618.FINROW.38.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.38.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.38.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.38.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.38.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.38.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.38.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.38.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.38.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.39 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4526 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Extinguishment of debt
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.39.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.39.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.39.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.39.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.39.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.39.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.39.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.39.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.39.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.39.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.39.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	(437
</TD>
<TD ID=TBL4618.FINROW.39.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL4618.FINROW.40 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4530 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net proceeds from issuance of common stock through equity plans and exercise of warrants
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.40.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.40.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.40.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	3,199
</TD>
<TD ID=TBL4618.FINROW.40.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.40.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.40.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.40.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	1,869
</TD>
<TD ID=TBL4618.FINROW.40.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.40.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.40.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.40.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	1,757
</TD>
<TD ID=TBL4618.FINROW.40.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.42 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 108PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4538 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 108PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net cash provided by financing activities
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.42.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.42.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.42.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	59,634
</TD>
<TD ID=TBL4618.FINROW.42.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.42.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.42.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.42.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	11,869
</TD>
<TD ID=TBL4618.FINROW.42.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.42.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.42.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.42.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	47,876
</TD>
<TD ID=TBL4618.FINROW.42.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.44 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4546 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.44.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.44.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.44.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	47,884
</TD>
<TD ID=TBL4618.FINROW.44.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.44.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.44.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.44.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	(28,363
</TD>
<TD ID=TBL4618.FINROW.44.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4618.FINROW.44.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.44.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.44.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	40,469
</TD>
<TD ID=TBL4618.FINROW.44.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.45 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4550 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	CASH AND CASH EQUIVALENTS&#8212;Beginning of period
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.45.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.45.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.45.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	60,038
</TD>
<TD ID=TBL4618.FINROW.45.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.45.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.45.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.45.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	88,401
</TD>
<TD ID=TBL4618.FINROW.45.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.45.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.45.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.45.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	47,932
</TD>
<TD ID=TBL4618.FINROW.45.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.47 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4558 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	CASH AND CASH EQUIVALENTS&#8212;End of period
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.47.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.47.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.47.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	107,922
</TD>
<TD ID=TBL4618.FINROW.47.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.47.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.47.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.47.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	60,038
</TD>
<TD ID=TBL4618.FINROW.47.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.47.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.47.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.47.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	88,401
</TD>
<TD ID=TBL4618.FINROW.47.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.49 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4566 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.49.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.49.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.50 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4570 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash paid for interest
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.50.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.50.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.50.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	2,115
</TD>
<TD ID=TBL4618.FINROW.50.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.50.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.50.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.50.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	1,752
</TD>
<TD ID=TBL4618.FINROW.50.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.50.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.50.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.50.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	1,105
</TD>
<TD ID=TBL4618.FINROW.50.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.51 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4574 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Income taxes paid
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.51.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.51.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.51.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	782
</TD>
<TD ID=TBL4618.FINROW.51.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.51.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.51.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.51.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.51.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.51.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.51.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.51.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.51.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.53 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4582 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 12PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	NONCASH INVESTING AND FINANCING ACTIVITIES:
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.53.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.53.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.54 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4586 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of common stock upon cashless exercise of warrants
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.54.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.54.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.54.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	2,544
</TD>
<TD ID=TBL4618.FINROW.54.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.54.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.54.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.54.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	546
</TD>
<TD ID=TBL4618.FINROW.54.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.54.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.54.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.54.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	8,428
</TD>
<TD ID=TBL4618.FINROW.54.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.55 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4590 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Issuance of warrants for common stock
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.55.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.55.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.55.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.55.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.55.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.55.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.55.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.55.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.55.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.55.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.55.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	1,130
</TD>
<TD ID=TBL4618.FINROW.55.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.56 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4594 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Modification of warrants for common stock
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.56.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.56.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.56.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	100
</TD>
<TD ID=TBL4618.FINROW.56.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.56.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.56.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.56.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.56.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.56.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.56.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.56.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.56.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.57 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4598 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Tenant improvement allowance receivable
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.57.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.57.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.57.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.57.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.57.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.57.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.57.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	239
</TD>
<TD ID=TBL4618.FINROW.57.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.57.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.57.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.57.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.57.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.58 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4602 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Contingent put option liability
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.58.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.58.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.58.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.58.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.58.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.58.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.58.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.58.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.58.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.58.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.58.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	334
</TD>
<TD ID=TBL4618.FINROW.58.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.59 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4606 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Purchases of property and equipment in Accounts payable
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.59.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.59.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.59.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	98
</TD>
<TD ID=TBL4618.FINROW.59.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.59.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.59.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.59.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	182
</TD>
<TD ID=TBL4618.FINROW.59.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.59.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.59.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4618.FINROW.59.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.59.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4618.FINROW.60 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 36PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4610 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 36PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -12PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Purchases of property and equipment in Accrued liabilities
</FONT>
</P>
</TD>
<TD ID=TBL4618.FINROW.60.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.60.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.60.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4618.FINROW.60.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.60.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.60.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.60.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	23
</TD>
<TD ID=TBL4618.FINROW.60.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.60.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4618.FINROW.60.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL4618.FINROW.60.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 4.2PT; BACKGROUND-COLOR: #CCEEFF">
	725
</TD>
<TD ID=TBL4618.FINROW.60.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P ID=PARA4620 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4619 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	See notes to consolidated financial statements.
</FONT>
</P>
<P ID=PARA4622 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
</P>
<DIV ID=PGBK3 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR3 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM3 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-7
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage95"></A>
<DIV ID=PGHDR3 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA3.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA14 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA16 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P ID=PARA15 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
<BR>
<BR>
</B>
</FONT>
</P>
</FONT>
<P ID=PARA4623 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	1. Organization and Summary of Significant Accounting Policies
</B>
</FONT>
</P>
<P ID=PARA4625 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4624 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	The Company
</I>
</B>
</FONT>
</P>
<P ID=PARA4627 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4626 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	AcelRx Pharmaceuticals, Inc., or the Company or AcelRx, was incorporated in Delaware on July 13, 2005 as SuRx, Inc., and in January 2006, the Company changed its name to AcelRx Pharmaceuticals, Inc. The Company&#8217;s operations are based in Redwood City, California.
</FONT>
</P>
<P ID=PARA4628 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4629 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain. AcelRx intends to commercialize its product candidates in the United States and license the development and commercialization rights to its product candidates for sale outside of the United States through strategic partnerships and collaborations. AcelRx may also consider the option to enter into strategic partnerships for its product candidates in the United States.
</FONT>
</P>
<P ID=PARA146 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In September 2015, the Company reported that SAP301, a pivotal Phase 3 study for ARX-04 (sufentanil sublingual tablet, 30 mcg), a proprietary, non-invasive, single-use tablet in a disposable, pre-filled single-dose applicator, or SDA, for the treatment of moderate-to-severe acute pain, met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled trial designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery. In October 2015, we announced the initiation of SAP302, an open-label Phase 3 study of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. The SAP302 study is expected to be completed by the third quarter of 2016. The Company has initiated SAP303, an open-label, single-arm study of ARX-04 in post-operative patients over 40 years of age that will allow for administration of ARX-04 for up to 12 hours. This study is also expected to be completed by the third quarter of 2016. The Company believes ARX-04 may be a candidate for use in a variety of medically supervised settings to manage moderate-to-severe acute pain, including emergency room patients; patients who are recovering from short-stay or ambulatory surgery and do not require more long-term patient-controlled analgesia; post-operative patients who are transitioning from the operating room to the recovery floor; patients being transported by paramedics; and battlefield casualties.
</FONT>
</P>
<P ID=PARA4630 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA4632 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company&#8217;s other late-stage investigational product candidate, Zalviso&#8482;, delivers 15 mcg sufentanil sublingually through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. In response to the New Drug Application, or NDA, the Company submitted to the U.S. Food and Drug Administration, or FDA, seeking approval for Zalviso, the Company received a Complete Response Letter, or CRL, on July 25, 2014. The FDA has requested an additional clinical study and the Company is planning to begin this study, IAP312, in the first quarter of 2016.
</FONT>
</P>
<P ID=PARA4634 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4635 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December 16, 2013, AcelRx and Gr&#252;nenthal GmbH, or Gr&#252;nenthal, entered into a Collaboration and License Agreement, or the License Agreement, which was amended effective July 17, 2015, or the Amended License Agreement, which grants Gr&#252;nenthal rights to commercialize Zalviso in the countries of the European Union, Switzerland, Liechtenstein, Iceland, Norway and Australia. In September 2015, the European Commission approved the Marketing Authorization Application, or MAA, previously submitted to the European Medicines Agency, or EMA, for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. The approval allows Gr&#252;nenthal to market Zalviso in the 28 European Union member states as well as for the European Economic Area countries, Norway, Iceland and Liechtenstein, or EEA. Also on December&nbsp;16, 2013, AcelRx and Gr&#252;nenthal, entered into a related Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. Under the MSA, the Company will exclusively manufacture and supply the Product to Gr&#252;nenthal for the Field in the Territory. On July 22, 2015, the Company entered into an amendment to the MSA, or the MSA Amendment, and together with the MSA, the Amended MSA, between the Company and Gr&#252;nenthal, each effective as of July 17, 2015, and together, with the Amended License Agreement, the Amended Agreements.
</FONT>
</P>
<P ID=PARA4637 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4636 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company has incurred recurring operating losses and negative cash flows from operating activities since inception and expects to continue to incur negative cash flows. Although Zalviso has been approved for sale in the European Union, the Company sold the majority of the royalty rights and certain commercial sales milestones it is entitled to receive under the Amended License Agreement with Gr&#252;nenthal to PDL BioPharma, Inc., or PDL. As a result, the Company expects to continue to incur negative cash flows.
</FONT>
</P>
<P ID=PARA4638 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK4 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR4 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM4 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-8
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage96"></A>
<DIV ID=PGHDR4 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA4.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA17 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA19 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA18 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
<P ID=PARA4.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
	&nbsp;
</FONT>
</P>
<P ID=PARA4639 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	When we refer to "we," "our," "us," the "Company" or "AcelRx" in this document, we mean the current Delaware corporation, or AcelRx Pharmaceuticals, Inc., and its predecessor, as well as its consolidated subsidiary.
</FONT>
</P>
<P ID=PARA4640 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4641 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Basis of Presentation
</I>
</B>
</FONT>
</P>
<P ID=PARA4643 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4642 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates.
</FONT>
</P>
<P ID=PARA4644 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P ID=PARA4645 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Reclassifications
</I>
</B>
</FONT>
</P>
<P ID=PARA4647 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4646 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year&#39;s presentation. Refer to &#8220;Recently Issued Accounting Standards&#8221; below for additional information.
</FONT>
</P>
<P ID=PARA4648 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P ID=PARA4649 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Principles of Consolidation
</I>
</B>
</FONT>
</P>
<P ID=PARA4651 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4650 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiary, ARPI&nbsp;LLC, which was formed in September 2015 for the sole purpose of facilitating the monetization transaction with PDL of the expected royalty stream and milestone payments due from the sales of Zalviso in the European Union by its commercial partner,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal, pursuant to the Amended License Agreement, or the Royalty Monetization. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note 8 &#8220;Liability Related to Sale of Future Royalties&#8221; for additional information.
</FONT>
</P>
<P ID=PARA4653 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4652 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Use of Estimates
</I>
</B>
</FONT>
</P>
<P ID=PARA4655 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4654 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
</FONT>
</P>
<P ID=PARA4657 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4656 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Cash, Cash Equivalents and Marketable Securities
</I>
</B>
</FONT>
</P>
<P ID=PARA4659 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4658 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company considers all highly liquid investments with an original maturity (at date of purchase) of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market instruments.
</FONT>
</P>
<P ID=PARA4661 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4660 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	All marketable securities are classified as available-for-sale and consist of U.S. Treasury and U.S. government sponsored enterprise debt securities. These securities are carried at estimated fair value, which is based on quoted market prices or observable market inputs of almost identical assets, with unrealized gains and losses included in accumulated other comprehensive income (loss). The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income or expense. The cost of securities sold is based on specific identification. The Company&#8217;s investments are subject to a periodic impairment review for other-than-temporary declines in fair value. The Company&#8217;s review includes the consideration of the cause of the impairment including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss in the amount of such decline.
</FONT>
</P>
<P ID=PARA4663 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4662 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Fair Value of Financial Instruments
</I>
</B>
</FONT>
</P>
<P ID=PARA4665 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4664 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company measures and reports its cash equivalents, investments and financial liabilities at fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:
</FONT>
</P>
<P ID=PARA4667 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK5 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR5 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM5 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-9
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage97"></A>
<DIV ID=PGHDR5 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA5.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA20 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA22 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA21 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
<BR>
</FONT>
<P ID=PARA4666 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level I&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;
</FONT>
</P>
<P ID=PARA4669 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4668 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level II&#8212;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and
</FONT>
</P>
<P ID=PARA4671 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4670 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Level III&#8212;Unobservable inputs that are supported by little or no market activity for the related assets or liabilities.
</FONT>
</P>
<P ID=PARA4673 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4672 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
</FONT>
</P>
<P ID=PARA4675 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4674 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Segment Information
</I>
</B>
</FONT>
</P>
<P ID=PARA4677 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4676 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company operates in a single segment, the development and commercialization of product candidates for the treatment of pain. The Company&#8217;s contract revenue relates to sales in the United States. The Company&#8217;s collaboration revenue relates to the Amended License Agreement with Gr&#252;nenthal to commercialize Zalviso in the countries of the European Union, Switzerland, Liechtenstein, Iceland, Norway and Australia.
</FONT>
</P>
<P ID=PARA4679 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4678 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Concentration of Risk
</I>
</B>
</FONT>
</P>
<P ID=PARA4681 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4680 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company invests cash that is currently not being used for operational purposes in accordance with its investment policy in debt securities of the U.S. Treasury and U.S. government sponsored agencies and overnight deposits. The Company is exposed to credit risk in the event of default by the institutions holding the cash equivalents and available-for-sale securities to the extent recorded on the Consolidated Balance Sheet.
</FONT>
</P>
<P ID=PARA4683 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4682 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company relies on a single third-party supplier for the supply of sufentanil, the active pharmaceutical ingredient in Zalviso, and various sole-source third-party contract manufacturer organizations to manufacture the Zalviso drug cartridge and device components, including the controller, the dispenser kit and the accessories.
</FONT>
</P>
<P ID=PARA4685 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4684 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	To date, the Company has had only two customers. These two customers account for 100% of the revenues for the years ended December 31, 2015, 2014 and 2013. One of these customers accounted for 84% of the accounts receivable balance as of December 31, 2015. The Company did not have an Accounts receivable balance as of December 31, 2014.
</FONT>
</P>
<P ID=PARA4687 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4686 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company has not experienced any losses with respect to the collection of its Accounts receivable and believes that the entire Accounts receivable balance as of December 31, 2015 is collectible.
</FONT>
</P>
<P ID=PARA4689 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4688 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 10PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Accounts Receivable, Net
</I>
</B>
</FONT>
</P>
<P ID=PARA4690 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4691 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company has receivables from its collaboration partner and the U.S. Department of Defense, or DoD. To date, the Company has not had a bad debt allowance because of the limited number of financially sound customers who have historically paid their balances timely. The need for a bad debt allowance is evaluated each reporting period based on the Company&#8217;s assessment of the credit worthiness of its customers or any other potential circumstances that could result in bad debt.
</FONT>
</P>
<P ID=PARA4692 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4693 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 10PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Inventories
</I>
</B>
</FONT>
</P>
<P ID=PARA4694 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4695 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Inventories are valued at the lower of cost or market. Cost is determined using the first-in, first-out method for all inventories. Inventory includes the cost of the active pharmaceutical ingredients, or API, raw materials and third-party contract manufacturing and packaging services. Indirect overhead costs associated with production and distribution are allocated to the appropriate cost pool and then absorbed into inventory based on the units produced or distributed, assuming normal capacity, in the applicable period.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.
</FONT>
</P>
<P ID=PARA4696 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4697 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company&#39;s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The Company periodically evaluates the carrying value of inventory on hand for potential excess amount over demand using the same lower of cost or market approach as that used to value the inventory.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Because selling prices to Gr&#252;nenthal
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	are set to recover only direct costs with minimal mark up, all inventories are carried at net realizable value.
</FONT>
</P>
<P ID=PARA4698 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK6 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR6 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM6 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-10
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage98"></A>
<DIV ID=PGHDR6 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA6.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA23 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA25 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA24 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
</FONT>
<P STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
	&nbsp;
</P>
<P ID=PARA4699 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Property and Equipment
</I>
</B>
</FONT>
</P>
<P ID=PARA4701 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4700 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the improvements or the remaining lease term. Expenditures for repairs and maintenance, which do not extend the useful life of the property and equipment, are expensed as incurred. Upon retirement, the asset cost and related accumulated depreciation are relieved from the accompanying Consolidated Balance Sheets. Gains and losses associated with dispositions are reflected as a component of Other (expense) income in the accompanying Consolidated Statements of Comprehensive Loss.
</FONT>
</P>
<P ID=PARA4703 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4702 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Impairment of Long-Lived Assets
</I>
</B>
</FONT>
</P>
<P ID=PARA4705 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4704 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company periodically assesses the impairment of long-lived assets and, if indicators of asset impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through an analysis of the undiscounted future expected operating cash flows. If impairment is indicated, the Company records the amount of such impairment for the excess of the carrying value of the asset over its estimated fair value. For example, purchased equipment and manufacturing-related facility improvements the Company has made at Patheon&#8217;s facility in Ohio, are utilized for continued research and development, commercial manufacturing of Zalviso for Gr&#252;nenthal and potential commercialization of its other product candidates. If the Company does not receive regulatory approval for its other product candidates, the Company may determine that it is no longer probable that the Company will realize the future economic benefit associated with the costs of these assets through future manufacturing activities, and if so, the Company would record an impairment charge associated with these assets. As of September 30, 2015, the Company remeasured on a non-recurring basis a portion of its leasehold improvements in its corporate offices using Level III valuation techniques. The write down to fair value of these long-lived assets resulted in an impairment charge of $0.5 million in the year ended December 31, 2015, which was recorded in interest income and other income (expense), net in the Consolidated Statements of Comprehensive Loss. As of December&nbsp;31, 2015, the Company has not written down any additional long-lived assets as a result of impairment.
</FONT>
</P>
<P ID=PARA4707 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4706 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Restricted Cash
</I>
</B>
</FONT>
</P>
<P ID=PARA4709 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4708 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the Company&#8217;s facility lease and corporate credit card agreements, the Company is required to maintain letters of credit as security for performance under these agreements. The letters of credit are secured by certificates of deposit in amounts equal to the letters of credit, which are classified as restricted cash on the Consolidated Balance Sheets.
</FONT>
</P>
<P ID=PARA4711 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4710 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 10PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Debt Issuance Costs
</I>
</B>
</FONT>
</P>
<P ID=PARA4712 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4713 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Debt issuance costs, which are included in long-term debt, net of current portion, are amortized as interest expense over the contractual terms of the related credit facilities.
</FONT>
</P>
<P ID=PARA4714 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4715 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Contingent put option
</I>
</B>
</FONT>
</P>
<P ID=PARA4717 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4716 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The contingent put option associated with the Company&#8217;s loan and security agreement with Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc., collectively referred to as Hercules, is recorded as a liability. Changes in the fair value of the contingent put option are recognized as interest income and other income (expense), net in the Consolidated Statements of Comprehensive Loss. For additional information regarding the contingent put option, see Note 7 &#8220;Long-Term Debt.&#8221;
<B>
<I>
</I>
</B>
</FONT>
</P>
<P ID=PARA4719 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4718 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Warrants
</I>
</B>
</FONT>
</P>
<P ID=PARA4721 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4720 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Warrants issued in connection with the Company&#8217;s Private Placement, completed in June 2012, are recorded as liabilities as they have the potential for cash settlement upon the occurrence of certain transactions (as defined in the warrant; see Note 9 &#8220;Warrants&#8221;). Changes in the fair value of the warrants are recognized as interest income and other income (expense), net in the Consolidated Statements of Comprehensive Loss.
</FONT>
</P>
<P ID=PARA4723 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4722 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Revenue Recognition
</I>
</B>
</FONT>
</P>
<P ID=PARA4725 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4724 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company recognizes revenue when all of the following criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured.
</FONT>
</P>
<P ID=PARA4727 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK7 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR7 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM7 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-11
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage99"></A>
<DIV ID=PGHDR7 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA7.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA26 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA28 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA27 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
<P ID=PARA7.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
	&nbsp;
</FONT>
</P>
<P STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA4728 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Collaboration Revenue
</I>
</FONT>
</P>
<P ID=PARA4730 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4729 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Collaboration revenue, which is earned under license agreements with third parties, may include nonrefundable license fees, cost reimbursements, research and development services, commercial manufacturing services, contingent development and commercial milestones and royalties.
</FONT>
</P>
<P ID=PARA4732 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4731 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	AcelRx accounts for multiple-element arrangements in accordance with ASC Topic 605-25,
<I>
	Revenue Recognition&#8212;Multiple-Element Arrangements
</I>
	, or ASC 605-25.The Company evaluates if the deliverables in the arrangement represent separate units of accounting. In determining the units of accounting, AcelRx evaluates certain criteria, including whether the deliverables have value to our customers on a stand-alone basis. Factors considered in this determination include whether the deliverable is proprietary to the Company, whether the customer can use the license or other deliverables for their intended purpose without the receipt of the remaining elements, whether the value of the deliverable is dependent on the undelivered items, and whether there are other vendors that can provide the undelivered items. Deliverables that meet these criteria are considered a separate unit of accounting. Deliverables that do not meet these criteria are combined and accounted for as a single unit of accounting.
</FONT>
</P>
<P ID=PARA4733 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4734 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	For revenue agreements with multiple-element arrangements, such as the collaboration and license agreement with Gr&#252;nenthal, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using vendor-specific objective evidence, or
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	VSOE, of selling price or third-party evidence, or
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	TPE, of selling price. If neither exists the Company uses best estimated selling price, or
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	BESP, for that deliverable. Revenue allocated is then recognized when the four basic revenue recognition criteria are met for each element.
</FONT>
</P>
<P ID=PARA4736 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4735 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	VSOE is based on the price charged when the element is sold separately and is the price actually charged for that deliverable. Establishing VSOE may not be possible for the elements of a license arrangement because each arrangement is unique, an arrangement typically consists of multiple elements and AcelRx has limited history of entering into license arrangements. When VSOE cannot be established, AcelRx attempts to establish the selling price of the elements of a license arrangement based on TPE. TPE is determined based on a competitor&#8217;s price for similar deliverables when sold separately. AcelRx may not be able to determine TPE for license arrangements, as they contain a significant level of differentiation such that the comparable pricing of a competitor&#8217;s license arrangement with similar functionality cannot be obtained, and AcelRx is therefore unable to reliably determine what a similar competitor&#8217;s license arrangement&#8217;s selling price would be on a standalone basis.
</FONT>
</P>
<P ID=PARA4738 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4737 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	When AcelRx is unable to establish the selling price of an element using VSOE or TPE, BESP is utilized in the allocation of the elements of the arrangement. The objective of the BESP is to determine the price at which AcelRx would transact a sale if the element of the license arrangement were sold on a standalone basis.
</FONT>
</P>
<P ID=PARA4740 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4739 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The process for determining BESPs involves management&#8217;s judgment. AcelRx&#8217; process considers multiple factors such as discounted cash flows, estimated direct expenses and other costs and available data, which may vary over time, depending upon the circumstances, and relate to each deliverable. If the estimated obligation period of one or more deliverables should change, the future amortization of the revenue would also change.
</FONT>
</P>
<P ID=PARA4742 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4741 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	AcelRx recognizes a contingent milestone payment as revenue in its entirety upon our achievement of the milestone. A milestone is substantive if the consideration earned from the achievement of the milestone (i)&nbsp;is consistent with performance required to achieve the milestone or the increase in value to the delivered item, (ii)&nbsp;relates solely to past performance and (iii)&nbsp;is reasonable relative to all of the other deliverables and payments within the arrangement.
</FONT>
</P>
<P ID=PARA4743 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	&nbsp;
</I>
</FONT>
</P>
<P ID=PARA4744 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Contract and Other Revenue
</I>
</FONT>
</P>
<P ID=PARA4746 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4745 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In May 2011, the Company received a grant from the USAMRMC to support the development of ARX-04. The grant provided for the reimbursement of qualified expenses for research and development activities as defined under the terms of the grant agreement. Revenue under the grant agreement was recognized when the related qualified research expenses were incurred.
</FONT>
</P>
<P ID=PARA4748 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4747 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In May 2015, the Company entered into the DoD Contract with the USAMRMC to support the development of ARX-04. The DoD Contract provides for the reimbursement of qualified expenses for development, manufacturing, regulatory and clinical costs outlined in the contract in order to submit an NDA to the FDA, including reimbursement for certain personnel and overhead expenses, as defined under the terms of the contract. Revenue under the contract is recognized when the related qualified expenses are incurred. The Company is entitled to reimbursement of overhead costs associated with the study costs incurred under the DoD Contract. The Company estimates this overhead rate by utilizing forecasted expenditures. Final reimbursable overhead expenses are dependent on direct labor and direct reimbursable expenses throughout the life of the DoD Contract, so it may increase or decrease based on actual expenses incurred.
</FONT>
</P>
<P ID=PARA4750 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK8 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR8 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM8 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-12
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage100"></A>
<DIV ID=PGHDR8 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA8.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA29 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA31 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA30 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
</FONT>
<P STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
	&nbsp;
</P>
<P ID=PARA4749 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 10PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -10PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Cost of Goods Sold
</I>
</B>
</FONT>
</P>
<P ID=PARA4751 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4752 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the Amended Agreements with Gr&#252;nenthal, the Company will sell Zalviso to Gr&#252;nenthal at direct cost with minimal markup and will recognize indirect costs as period costs where they are in excess of normal capacity and not realizable on a lower of cost or market basis. Cost of goods sold for Zalviso shipped to Gr&#252;nenthal includes the inventory costs of API, third-party contract manufacturing costs, packaging and distribution costs, shipping, handling and storage costs, depreciation and costs of the employees involved with production.
</FONT>
</P>
<P ID=PARA4753 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4754 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Research and Development Expenses
</I>
</B>
</FONT>
</P>
<P ID=PARA4756 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4755 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Research and development costs are charged to expense when incurred. Research and development expenses include salaries, employee benefits, including stock-based compensation, consultant fees, laboratory supplies, costs associated with clinical trials and manufacturing, including contract research organization fees, other professional services and allocations of corporate costs. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events.
</FONT>
</P>
<P ID=PARA4758 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4757 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</FONT>
</P>
<P ID=PARA4760 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4759 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Compensation expense for all share-based payment awards made to employees and directors, including employee stock options, restricted stock units and employee share purchases related to the 2011 Employee Stock Purchase Plan, or ESPP, is based on estimated fair values at grant date. The Company determines the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognizes the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards.
</FONT>
</P>
<P ID=PARA4762 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4761 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Black-Scholes option pricing model requires inputs such as expected term, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. Estimates of expected life are primarily determined using the simplified method in accordance with guidance provided by the SEC. Such method was utilized as the Company did not believe its historical option exercise experience, which was limited, provided a reasonable basis upon which to estimate expected term. Volatility is derived from historical volatilities of several public companies within AcelRx&#8217;s industry that are deemed to be comparable to AcelRx&#8217;s business because AcelRx&#8217;s has insufficient history on the volatility of its common stock relative to the expected life assumptions used by the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. Further, the Company estimates forfeitures at the time of grant and revises those estimates in subsequent periods if actual forfeitures differ from those estimates.
</FONT>
</P>
<P ID=PARA4763 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P ID=PARA4764 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Restructuring Costs
</I>
</B>
</FONT>
</P>
<P ID=PARA4766 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4765 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company&#39;s restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the entity notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period.
</FONT>
</P>
<P ID=PARA4767 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	&nbsp;
</I>
</B>
</FONT>
</P>
<P ID=PARA4768 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Non-Cash Interest Expense on Liability Related to Sale of Future Royalties
</I>
</B>
</FONT>
</P>
<P ID=PARA4770 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4769 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In September 2015, the Company
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by its commercial partner, Gr&#252;nenthal, pursuant to the Collaboration and License Agreement, dated as of December 16, 2013, as amended, to PDL for an upfront cash purchase price of $65.0 million, referred to as the Royalty Monetization. The Company continues to have significant continuing involvement in the Royalty Monetization primarily due to an obligation to act as the intermediary for the supply of Zalviso to
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal. Under the relevant accounting guidance, because of the Company&#8217;s significant continuing involvement, the Royalty Monetization has been accounted for as a liability that will be amortized using the interest method over the life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	and milestone payments to be received by PDL and payments the Company is required to make to PDL, up to a capped amount of $195.0 million, over the life of the arrangement. The sum of the capped amount of $195.0 million, less the $61.2 million of net proceeds the Company received will be recorded as interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and record interest expense using an estimated interest rate for an arms-length debt transaction. The Company&#8217;s estimate of the interest rate under the arrangement is based on the amount of royalty and milestone payments expected to be received by PDL over the life of the arrangement. The Company&#8217;s estimate of this total interest expense resulted in an effective annual interest rate of approximately 14%. The Company will periodically assess the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than its initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the interest rate.
</FONT>
</P>
<P ID=PARA4772 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK9 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR9 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM9 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-13
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage101"></A>
<DIV ID=PGHDR9 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA9.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA32 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA34 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA33 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
<BR>
</FONT>
<P ID=PARA4771 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company will record non-cash royalty revenues and non-cash interest expense within its Consolidated Statements of Comprehensive Loss over the term of the PDL agreement.
</FONT>
</P>
<P ID=PARA4774 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4773 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Comprehensive Loss
</I>
</B>
</FONT>
</P>
<P ID=PARA4776 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4775 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Comprehensive loss is comprised of net loss and other comprehensive income (loss) and is disclosed in the Consolidated Statements of Comprehensive Loss. For the Company, other comprehensive income (loss) consists of changes in unrealized gains and losses on the Company&#8217;s investments.
</FONT>
</P>
<P ID=PARA4778 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA4779 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Income Taxes
</I>
</B>
</FONT>
</P>
<P ID=PARA4781 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4780 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Deferred tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than not.
</FONT>
</P>
<P ID=PARA4783 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4782 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Net Loss per Share of Common Stock
</I>
</B>
</FONT>
</P>
<P ID=PARA4785 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4784 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company&#8217;s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, options to purchase common stock, restricted stock subject to repurchase, warrants to purchase convertible preferred stock and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. For additional information regarding the net loss per share, see Note 14 &#8220;Net Loss per Share of Common Stock.&#8221;
</FONT>
</P>
<P ID=PARA4787 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4786 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Recently Issued Accounting Pronouncements
</I>
</B>
</FONT>
</P>
<P ID=PARA4789 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4788 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2014-09,
<I>
	Revenue from Contracts with Customers
</I>
	, or ASU 2014-09, to provide guidance on revenue recognition. ASU 2014-09 requires a company to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today&#8217;s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. In August 2015, the FASB issued Update No. 2015-14,
<I>
	Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date
</I>
	, or ASU-2015-14, that provided for the adoption of the new standard for fiscal years beginning after December 15, 2017. Accordingly, ASU 2014-09 is effective for the Company in the first quarter of 2018. Early adoption up to the first quarter of 2017 is permitted. Upon adoption, ASU 2014-09 can be applied retrospectively to all periods presented or only to the most current period presented with the cumulative effect of changes reflected in the opening balance of retained earnings in the most current period presented. The Company is currently evaluating the method of adoption and the impact of adopting ASU 2014-09 on its results of operations, cash flows and financial position.
</FONT>
</P>
<P ID=PARA4791 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4790 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In July 2015, the FASB issued ASU 2015-11,
<I>
	Inventory (Topic 330) Related to Simplifying the Measurement of Inventory
</I>
	which applies to all inventory measured using first-in, first-out (&#8220;FIFO&#8221;) or average cost.&nbsp;Inventory within the scope of the new guidance should be measured at the lower of cost and net realizable value.&nbsp;Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.&nbsp;The amendments will be effective for AcelRx beginning in fiscal 2017, including interim periods within fiscal 2017.&nbsp;The new guidance should be applied prospectively, and earlier application is permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the method of adoption and the impact of adopting ASU 2014-11 on its results of operations, cash flows and financial position.
</FONT>
</P>
<P ID=PARA4793 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK10 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR10 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM10 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-14
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage102"></A>
<DIV ID=PGHDR10 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA10.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA35 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA37 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA36 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
</FONT>
<P STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
	&nbsp;
</P>
<P ID=PARA4792 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In April 2015, the FASB issued ASU 2015-03,
<I>
	Interest&#8212;Imputation of Interest
</I>
	. ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable IFRS standards by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability, similar to the presentation of debt discounts or premiums. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015 and is required to be applied retrospectively to all prior periods presented. As permitted by ASU 2015-03, the Company elected to early adopt this guidance beginning with the first quarter of fiscal 2015, in order to simplify the presentation of its debt issuance costs. The resulting reclassifications of unamortized debt issuance costs from other assets to long-term debt, net of current portion on the Consolidated Balance Sheets as of December 31, 2014 was $31,000. Refer to Note 7 &#8220;Long-Term Debt&#8221; for additional information.
</FONT>
</P>
<P ID=PARA4795 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4794 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2. Investments and Fair Value Measurement
</B>
</FONT>
</P>
<P ID=PARA4797 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4796 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Investments
</I>
</B>
</FONT>
</P>
<P ID=PARA4799 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4798 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income. Marketable securities which have maturities beyond one year as of the end of the reporting period are classified as non-current.
</FONT>
</P>
<P ID=PARA4801 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4800 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The table below summarizes the Company&#8217;s cash, cash equivalents and investments (in thousands):
</FONT>
</P>
<P ID=PARA4802 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE ID=TBL4948S1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL4948.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=14>
<P ID=PARA4804 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	As of December 31, 2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL4948.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA4807 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amortized Cost
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA4809 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Gross Unrealized
<BR>
	Gains
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA4811 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Gross Unrealized
<BR>
	Losses
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA4813 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Fair
<BR>
	Value
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL4948.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 52%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4815 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash and cash equivalents:
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.3.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.3.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4820 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	83,112
</TD>
<TD ID=TBL4948.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.4.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.4.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.4.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	83,112
</TD>
<TD ID=TBL4948.FINROW.4.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4825 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	U.S. government agency securities
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	24,809
</TD>
<TD ID=TBL4948.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	1
</TD>
<TD ID=TBL4948.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	24,810
</TD>
<TD ID=TBL4948.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4835 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total cash and cash equivalents
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	107,921
</TD>
<TD ID=TBL4948.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	1
</TD>
<TD ID=TBL4948.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.7.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	107,922
</TD>
<TD ID=TBL4948.FINROW.7.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.8 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4840 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Marketable securities:
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.8.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.8.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.9 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4845 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	U.S. government agency securities
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	5,544
</TD>
<TD ID=TBL4948.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(2
</TD>
<TD ID=TBL4948.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4948.FINROW.9.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.9.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.9.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	5,542
</TD>
<TD ID=TBL4948.FINROW.9.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.11 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4855 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total marketable securities
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	5,544
</TD>
<TD ID=TBL4948.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.11.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.11.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.11.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(2
</TD>
<TD ID=TBL4948.FINROW.11.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4948.FINROW.11.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.11.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.11.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	5,542
</TD>
<TD ID=TBL4948.FINROW.11.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.13 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4865 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total cash, cash equivalents and investments
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.13.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.13.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.13.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	113,465
</TD>
<TD ID=TBL4948.FINROW.13.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.13.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.13.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.13.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	1
</TD>
<TD ID=TBL4948.FINROW.13.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.13.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.13.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.13.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(2
</TD>
<TD ID=TBL4948.FINROW.13.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4948.FINROW.13.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.13.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.13.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	113,464
</TD>
<TD ID=TBL4948.FINROW.13.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA12 STYLE="MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<P STYLE="MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE ID=TBL4948 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL4948.FINROW.17>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.17.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.17.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=14>
<P ID=PARA4877 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	As of December 31, 2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.17.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL4948.FINROW.18>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.18.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.18.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA4880 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Amortized Cost
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.18.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.18.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.18.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA4882 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Gross Unrealized
<BR>
	Gains
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.18.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.18.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.18.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA4884 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Gross Unrealized
<BR>
	Losses
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.18.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.18.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL4948.FINROW.18.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA4886 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Fair
<BR>
	Value
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.18.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL4948.FINROW.19 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4888 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash and cash equivalents:
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.19.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.19.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.20 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4893 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cash
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.20.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.20.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.20.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	60,005
</TD>
<TD ID=TBL4948.FINROW.20.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.20.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.20.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.20.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.20.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.20.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.20.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.20.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.20.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.20.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.20.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.20.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	60,005
</TD>
<TD ID=TBL4948.FINROW.20.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.21 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4898 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Money market funds
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.21.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	33
</TD>
<TD ID=TBL4948.FINROW.21.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.21.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.21.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.21.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	33
</TD>
<TD ID=TBL4948.FINROW.21.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.23 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4908 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total cash and cash equivalents
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.23.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	60,038
</TD>
<TD ID=TBL4948.FINROW.23.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.23.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.23.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.23.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	60,038
</TD>
<TD ID=TBL4948.FINROW.23.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.24 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4913 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Marketable securities:
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.24.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.24.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.25 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4918 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	U.S. government agency securities
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.25.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.25.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.25.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	15,316
</TD>
<TD ID=TBL4948.FINROW.25.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.25.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.25.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.25.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.25.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.25.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.25.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.25.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(4
</TD>
<TD ID=TBL4948.FINROW.25.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4948.FINROW.25.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.25.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.25.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	15,312
</TD>
<TD ID=TBL4948.FINROW.25.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.27 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4928 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total marketable securities
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.27.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.27.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.27.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	15,316
</TD>
<TD ID=TBL4948.FINROW.27.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.27.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.27.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.27.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.27.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.27.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.27.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.27.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(4
</TD>
<TD ID=TBL4948.FINROW.27.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL4948.FINROW.27.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.27.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.27.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	15,312
</TD>
<TD ID=TBL4948.FINROW.27.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL4948.FINROW.29 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4938 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total cash, cash equivalents and investments
</FONT>
</P>
</TD>
<TD ID=TBL4948.FINROW.29.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.29.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.29.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	75,354
</TD>
<TD ID=TBL4948.FINROW.29.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.29.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.29.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.29.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL4948.FINROW.29.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.29.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.29.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.29.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(4
</TD>
<TD ID=TBL4948.FINROW.29.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL4948.FINROW.29.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL4948.FINROW.29.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL4948.FINROW.29.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	75,350
</TD>
<TD ID=TBL4948.FINROW.29.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA4950 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4949 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	None of the available-for-sale securities held by the Company had material unrealized losses and there were no realized losses for the years ended December&nbsp;31, 2015 and 2014. There were no other-than-temporary impairments for these securities as of December&nbsp;31, 2015 or 2014. No gross realized gains or losses were recognized on the available-for-sale securities and, accordingly, there were no amounts reclassified out of accumulated other comprehensive income to earnings during the years ended December 31, 2015 and 2014.
</FONT>
</P>
<P ID=PARA4952 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK11 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR11 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM11 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-15
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage103"></A>
<DIV ID=PGHDR11 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA11.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA38 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA40 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA39 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
</FONT>
<P STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
	&nbsp;
</P>
<P ID=PARA4951 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December&nbsp;31, 2015 and 2014, the contractual maturity of all investments held was less than one year.
</FONT>
</P>
<P ID=PARA4954 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4953 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Fair Value Measurement
</I>
</B>
</FONT>
</P>
<P ID=PARA4956 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4955 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company&#8217;s financial instruments consist of Level I and Level II assets and Level III liabilities. Level I securities include highly liquid money market funds and are valued based on quoted market prices. For Level II instruments, the Company estimates fair value by utilizing third party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. Such Level II instruments typically include U.S. treasury and U.S. government agency obligations. As of December&nbsp;31, 2015 and December&nbsp;31, 2014, the Company held, in addition to Level I and Level II assets, a contingent put option liability associated with the Company&#8217;s Amended and Restated Loan and Security Agreement, or the Amended Loan Agreement, with Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc., collectively referred to as Hercules, which amends and restates the loan and security agreement with Hercules dated as of June&nbsp;29, 2011, or the Original Loan Agreement, and
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	which was classified as a Level III liability. See Note 7 &#8220;Long-Term Debt&#8221; for further description
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	. The Company&#8217;s estimate of fair value of the contingent put option liability was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated both with and without the presence of the default provisions, holding all other assumptions constant. The resulting difference between the two estimated fair values is the estimated fair value of the default provisions, or the contingent put option. Changes to the estimated fair value of these liabilities are recorded in interest income and other income (expense), net in the Consolidated Statements of Comprehensive Loss. The fair value of the underlying debt facility is estimated by calculating the expected cash flows in consideration of an estimated probability of default and expected recovery rate in default, and discounting such cash flows back to the reporting date using a risk-free rate. As of December&nbsp;31, 2015 and 2014, the Company also held a Level III liability associated with warrants, or PIPE warrants, issued in connection with the Company&#8217;s private placement equity offering, completed in June 2012. For a detailed description, see Note 11 &#8220;Stockholders&#8217; Equity.&#8221; The PIPE warrants are considered a liability and are valued using the Black-Scholes option-pricing model, the inputs for which include exercise price of the PIPE warrants, market price of the underlying common shares, expected term, volatility based on a group of the Company&#8217;s peers and the risk-free rate corresponding to the expected term of the PIPE warrants. Changes to any of these inputs can have a significant impact to the estimated fair value of the PIPE warrants. As of September 30, 2015, the Company remeasured on a non-recurring basis a portion of its leasehold improvements in its corporate offices using Level III valuation techniques. The write down to fair value of these long-lived assets resulted in an impairment charge of $0.5 million in the year ended December 31, 2015, which was recorded in interest income and other income (expense), net in the Consolidated Statements of Comprehensive Loss.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA4958 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4957 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA4959 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities by level within the fair value hierarchy (in thousands):
</FONT>
</P>
<P ID=PARA4960 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE ID=TBL5100S1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 95%; MARGIN-LEFT: 2.5%; MARGIN-RIGHT: 2.5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5100S1.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=14>
<P ID=PARA4962 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	As of December 31, 2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100S1.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA4965 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Fair Value
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA4967 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Level I
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA4969 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Level II
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 18PT" COLSPAN=2>
<P ID=PARA4971 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 18PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Level III
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100S1.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 48%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4973 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Assets
</B>
</FONT>
</U>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.3.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.3.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5100S1.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4978 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Money market funds
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	2
</TD>
<TD ID=TBL5100S1.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	2
</TD>
<TD ID=TBL5100S1.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.4.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.4.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.4.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.4.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100S1.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA4983 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	U.S. government agency obligations
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	30,352
</TD>
<TD ID=TBL5100S1.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	30,352
</TD>
<TD ID=TBL5100S1.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100S1.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA4993 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total assets measured at fair value
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	30,354
</TD>
<TD ID=TBL5100S1.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	2
</TD>
<TD ID=TBL5100S1.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	30,352
</TD>
<TD ID=TBL5100S1.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.6.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.6.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.6.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.6.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100S1.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5003 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Liabilities
</B>
</FONT>
</U>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.7.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100S1.FINROW.7.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5100S1.FINROW.8 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5008 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PIPE warrant
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	913
</TD>
<TD ID=TBL5100S1.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.8.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.8.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.8.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	913
</TD>
<TD ID=TBL5100S1.FINROW.8.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100S1.FINROW.9 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5013 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Contingent put option
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	266
</TD>
<TD ID=TBL5100S1.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.9.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
	266
</TD>
<TD ID=TBL5100S1.FINROW.9.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100S1.FINROW.10 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5023 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total liabilities measured at fair value
</FONT>
</P>
</TD>
<TD ID=TBL5100S1.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	1,179
</TD>
<TD ID=TBL5100S1.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.10.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.10.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.10.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100S1.FINROW.10.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.10.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100S1.FINROW.10.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100S1.FINROW.10.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	1,179
</TD>
<TD ID=TBL5100S1.FINROW.10.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA13 STYLE="MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK14 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR14 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM14 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-16
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage104"></A>
<DIV ID=PGHDR14 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA14.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<P ID=PARA41 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA43 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA42 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
</FONT>
<P STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
	&nbsp;
</P>
<TABLE ID=TBL5100 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 95%; MARGIN-LEFT: 2.5%; MARGIN-RIGHT: 2.5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5100.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=14>
<P ID=PARA5034 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	As of December 31, 2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA5037 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Fair Value
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA5039 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Level I
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA5041 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Level II
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 18PT" COLSPAN=2>
<P ID=PARA5043 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 18PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Level III
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 48%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5045 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Assets
</B>
</FONT>
</U>
</P>
</TD>
<TD ID=TBL5100.FINROW.3.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.3.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5100.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5050 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Money market funds
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	33
</TD>
<TD ID=TBL5100.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	33
</TD>
<TD ID=TBL5100.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.4.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.4.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.4.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.4.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5055 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	U.S. government agency obligations
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	15,312
</TD>
<TD ID=TBL5100.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	15,312
</TD>
<TD ID=TBL5100.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5065 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total assets measured at fair value
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	15,345
</TD>
<TD ID=TBL5100.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	33
</TD>
<TD ID=TBL5100.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	15,312
</TD>
<TD ID=TBL5100.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.6.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.6.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.6.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.6.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5075 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Liabilities
</B>
</FONT>
</U>
</P>
</TD>
<TD ID=TBL5100.FINROW.7.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5100.FINROW.7.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; BACKGROUND-COLOR: #CCEEFF">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5100.FINROW.8 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5080 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PIPE warrant
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	5,577
</TD>
<TD ID=TBL5100.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.8.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.8.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.8.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	5,577
</TD>
<TD ID=TBL5100.FINROW.8.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100.FINROW.9 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5085 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Contingent put option
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	282
</TD>
<TD ID=TBL5100.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.9.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
	282
</TD>
<TD ID=TBL5100.FINROW.9.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5100.FINROW.10 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5095 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total liabilities measured at fair value
</FONT>
</P>
</TD>
<TD ID=TBL5100.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	5,859
</TD>
<TD ID=TBL5100.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.10.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.10.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.10.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5100.FINROW.10.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.10.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5100.FINROW.10.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5100.FINROW.10.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 10%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
	5,859
</TD>
<TD ID=TBL5100.FINROW.10.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5101 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<BR>
	The following table sets forth the assumptions used in the Black-Scholes option-pricing model to estimate the fair value of the PIPE warrants as of December&nbsp;31, 2015 and 2014:
</FONT>
</P>
<P ID=PARA5102 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE ID=TBL5126 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; MARGIN-LEFT: 36PT; MARGIN-RIGHT: 10%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5126.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5126.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5126.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA5104 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	As of December 31,
<BR>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5126.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5126.FINROW.1.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5126.FINROW.1.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA5106 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	As of December 31,
<BR>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5126.FINROW.1.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5126.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 66%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5108 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Market Price
</FONT>
</P>
</TD>
<TD ID=TBL5126.FINROW.2.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.2.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.2.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #CCEEFF">
	$3.85
</TD>
<TD ID=TBL5126.FINROW.2.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.2.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.2.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.2.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #CCEEFF">
	$6.73
</TD>
<TD ID=TBL5126.FINROW.2.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5126.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5111 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Exercise Price
</FONT>
</P>
</TD>
<TD ID=TBL5126.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #FFFFFF">
	$3.40
</TD>
<TD ID=TBL5126.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #FFFFFF">
	$3.40
</TD>
<TD ID=TBL5126.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5126.FINROW.4>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5114 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Risk-free interest rate
</FONT>
</P>
</TD>
<TD ID=TBL5126.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #CCEEFF">
	1.06%
</TD>
<TD ID=TBL5126.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #CCEEFF">
	1.10%
</TD>
<TD ID=TBL5126.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5126.FINROW.5>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5117 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Expected volatility
</FONT>
</P>
</TD>
<TD ID=TBL5126.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #FFFFFF">
	80.0%
</TD>
<TD ID=TBL5126.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #FFFFFF">
	61.0%
</TD>
<TD ID=TBL5126.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5126.FINROW.6>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5120 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Expected life (in years)
</FONT>
</P>
</TD>
<TD ID=TBL5126.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #CCEEFF">
	1.92
</TD>
<TD ID=TBL5126.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #CCEEFF">
	2.92
</TD>
<TD ID=TBL5126.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5126.FINROW.7>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5123 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Expected dividend yield
</FONT>
</P>
</TD>
<TD ID=TBL5126.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #FFFFFF">
	0.0%
</TD>
<TD ID=TBL5126.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5126.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 31.05PT; BACKGROUND-COLOR: #FFFFFF">
	0.0%
</TD>
<TD ID=TBL5126.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5128 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA5129 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level III financial liabilities for the years ended December&nbsp;31, 2015 and 2014 (in thousands):
</FONT>
</P>
<P ID=PARA5130 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE ID=TBL5148 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; MARGIN-LEFT: 72PT; MARGIN-RIGHT: 20%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5148.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5148.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5148.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5132 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year Ended
<BR>
	December 31,
<BR>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5148.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5148.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 81%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5134 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Fair value&#8212;beginning of period
</FONT>
</P>
</TD>
<TD ID=TBL5148.FINROW.2.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5148.FINROW.2.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5148.FINROW.2.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	5,859
</TD>
<TD ID=TBL5148.FINROW.2.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5148.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5136 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Change in fair value of PIPE warrants
</FONT>
</P>
</TD>
<TD ID=TBL5148.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5148.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5148.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	(2,120
</TD>
<TD ID=TBL5148.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL5148.FINROW.4>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5138 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Exercise of PIPE warrants
</FONT>
</P>
</TD>
<TD ID=TBL5148.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5148.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5148.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	(2,544
</TD>
<TD ID=TBL5148.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL5148.FINROW.5>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5140 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Change in fair value of contingent put option associated with Amended Loan Agreement with Hercules
</FONT>
</P>
</TD>
<TD ID=TBL5148.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5148.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5148.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	(16
</TD>
<TD ID=TBL5148.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL5148.FINROW.6>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5144 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Fair value&#8212;end of period
</FONT>
</P>
</TD>
<TD ID=TBL5148.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5148.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5148.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	1,179
</TD>
<TD ID=TBL5148.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
<P ID=PARA5149 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL5167 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; MARGIN-LEFT: 72PT; MARGIN-RIGHT: 20%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5167.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5167.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5167.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5151 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year Ended
<BR>
	December 31,
<BR>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5167.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5167.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 81%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5153 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Fair value&#8212;beginning of period
</FONT>
</P>
</TD>
<TD ID=TBL5167.FINROW.2.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5167.FINROW.2.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5167.FINROW.2.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	13,445
</TD>
<TD ID=TBL5167.FINROW.2.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5167.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5155 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Change in fair value of PIPE warrants
</FONT>
</P>
</TD>
<TD ID=TBL5167.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5167.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5167.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	(6,988
</TD>
<TD ID=TBL5167.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL5167.FINROW.4>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5157 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Exercise of PIPE warrants
</FONT>
</P>
</TD>
<TD ID=TBL5167.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5167.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5167.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	(546
</TD>
<TD ID=TBL5167.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL5167.FINROW.5>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA5159 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Change in fair value of contingent put option associated with 2011 loan and security agreement with Hercules
</FONT>
</P>
</TD>
<TD ID=TBL5167.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5167.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5167.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #FFFFFF">
	(52
</TD>
<TD ID=TBL5167.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL5167.FINROW.6>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5163 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Fair value&#8212;end of period
</FONT>
</P>
</TD>
<TD ID=TBL5167.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5167.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5167.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.85PT; BACKGROUND-COLOR: #CCEEFF">
	5,859
</TD>
<TD ID=TBL5167.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5168 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK16 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR16 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM16 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-17
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage105"></A>
<DIV ID=PGHDR16 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA16.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</P>
<P ID=PARA47 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<P ID=PARA44 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA46 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA45 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
<BR>
</B>
</FONT>
</P>
</FONT>
<P ID=PARA5169 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	3. Inventories
</B>
</FONT>
</P>
<P ID=PARA5171 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5172 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Inventories consist of finished goods, raw materials and work in process and are stated at the lower of cost or market and consist of the following (in thousands):
</FONT>
</P>
<P ID=PARA5173 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE ID=TBL5221 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; MARGIN-LEFT: 27PT; MARGIN-RIGHT: 20%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5221.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5221.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5221.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5179 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<B>
	Balance as
</B>
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<B>
	of
</B>
</B>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<B>
</B>
	December 31,
<BR>
	2015
</B>
</FONT>
</P>
</TD>
<TD ID=TBL5221.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5221.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 81%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5181 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Raw materials
</FONT>
</P>
</TD>
<TD ID=TBL5221.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5221.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5221.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	140
</TD>
<TD ID=TBL5221.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5221.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5186 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Work-in-process
</FONT>
</P>
</TD>
<TD ID=TBL5221.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5221.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5221.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	181
</TD>
<TD ID=TBL5221.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5221.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5191 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Finished goods
</FONT>
</P>
</TD>
<TD ID=TBL5221.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5221.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5221.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	145
</TD>
<TD ID=TBL5221.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5221.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5201 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Inventories
</FONT>
</P>
</TD>
<TD ID=TBL5221.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5221.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5221.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	466
</TD>
<TD ID=TBL5221.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5223 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5222 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	4. Property and Equipment
</B>
</FONT>
</P>
<P ID=PARA5225 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5224 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Property and equipment consist of the following (in thousands):
</FONT>
</P>
<P ID=PARA5226 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE ID=TBL5267 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 95%; MARGIN-LEFT: 27PT; MARGIN-RIGHT: 5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5267.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5267.FINROW.1.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5267.FINROW.1.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 12.95PT" COLSPAN=6>
<P ID=PARA5228 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	As of December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.1.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5267.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5267.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5267.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 12.95PT" COLSPAN=2>
<P ID=PARA5231 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT 0PT 12.95PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5267.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5267.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 12.95PT" COLSPAN=2>
<P ID=PARA5233 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT 0PT 12.95PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5267.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 68%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5235 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Laboratory equipment
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5267.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	3,522
</TD>
<TD ID=TBL5267.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5267.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	2,549
</TD>
<TD ID=TBL5267.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5267.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5238 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Leasehold improvements
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #FFFFFF">
	4,609
</TD>
<TD ID=TBL5267.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #FFFFFF">
	4,469
</TD>
<TD ID=TBL5267.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5267.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5241 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Computer equipment and software
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	266
</TD>
<TD ID=TBL5267.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	334
</TD>
<TD ID=TBL5267.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5267.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5244 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Construction in process
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #FFFFFF">
	3,950
</TD>
<TD ID=TBL5267.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #FFFFFF">
	4,844
</TD>
<TD ID=TBL5267.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5267.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5247 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Tooling
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	1,062
</TD>
<TD ID=TBL5267.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	527
</TD>
<TD ID=TBL5267.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5267.FINROW.8 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5250 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Furniture and fixtures
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #FFFFFF">
	55
</TD>
<TD ID=TBL5267.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #FFFFFF">
	50
</TD>
<TD ID=TBL5267.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5267.FINROW.10 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	13,464
</TD>
<TD ID=TBL5267.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	12,773
</TD>
<TD ID=TBL5267.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5267.FINROW.11 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5258 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Less accumulated depreciation and amortization
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #FFFFFF">
	(4,854
</TD>
<TD ID=TBL5267.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL5267.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #FFFFFF">
	(2,955
</TD>
<TD ID=TBL5267.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL5267.FINROW.12 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5261 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Property and equipment, net
</FONT>
</P>
</TD>
<TD ID=TBL5267.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5267.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	8,610
</TD>
<TD ID=TBL5267.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5267.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5267.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.95PT; BACKGROUND-COLOR: #CCEEFF">
	9,818
</TD>
<TD ID=TBL5267.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5269 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5268 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Depreciation and amortization expense was $2.0 million, $0.9 million and $0.6 million during the years ended December&nbsp;31, 2015, 2014 and 2013, respectively. Property and equipment, net in the Consolidated Balance Sheets at December 31, 2015 and 2014, includes $3.0 million and $3.8 million, respectively, related to certain modifications the Company has made at Patheon Pharmaceutical Inc.&#8217;s, or Patheon&#8217;s, Cincinnati facility under the terms of the Capital Expenditure and Equipment Agreement, or the Capital Agreement.
</FONT>
</P>
<P ID=PARA5271 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5270 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	5. U.S. Department of Defense Funding
</B>
</FONT>
</P>
<P ID=PARA5273 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5272 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In May 2011, AcelRx received a grant from the USAMRMC in which the USAMRMC granted $5.6 million to the Company in order to support the development of investigational product candidate, ARX-04, for the treatment of moderate-to-severe acute pain. Under the terms of the grant, the USAMRMC will reimburse the Company for development, manufacturing and clinical costs necessary to prepare for and complete the planned Phase 2 dose-finding trial in a study of acute moderate-to-severe pain, and to prepare to enter Phase 3 development. The grant gives the USAMRMC the option to extend the term of the grant and provide additional funding for the research. As of December&nbsp;31, 2013, the full amount of the grant, $5.6 million, had been recognized as revenue. There was no revenue recognized for years ended December 31, 2015 or 2014. Revenue attributable to the research and development performed under the USAMRMC grant, recorded as Contract and other revenue in the Consolidated Statements of Comprehensive Loss, was $2.1&nbsp;million for the year ended December&nbsp;31, 2013.
</FONT>
</P>
<P ID=PARA148 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P ID=PARA218 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA217 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On May 11, 2015, the Company entered into a new award contract supported by the USAMRMC, within the U.S. Department of Defense, or the DoD, in which the DoD
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	agreed to provide up to $17.0 million to the Company in order to support the development of the Company&#8217;s product candidate,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04 (sufentanil sublingual tablet, 30 mcg), a proprietary,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	non-invasive, single-use tablet in a disposable, pre-filled single-dose applicator, or SDA, for the treatment of moderate-to-severe acute pain, referred to as the DoD Contract. The DoD Contract supports development of
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04. Under the terms of the contract, the DoD will reimburse us for costs incurred for development, manufacturing, regulatory and clinical costs outlined in the contract in order to submit an NDA to the FDA, including reimbursement for certain personnel and overhead expenses. The period of performance under the contract began on May 11, 2015. The contract gives the DoD the option to extend the term of the contract and provide additional funding for the research.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On March 2, 2016, the DoD Contract was amended
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	to approve enrollment of additional patients in the SAP302 study, approve the addition of the SAP303 study, and extend the contract period of performance by four months from November 10, 2016 to March 9, 2017, to accommodate the increased SAP302 patient enrollment and the SAP303 study. The costs for these changes will be absorbed within the current contract value. If
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARX-04 is approved by the FDA, the DoD has the option to purchase a certain number of units of commercial product pursuant to the terms of the contract.
</FONT>
</P>
<P ID=PARA148 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA5276 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Revenue attributable to the work performed under the DoD Contract, recorded as Contract and other revenue in the Consolidated Statements of Comprehensive Loss, was $4.4 million for the year ended December 31, 2015. There was no revenue recognized under the DOD Contract for years ended December 31, 2014 or 2013.
</FONT>
</P>
<P ID=PARA5279 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK17 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR17 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM17 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-18
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage106"></A>
<DIV ID=PGHDR17 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA17.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA50 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA52 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA51 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
<BR>
</B>
</FONT>
</P>
</FONT>
<P ID=PARA5278 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	6. Collaboration Agreement
</B>
</FONT>
</P>
<P ID=PARA5281 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5280 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December&nbsp;16, 2013, AcelRx and Gr&#252;nenthal, entered into a Collaboration and License Agreement, or the License Agreement, and related Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. The License Agreement grants Gr&#252;nenthal rights to commercialize Zalviso, the Company&#8217;s novel sublingual patient-controlled analgesia, or PCA, system, or the Product, in the countries of the European Union, Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory, for human use in pain treatment within or dispensed by hospitals, hospices, nursing homes and other medically-supervised settings, or the Field. The Company retains rights with respect to the Product in countries outside the Territory, including the United States, Asia and Latin America. Under the MSA, the Company will exclusively manufacture and supply the Product to Gr&#252;nenthal for the Field in the Territory. On July 22, 2015, the Company entered into amendments to the License Agreement, or the License Amendment, and together with the License Agreement, the Amended License Agreement, and the MSA, or the MSA Amendment, and together with the MSA, the Amended MSA, between the Company and Gr&#252;nenthal, each effective as of July 17, 2015, and together, the Amended Agreements.
</FONT>
</P>
<P ID=PARA5283 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5282 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In the Amended Agreements, the parties amended the Product supply configurations and packaging of Product components and accessories, and associated pricing therefor, which the Company will manufacture and supply to Gr&#252;nenthal for the Territory. The parties agreed to increase the pricing of the Product components and accessories in exchange for a reduction of $5.5 million in the total milestone payments due from Gr&#252;nenthal contingent upon achieving specified net sales targets from a total of $171.5 million to $166.0 million. The parties also updated the development plan for the Product in the Territory, providing for additional near-term development services to be rendered by AcelRx in exchange for payments by Gr&#252;nenthal of $0.7 million. In accordance with the terms of the Amended MSA, AcelRx also received a binding Product forecast from Gr&#252;nenthal for approximately $3.7 million.
</FONT>
</P>
<P ID=PARA5284 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5285 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Amended License Agreement
</U>
</FONT>
</P>
<P ID=PARA5287 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5286 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the terms of the Amended License Agreement, Gr&#252;nenthal has the exclusive right to commercialize the Product in the Field in the Territory. The Company retains control of clinical development, while Gr&#252;nenthal and the Company will be responsible for certain development activities pursuant to a development plan as agreed between the parties. The Company will not receive separate payment for such development activities, apart from the $0.7 million included under the Amended Agreements. Gr&#252;nenthal is exclusively responsible for marketing approval applications and other regulatory filings relating to the sufentanil sublingual tablet drug cartridge for the Product in the Field in the Territory, while the Company is responsible for the CE Mark and other regulatory filings relating to device portions of the Product. In July 2014, Gr&#252;nenthal submitted an MAA to the European Medicines Agency, or EMA, for Zalviso&#8482; (15 micrograms sufentanil sublingual tablets) for the management of acute moderate-to-severe post-operative pain in adult patients. A CE Mark for Zalviso was obtained in the fourth quarter of 2014 which specifies AcelRx as the device design authority and manufacturer. In September 2015, the European Commission approved the MAA for Zalviso for the 28 European Union member states as well as for the EEA.
</FONT>
</P>
<P ID=PARA151 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA150 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company received an upfront non-refundable cash payment of $30.0 million in December 2013,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	and a milestone payment of $5.0 million related to the MAA submission in the third quarter of 2014, and an additional $15.0 million milestone payment upon the EC approval of the MAA for Zalviso, which was approved in September 2015. Under the Amended License Agreement, the Company is eligible to receive approximately $194.5 million in additional milestone payments, based upon successful regulatory and product development efforts ($28.5 million) and net sales target achievements ($166.0 million). Gr&#252;nenthal will also make tiered royalty and supply and trademark fee payments in the mid-teens up to the mid-twenties percent range, depending on the level of sales achieved, on net sales of Zalviso.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A portion of the tiered royalty payment, exclusive of the supply and trademark fee payments, will be paid to PDL in connection with the Royalty Monetization. For additional information on the Royalty Monetization with PDL, see Note 8 &#8220;Liability Related to Sale of Future Royalties.&#8221; Unless earlier terminated, the Amended License Agreement continues in effect until the expiration of the obligation of Gr&#252;nenthal to make royalty and supply and trademark fee payments, which supply and trademark fee continues for so long as the Company continues to supply the Product to Gr&#252;nenthal. The Amended License Agreement is subject to earlier termination in the event the parties mutually agree, by a party in the event of an uncured material breach by the other party, upon the bankruptcy or insolvency of either party, or by Gr&#252;nenthal for convenience.
</FONT>
</P>
<P ID=PARA152 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA5294 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<U>
	Amended MSA
</U>
</FONT>
</P>
<P ID=PARA5296 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5295 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under the terms of the Amended MSA, the Company will manufacture and supply the Product for use in the Field for the Territory exclusively for Gr&#252;nenthal. Gr&#252;nenthal shall purchase from AcelRx, during the first five years after the effective date of the MSA, 100% and thereafter 80% of Gr&#252;nenthal&#8217;s and its sublicensees&#8217; and distributors&#8217; requirements of Product for use in the Field for the Territory. The Product will be supplied at prices approximating the Company&#8217;s manufacturing cost, subject to certain caps, as defined in the MSA Amendment. The MSA Amendment requires the Company to use commercially reasonable efforts to enter stand-by contracts with third parties providing significant supply and manufacturing services and, under certain specified conditions, permits Gr&#252;nenthal to use a third party back-up manufacturer to manufacture the Product for Gr&#252;nenthal&#8217;s commercial sale in the Territory.
</FONT>
</P>
<P ID=PARA5298 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK18 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR18 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM18 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-19
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage107"></A>
<DIV ID=PGHDR18 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA18.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA53 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA55 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA54 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
<BR>
</FONT>
<P ID=PARA5297 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Unless earlier terminated, the Amended MSA continues in effect until the later of the expiration of the obligation of Gr&#252;nenthal to make royalty and supply and trademark fee payments or the end of any transition period for manufacturing obligations due to the expiration or termination of the Amended License Agreement. The Amended MSA is subject to earlier termination in connection with certain termination events in the Amended License Agreement, in the event the parties mutually agree, by a party in the event of an uncured material breach by the other party or upon the bankruptcy or insolvency of either party.
</FONT>
</P>
<P ID=PARA5300 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5299 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company identified the following four significant non-contingent performance deliverables under the original Agreements: 1) intellectual property (license), 2) the obligation to provide research and development services, 3) the significant and incremental discount on the manufacturing of Zalviso for commercial purposes, and 4) the obligation to participate on the joint steering committee.
</FONT>
</P>
<P ID=PARA5302 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5301 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	At the time the Amended Agreements were executed, with the exception of the intellectual property license, these obligations remained partially undelivered. Additionally, the Company identified the following three performance deliverables under the License Amendment and the MSA Amendment: 1) the obligation to provide additional research and development services, 2) the obligation to provide Zalviso demonstration device systems, and 3) the obligation to manufacture and deliver Product under the binding forecast. The Company determined that the License Amendment and MSA Amendment are modifications to the original Agreements.
</FONT>
</P>
<P ID=PARA5304 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5303 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company considered the provisions of the multiple-element arrangement guidance in determining whether the deliverables outlined above have standalone value and thus should be treated as separate units of accounting. The Company&#8217;s management determined that the license under the original License Agreement had standalone value and represented a separate unit of accounting because the rights conveyed permitted Gr&#252;nenthal to perform all efforts necessary to commercialize and begin selling the product upon regulatory approval. In addition, Gr&#252;nenthal has the appropriate development, regulatory and commercial expertise with products similar to the product licensed under the agreement and has the ability to engage third parties to manufacture the product allowing Gr&#252;nenthal to realize the value of the license without receiving any of the remaining deliverables. Gr&#252;nenthal can also sublicense its license rights to third parties. Also, the Company&#8217;s management determined that the research and development services, Zalviso demonstration device systems, joint steering committee participation, the significant and incremental discount on the manufacturing of Zalviso, and the obligation to manufacture and deliver Products each represent individual units of accounting, as Gr&#252;nenthal could perform such services and/or could acquire these on a separate basis.
</FONT>
</P>
<P ID=PARA5306 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5305 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company believes that none of the deliverables have vendor-specific objective evidence, or VSOE, or sufficient third-party evidence, or TPE, of selling price, as none of them have been sold separately by the Company, and as there is only limited information about third party pricing for similar deliverables. Accordingly, the Company developed best estimates of selling prices, or ESP, for each deliverable in order to allocate the noncontingent arrangement consideration to the units of accounting, based on current information available as of the modification date.
</FONT>
</P>
<P ID=PARA5308 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5307 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company&#8217;s management determined the best estimate of selling price for the license based on Gr&#252;nenthal&#8217;s estimated future cash flows arising from the arrangement. Embedded in the estimate were significant assumptions regarding regulatory expenses, revenue, including potential customer market for the product and product price, costs to manufacture the product and the discount rate. The Company&#8217;s management determined the best estimate of selling price of the research and development services and committee participation based on the nature and timing of the services to be performed and in consideration of personnel and other costs incurred in the delivery of the services.&nbsp;For the discount on manufacturing services, the Company&#8217;s management estimated the selling price based on the market level of contract manufacturing margin it could have received if it were engaged to supply products to a customer in a separate transaction, the estimated cost of manufacturing, and the anticipated volume of Gr&#252;nenthal&#8217;s orders over the course of the agreement, to which the discount would apply. For the Zalviso demonstration devices and the obligation to manufacture and deliver Product, the Company&#8217;s management estimated the selling price based on the binding volume of such devices and Products, the estimated cost of manufacturing, and the market level of contract manufacturing margin. ESP of the license, research and development and committee participation services and the discount on manufacturing services were updated at the time the Amended Agreements were executed for purposes of allocating the amended arrangement consideration.
</FONT>
</P>
<P ID=PARA5310 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK19 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR19 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM19 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-20
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage108"></A>
<DIV ID=PGHDR19 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA19.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA5311 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Amended Agreements entitle the Company to receive additional payments upon the achievement of certain development and sales milestones. Based on ASC Topic 605-28,
<I>
	Revenue Recognition &#8212; Milestone Method
</I>
	, the Company evaluates contingent milestones at inception or modification of the agreement, and recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is considered substantive in its entirety. Milestones are events which have the following characteristics: (i) they can be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance, (ii) there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and, (iii) they would result in additional payments due to the Company. A milestone is considered substantive if the following criteria are met: (i) the consideration is commensurate with either (1) the entity&#8217;s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item (s) as a result of a specific outcome resulting from the entity&#8217;s performance to achieve the milestone, (ii)&nbsp;the consideration relates solely to past performance and, (iii) the consideration is reasonable relative to all of the other deliverables and payment terms, including other potential milestone consideration, within the arrangement.
</FONT>
</P>
<P ID=PARA5313 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5312 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The substantive milestone payments will be recognized as revenue in their entirety upon the achievement of each substantive milestone. Based on the criteria noted above, the identified substantive milestones in the original Agreements pertain to post approval product enhancements, expanded market opportunities and manufacturing efficiencies for Zalviso. Each of these potential achievements is based primarily on the Company&#8217;s performance and involves substantive uncertainty as achievement of these milestones requires future research, development and regulatory activities, which are inherently uncertain in nature. The Company determined that the consideration for each milestone was commensurate with the Company&#8217;s performance to achieve the milestone, including future research, development, manufacturing and regulatory activities and that the consideration is reasonable relative to all of the other deliverables and payments within the arrangement. Aggregate potential payments for these milestones total $28.5&nbsp;million.
</FONT>
</P>
<P ID=PARA5315 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5314 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition to substantive milestones, two milestones associated with the original Agreements were deemed not to be substantive. These milestones pertain to regulatory developments for Zalviso in Europe, which the Company&#8217;s management deemed to be not substantive due to the high likelihood of achievement, both at inception of the original Agreements and at the time the Amended Agreements were executed. Aggregate potential payments for these milestones totaled $20.0 million. In July 2014, Gr&#252;nenthal submitted an MAA to the EMA for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients, triggering the first of these two milestones, a cash payment of $5.0 million. In September of 2015, the MAA was approved by the European Commission, triggering the second of these two milestones, a cash payment of $15.0 million. Amounts received under these non-substantive milestones were allocated to performance deliverables based on the relative selling price method and recognized as appropriate for such deliverables.
</FONT>
</P>
<P ID=PARA5317 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5316 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Amended Agreements also include milestone payments related to specified net sales targets, totaling $166.0 million. These milestones do not meet the definition of a milestone under ASU 2010-17 because the achievement of these milestones is solely dependent on counter-party performance and not on any performance obligations of the Company.
</FONT>
</P>
<P ID=PARA5319 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5318 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	At the time the Amended Agreements were executed, approximately $33.3 million of revenue had been recognized, and $1.7 million remained unrecognized from the aggregate to-date consideration of $35.0 million received under the original Agreements. Upon execution of the Amended Agreements, the Company updated the allocation of this arrangement consideration, along with the consideration owed under the Amended Agreements totaling $54.4 million, consisting of $0.7 million related to research and development services and the demonstration device systems, and $3.7 million related to the Product binding purchase forecast, to all of the identified deliverables in the arrangement (both delivered and undelivered) using their relative selling prices. Further, the $15.0 million non-substantive milestone achieved in September of 2015 was also allocated to the deliverables in the same manner. As a result of such allocations, additional amounts of $13.2 million and $0.5 million were allocated to the previously delivered license and research and development and committee participation services, respectively. A total of $4.4 million was allocated to the significant and incremental discount on manufacturing services, and is expected to be recognized over the period such discount is made available to Gr&#252;nenthal, beginning in February 2016, on a straight-line basis over the estimated period through 2029. An additional $0.2 million has been allocated to committee participation services and is recognized on a straight-line basis over the performance obligation period extending through 2018. A total of $2.3 million was allocated to manufacturing services for the binding forecast of Products, and is expected to be recognized when the Products are delivered in the first quarter of 2016. The remaining $0.5 million was allocated to the additional research and development services under the Amended License Agreement and demonstration device systems, and manufacturing and delivery of the Products, and will be recognized as those services are performed or as the devices are delivered, as applicable.
</FONT>
</P>
<P ID=PARA5320 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK20 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR20 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM20 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-21
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage109"></A>
<DIV ID=PGHDR20 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA20.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<P ID=PARA56 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA58 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA57 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
<BR>
</FONT>
<P ID=PARA5321 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Below is a summary of revenue recognized under the Amended Agreements during the years ended December 30, 2015, 2014 and 2013 (in thousands):
</FONT>
</P>
<P ID=PARA5322 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL5353 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; MARGIN-LEFT: 5%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5353.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5353.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5353.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0.75PT" COLSPAN=10>
<P ID=PARA5324 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 0PT 0PT 0.75PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Years Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5353.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5353.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5353.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5353.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA5327 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5353.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5353.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5353.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA5329 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5353.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5353.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5353.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA5331 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5353.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5353.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5333 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	License
</FONT>
</P>
</TD>
<TD ID=TBL5353.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5353.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	13,167
</TD>
<TD ID=TBL5353.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5353.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	4,560
</TD>
<TD ID=TBL5353.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5353.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	27,370
</TD>
<TD ID=TBL5353.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5353.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; MARGIN-TOP: 0PX; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA5337 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Joint steering committee, research and development services and demonstration devices
</FONT>
</P>
</TD>
<TD ID=TBL5353.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	1,690
</TD>
<TD ID=TBL5353.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	657
</TD>
<TD ID=TBL5353.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5353.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5353.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5345 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total
</FONT>
</P>
</TD>
<TD ID=TBL5353.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5353.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	14,857
</TD>
<TD ID=TBL5353.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5353.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	5,217
</TD>
<TD ID=TBL5353.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5353.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5353.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	27,370
</TD>
<TD ID=TBL5353.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5355 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5354 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December 31, 2015, the Company had current and noncurrent portions of the deferred revenue balance under the Amended Agreements of $2.6&nbsp;million and $0.6 million, respectively.
</FONT>
</P>
<P ID=PARA5357 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA5358 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	7. Long-Term Debt
</B>
</FONT>
</P>
<P ID=PARA5360 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5359 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Hercules Loan and Security Agreements
</I>
</B>
</FONT>
</P>
<P ID=PARA5362 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5361 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In June 2011, AcelRx entered into the Loan and Security Agreement, or the Loan Agreement, between the Company and with Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc., together, the Lenders, under which AcelRx borrowed $20.0 million in two tranches of $10.0 million each, represented by secured convertible term promissory notes.
</FONT>
</P>
<P ID=PARA5364 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5363 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company borrowed the first tranche of $10.0 million upon the closing of the transaction on June&nbsp;29, 2011 and borrowed the second tranche of $10.0 million in December 2011. The Company used a portion of the proceeds from the first tranche to repay the remaining obligations under that certain loan and security agreement between the Company and Pinnacle Ventures, L.L.C., or Pinnacle Ventures, dated September&nbsp;16, 2008. The interest rate for each tranche was&nbsp;8.50%. In connection with the loan, the Company issued Hercules seven-year warrants to purchase an aggregate of 274,508 shares of common stock at a price of $3.06 per share. See Note 9 &#8220;Warrants&#8221; for further description.
</FONT>
</P>
<P ID=PARA5366 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5365 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On December&nbsp;16, 2013, AcelRx entered into an Amended and Restated Loan and Security Agreement with the Lenders, or the Amended Loan Agreement, under which the Company may borrow up to $40.0 million in three tranches. The loans are represented by secured convertible term promissory notes, collectively, the Notes. The Amended Loan Agreement amends and restates the Loan Agreement between the Company and the Lenders dated as of June&nbsp;29, 2011. The Company borrowed the first tranche of $15.0 million upon closing of the transaction on December&nbsp;16, 2013, and the second tranche of $10.0 million on June 16, 2014
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	. The Company used approximately $8.6 million of the proceeds from the first tranche to repay its obligations under the Loan and Security Agreement with the Lenders. The Company recorded the new debt at an estimated fair value of
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$24.9 million as of December 31, 2014.
</FONT>
</P>
<P ID=PARA5368 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5367 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In accordance with ASC Topic No.&nbsp;470, &#8220;Debt &#8211; Modifications and Extinguishments&#8221; (Topic No.&nbsp;470), the amendment noted above was determined to be an extinguishment of the existing debt and an issuance of new debt. The Company reached this conclusion based on a comparison of discounted remaining cash flows of the original loan agreement compared to the amended loan agreement, the result of which was a greater than 10% difference in discounted cash flows. The Company determined this difference to be significant and recorded the new debt at estimated fair value.
</FONT>
</P>
<P ID=PARA5370 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5369 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As a result of the extinguishment, the Company recorded a $1.2 million loss on extinguishment of debt which was recorded as interest income and other income (expense), net on the Consolidated Statements of Comprehensive Loss during the year ended December 31, 2013. The loss on extinguishment was a non-cash write off, consisting of deferred debt charges, the unamortized portion of the original issue discount related to the Loan Agreement and other fees associated with extinguishing the debt, including the estimated fair value of warrants issued in connection with the Amended Loan Agreement, facility and legal fees associated with the Amended Loan Agreement and the value of the contingent put option liability associated with the Loan Agreement at the time of the amendment.
</FONT>
</P>
<P ID=PARA5372 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5371 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September&nbsp;24, 2014, the Company entered into Amendment No. 1 to the Amended Loan Agreement with Hercules. Amendment No. 1 extended the time period under which the Company could draw down the third tranche, of up to $15.0 million, from March&nbsp;15, 2015 to August&nbsp;1, 2015, subject to the Company obtaining approval for Zalviso from the FDA. The Company did not receive FDA approval of Zalviso by August 1, 2015 and as such, will not have access to the third tranche.
</FONT>
</P>
<P ID=PARA5374 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK21 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR21 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM21 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-22
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage110"></A>
<DIV ID=PGHDR21 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA21.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA59 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA61 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA60 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
</FONT>
<P ID=PARA155 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
	&nbsp;
</P>
<P ID=PARA154 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September 18, 2015, concurrently with the closing of the Royalty Monetization, the Company entered into a Consent and Amendment No. 2, or Amendment No. 2, to the Amended Loan Agreement with the Lenders. Amendment No. 2 includes an interest only period from October 1, 2015 through March 31, 2016, with the potential for further extension to September 30, 2016 upon satisfaction of certain conditions
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	, which have since been satisfied. Loans under the Amended Loan Agreement mature on October 31, 2017. In connection with Amendment No. 2, the Company reduced the exercise price of the warrants already held by the Lenders, which are exercisable for an aggregate of 176,730 shares of Common Stock, from the previous exercise price of $6.79 per share to $3.88 per share, or the Warrant Amendments. See Note 9 &#8220;Warrants&#8221; for further description.
</FONT>
</P>
<P ID=PARA5376 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5375 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The interest rate for each tranche will be calculated at a rate equal to the greater of either (i) 9.10% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii) 9.10%. Payments under the Amended Loan Agreement were interest only until April 1, 2015, followed by equal monthly payments of principal and interest through September 30, 2015, to be followed by an interest only period from October 1, 2015 through September 30, 2016, and by equal monthly payments of principal and interest from October 1, 2016 through the scheduled maturity date on October 1, 2017, or the Loan Maturity Date. In addition, a final payment equal to $1.7 million will be due on the Loan Maturity Date, or such earlier date specified in the Amended Loan Agreement. The Company&#8217;s obligations under the Amended Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property and those assets sold under the Royalty Monetization.
</FONT>
</P>
<P ID=PARA5378 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5377 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	If the Company prepays the Amended Loan Agreement prior to maturity, it will pay Hercules a prepayment charge based on a percentage of the then outstanding principal balance, or 1% if the prepayment occurs after December&nbsp;16, 2015.
</FONT>
</P>
<P ID=PARA5380 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5379 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Subject to certain conditions and limitations set forth in the Amended Loan Agreement, the Company has the right to convert up&nbsp;to $5.0&nbsp;million of scheduled principal installments under the Notes into freely tradeable shares of the Company&#8217;s common stock, or Common Stock. The number of shares of Common Stock that would be issued upon conversion of the Amended Notes would be equal to the number determined by dividing (x)&nbsp;the product of (A)&nbsp;the principal amount to be paid in shares of Common Stock and (B)&nbsp;103%, by (y)&nbsp;$9.30 (subject to certain proportional adjustments as provided for in the Amended Loan Agreement).
</FONT>
</P>
<P ID=PARA5382 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5381 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Amended Loan Agreement includes customary affirmative and restrictive covenants, but does not include any financial maintenance covenants, and also includes standard events of default, including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of Hercules&#8217; security interest or in the value of the collateral, and events relating to bankruptcy or insolvency. Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and Hercules may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Amended Loan Agreement.
</FONT>
</P>
<P ID=PARA5384 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5383 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Upon an event of default, including a change of control, Hercules has the option to accelerate repayment of the Amended Loan Agreement, including payment of any applicable prepayment charges, which range from 1%-3% of the outstanding loan balance and accrued interest, as well as a final payment fee of $1.7 million. This option is considered a contingent put option liability, as the holder of the loan may exercise the option in the event of default, and is considered an embedded derivative, which must be valued and separately accounted for in the Company&#8217;s Consolidated Financial Statements. As the Amended Loan Agreement entered into on December 16, 2013 was considered an extinguishment, the contingent put option liability associated with the Loan Agreement, which had an estimated fair value of $32,000 at the time of the amendment, was written off as a part of the loss on extinguishment, and a new contingent put option liability was established. As of December 31, 2015 and 2014, the estimated fair value of the contingent put option liability was $266,000 and $282,000, respectively, which was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated both with and without the presence of the default provisions, holding all other assumptions constant. The resulting difference between the two estimated fair values is the estimated fair value of the default provisions, or the contingent put option. The fair value of the underlying debt facility is estimated by calculating the expected cash flows in consideration of an estimated probability of default and expected recovery rate in default, and discounting such cash flows back to the reporting date using a risk-free rate. The contingent put option liability was recorded as a debt discount to the loan and consequently a reduction to the carrying value of the loan. The contingent put option liability is revalued at the end of each reporting period and any change in the fair value is recognized in interest income and
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	other income (expense), net in the Consolidated Statements of Comprehensive Loss.
</FONT>
</P>
<P ID=PARA5386 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5385 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company performed an analysis of Amendment No. 2 to determine if it was a modification or extinguishment of the debt under the Amended Loan Agreement. The Company assumed immediate prepayment of both the pre-modification debt and post-modification debt, including the change in the fair value due to the Warrant Amendments, and concluded that Amendment No. 2 was a modification rather than an extinguishment of the debt.
</FONT>
</P>
<P ID=PARA5388 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK22 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR22 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM22 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-23
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage111"></A>
<DIV ID=PGHDR22 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA22.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</P>
<P ID=PARA62 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	AcelRx Pharmaceuticals, Inc.
</B>
</FONT>
</P>
<P ID=PARA64 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA63 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Notes to Consolidated Financial Statements
</B>
</FONT>
</P>
</FONT>
<P STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
	&nbsp;
</P>
<P ID=PARA5387 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The principal balance due under the Amended Loan Agreement was $20.9 million at December 31, 2015, and $24.9 million at December 31, 2014. Interest expense related to the Amended Loan Agreement was $3.0 million, $0.8 million of which represented amortization of the debt discount, for the year ended December 31, 2015, and $2.6 million,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	$0.5 million of which represented amortization of the debt discount, for the year ended December 31, 2014. Amortization of the debt discount prior to amending the Hercules loan and security agreement in December 2013, which was recorded as interest expense, was $0.4 million for the year ended December&nbsp;31, 2013.
</FONT>
</P>
<P ID=PARA5390 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<P ID=PARA5389 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Future Payments on Long-Term Debt
</I>
</B>
</FONT>
</P>
<P ID=PARA5392 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5391 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table summarizes our outstanding future payments associated with the Company&#8217;s long-term debt as of December&nbsp;31, 2015 (in thousands):
</FONT>
</P>
<P ID=PARA5394 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<TABLE ID=TBL5463 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5463.FINROW.2 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5399 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2016
</FONT>
</P>
</TD>
<TD ID=TBL5463.FINROW.2.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.2.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5463.FINROW.2.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	6,400
</TD>
<TD ID=TBL5463.FINROW.2.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5463.FINROW.3 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5404 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2017
</FONT>
</P>
</TD>
<TD ID=TBL5463.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	18,305
</TD>
<TD ID=TBL5463.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5463.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5413 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total payments
</FONT>
</P>
</TD>
<TD ID=TBL5463.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	24,705
</TD>
<TD ID=TBL5463.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5463.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5418 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Less amount representing interest
</FONT>
</P>
</TD>
<TD ID=TBL5463.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(2,539
</TD>
<TD ID=TBL5463.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
<P ID=PARA5422 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL5463.FINROW.6 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5427 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notes payable, gross
</FONT>
</P>
</TD>
<TD ID=TBL5463.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	22,166
</TD>
<TD ID=TBL5463.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5463.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5432 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Unamortized portion of final payment
</FONT>
</P>
</TD>
<TD ID=TBL5463.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(1,224
</TD>
<TD ID=TBL5463.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
<P ID=PARA5436 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL5463.FINROW.8 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5437 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Unamortized discount on notes payable
</FONT>
</P>
</TD>
<TD ID=TBL5463.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(20
</TD>
<TD ID=TBL5463.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA5441 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL5463.FINROW.9 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	20,922
</TD>
<TD ID=TBL5463.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5463.FINROW.10 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5450 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Less current portion of notes payable, including unamortized discount
</FONT>
</P>
</TD>
<TD ID=TBL5463.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	4,541
</TD>
<TD ID=TBL5463.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5463.FINROW.11 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5459 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Notes payable, less current portion
</FONT>
</P>
</TD>
<TD ID=TBL5463.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5463.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5463.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	16,381
</TD>
<TD ID=TBL5463.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5465 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5464 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	8. Liability Related to Sale of Future Royalties
</B>
</FONT>
</P>
<P ID=PARA5467 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5466 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On September 18, 2015, the Company consummated the Royalty Monetization, in which it sold certain royalty and milestone payment rights to its newly formed wholly owned subsidiary, ARPI LLC, pursuant to a Purchase and Sale Agreement, or PSA. Subsequently, ARPI LLC sold the royalty and milestone payment rights to PDL for an upfront cash purchase price of $65.0&nbsp;million, subject to a capped amount of $195.0 million pursuant to the Subsequent Purchase and Sale Agreement, or SPSA. Under the SPSA, PDL will receive 75% of the European royalties under the Amended License Agreement as well as 80% of the first four commercial milestones, worth $35.6 million (or 80% of $44.5 million), subject to the capped amount. The Company is entitled to receive 25% of the royalties, 20% of the first four commercial milestones, 100% of the remaining commercial milestones and all remaining development milestones of $43.5 million, including the $15.0 million payment for the EC approval of the MAA for Zalviso.
</FONT>
</P>
<P ID=PARA5469 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5468 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company and ARPI LLC continue to retain certain duties and obligations under the Amended License Agreement. These include the collection of the royalty and milestones amounts due and enforcement of related provisions under the Amended License Agreement, among others. In addition, the Company must prepare a quarterly distribution report relating to the Amended License Agreement, containing among other items, the amount of royalty and milestone payments received, reimbursable expenses and set-offs. The Company and ARPI LLC must also provide PDL with notice of certain communications, events or actions with respect to the Amended License Agreement and infringement of any underlying intellectual property.
</FONT>
</P>
<P ID=PARA5471 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5470 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company has significant continuing involvement in the Royalty Monetization primarily due to an obligation to act as the intermediary for the supply of Zalviso to
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gr&#252;nenthal. Under the relevant accounting guidance, because of its significant continuing involvement, the Royalty Monetization has been accounted for as a liability that will be amortized using the interest method over the life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	and milestone payments to be received by PDL and payments the Company is required to make to PDL, up to a capped amount of $195.0 million, over the life of the arrangement. The sum of the capped amount of $195.0 million, less the $61.2 million of net proceeds the Company received will be recorded as interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records interest expense. The Company&#8217;s estimate of the interest rate under the arrangement is based on the amount of royalty and milestone payments expected to be received by PDL over the life of the arrangement. The Company&#8217;s estimate of this total interest expense resulted in an effective annual interest rate of approximately 14%.
</FONT>
</P>
<P ID=PARA5473 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5472 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company will periodically assess the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, the Company will prospectively adjust the amortization of the liability and the interest rate.
</FONT>
</P>
<P ID=PARA5475 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK23 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR23 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM23 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-24
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage112"></A>
<DIV ID=PGHDR23 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA23.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA5474 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table shows the activity within the liability account during the year ended December 31, 2015 (in thousands):
<BR>
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE ID=TBL235 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL235.FINROW.1 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 85%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA219 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Liability related to sale of future royalties&#8212;beginning balance (as of December 31, 2014)
</FONT>
</P>
</TD>
<TD ID=TBL235.FINROW.1.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.1.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL235.FINROW.1.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL235.FINROW.1.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL235.FINROW.2 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA222 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net proceeds from sale of future royalties
</FONT>
</P>
</TD>
<TD ID=TBL235.FINROW.2.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.2.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.2.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	61,184
</TD>
<TD ID=TBL235.FINROW.2.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL235.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA224 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Non-cash interest expense recognized
</FONT>
</P>
</TD>
<TD ID=TBL235.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	2,428
</TD>
<TD ID=TBL235.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL235.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA226 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Payments from AcelRx to PDL
</FONT>
</P>
</TD>
<TD ID=TBL235.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL235.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL235.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.5.LEAD.B2 STYLE="BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.5.SYMB.B2 STYLE="BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.5.AMT.B2 STYLE="BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.5.TRAIL.B2 STYLE="BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL235.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA228 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total liability related to sale of future royalties as of December 31, 2015
</FONT>
</P>
</TD>
<TD ID=TBL235.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	63,612
</TD>
<TD ID=TBL235.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL235.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA230 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Less: current portion
</FONT>
</P>
</TD>
<TD ID=TBL235.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	118
</TD>
<TD ID=TBL235.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL235.FINROW.8 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.8.LEAD.B2 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.8.SYMB.B2 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.8.AMT.B2 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.8.TRAIL.B2 STYLE="BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL235.FINROW.9 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA232 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Liability related to sale of future royalties, less current portion
</FONT>
</P>
</TD>
<TD ID=TBL235.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL235.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL235.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	63,494
</TD>
<TD ID=TBL235.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5522 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5521 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As royalties are remitted to PDL from ARPI LLC, as described in Note&nbsp;1 &#8220;Organization and Summary of Significant Accounting Policies,&#8221; the balance of the liability will be effectively repaid over the life of the agreement. The Company will record non-cash royalty revenues and non-cash interest expense within its Consolidated Statements of Comprehensive Loss over the term of the Royalty Monetization.
</FONT>
</P>
<P ID=PARA5524 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5523 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	9. Warrants
</B>
</FONT>
</P>
<P ID=PARA5526 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5525 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Series A Warrants
</I>
</B>
</FONT>
</P>
<P ID=PARA5528 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5527 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December&nbsp;31, 2015, warrants to purchase 3,425 shares of common stock had not been exercised and were still outstanding. These warrants expire in March 2017.
</FONT>
</P>
<P ID=PARA5530 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5529 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Pinnacle Warrants
</I>
</B>
</FONT>
</P>
<P ID=PARA5532 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5531 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In February 2013, warrants to purchase 228,264 shares were net exercised, for 58,580 shares of common stock. As of December 31, 2015, no warrants to purchase shares of common stock issued to Pinnacle were outstanding.
</FONT>
</P>
<P ID=PARA5534 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5533 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Hercules Warrants
</I>
</B>
</FONT>
</P>
<P ID=PARA5536 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5535 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In connection with the Amended Loan Agreement, executed in December 2013, the Company issued warrants to Hercules which were exercisable for an aggregate of 176,730 shares of common stock with an exercise price of $6.79 per share, or the Warrants. In connection with Amendment No. 2 to the Amended Loan Agreement, the Company reduced the exercise price of the warrants already held by the Lenders from the previous exercise price of $6.79 per share to $3.88 per share, or the Warrant Amendments.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Each Warrant may be exercised on a cashless basis. The Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of five years from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the Warrants. The number of shares for which the Warrants are exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in the Warrants. The Company estimated the fair value of these Warrants as of the issuance date to be $1.1 million, which was used in the estimating the fair value of the amended debt instrument and was recorded as equity. The fair value of the Warrants was calculated using the Black-Scholes option-valuation model, and was based on the original strike price of $6.79, the stock price at issuance of $9.67, the five-year contractual term of the warrants, a risk-free interest rate of 1.55%, expected volatility of 71% and 0% expected dividend yield. The Company estimated the fair value of the modification of the Warrants, or the Warrant Amendments, as of the issuance date to be $0.1 million, which was used in estimating the fair value of the amended debt instrument and was recorded as equity.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA5537 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5539 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December 31, 2015, warrants to purchase 176,730 shares of common stock issued to Hercules had not been exercised and were still outstanding. These warrants expire in December 2018.
</FONT>
</P>
<P ID=PARA5541 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5540 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In connection with the Loan Agreement with Hercules, executed in June 2011, the Company issued to Hercules warrants to purchase an aggregate of 274,508 shares of common stock at a price of $3.06 per share, which were net exercised for 183,404 shares of common stock during the year ended December 31, 2013.
</FONT>
</P>
<P ID=PARA5543 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK24 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR24 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM24 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-25
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage113"></A>
<DIV ID=PGHDR24 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA24.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA5542 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	2012 Private Placement Warrants
</I>
</B>
</FONT>
</P>
<P ID=PARA5545 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5544 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In connection with the Private Placement, completed in June 2012, the Company issued PIPE warrants to purchase up to 2,630,103 shares of common stock. The per share exercise price of the PIPE warrants was $3.40 which equals the closing consolidated bid price of the Company&#8217;s common stock on May&nbsp;29, 2012, the effective date of the Purchase Agreement. The PIPE warrants issued in the Private Placement became exercisable six months after the issuance date, and expire on the five year anniversary of the initial exercisability date. Under the terms of the PIPE warrants, upon certain transactions, including a merger, tender offer, sale of all or substantially all of the assets of the Company or if a person or group shall become the owner of 50% of the Company&#8217;s issued and outstanding common stock, which is outside of the Company&#8217;s control, each PIPE warrant holder may elect to receive a cash payment in exchange for the warrant, in an amount determined by application of the Black-Scholes option-pricing model. Accordingly, the PIPE warrants were recorded as a liability at fair value, as determined by the Black-Scholes option-pricing model, and then marked to fair value each reporting period, with changes in estimated fair value recorded through the Consolidated Statements of Comprehensive Loss in interest income and other income (expense), net. The Black-Scholes assumptions used to value the PIPE warrants are disclosed in Note 2 &#8220;Investments and Fair Value Measurement.&#8221;
</FONT>
</P>
<P ID=PARA5547 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5546 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Upon execution of the Purchase Agreement, the fair value of the PIPE warrants was estimated to be $5.8 million, which was recorded as a liability. As of December 31, 2015, the fair value of the PIPE warrants was estimated to be $0.9 million. The change in fair value for the years ended December 31, 2015, and 2014, which was recorded as other income, was $2.1 million, and $7.0 million, respectively. The change in fair value for the year ended December&nbsp;31, 2013, which was recorded as other expense, was $14.1 million.
</FONT>
</P>
<P ID=PARA5549 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5548 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During the year ended December 31, 2015, PIPE warrants to purchase 847,058 shares were net exercised for 527,101 shares of common stock. During the year ended December 31, 2014, PIPE warrants to purchase 135,000 shares were net exercised for 91,488 shares of common stock. During the year ended December&nbsp;31, 2013, warrants to purchase 1,135,589 shares were net exercised, for 808,078 shares of common stock. As of December 31, 2015, PIPE warrants to purchase 512,456 shares of common stock issued in connection with the Private Placement had not been exercised and were outstanding. These warrants expire in November 2017.
</FONT>
</P>
<P ID=PARA5551 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5550 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	10. Commitments and Contingencies
</B>
</FONT>
</P>
<P ID=PARA5553 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5552 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Operating Leases
</I>
</B>
</FONT>
</P>
<P ID=PARA5555 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5554 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In December 2011, the Company entered into a non-cancelable lease agreement for approximately 13,787 square feet of office and laboratory facilities in Redwood City, California, which serve as the Company headquarters, effective April 2012. The lease agreement expires in May 2016. Rent expense from the facility lease is recognized on a straight-line basis from the inception of the lease in December 2011, the early access date, through the end of the lease.
</FONT>
</P>
<P ID=PARA5556 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5557 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In May 2014, the Company entered into an amendment, or the Lease Amendment, to that certain lease dated December 21, 2011, with Metropolitan Life Insurance Company, or the Existing Lease, for 13,787 square feet of space located at 301 Galveston Drive, Redwood City, California, or the Current Premises. Pursuant to the Lease Amendment, the term of the Existing Lease has been extended for a period of twenty (20) months and twenty-two (22) days and expiring January 31, 2018, or the Expiration Date, unless sooner terminated pursuant to the terms of the Existing Lease. In addition, the Lease Amendment included a new lease on an additional 12,106 square feet of office space, or the Expansion Space, which is adjacent to the current premises.&nbsp;The new lease for the Expansion Space has a term of 42 months commencing on August 1, 2014, and expiring on the Expiration Date. The Company has an option to extend the term of the Lease Amendment for an additional five years, which would commence upon the Expiration Date, at a market rate determined according to the Existing Lease.
</FONT>
</P>
<P ID=PARA5559 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5558 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On October 2, 2015, the Company executed an agreement to sublease 11,871 sq. of its Expansion Space located at 301 Galveston Drive, Redwood City, California for a term of 26 months commencing on December 1, 2015. The sublessee is entitled to abatement of the first two monthly installments of rent. Subsequent monthly installments of rent start at a rental rate of $2.05 per square foot (subject to agreed nominal increases). Upon the completion of the sublease, the Company has the option to take back the subleased space. Minimum rents expected to be received under this sublease are $0.3 million, $0.3 million and $0.0 million for the years ending December 31, 2016, 2017 and 2018, respectively.
</FONT>
</P>
<P ID=PARA5560 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5561 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Rent expense was $0.6 million, $0.5 million and $0.3 million during the years ended December&nbsp;31, 2015, 2014 and 2013, respectively.
</FONT>
</P>
<P ID=PARA5563 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK25 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR25 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM25 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-26
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage114"></A>
<DIV ID=PGHDR25 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA25.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA5562 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Future minimum payments under the lease agreement as of December&nbsp;31, 2015, are as follows (in thousands):
</FONT>
</P>
<P ID=PARA5564 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE ID=TBL5579 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 85%; MARGIN-LEFT: 7.5%; MARGIN-RIGHT: 7.5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5579.FINROW.1 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 82%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5565 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Year Ending December 31:
</FONT>
</P>
</TD>
<TD ID=TBL5579.FINROW.1.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5579.FINROW.1.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5579.FINROW.1.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5579.FINROW.1.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5579.FINROW.2 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5567 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2016
</FONT>
</P>
</TD>
<TD ID=TBL5579.FINROW.2.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5579.FINROW.2.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 10.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5579.FINROW.2.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.6PT; BACKGROUND-COLOR: #FFFFFF">
	717
</TD>
<TD ID=TBL5579.FINROW.2.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5579.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5569 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2017
</FONT>
</P>
</TD>
<TD ID=TBL5579.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5579.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5579.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	737
</TD>
<TD ID=TBL5579.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5579.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5571 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2018
</FONT>
</P>
</TD>
<TD ID=TBL5579.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5579.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5579.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	62
</TD>
<TD ID=TBL5579.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5579.FINROW.6 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5575 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total minimum payments
</FONT>
</P>
</TD>
<TD ID=TBL5579.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5579.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5579.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.6PT; BACKGROUND-COLOR: #CCEEFF">
	1,516
</TD>
<TD ID=TBL5579.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5581 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5580 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In addition, the Company will pay the Landlord specified percentages of certain operating expenses and taxes related to the leased facility incurred by the Landlord.
</FONT>
</P>
<P ID=PARA5583 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5582 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Litigation
</I>
</B>
</FONT>
</P>
<P ID=PARA5585 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA156 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On October 1, 2014, a securities class action complaint was filed in the U.S. District Court for the Northern District of California against AcelRx and certain of its current and former officers. On April 17, 2015, lead plaintiff filed an amended complaint. The amended complaint alleged that between September 30, 2013 and July 25, 2014, AcelRx and certain of its current and former officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 in connection with statements related to our lead drug candidate, Zalviso. On November 25, 2015, the Court granted the Company&#8217;s Motion to Dismiss. Plaintiffs had the opportunity to file an amended complaint within 30 days&#8217; which they declined to do. On January 18, 2016, the Court issued an order dismissing the case with prejudice. From time to time the Company may be involved in additional legal proceedings arising in the ordinary course of business. The Company does not have contingent liabilities established for any litigation matters.
</FONT>
</P>
<P ID=PARA5587 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA5588 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	11. Stockholders&#8217; Equity
</B>
</FONT>
</P>
<P ID=PARA5590 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5589 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Common Stock
</I>
</B>
</FONT>
</P>
<P ID=PARA5592 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5591 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Public Offerings
</I>
</FONT>
</P>
<P ID=PARA5594 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5593 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On July&nbsp;23, 2013, AcelRx completed an underwritten public offering of 4,370,000 shares of common stock, at a price of $11.65 per share to the public. The total gross proceeds of this offering were $50.9 million with net proceeds to AcelRx of $47.9 million after deducting underwriting discounts and commissions and other expenses payable by AcelRx.
</FONT>
</P>
<P ID=PARA5596 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5595 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Private Placement Offering
</I>
</FONT>
</P>
<P ID=PARA5598 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5597 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On June&nbsp;1, 2012, or the Issuance Date, the Company issued an aggregate of 2,922,337 shares of common stock and warrants to purchase up to 2,630,103 shares of common stock, or the PIPE warrants, for aggregate gross proceeds of $10.0 million, or the Private Placement. Costs related to the offering were $0.9 million.&nbsp;The shares of common stock and PIPE warrants issued in the Private Placement were sold pursuant to a Securities Purchase Agreement, or Purchase Agreement, dated May&nbsp;29, 2012, between the Company and certain purchasers, including certain entities affiliated with Mark Wan and Stephen J. Hoffman, members of the Company&#8217;s board of directors. Pursuant to the Purchase Agreement, AcelRx sold shares of common stock and PIPE warrants to purchase common stock in immediately separable &#8220;Units,&#8221; with each Unit consisting of (i)&nbsp;one share of common stock and (ii)&nbsp;a PIPE warrant to purchase 0.9 of a share of common stock. The per share exercise price of the PIPE warrants was $3.40. The offering price per Unit was $3.40 for non-affiliated investors, and $3.5125 for affiliated investors, which equals the sum of (i)&nbsp;$3.40, the closing consolidated bid price of the Company&#8217;s common stock on May&nbsp;29, 2012, plus (ii)&nbsp;$0.1125 (which is equal to $0.125 per PIPE warrant share, multiplied by 0.9), for an aggregate amount of $10.0 million. The PIPE warrants issued in the Private Placement became exercisable six months after the Issuance Date, and expire on the five year anniversary of the initial exercisability date.
</FONT>
</P>
<P ID=PARA5600 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5599 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In connection with the Private Placement, the Company filed a registration statement with the U.S. Securities and Exchange Commission, or SEC, registering for resale the shares of common stock and shares of common stock issuable upon exercise of the warrants sold in the Private Placement. The registration statement was declared effective by the SEC in July 2012.
</FONT>
</P>
<P ID=PARA5602 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK26 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR26 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM26 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-27
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage115"></A>
<DIV ID=PGHDR26 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA26.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA5601 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Stock Plans
</I>
</B>
</FONT>
</P>
<P ID=PARA5604 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5603 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	2006 Stock Plan
</I>
</FONT>
</P>
<P ID=PARA5606 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5605 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In August 2006, the Company established the 2006 Plan in which 342,000 shares of common stock were originally reserved for the issuance of incentive stock options, or ISOs, and nonstatutory stock options, or NSOs, to employees, directors or consultants of the Company. In February 2008, an additional 375,000 shares of common stock were reserved for issuance under the 2006 Plan and, in November 2009, an additional 1,376,059 shares of common stock were reserved for issuance under the 2006 Plan. Per the 2006 Plan, the exercise price of ISOs and NSOs granted to a stockholder who at the time of grant owns stock representing more than 10% of the voting power of all classes of the stock of the Company could not be less than 110% of the fair value per share of the underlying common stock on the date of grant. Effective upon the execution and delivery of the underwriting agreement for the Company&#8217;s IPO, no additional stock options or other stock awards may be granted under the 2006 Plan.
</FONT>
</P>
<P ID=PARA5608 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5607 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	2011 Equity Incentive Plan
</I>
</FONT>
</P>
<P ID=PARA5610 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5609 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In January 2011, the board of directors adopted, and the Company&#8217;s stockholders approved, the 2011 Equity Incentive Plan, or 2011 Incentive Plan, as a successor to the 2006 Plan. The 2011 Incentive Plan became effective immediately upon the execution and delivery of the underwriting agreement for the IPO on February&nbsp;10, 2011. As of February&nbsp;10, 2011, no more awards may be granted under the 2006 Plan, although all outstanding stock options and other stock awards previously granted under the 2006 Plan will continue to remain subject to the terms of the 2006 Plan. The 51,693 shares reserved under the 2006 Plan that remained available for future grant at the time of the IPO were transferred to the share reserve of the 2011 Incentive Plan.
</FONT>
</P>
<P ID=PARA5612 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5611 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The initial aggregate number of shares of the Company&#8217;s common stock that may be issued pursuant to stock awards under the 2011 Incentive Plan is 1,875,000 shares, which number was the sum of (i)&nbsp;51,693 shares remaining available for future grant under the 2006 Plan at the time of the execution and delivery of the underwriting agreement for the Company&#8217;s IPO, and (ii)&nbsp;an additional 1,823,307 new shares. Then, the number of shares of common stock reserved for issuance under the 2011 Incentive Plan will automatically increase on January&nbsp;1st each year, starting on January&nbsp;1, 2012 and continuing through January&nbsp;1, 2020, by 4% of the total number of shares of the Company&#8217;s common stock outstanding on December&nbsp;31 of the preceding calendar year, or such lesser number of shares of common stock as determined by the board of directors. The term of the option is determined by the board of directors on the date of grant but shall not be longer than 10 years. Options under the 2011 Equity Incentive Plan generally vest over four years, and all options expire after 10 years. The Company issues new shares for settlement of vested restricted stock units and exercises of stock options. The Company does not have a policy of purchasing its shares relating to its share-based programs.
</FONT>
</P>
<P ID=PARA5614 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5613 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5615 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	2011 Employee Stock Purchase Plan
</I>
</FONT>
</P>
<P ID=PARA5617 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5616 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additionally, in January 2011, the board of directors adopted, and the Company&#8217;s stockholders approved, the 2011 Employee Stock Purchase Plan, or the ESPP, which also became effective immediately upon the execution and delivery of the underwriting agreement for the IPO.
</FONT>
</P>
<P ID=PARA5619 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5618 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Initially, 250,000 shares of the Company&#8217;s common stock were authorized for issuance under the ESPP pursuant to purchase rights granted to the Company&#8217;s employees or to employees of any of its designated affiliates. The number of shares of the Company&#8217;s common stock reserved for issuance will automatically increase on January&nbsp;1st each year, starting January&nbsp;1, 2012 and continuing through January&nbsp;1, 2020, in an amount equal to the lower of (1)&nbsp;2% of the total number of shares of the Company&#8217;s common stock outstanding on December&nbsp;31 of the preceding calendar year, or (2)&nbsp;a number of shares of common stock as determined by the board of directors. If a purchase right granted under the ESPP terminates without having been exercised, the shares of the Company&#8217;s common stock not purchased under such purchase right will be available for issuance under the ESPP.
</FONT>
</P>
<P ID=PARA5621 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5620 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December&nbsp;31, 2015, 350,148 shares have been issued to employees and there are 291,207&nbsp;shares available for issuance under the ESPP. The weighted average fair value of shares issued under the ESPP in 2015, 2014 and 2013 was $4.48, $4.35 and $3.97 per share, respectively.
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In January 2016, an additional 904,953 shares were authorized for issuance under the 2011 Employee Stock Purchase Plan.
</FONT>
</P>
<P ID=PARA5623 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK27 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR27 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM27 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-28
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage116"></A>
<DIV ID=PGHDR27 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA27.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA5622 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	12. Stock-Based Compensation
</B>
</FONT>
</P>
<P ID=PARA5625 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5624 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company recorded total stock-based compensation expense for stock options, stock awards and the ESPP as follows
<BR>
	(in thousands):
</FONT>
</P>
<P ID=PARA5626 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE ID=TBL5703 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5703.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5703.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5703.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5629 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	December 31,
<BR>
	2015
</B>
</FONT>
</P>
</TD>
<TD ID=TBL5703.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5703.FINROW.1.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5703.FINROW.1.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5631 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	December 31,
<BR>
	2014
</B>
</FONT>
</P>
</TD>
<TD ID=TBL5703.FINROW.1.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5703.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5703.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5633 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	December 31,
<BR>
	2013
</B>
</FONT>
</P>
</TD>
<TD ID=TBL5703.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5703.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 55%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5635 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Cost of goods sold
</FONT>
</P>
</TD>
<TD ID=TBL5703.FINROW.2.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.2.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5703.FINROW.2.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	67
</TD>
<TD ID=TBL5703.FINROW.2.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.2.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.2.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5703.FINROW.2.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5703.FINROW.2.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.2.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.2.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5703.FINROW.2.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5703.FINROW.2.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5703.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5646 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Research and development
</FONT>
</P>
</TD>
<TD ID=TBL5703.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	2,587
</TD>
<TD ID=TBL5703.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	2,252
</TD>
<TD ID=TBL5703.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	1,657
</TD>
<TD ID=TBL5703.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5703.FINROW.4>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5657 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	General and administrative
</FONT>
</P>
</TD>
<TD ID=TBL5703.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	2,356
</TD>
<TD ID=TBL5703.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	2,188
</TD>
<TD ID=TBL5703.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	1,822
</TD>
<TD ID=TBL5703.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5703.FINROW.5>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5684 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total
</FONT>
</P>
</TD>
<TD ID=TBL5703.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5703.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	5,010
</TD>
<TD ID=TBL5703.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5703.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	4,440
</TD>
<TD ID=TBL5703.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5703.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5703.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	3,479
</TD>
<TD ID=TBL5703.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5704 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5705 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table summarizes option activity under the 2011 Plan and 2006 Plan:
</FONT>
</P>
<P ID=PARA5706 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE ID=TBL5769 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5769.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<B>
	Number
<BR>
	of Stock Options
<BR>
	Outstanding
</B>
</TD>
<TD ID=TBL5769.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.1.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.1.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Weighted-
<BR>
	Average
<BR>
	Exercise
<BR>
	Price
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL5769.FINROW.1.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Weighted-
<BR>
	Average
<BR>
	Remaining
<BR>
	Contractual
<BR>
	Life (Years)
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL5769.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Aggregate
<BR>
	Intrinsic
<BR>
	Value
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL5769.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5769.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5769.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT" COLSPAN=2>
<B>
	(in thousands)
</B>
</TD>
<TD ID=TBL5769.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5769.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 52%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5720 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	December 31, 2014
</FONT>
</P>
</TD>
<TD ID=TBL5769.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	6,366,763
</TD>
<TD ID=TBL5769.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5769.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	5.74
</TD>
<TD ID=TBL5769.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.3.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5769.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5724 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Granted
</FONT>
</P>
</TD>
<TD ID=TBL5769.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	560,500
</TD>
<TD ID=TBL5769.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	4.28
</TD>
<TD ID=TBL5769.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.4.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5769.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5729 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Forfeited
</FONT>
</P>
</TD>
<TD ID=TBL5769.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.3PT; BACKGROUND-COLOR: #CCEEFF">
	(997,099
</TD>
<TD ID=TBL5769.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL5769.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 13.5PT; BACKGROUND-COLOR: #CCEEFF">
	7.22
</TD>
<TD ID=TBL5769.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.5.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5769.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5734 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Expired
</FONT>
</P>
</TD>
<TD ID=TBL5769.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.3PT; BACKGROUND-COLOR: #FFFFFF">
	(372,718
</TD>
<TD ID=TBL5769.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL5769.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 13.5PT; BACKGROUND-COLOR: #FFFFFF">
	6.19
</TD>
<TD ID=TBL5769.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.6.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5769.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 18PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5739 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Exercised
</FONT>
</P>
</TD>
<TD ID=TBL5769.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.3PT; BACKGROUND-COLOR: #CCEEFF">
	(938,497
</TD>
<TD ID=TBL5769.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL5769.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 13.5PT; BACKGROUND-COLOR: #CCEEFF">
	2.95
</TD>
<TD ID=TBL5769.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.7.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5769.FINROW.9 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5749 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	December 31, 2015
</FONT>
</P>
</TD>
<TD ID=TBL5769.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	4,618,949
</TD>
<TD ID=TBL5769.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 13.5PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5769.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 13.5PT; BACKGROUND-COLOR: #FFFFFF">
	5.77
</TD>
<TD ID=TBL5769.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #FFFFFF">
	7.3
</TD>
<TD ID=TBL5769.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.9.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.9.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 18.15PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5769.FINROW.9.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18.15PT; BACKGROUND-COLOR: #FFFFFF">
	1,079
</TD>
<TD ID=TBL5769.FINROW.9.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 0PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5769.FINROW.11 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5759 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Vested and exercisable options&#8212;December 31, 2015
</FONT>
</P>
</TD>
<TD ID=TBL5769.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	2,919,289
</TD>
<TD ID=TBL5769.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 13.5PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5769.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 13.5PT; BACKGROUND-COLOR: #CCEEFF">
	5.14
</TD>
<TD ID=TBL5769.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.11.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.11.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.11.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #CCEEFF">
	6.5
</TD>
<TD ID=TBL5769.FINROW.11.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.11.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.11.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 18.15PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5769.FINROW.11.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18.15PT; BACKGROUND-COLOR: #CCEEFF">
	1,036
</TD>
<TD ID=TBL5769.FINROW.11.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5769.FINROW.12 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5764 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Vested and expected to vest&#8212;December 31, 2015
</FONT>
</P>
</TD>
<TD ID=TBL5769.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	4,523,784
</TD>
<TD ID=TBL5769.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 13.5PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5769.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 13.5PT; BACKGROUND-COLOR: #FFFFFF">
	5.75
</TD>
<TD ID=TBL5769.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.12.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.12.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.12.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #FFFFFF">
	7.2
</TD>
<TD ID=TBL5769.FINROW.12.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.12.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5769.FINROW.12.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 18.15PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5769.FINROW.12.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 9%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 18.15PT; BACKGROUND-COLOR: #FFFFFF">
	1,076
</TD>
<TD ID=TBL5769.FINROW.12.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5771 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5770 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December&nbsp;31, 2015, there were 2,654,302 shares available for future grant under the 2011 Plan. In January 2016, an additional 1,809,906 shares were authorized for issuance under the 2011 Incentive Plan.
</FONT>
</P>
<P ID=PARA5773 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5772 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Additional information regarding the Company&#8217;s stock options outstanding and vested and exercisable as of December&nbsp;31, 2015 is summarized below:
</FONT>
</P>
<P ID=PARA5774 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE ID=TBL5834 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5834.FINROW.1>
<TD ID=TBL5834.FINROW.1.SYMB.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5834.FINROW.1.SYMB.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.1.SYMB.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.1.AMT.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5834.FINROW.1.TRAIL.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5834.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 35%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=10>
<P ID=PARA5776 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Options Outstanding
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5834.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.1.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.1.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 18%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=6>
<P ID=PARA5778 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Options Vested and Exercisable
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5834.FINROW.1.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5834.FINROW.2>
<TD ID=TBL5834.FINROW.2.AMT.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 6%; VERTICAL-ALIGN: BOTTOM" COLSPAN=4>
<P ID=PARA5780 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<U>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exercise Prices
</B>
</FONT>
</U>
</P>
</TD>
<TD ID=TBL5834.FINROW.2.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5782 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Number of
<BR>
	Stock Options
<BR>
	Outstanding
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5834.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 7.2PT" COLSPAN=2>
<P ID=PARA5784 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Weighted-Average
<BR>
	Remaining
<BR>
	Contractual Life
<BR>
	(Years)
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5834.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 7.2PT" COLSPAN=2>
<P ID=PARA5786 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Weighted-Average
<BR>
	Exercise Price per
<BR>
	Share
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5834.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5788 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Shares Subject
<BR>
	to Stock
<BR>
	Options
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5834.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.2.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.2.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 7.2PT" COLSPAN=2>
<P ID=PARA5790 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Weighted-Average
<BR>
	Exercise Price per
<BR>
	Share
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5834.FINROW.2.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR ID=TBL5834.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD ID=TBL5834.FINROW.3.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5834.FINROW.3.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	1.20
</TD>
<TD ID=TBL5834.FINROW.3.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF">
	-
</TD>
<TD ID=TBL5834.FINROW.3.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
	$2.56
</TD>
<TD ID=TBL5834.FINROW.3.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	463,444
</TD>
<TD ID=TBL5834.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #CCEEFF">
	4.1
</TD>
<TD ID=TBL5834.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5834.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	2.33
</TD>
<TD ID=TBL5834.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.25PT; BACKGROUND-COLOR: #CCEEFF">
	463,444
</TD>
<TD ID=TBL5834.FINROW.3.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.3.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5834.FINROW.3.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	2.33
</TD>
<TD ID=TBL5834.FINROW.3.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5834.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD ID=TBL5834.FINROW.4.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5834.FINROW.4.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	3.11
</TD>
<TD ID=TBL5834.FINROW.4.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF">
	-
</TD>
<TD ID=TBL5834.FINROW.4.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
	$4.73
</TD>
<TD ID=TBL5834.FINROW.4.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	1,396,208
</TD>
<TD ID=TBL5834.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #FFFFFF">
	7.0
</TD>
<TD ID=TBL5834.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5834.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #FFFFFF">
	3.67
</TD>
<TD ID=TBL5834.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.25PT; BACKGROUND-COLOR: #FFFFFF">
	1,033,204
</TD>
<TD ID=TBL5834.FINROW.4.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.4.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5834.FINROW.4.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #FFFFFF">
	3.56
</TD>
<TD ID=TBL5834.FINROW.4.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5834.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD ID=TBL5834.FINROW.5.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5834.FINROW.5.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	5.31
</TD>
<TD ID=TBL5834.FINROW.5.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF">
	-
</TD>
<TD ID=TBL5834.FINROW.5.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #CCEEFF">
	$8.18
</TD>
<TD ID=TBL5834.FINROW.5.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	1,820,297
</TD>
<TD ID=TBL5834.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #CCEEFF">
	7.7
</TD>
<TD ID=TBL5834.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5834.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	5.92
</TD>
<TD ID=TBL5834.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.25PT; BACKGROUND-COLOR: #CCEEFF">
	948,650
</TD>
<TD ID=TBL5834.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.5.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5834.FINROW.5.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	5.64
</TD>
<TD ID=TBL5834.FINROW.5.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5834.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD ID=TBL5834.FINROW.6.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5834.FINROW.6.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	10.22
</TD>
<TD ID=TBL5834.FINROW.6.SYMB.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF">
	-
</TD>
<TD ID=TBL5834.FINROW.6.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 12PT; BACKGROUND-COLOR: #FFFFFF">
	$10.55
</TD>
<TD ID=TBL5834.FINROW.6.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #FFFFFF">
	939,000
</TD>
<TD ID=TBL5834.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #FFFFFF">
	8.3
</TD>
<TD ID=TBL5834.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5834.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #FFFFFF">
	10.33
</TD>
<TD ID=TBL5834.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.25PT; BACKGROUND-COLOR: #FFFFFF">
	473,991
</TD>
<TD ID=TBL5834.FINROW.6.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.6.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5834.FINROW.6.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #FFFFFF">
	10.35
</TD>
<TD ID=TBL5834.FINROW.6.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5834.FINROW.8 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD ID=TBL5834.FINROW.8.SYMB.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.SYMB.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.SYMB.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.AMT.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 8%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.TRAIL.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.8PT; BACKGROUND-COLOR: #CCEEFF">
	4,618,949
</TD>
<TD ID=TBL5834.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #CCEEFF">
	7.3
</TD>
<TD ID=TBL5834.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5834.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	5.77
</TD>
<TD ID=TBL5834.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 12.25PT; BACKGROUND-COLOR: #CCEEFF">
	2,919,289
</TD>
<TD ID=TBL5834.FINROW.8.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5834.FINROW.8.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5834.FINROW.8.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 25.9PT; BACKGROUND-COLOR: #CCEEFF">
	5.14
</TD>
<TD ID=TBL5834.FINROW.8.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5836 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5835 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The weighted average grant-date fair value of options granted during the years ended December&nbsp;31, 2015, 2014 and 2013 was $2.69, $5.57 and $4.15 per share, respectively. As of December&nbsp;31, 2015, total stock-based compensation expense related to unvested options to be recognized in future periods was $7.3 million which is expected to be recognized over a weighted-average period of 2.3 years. The grant date fair value of shares vested during the years ended December&nbsp;31, 2015, 2014 and 2013 was $5.4 million, $3.2 million and $1.9 million, respectively. The total intrinsic value of options exercised during the years ended December&nbsp;31, 2015, 2014 and 2013 was $1.3 million, $2.3 million and $3.6&nbsp;million, respectively.
</FONT>
</P>
<P ID=PARA5838 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA5839 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company used the following assumptions to calculate the fair value of each employee stock option:
</FONT>
</P>
<P ID=PARA5840 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE ID=TBL5867 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 95%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5867.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5867.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5867.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 51%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 7.2PT" COLSPAN=16>
<P ID=PARA5842 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5867.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5867.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5867.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5867.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 7.2PT" COLSPAN=4>
<P ID=PARA5845 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5867.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5867.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5867.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 7.2PT" COLSPAN=4>
<P ID=PARA5847 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5867.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5867.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5867.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 7.2PT" COLSPAN=4>
<P ID=PARA5849 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 0PT 0PT 7.2PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL5867.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5867.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5851 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Expected term (in years)
</FONT>
</P>
</TD>
<TD ID=TBL5867.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	5.25
</TD>
<TD ID=TBL5867.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF">
	-
</TD>
<TD ID=TBL5867.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #CCEEFF">
	6.25
</TD>
<TD ID=TBL5867.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	5.25
</TD>
<TD ID=TBL5867.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF">
	-
</TD>
<TD ID=TBL5867.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 4.15PT; BACKGROUND-COLOR: #CCEEFF">
	6.25
</TD>
<TD ID=TBL5867.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	5.75
</TD>
<TD ID=TBL5867.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF">
	-
</TD>
<TD ID=TBL5867.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #CCEEFF">
	6.25
</TD>
<TD ID=TBL5867.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5867.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5855 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Risk-free interest rate
</FONT>
</P>
</TD>
<TD ID=TBL5867.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF">
	1.35%
</TD>
<TD ID=TBL5867.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF">
	-
</TD>
<TD ID=TBL5867.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #FFFFFF">
	1.82%
</TD>
<TD ID=TBL5867.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF">
	1.76%
</TD>
<TD ID=TBL5867.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF">
	-
</TD>
<TD ID=TBL5867.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #FFFFFF">
	1.92%
</TD>
<TD ID=TBL5867.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #FFFFFF">
	1.02%
</TD>
<TD ID=TBL5867.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF">
	-
</TD>
<TD ID=TBL5867.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #FFFFFF">
	2.96%
</TD>
<TD ID=TBL5867.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5867.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5859 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Expected volatility
</FONT>
</P>
</TD>
<TD ID=TBL5867.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF">
	72%
</TD>
<TD ID=TBL5867.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; BACKGROUND-COLOR: #CCEEFF">
	69
</TD>
<TD ID=TBL5867.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF">
	-
</TD>
<TD ID=TBL5867.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: LEFT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #CCEEFF">
	72%
</TD>
<TD ID=TBL5867.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF">
	80%
</TD>
<TD ID=TBL5867.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5867.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5863 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Expected dividend rate
</FONT>
</P>
</TD>
<TD ID=TBL5867.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF">
	0%
</TD>
<TD ID=TBL5867.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF">
	0%
</TD>
<TD ID=TBL5867.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 3%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #FFFFFF">
	0%
</TD>
<TD ID=TBL5867.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 7.2PT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5867.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5869 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK30 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR30 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM30 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-29
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage117"></A>
<DIV ID=PGHDR30 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA30.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA5868 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<I>
	Restricted Stock Units
</I>
</FONT>
</P>
<P ID=PARA5871 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5870 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	In March 2011, the Company granted 343,815 Restricted Stock Units, or RSUs, to employees and directors under the 2011 Plan at a grant date fair value of $3.45. The fair value of the RSUs was determined on the date of grant based on the market price of the Company&#8217;s common stock. RSUs are recognized as expense ratably over the vesting period and the Company&#8217;s RSU&#8217;s generally vest over three years as follows: 25% on the 6 month anniversary of the vesting commencement date, 25% on the 12 month anniversary of the vesting commencement date, 25% on the 24 month anniversary of the vesting commencement date and 25% on the 36 month anniversary of the vesting commencement date, so long as the RSU recipient continues to provide services to the Company. As of December&nbsp;31, 2015 and 2014, there were no RSUs outstanding. The expense related to RSUs during the years ended December&nbsp;31, 2015, 2014 and 2013 was $0, $56,000 and $290,000, respectively.
</FONT>
</P>
<P ID=PARA5873 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5872 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	13. Restructuring Costs
</B>
</FONT>
</P>
<P ID=PARA5875 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5874 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On March 19, 2015, the Board of Directors of the Company, in connection with its efforts to reduce operating costs, conserve capital, focus the Company&#39;s financial and development resources on working with the FDA to seek marketing approval for Zalviso, and continuing development of ARX-04, implemented a cost reduction plan. The cost reduction plan reduced the Company&#8217;s workforce by 19 employees, approximately 36% of total headcount, in the first quarter of 2015. Employee termination benefits related to this restructuring, are charged to restructuring costs in the Consolidated Statements of Comprehensive Loss.
</FONT>
</P>
<P ID=PARA5877 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA5878 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company recorded restructuring costs as follows (in thousands):
</FONT>
</P>
<P ID=PARA5879 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<TABLE ID=TBL5903 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 80%; MARGIN-LEFT: 10%; MARGIN-RIGHT: 10%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5903.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5903.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5903.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5883 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	December 31, 2015
</B>
</FONT>
</P>
</TD>
<TD ID=TBL5903.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5903.FINROW.2 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 81%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5885 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Employee termination benefits
</FONT>
</P>
</TD>
<TD ID=TBL5903.FINROW.2.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5903.FINROW.2.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5903.FINROW.2.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	756
</TD>
<TD ID=TBL5903.FINROW.2.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5903.FINROW.3 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5894 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total restructuring costs
</FONT>
</P>
</TD>
<TD ID=TBL5903.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5903.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5903.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 16%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	756
</TD>
<TD ID=TBL5903.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5904 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5905 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table presents activities related to the cost reduction plan for the year ended December 31, 2015 (in thousands):&nbsp;
</FONT>
</P>
<P STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<TABLE ID=TBL5928 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 85%; MARGIN-RIGHT: 15%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL5928.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5928.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL5928.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5908 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Employee severance and related costs
</B>
</FONT>
</P>
</TD>
<TD ID=TBL5928.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL5928.FINROW.2 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 82%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5911 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Balance of restructuring liability at December 31, 2014
</FONT>
</P>
</TD>
<TD ID=TBL5928.FINROW.2.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5928.FINROW.2.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL5928.FINROW.2.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL5928.FINROW.2.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5928.FINROW.3 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5917 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Charges
</FONT>
</P>
</TD>
<TD ID=TBL5928.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5928.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5928.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	756
</TD>
<TD ID=TBL5928.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL5928.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5921 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Payments
</FONT>
</P>
</TD>
<TD ID=TBL5928.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5928.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL5928.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(756
</TD>
<TD ID=TBL5928.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA5924 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL5928.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5925 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Balance of restructuring liability at December 31, 2015
</FONT>
</P>
</TD>
<TD ID=TBL5928.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL5928.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL5928.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL5928.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA5929 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5930 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The restructuring liability has been fully disbursed as of December 31, 2015.
</FONT>
</P>
<P ID=PARA5932 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5931 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	14. Net Loss per Share of Common Stock
</B>
</FONT>
</P>
<P ID=PARA5934 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5933 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company&#8217;s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive.
</FONT>
</P>
<P ID=PARA5936 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA5935 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	During the years ended December 31, 2015 and 2014, the PIPE warrants had a dilutive impact to net loss per share due to a lower share price at December 31, 2015 and 2014, compared to the closing share price on December&nbsp;31, 2014 and 2013, respectively. The decrease in share price created a lower Black-Scholes value and lower liability for the PIPE warrants, which resulted in other income during the years ended December 31, 2015 and 2014. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the PIPE warrants and the presumed exercise of such securities are dilutive to loss per share for the period, adjustments to net loss used in the calculation are required to remove the change in fair value of the PIPE warrants for the period. Likewise, adjustments to the denominator are required to reflect the related dilutive shares.
</FONT>
</P>
<P ID=PARA5937 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK31 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR31 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM31 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-30
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage118"></A>
<DIV ID=PGHDR31 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA31.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA5938 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table is a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations for the years ended December&nbsp;31, 2015, 2014 and 2013:
</FONT>
</P>
<P ID=PARA5939 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<TABLE ID=TBL6078 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; MARGIN-LEFT: 5%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL6078.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=10>
<P ID=PARA5942 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Years Ended December 31,
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5946 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2015
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5949 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2014
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA5952 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2013
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.3>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.3.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.3.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=10>
<P ID=PARA5956 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(in thousands, except share and per share amounts)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.3.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5958 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Numerator:
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.4.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.4.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5962 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss used to compute net loss per share
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.5.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.5.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.6 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5966 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Basic
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6078.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(24,399
</TD>
<TD ID=TBL6078.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA5970 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6078.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(33,353
</TD>
<TD ID=TBL6078.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA5974 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6078.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(23,426
</TD>
<TD ID=TBL6078.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA5978 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6078.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 45PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA5979 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Adjustments for change in fair value of warrant liability
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(2,120
</TD>
<TD ID=TBL6078.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
<P ID=PARA5983 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(6,988
</TD>
<TD ID=TBL6078.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
<P ID=PARA5987 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6078.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.8 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA5992 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Diluted
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6078.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(26,519
</TD>
<TD ID=TBL6078.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA5996 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6078.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(40,341
</TD>
<TD ID=TBL6078.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA6000 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6078.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(23,426
</TD>
<TD ID=TBL6078.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA6004 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6078.FINROW.9 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6005 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Denominator:
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.9.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.9.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.10 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA6009 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Weighted average shares outstanding used to compute net loss per share:
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.10.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.10.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.11 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6013 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Basic
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	44,300,099
</TD>
<TD ID=TBL6078.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	43,427,111
</TD>
<TD ID=TBL6078.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.11.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.11.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.11.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	39,746,678
</TD>
<TD ID=TBL6078.FINROW.11.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.12 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 45PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6026 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Dilutive effect of warrants
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.12.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.12.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.12.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	168,341
</TD>
<TD ID=TBL6078.FINROW.12.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.12.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.12.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.12.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	895,186
</TD>
<TD ID=TBL6078.FINROW.12.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.12.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.12.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.12.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL6078.FINROW.12.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.13 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6039 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Diluted
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.13.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.13.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.13.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	44,468,440
</TD>
<TD ID=TBL6078.FINROW.13.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.13.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.13.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.13.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	44,322,297
</TD>
<TD ID=TBL6078.FINROW.13.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.13.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.13.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.13.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	39,746,678
</TD>
<TD ID=TBL6078.FINROW.13.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6078.FINROW.14 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6052 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss per share&#8212;basic
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.14.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.14.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6078.FINROW.14.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(0.55
</TD>
<TD ID=TBL6078.FINROW.14.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA6056 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.14.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.14.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6078.FINROW.14.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(0.77
</TD>
<TD ID=TBL6078.FINROW.14.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA6060 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.14.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.14.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6078.FINROW.14.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	(0.59
</TD>
<TD ID=TBL6078.FINROW.14.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
<P ID=PARA6064 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6078.FINROW.15 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6065 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net loss per share&#8212;diluted
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.15.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.15.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6078.FINROW.15.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(0.60
</TD>
<TD ID=TBL6078.FINROW.15.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
<P ID=PARA6069 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.15.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.15.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6078.FINROW.15.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(0.91
</TD>
<TD ID=TBL6078.FINROW.15.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
<P ID=PARA6073 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
<TD ID=TBL6078.FINROW.15.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6078.FINROW.15.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6078.FINROW.15.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF">
	(0.59
</TD>
<TD ID=TBL6078.FINROW.15.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
<P ID=PARA6077 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	)
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA6080 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6079 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive:
</FONT>
</P>
<P ID=PARA6081 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<TABLE ID=TBL6108 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 95%; MARGIN-LEFT: 2.5%; MARGIN-RIGHT: 2.5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL6108.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6108.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6108.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=10>
<P ID=PARA6083 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6108.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6108.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6108.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6108.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6086 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6108.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6108.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6108.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6088 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6108.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6108.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6108.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6090 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 6.5PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6108.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6108.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 52%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6092 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ESPP and stock options to purchase common stock
</FONT>
</P>
</TD>
<TD ID=TBL6108.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	4,699,121
</TD>
<TD ID=TBL6108.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	6,411,003
</TD>
<TD ID=TBL6108.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	4,988,459
</TD>
<TD ID=TBL6108.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6108.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6096 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Restricted Stock Units
</FONT>
</P>
</TD>
<TD ID=TBL6108.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6108.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6108.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	65,765
</TD>
<TD ID=TBL6108.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6108.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6100 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Convertible debt into common stock
</FONT>
</P>
</TD>
<TD ID=TBL6108.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	553,763
</TD>
<TD ID=TBL6108.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	553,763
</TD>
<TD ID=TBL6108.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	553,763
</TD>
<TD ID=TBL6108.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6108.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6104 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Common stock warrants
</FONT>
</P>
</TD>
<TD ID=TBL6108.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	180,155
</TD>
<TD ID=TBL6108.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	180,155
</TD>
<TD ID=TBL6108.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6108.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	1,674,669
</TD>
<TD ID=TBL6108.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA6109 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	&nbsp;
</B>
</FONT>
</P>
<P ID=PARA6110 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	15. Accrued Liabilities
</B>
</FONT>
</P>
<P ID=PARA6112 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6111 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accrued liabilities consist of the following (in thousands):
</FONT>
</P>
<P ID=PARA6113 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<TABLE ID=TBL6143 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 95%; MARGIN-LEFT: 2.5%; MARGIN-RIGHT: 2.5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL6143.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6143.FINROW.1.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6143.FINROW.1.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=6>
<P ID=PARA6115 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6143.FINROW.1.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6143.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6143.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6143.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6118 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6143.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6143.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6143.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6120 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6143.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6143.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 68%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6122 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accrued compensation and employee benefits
</FONT>
</P>
</TD>
<TD ID=TBL6143.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6143.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	2,876
</TD>
<TD ID=TBL6143.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6143.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	2,540
</TD>
<TD ID=TBL6143.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6143.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6125 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accrued liabilities associated with Gr&#252;nenthal collaboration
</FONT>
</P>
</TD>
<TD ID=TBL6143.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6143.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	499
</TD>
<TD ID=TBL6143.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6143.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6128 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Inventory and other contract manufacturing accruals
</FONT>
</P>
</TD>
<TD ID=TBL6143.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	272
</TD>
<TD ID=TBL6143.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL6143.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6143.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6131 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Other accrued liabilities
</FONT>
</P>
</TD>
<TD ID=TBL6143.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	808
</TD>
<TD ID=TBL6143.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	615
</TD>
<TD ID=TBL6143.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6143.FINROW.8 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6137 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total accrued liabilities
</FONT>
</P>
</TD>
<TD ID=TBL6143.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6143.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	3,956
</TD>
<TD ID=TBL6143.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6143.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6143.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 13%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	3,654
</TD>
<TD ID=TBL6143.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA6145 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6144 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	16. 401(k) Plan
</B>
</FONT>
</P>
<P ID=PARA6147 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6146 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company sponsors a 401(k) plan that stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations. Pursuant to the 401(k) plan, the Company makes a matching contribution of up to 4% of the related compensation. Under the vesting schedule, employees have ownership in the matching Employer Contributions based on the number of years of vesting service completed. Company contributions were $263,000, $201,000 and $143,000 for the years ended December 31, 2015, 2014 and 2013, respectively.
</FONT>
</P>
<P ID=PARA6149 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK32 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR32 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM32 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-31
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage119"></A>
<DIV ID=PGHDR32 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA32.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA6148 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	17. Related Party Transactions
</B>
</FONT>
</P>
<P ID=PARA6150 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6151 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Stephen Hoffman is a Senior Advisor to PDL and a member of the Company&#39;s Board of Directors, or the Board. The Board was aware of Dr. Hoffman&#8217;s status as an interested party in the Royalty Monetization and Dr.&nbsp;Hoffman recused himself from all deliberations and actions taken by the Board with respect to the Royalty Monetization. Dr. Hoffman&#8217;s consulting compensation from PDL is composed, in part, of a success fee which is formula driven based on a minimum dollar value of deals and the total dollar value of the deals, his relative contribution to each of the concluded deals and the total dollar value deployed in 2015. PDL estimates the amount attributable to the AcelRx transaction to be approximately $260,000.
</FONT>
</P>
<P ID=PARA6152 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6153 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	18. Income Taxes
</B>
</FONT>
</P>
<P ID=PARA6155 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6154 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company did record a provision for income taxes of $0.8 million during the year ended December&nbsp;31, 2015. The Company did not record a provision for income taxes during the years ended December&nbsp;31, 2014 and 2013. Net deferred tax assets as of December&nbsp;31, 2015 and 2014 consist of the following (in thousands):
</FONT>
</P>
<P ID=PARA6156 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<TABLE ID=TBL6201 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 85%; MARGIN-LEFT: 7.5%; MARGIN-RIGHT: 7.5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL6201.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6201.FINROW.1.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6201.FINROW.1.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.8PT" COLSPAN=2>
<P ID=PARA6158 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	December 31,
<BR>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.1.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6201.FINROW.1.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6201.FINROW.1.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 10.8PT" COLSPAN=2>
<P ID=PARA6160 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	December 31,
<BR>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.1.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6201.FINROW.2 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 64%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6162 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Deferred tax assets:
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.2.LEAD.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.2.SYMB.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.2.AMT.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.2.TRAIL.B2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.2.LEAD.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.2.SYMB.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.2.AMT.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.2.TRAIL.B3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6201.FINROW.3 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6165 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accruals and other
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6201.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	3,162
</TD>
<TD ID=TBL6201.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6201.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	4,446
</TD>
<TD ID=TBL6201.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6201.FINROW.4 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6168 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Research credits
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #CCEEFF">
	5,105
</TD>
<TD ID=TBL6201.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #CCEEFF">
	4,413
</TD>
<TD ID=TBL6201.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6201.FINROW.5 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6171 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net operating loss carryforward
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	30,294
</TD>
<TD ID=TBL6201.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	42,330
</TD>
<TD ID=TBL6201.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6201.FINROW.6 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6174 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Section 59(e) R&amp;D expenditures
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #CCEEFF">
	12,785
</TD>
<TD ID=TBL6201.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #CCEEFF">
	17,083
</TD>
<TD ID=TBL6201.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6201.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6177 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Deferred revenue
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	21,677
</TD>
<TD ID=TBL6201.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6201.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6201.FINROW.8 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6180 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	AMT credit
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #CCEEFF">
	742
</TD>
<TD ID=TBL6201.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #CCEEFF">
	&#8212;
</TD>
<TD ID=TBL6201.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6201.FINROW.10 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 54PT; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6186 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Total deferred tax assets
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.10.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.10.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.10.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	73,765
</TD>
<TD ID=TBL6201.FINROW.10.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.10.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.10.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.10.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	68,272
</TD>
<TD ID=TBL6201.FINROW.10.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6201.FINROW.11 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 27PT; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6189 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Valuation allowance
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #CCEEFF">
	(73,765
</TD>
<TD ID=TBL6201.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6201.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #CCEEFF">
	(68,272
</TD>
<TD ID=TBL6201.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL6201.FINROW.13 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6195 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net deferred tax assets
</FONT>
</P>
</TD>
<TD ID=TBL6201.FINROW.13.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.13.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6201.FINROW.13.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6201.FINROW.13.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.13.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6201.FINROW.13.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6201.FINROW.13.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 15%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 15.1PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6201.FINROW.13.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA6203 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6202 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6204 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Reconciliations of the statutory federal income tax to the Company&#8217;s effective tax during the years ended December&nbsp;31, 2015, 2014 and 2013 are as follows (in thousands):
</FONT>
</P>
<P ID=PARA6205 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<TABLE ID=TBL6256 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; MARGIN-LEFT: 5%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL6256.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6256.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6256.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=10>
<P ID=PARA6207 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6256.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6256.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6256.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6210 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6256.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6256.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6212 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6256.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6256.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6214 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 7.2PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6256.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6216 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Tax at statutory federal rate
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6256.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	(8,037
</TD>
<TD ID=TBL6256.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6256.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6256.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	(11,392
</TD>
<TD ID=TBL6256.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6256.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6256.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	(7,965
</TD>
<TD ID=TBL6256.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL6256.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6220 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	State tax&#8212;net of federal benefit
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	2,853
</TD>
<TD ID=TBL6256.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	(2,501
</TD>
<TD ID=TBL6256.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL6256.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	(716
</TD>
<TD ID=TBL6256.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL6256.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6224 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	PIPE Warrant liability
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	(726
</TD>
<TD ID=TBL6256.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6256.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	(2,393
</TD>
<TD ID=TBL6256.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6256.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	4,898
</TD>
<TD ID=TBL6256.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6256.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6228 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	General Business credits
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	(455
</TD>
<TD ID=TBL6256.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL6256.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	(628
</TD>
<TD ID=TBL6256.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL6256.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	(1,326
</TD>
<TD ID=TBL6256.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL6256.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6232 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Stock Options
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF">
	1,559
</TD>
<TD ID=TBL6256.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 30.15PT; BACKGROUND-COLOR: #CCEEFF">
	543
</TD>
<TD ID=TBL6256.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.7.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.7.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.7.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.7.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6256.FINROW.8 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6236 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Other
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.8.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.8.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.8.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	73
</TD>
<TD ID=TBL6256.FINROW.8.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.8.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.8.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.8.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	20
</TD>
<TD ID=TBL6256.FINROW.8.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.8.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.8.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.8.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	(80
</TD>
<TD ID=TBL6256.FINROW.8.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL6256.FINROW.9 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6240 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Change in valuation allowance
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.9.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.9.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.9.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	5,493
</TD>
<TD ID=TBL6256.FINROW.9.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.9.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.9.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.9.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	16,351
</TD>
<TD ID=TBL6256.FINROW.9.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	5,189
</TD>
<TD ID=TBL6256.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6256.FINROW.11 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6248 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Provision for income taxes
</FONT>
</P>
</TD>
<TD ID=TBL6256.FINROW.11.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.11.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 10.2PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6256.FINROW.11.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 10.2PT; BACKGROUND-COLOR: #FFFFFF">
	760
</TD>
<TD ID=TBL6256.FINROW.11.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.11.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.11.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6256.FINROW.11.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6256.FINROW.11.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.11.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6256.FINROW.11.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6256.FINROW.11.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6256.FINROW.11.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA6258 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6257 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of deferred tax assets is dependent on future taxable income, if any, the timing and the amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $5.5 million, $16.4 million, and $4.8 million during the years ended December&nbsp;31, 2015, 2014 and 2013, respectively.
</FONT>
</P>
<P ID=PARA6260 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6259 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December&nbsp;31, 2015, the Company had federal net operating loss carryforwards of $73.8 million, which begin to expire in 2029. As of December&nbsp;31, 2015, the Company had state net operating loss carryforwards of $108.9 million, which begin to expire in 2016.
</FONT>
</P>
<P ID=PARA6262 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6261 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December 31, 2015, approximately $2.9 million of federal and $2.8 million of state net operating loss is attributable to stock-based compensation deductions in excess of book expense. When realized, the benefit of the tax deduction related to these options will be accounted for as a credit to stockholders&#8217; equity rather than as a reduction of the income tax provision.
</FONT>
</P>
<P ID=PARA6264 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6263 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December 31, 2015, the Company had a federal alternative minimum tax credit carryover of $0.7 million.
</FONT>
</P>
<P ID=PARA6266 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6265 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	As of December&nbsp;31, 2015, the Company had federal research credit carryovers of $5.0 million, which begin to expire in 2026. As of December&nbsp;31, 2015, the Company had state research credit carryovers of $2.8 million, which will carryforward indefinitely.
</FONT>
</P>
<P ID=PARA6268 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK33 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR33 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM33 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-32
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage120"></A>
<DIV ID=PGHDR33 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
<P ID=PARA33.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<P ID=PARA6267 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Under Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research credits, to offset its post-change income may be limited. Based on an analysis performed by the Company as of December&nbsp;31, 2013, it was determined that two ownership changes have occurred since inception of the Company. The first ownership change occurred in 2006 at the time of the Series A financing and, as a result of the change, $1.4 million in federal and state net operating loss carryforwards will expire unutilized. In addition, $26,000 in federal and state research and development credits will expire unutilized. The second ownership change occurred in July 2013 at the time of the underwritten public offering; however, the Company believes the resulting annual imposed limitation on use of pre-change tax attributes is sufficiently high that the limit itself will not result in unutilized pre-change tax attributes.
</FONT>
</P>
<P ID=PARA6270 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<P ID=PARA6271 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<I>
	Uncertain Tax Positions
</I>
</B>
</FONT>
</P>
<P ID=PARA6273 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6272 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	A reconciliation of the beginning and ending balances of the unrecognized tax benefits during the years ended December&nbsp;31, 2015, 2014 and 2013 is as follows (in thousands):
</FONT>
</P>
<P ID=PARA6274 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL6309 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 90%; MARGIN-LEFT: 5%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL6309.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6309.FINROW.1.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6309.FINROW.1.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=10>
<P ID=PARA6276 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Year Ended December 31,
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6309.FINROW.1.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6309.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6309.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6309.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6279 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6309.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6309.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6309.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6281 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 5.75PT 0PT 14.4PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2014
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6309.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6309.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6309.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 14.4PT" COLSPAN=2>
<P ID=PARA6283 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 4.3PT 0PT 14.4PT; LINE-HEIGHT: 1.25; TEXT-INDENT: -5.3PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2013
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6309.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6309.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 49%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6285 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Unrecognized benefit&#8212;beginning of period
</FONT>
</P>
</TD>
<TD ID=TBL6309.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6309.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	1,667
</TD>
<TD ID=TBL6309.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6309.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	1,341
</TD>
<TD ID=TBL6309.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6309.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	810
</TD>
<TD ID=TBL6309.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6309.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6289 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gross decreases&#8212;prior period tax positions
</FONT>
</P>
</TD>
<TD ID=TBL6309.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6309.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	&#8212;
</TD>
<TD ID=TBL6309.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	221
</TD>
<TD ID=TBL6309.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6309.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6293 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Gross increases&#8212;current period tax positions
</FONT>
</P>
</TD>
<TD ID=TBL6309.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	272
</TD>
<TD ID=TBL6309.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	326
</TD>
<TD ID=TBL6309.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #CCEEFF">
	310
</TD>
<TD ID=TBL6309.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6309.FINROW.7 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6301 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Unrecognized benefit&#8212;end of period
</FONT>
</P>
</TD>
<TD ID=TBL6309.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6309.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	1,939
</TD>
<TD ID=TBL6309.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 13PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6309.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 13PT; BACKGROUND-COLOR: #FFFFFF">
	1,667
</TD>
<TD ID=TBL6309.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6309.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6309.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 14%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 3PX DOUBLE; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 14.4PT; BACKGROUND-COLOR: #FFFFFF">
	1,341
</TD>
<TD ID=TBL6309.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 3PX; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA6311 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6310 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The entire amount of the unrecognized tax benefits would not impact the Company&#8217;s effective tax rate if recognized.
</FONT>
</P>
<P ID=PARA6313 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6312 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Accrued interest and penalties related to unrecognized tax benefits are classified as income tax expense and were immaterial. The Company files income tax returns in the United States and in California. The tax years 2005 through 2015 remain open in both jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other foreign jurisdictions. The Company does not anticipate any significant changes within 12 months of this reporting date of its uncertain tax positions.
</FONT>
</P>
<P ID=PARA159 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA158 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	1
</B>
<B>
	9
</B>
<B>
	. Subsequent Events
</B>
</FONT>
</P>
<P ID=PARA161 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P ID=PARA220 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA219 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	On March 2, 2016, the Company entered into an amendment to the award contract with the DoD in which the DoD
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	agreed to approve enrollment of additional patients in the SAP302 study, approve the addition of the SAP303 study, and extend the contract period of performance by four months from November 10, 2016 to March 9, 2017, to accommodate the increased SAP302 patient enrollment and the SAP303 study. The costs for these changes will be absorbed within the current contract value. All other terms and conditions remain unchanged.
</FONT>
</P>
<P ID=PARA221 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6314 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	20. Unaudited Quarterly Financial Data
</B>
	(in thousands, except per share amounts)
<B>
</B>
</FONT>
</P>
<P ID=PARA6317 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6316 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&nbsp;31, 2015. The unaudited information set forth below has been prepared on the same basis as the audited information and includes all adjustments necessary to present fairly the information set forth herein. The operating results for any quarter are not indicative of results for any future period. All data is in thousands except per share data.
</FONT>
</P>
<P ID=PARA6318 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<TABLE ID=TBL6386 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL6386.FINROW.1>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.1.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.1.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=14>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	2015
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL6386.FINROW.1.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.1.LEAD.D9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.1.AMT.D9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=14>
<B>
	2014
</B>
</TD>
<TD ID=TBL6386.FINROW.1.TRAIL.D9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6386.FINROW.2>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.LEAD.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.AMT.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Q1
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL6386.FINROW.2.TRAIL.D2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.LEAD.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.AMT.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.15PT" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Q2
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL6386.FINROW.2.TRAIL.D3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Q3
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL6386.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.3PT" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Q4
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</TD>
<TD ID=TBL6386.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.LEAD.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.AMT.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Q1
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL6386.FINROW.2.TRAIL.D6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.LEAD.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.AMT.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 2.15PT" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Q2
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL6386.FINROW.2.TRAIL.D7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.LEAD.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.AMT.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Q3
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL6386.FINROW.2.TRAIL.D8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.LEAD.D9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6386.FINROW.2.AMT.D9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 3.6PT" COLSPAN=2>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Q4
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</TD>
<TD ID=TBL6386.FINROW.2.TRAIL.D9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
</TR>
<TR ID=TBL6386.FINROW.3 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 20%; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6341 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Revenues
</FONT>
</P>
</TD>
<TD ID=TBL6386.FINROW.3.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.3.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	181
</TD>
<TD ID=TBL6386.FINROW.3.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.3.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	1,924
</TD>
<TD ID=TBL6386.FINROW.3.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	15,428
</TD>
<TD ID=TBL6386.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.3PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.3.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.3PT; BACKGROUND-COLOR: #CCEEFF">
	1,730
</TD>
<TD ID=TBL6386.FINROW.3.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.3.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	95
</TD>
<TD ID=TBL6386.FINROW.3.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.3.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	71
</TD>
<TD ID=TBL6386.FINROW.3.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.3.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	4,825
</TD>
<TD ID=TBL6386.FINROW.3.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.LEAD.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.3.SYMB.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.3.AMT.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	226
</TD>
<TD ID=TBL6386.FINROW.3.TRAIL.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6386.FINROW.4 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #FFFFFF">
<P ID=PARA6350 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Operating costs and expenses
</FONT>
</P>
</TD>
<TD ID=TBL6386.FINROW.4.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.4.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	11,581
</TD>
<TD ID=TBL6386.FINROW.4.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.4.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #FFFFFF">
	10,047
</TD>
<TD ID=TBL6386.FINROW.4.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	8,323
</TD>
<TD ID=TBL6386.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.3PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.4.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.3PT; BACKGROUND-COLOR: #FFFFFF">
	9,266
</TD>
<TD ID=TBL6386.FINROW.4.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.4.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	8,636
</TD>
<TD ID=TBL6386.FINROW.4.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.4.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #FFFFFF">
	12,331
</TD>
<TD ID=TBL6386.FINROW.4.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.4.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	9,894
</TD>
<TD ID=TBL6386.FINROW.4.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.LEAD.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.4.SYMB.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.4.AMT.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	12,005
</TD>
<TD ID=TBL6386.FINROW.4.TRAIL.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
</TR>
<TR ID=TBL6386.FINROW.5 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; BACKGROUND-COLOR: #CCEEFF">
<P ID=PARA6359 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net income / (loss)
</FONT>
</P>
</TD>
<TD ID=TBL6386.FINROW.5.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.5.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.5.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	(10,026
</TD>
<TD ID=TBL6386.FINROW.5.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.5.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.5.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.5.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	(8,896
</TD>
<TD ID=TBL6386.FINROW.5.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	5,069
</TD>
<TD ID=TBL6386.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.3PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.3PT; BACKGROUND-COLOR: #CCEEFF">
	(10,546
</TD>
<TD ID=TBL6386.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.5.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.5.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.5.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	(9,631
</TD>
<TD ID=TBL6386.FINROW.5.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.5.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.5.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.5.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	(10,575
</TD>
<TD ID=TBL6386.FINROW.5.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.5.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.5.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.5.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	671
</TD>
<TD ID=TBL6386.FINROW.5.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.5.LEAD.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.5.SYMB.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.5.AMT.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	(13,818
</TD>
<TD ID=TBL6386.FINROW.5.TRAIL.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL6386.FINROW.6 STYLE="BACKGROUND-COLOR: #FFFFFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #FFFFFF; TEXT-INDENT: -9PT">
<P ID=PARA6368 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net income / (loss) per share (basic)
</FONT>
</P>
</TD>
<TD ID=TBL6386.FINROW.6.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.6.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.6.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	(0.23
</TD>
<TD ID=TBL6386.FINROW.6.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.6.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.6.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.6.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #FFFFFF">
	(0.20
</TD>
<TD ID=TBL6386.FINROW.6.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	0.11
</TD>
<TD ID=TBL6386.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.6.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.6.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.3PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.6.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.3PT; BACKGROUND-COLOR: #FFFFFF">
	(0.24
</TD>
<TD ID=TBL6386.FINROW.6.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.6.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.6.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.6.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	(0.22
</TD>
<TD ID=TBL6386.FINROW.6.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.6.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.6.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.6.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #FFFFFF">
	(0.24
</TD>
<TD ID=TBL6386.FINROW.6.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.6.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.6.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.6.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	0.02
</TD>
<TD ID=TBL6386.FINROW.6.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.6.LEAD.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #FFFFFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.6.SYMB.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	$
</TD>
<TD ID=TBL6386.FINROW.6.AMT.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #FFFFFF">
	(0.32
</TD>
<TD ID=TBL6386.FINROW.6.TRAIL.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #FFFFFF" NOWRAP>
	)
</TD>
</TR>
<TR ID=TBL6386.FINROW.7 STYLE="BACKGROUND-COLOR: #CCEEFF">
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; VERTICAL-ALIGN: TOP; PADDING-LEFT: 9PT; BACKGROUND-COLOR: #CCEEFF; TEXT-INDENT: -9PT">
<P ID=PARA6377 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Net income / (loss) per share (diluted)
</FONT>
</P>
</TD>
<TD ID=TBL6386.FINROW.7.LEAD.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.7.SYMB.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.7.AMT.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	(0.27
</TD>
<TD ID=TBL6386.FINROW.7.TRAIL.2 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.7.LEAD.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.7.SYMB.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.7.AMT.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	(0.20
</TD>
<TD ID=TBL6386.FINROW.7.TRAIL.3 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	0.11
</TD>
<TD ID=TBL6386.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.7.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.7.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.3PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.7.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.3PT; BACKGROUND-COLOR: #CCEEFF">
	(0.24
</TD>
<TD ID=TBL6386.FINROW.7.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.7.LEAD.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.7.SYMB.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.7.AMT.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	(0.22
</TD>
<TD ID=TBL6386.FINROW.7.TRAIL.6 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.7.LEAD.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.7.SYMB.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.7.AMT.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 2.15PT; BACKGROUND-COLOR: #CCEEFF">
	(0.30
</TD>
<TD ID=TBL6386.FINROW.7.TRAIL.7 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.7.LEAD.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.7.SYMB.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.7.AMT.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	(0.13
</TD>
<TD ID=TBL6386.FINROW.7.TRAIL.8 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
<TD ID=TBL6386.FINROW.7.LEAD.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BACKGROUND-COLOR: #CCEEFF">
	&nbsp;
</TD>
<TD ID=TBL6386.FINROW.7.SYMB.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	$
</TD>
<TD ID=TBL6386.FINROW.7.AMT.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 7%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 3.6PT; BACKGROUND-COLOR: #CCEEFF">
	(0.32
</TD>
<TD ID=TBL6386.FINROW.7.TRAIL.9 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT; BACKGROUND-COLOR: #CCEEFF" NOWRAP>
	)
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA6388 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK35 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR35 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM35 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
	F-33
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage121"></A>
<DIV ID=PGHDR35 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<P ID=PARA35.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P ID=PARA6390 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	EXHIBIT INDEX
</B>
</FONT>
</P>
<P ID=PARA6391 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<TABLE ID=TBL6766S1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL6766S1.FINROW.1>
<TD ID=TBL6766S1.FINROW.1.AMT.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6766S1.FINROW.1.TRAIL.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 35%; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=11>
<P STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Inco
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	rporation By Reference
</B>
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.2>
<TD ID=TBL6766S1.FINROW.2.AMT.D1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
<P ID=PARA8 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
<B>
	Exhibit
</B>
</B>
</P>
<P STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
	Number
</B>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.2.TRAIL.D1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
<P ID=PARA3 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT">
<B>
	Exhibit Description
</B>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6398 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 4.5PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Form
</B>
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.2.LEAD.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.2.AMT.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA6400 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	SEC
<BR>
</B>
<B>
	File No.
</B>
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.2.TRAIL.D4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" COLSPAN=2>
<P ID=PARA6402 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exhibit
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: MEDIUM NONE; PADDING-BOTTOM: 1PX">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6404 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Filing Date
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.3>
<TD ID=TBL6766S1.FINROW.3.AMT.B1 STYLE="WIDTH: 11%">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.TRAIL.B1 STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.LEAD.B4 STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.SYMB.B4 STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.AMT.B4 STYLE="WIDTH: 12%">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.TRAIL.B4 STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.LEAD.B5 STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.SYMB.B5 STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.AMT.B5 STYLE="WIDTH: 12%">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.TRAIL.B5 STYLE="WIDTH: 1%">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.4>
<TD ID=TBL6766S1.FINROW.4.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	3.1
</TD>
<TD ID=TBL6766S1.FINROW.4.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6407 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Certificate of Incorporation of the Registrant, currently in effect.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6408 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	8-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.4.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	3.1
</TD>
<TD ID=TBL6766S1.FINROW.4.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
<P ID=PARA6411 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2/28/2011
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.5>
<TD ID=TBL6766S1.FINROW.5.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.6>
<TD ID=TBL6766S1.FINROW.6.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	3.2
</TD>
<TD ID=TBL6766S1.FINROW.6.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6413 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Bylaws of the Registrant, currently in effect.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6414 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-1
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	333-170594
</TD>
<TD ID=TBL6766S1.FINROW.6.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	3.4
</TD>
<TD ID=TBL6766S1.FINROW.6.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
<P ID=PARA6417 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1/7/2011
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.7>
<TD ID=TBL6766S1.FINROW.7.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.8>
<TD ID=TBL6766S1.FINROW.8.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	4.1
</TD>
<TD ID=TBL6766S1.FINROW.8.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6419 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Reference is made to Exhibits 3.1 through 3.2.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.9>
<TD ID=TBL6766S1.FINROW.9.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.10>
<TD ID=TBL6766S1.FINROW.10.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	4.2
</TD>
<TD ID=TBL6766S1.FINROW.10.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6425 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Specimen Common Stock Certificate of the Registrant.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6426 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-1
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	333-170594
</TD>
<TD ID=TBL6766S1.FINROW.10.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	4.2
</TD>
<TD ID=TBL6766S1.FINROW.10.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
<P ID=PARA6429 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1/31/2011
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.11>
<TD ID=TBL6766S1.FINROW.11.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.12>
<TD ID=TBL6766S1.FINROW.12.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	4.3
</TD>
<TD ID=TBL6766S1.FINROW.12.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6431 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Second Amended and Restated Investors&#8217; Rights Agreement, among the Registrant and certain of its security holders, dated as of November 23, 2009.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6432 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-1
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	333-170594
</TD>
<TD ID=TBL6766S1.FINROW.12.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	4.3
</TD>
<TD ID=TBL6766S1.FINROW.12.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
<P ID=PARA6435 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/12/2010
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.13>
<TD ID=TBL6766S1.FINROW.13.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.14>
<TD ID=TBL6766S1.FINROW.14.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	4.4
</TD>
<TD ID=TBL6766S1.FINROW.14.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6437 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Warrant to Purchase Common Stock of the Registrant, issued to Hercules Technology II, L.P., dated as of December 16, 2013.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6438 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.14.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	4.4
</TD>
<TD ID=TBL6766S1.FINROW.14.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
<P ID=PARA6441 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3/17/2014
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.15>
<TD ID=TBL6766S1.FINROW.15.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.16>
<TD ID=TBL6766S1.FINROW.16.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	4.5
</TD>
<TD ID=TBL6766S1.FINROW.16.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6443 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Warrant to Purchase Common Stock of the Registrant, issued to Hercules Technology Growth Capital, Inc., dated as of December 16, 2013.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6444 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.16.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	4.5
</TD>
<TD ID=TBL6766S1.FINROW.16.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6447 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3/17/2014
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.17>
<TD ID=TBL6766S1.FINROW.17.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.18>
<TD ID=TBL6766S1.FINROW.18.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	4.6
</TD>
<TD ID=TBL6766S1.FINROW.18.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6449 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Form of Warrant issued to certain purchasers pursuant to the Securities Purchase Agreement dated May 29, 2012, between the Registrant and the purchasers identified therein.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6450 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	8-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.18.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	4.8
</TD>
<TD ID=TBL6766S1.FINROW.18.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6453 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5/30/2012
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.19>
<TD ID=TBL6766S1.FINROW.19.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.20>
<TD ID=TBL6766S1.FINROW.20.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	4.7
</TD>
<TD ID=TBL6766S1.FINROW.20.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6455 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Warrant Modification Agreement to Purchase Common Stock of the Registrant, issued to Hercules Technology II, L.P. dated as of September 17, 2015.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6456 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.20.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	4.7
</TD>
<TD ID=TBL6766S1.FINROW.20.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6459 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/3/2015
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.21>
<TD ID=TBL6766S1.FINROW.21.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.22>
<TD ID=TBL6766S1.FINROW.22.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	4.8
</TD>
<TD ID=TBL6766S1.FINROW.22.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6461 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Warrant Modification Agreement to Purchase Common Stock of the Registrant, issued to Hercules Technology Growth Capital, Inc. dated as of September 17, 2015.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6462 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.22.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	4.8
</TD>
<TD ID=TBL6766S1.FINROW.22.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6465 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/3/2015
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.23>
<TD ID=TBL6766S1.FINROW.23.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.24>
<TD ID=TBL6766S1.FINROW.24.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6466 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.1+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.24.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6467 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6468 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-1
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	333-170594
</TD>
<TD ID=TBL6766S1.FINROW.24.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.1
</TD>
<TD ID=TBL6766S1.FINROW.24.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6471 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1/7/2011
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.25>
<TD ID=TBL6766S1.FINROW.25.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.26>
<TD ID=TBL6766S1.FINROW.26.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6472 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.2+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.26.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6473 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2006 Stock Plan, as amended.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6474 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-1
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	333-170594
</TD>
<TD ID=TBL6766S1.FINROW.26.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.2
</TD>
<TD ID=TBL6766S1.FINROW.26.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6477 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/12/2010
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.27>
<TD ID=TBL6766S1.FINROW.27.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.28>
<TD ID=TBL6766S1.FINROW.28.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6478 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.3+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.28.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6479 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Forms of Notice of Grant of Stock Option, Stock Option Agreement and Stock Option Exercise Notice under 2006 Stock Plan.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6480 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.28.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.3
</TD>
<TD ID=TBL6766S1.FINROW.28.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6483 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3/30/2011
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.29>
<TD ID=TBL6766S1.FINROW.29.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.30>
<TD ID=TBL6766S1.FINROW.30.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6484 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.4+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.30.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6485 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2011 Equity Incentive Plan.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6486 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-8
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	333-172409
</TD>
<TD ID=TBL6766S1.FINROW.30.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	99.3
</TD>
<TD ID=TBL6766S1.FINROW.30.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6489 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2/24/2011
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.31>
<TD ID=TBL6766S1.FINROW.31.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.32>
<TD ID=TBL6766S1.FINROW.32.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6490 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.5+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.32.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6491 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Forms of Stock Option Grant Notice, Notice of Exercise and Option Agreement under 2011 Equity Incentive Plan.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6492 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.32.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.5
</TD>
<TD ID=TBL6766S1.FINROW.32.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6495 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3/30/2011
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.33>
<TD ID=TBL6766S1.FINROW.33.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.34>
<TD ID=TBL6766S1.FINROW.34.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6496 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.6+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.34.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6497 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under 2011 Equity Incentive Plan.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6498 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.34.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.6
</TD>
<TD ID=TBL6766S1.FINROW.34.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6501 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3/30/2011
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.35>
<TD ID=TBL6766S1.FINROW.35.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.36>
<TD ID=TBL6766S1.FINROW.36.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6502 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.7+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.36.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6503 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2011 Employee Stock Purchase Plan.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6504 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-8
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	333-172409
</TD>
<TD ID=TBL6766S1.FINROW.36.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	99.6
</TD>
<TD ID=TBL6766S1.FINROW.36.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6507 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2/24/2011
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.37>
<TD ID=TBL6766S1.FINROW.37.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.38>
<TD ID=TBL6766S1.FINROW.38.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	10.8
</TD>
<TD ID=TBL6766S1.FINROW.38.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6509 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Lease between Metropolitan Life Insurance Company and the Registrant, dated December 15, 2011.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6510 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.38.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.9
</TD>
<TD ID=TBL6766S1.FINROW.38.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6513 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3/23/2012
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.39>
<TD ID=TBL6766S1.FINROW.39.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.40>
<TD ID=TBL6766S1.FINROW.40.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	10.9
</TD>
<TD ID=TBL6766S1.FINROW.40.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6515 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amendment to Lease between Metropolitan Life Insurance and the Registrant, dated May 2, 2014
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6516 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	8-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.40.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.1
</TD>
<TD ID=TBL6766S1.FINROW.40.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6519 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5/7/2014
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.41>
<TD ID=TBL6766S1.FINROW.41.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.42>
<TD ID=TBL6766S1.FINROW.42.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	10.10
</TD>
<TD ID=TBL6766S1.FINROW.42.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6521 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Loan and Security Agreement among the Registrant, Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc., dated as of December 16, 2013.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6522 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.42.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.10
</TD>
<TD ID=TBL6766S1.FINROW.42.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6525 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3/17/2014
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.43>
<TD ID=TBL6766S1.FINROW.43.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766S1.FINROW.44>
<TD ID=TBL6766S1.FINROW.44.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6526 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.11+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.44.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6527 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Offer Letter between the Registrant and Larry Hamel, dated December 31, 2010.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
<P ID=PARA6528 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-1
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.44.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.44.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.44.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	333-170594
</TD>
<TD ID=TBL6766S1.FINROW.44.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.44.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.44.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.44.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.14
</TD>
<TD ID=TBL6766S1.FINROW.44.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT">
<P ID=PARA6531 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1/7/2011
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA36 STYLE="MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK37 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR37 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM37 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage122"></A>
<DIV ID=PGHDR37 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA37.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<TABLE ID=TBL6766S1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD ID=TBL6766S1.FINROW.1.AMT.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: MIDDLE" WIDTH=146>
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6766S1.FINROW.1.TRAIL.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: MIDDLE" WIDTH=10>
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: MIDDLE" WIDTH=518>
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 35%; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" WIDTH=494 COLSPAN=11>
<B>
	Incorporation By Reference
</B>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.2.AMT.D1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" WIDTH=146>
<B>
	Exhibit
<BR>
	Number
</B>
</TD>
<TD ID=TBL6766S1.FINROW.2.TRAIL.D1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; PADDING-BOTTOM: 1PX" WIDTH=10>
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" WIDTH=518>
<P ID=PARA4 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
	Exhibit Description
</B>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" WIDTH=47>
<P STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
	Form
</B>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.2.LEAD.D4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE" WIDTH=10>
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6766S1.FINROW.2.AMT.D4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" WIDTH=156 COLSPAN=2>
<P STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
	SEC
</B>
</P>
<P ID=PARA47 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
	File No.
</B>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.2.TRAIL.D4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; PADDING-BOTTOM: 1PX" WIDTH=10>
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6766S1.FINROW.2.LEAD.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: MIDDLE" WIDTH=10>
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6766S1.FINROW.2.AMT.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" WIDTH=156 COLSPAN=2>
<P STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
<B>
	Exhibit
</B>
</B>
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.2.TRAIL.D5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; PADDING-BOTTOM: 1PX" WIDTH=10>
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" WIDTH=85>
<P ID=PARA41 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
<B>
	Filing Date
</B>
<B>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</B>
</B>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.3.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6532 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.12+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.3.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6533 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Offer Letter between the Registrant and Badri (Anil) Dasu, dated December 30, 2010.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6534 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-1
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	333-170594
</TD>
<TD ID=TBL6766S1.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.3.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.15
</TD>
<TD ID=TBL6766S1.FINROW.3.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6537 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1/7/2011
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.4.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.4.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.5.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6538 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.13+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.5.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6539 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Offer Letter between the Registrant and Pamela Palmer, dated December 29, 2010.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6540 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-1
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	333-170594
</TD>
<TD ID=TBL6766S1.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.16
</TD>
<TD ID=TBL6766S1.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6543 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1/7/2011
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.6.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.6.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.7.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6544 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.14+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.7.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6545 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Offer Letter between the Registrant and Richard King, dated December 31, 2010.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6546 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	S-1
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	333-170594
</TD>
<TD ID=TBL6766S1.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.7.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.17
</TD>
<TD ID=TBL6766S1.FINROW.7.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6549 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1/7/2011
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.8.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.8.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.9.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6550 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.15+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.9.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6551 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Offer Letter between the Registrant and Timothy E. Morris, dated March 24, 2014.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6552 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.9.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.3
</TD>
<TD ID=TBL6766S1.FINROW.9.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6555 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5/8/2014
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.10.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.10.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.11.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6556 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.16+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.11.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6557 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Offer Letter between the Registrant and Jane Wright-Mitchell, dated June 13, 2014.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6558 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.11.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.11.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.3
</TD>
<TD ID=TBL6766S1.FINROW.11.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6561 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5/8/2014
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.12.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.12.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.13.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6562 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.17+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.13.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6563 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Separation Agreement between the Registrant and Richard King, dated December 15, 2014.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6564 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	8-K/A
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.13.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.13.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.1
</TD>
<TD ID=TBL6766S1.FINROW.13.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6567 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	12/16/2014
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.14.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.14.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.15.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6568 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.18+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.15.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6569 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Offer Letter, effective as of April 1, 2015, between the Registrant and Howard B. Rosen.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6570 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	8-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.15.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.15.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.1
</TD>
<TD ID=TBL6766S1.FINROW.15.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6573 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	4/3/2015
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.16.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.16.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.17.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6574 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.19+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.17.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6575 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Non-Employee Director Compensation Policy.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6576 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.17.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.LEAD.5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.SYMB.5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.17.AMT.5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT" WIDTH=146>
	Item 11
</TD>
<TD ID=TBL6766S1.FINROW.17.TRAIL.5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6579 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3/12/2013
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.18.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.18.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.19.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6580 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.20+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.19.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6581 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2015 Cash Bonus Plan Summary.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6582 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	8-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.19.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.19.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.1
</TD>
<TD ID=TBL6766S1.FINROW.19.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6585 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5/5/2015
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.20.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.20.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.21.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6586 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.21+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.21.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6587 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Supplemental Cash Bonus Plan.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6588 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	8-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.21.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.LEAD.5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.SYMB.5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.21.AMT.5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT" WIDTH=146>
	Item 5.02
</TD>
<TD ID=TBL6766S1.FINROW.21.TRAIL.5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6591 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/10/2014
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.22.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.22.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.23.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6592 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.22+
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.23.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6593 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Supplemental Retention Cash Bonus Plan.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6594 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	8-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.23.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.LEAD.5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.SYMB.5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.23.AMT.5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT" WIDTH=146>
	Item 5.02
</TD>
<TD ID=TBL6766S1.FINROW.23.TRAIL.5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6597 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	12/8/2014
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.24.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.24.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.25.AMT.1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX" WIDTH=146>
	10.23
</TD>
<TD ID=TBL6766S1.FINROW.25.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6599 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Supply Agreement between the Registrant and Mallinckrodt LLC, effective as of May 31, 2013.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6600 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.25.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.25.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.1
</TD>
<TD ID=TBL6766S1.FINROW.25.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6603 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/5/2013
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.26.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.26.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.27.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6604 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.24#
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.27.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6605 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Manufacture and Supply Agreement between the Registrant and Gr&#252;nenthal GmbH, effective as of December 16, 2013.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6606 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.27.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.27.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.28
</TD>
<TD ID=TBL6766S1.FINROW.27.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6609 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3/17/2014
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.28.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.28.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.29.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6610 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.25#
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.29.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6611 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Collaboration and License Agreement between the Registrant and Gr&#252;nenthal GmbH, effective as of December 16, 2013.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6612 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-K
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.29.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.29.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.29
</TD>
<TD ID=TBL6766S1.FINROW.29.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6615 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3/17/2014
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.30.AMT.B1 STYLE="MARGIN-BOTTOM: 0PX; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.30.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.31.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6616 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.26#
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.31.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6617 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	First Amendment to the Manufacture and Supply Agreement between the Registrant and Gr&#252;nenthal GmbH, effective as of July 17, 2015.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6618 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.31.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.31.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.2
</TD>
<TD ID=TBL6766S1.FINROW.31.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6621 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/3/2015
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.32.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.32.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.33.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6622 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.27#
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.33.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6623 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	First Amendment to the Collaboration and License Agreement between the Registrant and Gr&#252;nenthal GmbH, effective as of July 17, 2015.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6624 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.33.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.33.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.1
</TD>
<TD ID=TBL6766S1.FINROW.33.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6627 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/3/2015
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.34.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.34.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.35.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT" WIDTH=146>
	10.28
</TD>
<TD ID=TBL6766S1.FINROW.35.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6629 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Manufacturing Services Agreement between Registrant and Patheon Pharmaceuticals, Inc., dated as of January 18, 2013
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6630 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.35.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.35.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.1
</TD>
<TD ID=TBL6766S1.FINROW.35.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6633 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5/8/2013
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.36.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.36.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.37.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT" WIDTH=146>
	10.29
</TD>
<TD ID=TBL6766S1.FINROW.37.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6635 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Amended and Restated Capital Expenditure Agreement between Registrant and Patheon Pharmaceuticals, Inc., dated as of January 18, 2013
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6636 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.37.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.37.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.2
</TD>
<TD ID=TBL6766S1.FINROW.37.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6639 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5/8/2013
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.38.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.38.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.39.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT" WIDTH=146>
	10.30
</TD>
<TD ID=TBL6766S1.FINROW.39.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6641 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Second Amendment to Amended and Restated Capital Expenditure and Equipment Agreement, between the Registrant and Patheon Pharmaceuticals, Inc. effective as of January 30, 2014.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6642 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.39.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.39.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.4
</TD>
<TD ID=TBL6766S1.FINROW.39.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6645 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5/8/2014
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.40.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.40.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.41.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX" WIDTH=146>
<P ID=PARA6646 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.31#
</FONT>
</P>
</TD>
<TD ID=TBL6766S1.FINROW.41.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6647 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Award/Contract between the Registrant and the U.S. Army Medical Research and Materiel Command, dated May 11, 2015.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6648 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.41.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.41.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.2
</TD>
<TD ID=TBL6766S1.FINROW.41.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6651 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	8/4/2015
</FONT>
</P>
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.42.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP" WIDTH=518>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP" WIDTH=47>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=146>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.42.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP" WIDTH=85>
	&nbsp;
</TD>
</TR>
<TR>
<TD ID=TBL6766S1.FINROW.43.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT" WIDTH=146>
	10.32
</TD>
<TD ID=TBL6766S1.FINROW.43.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT" WIDTH=518>
<P ID=PARA6653 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Modification of Contract W81XWH-15-C-0046 between the Registrant and the U.S. Army Medical Research and Materiel Command, effective August 6, 2015.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=35>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=47>
<P ID=PARA6654 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER; MARGIN-LEFT: 0PT" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	001-35068
</TD>
<TD ID=TBL6766S1.FINROW.43.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP" WIDTH=10>
	&nbsp;
</TD>
<TD ID=TBL6766S1.FINROW.43.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT" WIDTH=146>
	10.3
</TD>
<TD ID=TBL6766S1.FINROW.43.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" WIDTH=10 NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 0PT" WIDTH=85>
<P ID=PARA6657 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/3/2015
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA38 STYLE="MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<DIV ID=PGBK39 STYLE="WIDTH: 100%; MARGIN-LEFT: 0PT; MARGIN-RIGHT: 0PT">
<DIV ID=PGFTR39 STYLE="WIDTH: 100%; TEXT-ALIGN: CENTER">
	&nbsp;
</DIV>
<DIV ID=PGNUM39 STYLE="FONT-SIZE: 10PT; WIDTH: 100%; TEXT-ALIGN: CENTER">
</DIV>
<HR STYLE="HEIGHT: 2PX; WIDTH: 100%; PAGE-BREAK-AFTER: ALWAYS; COLOR: #000000" NOSHADE>
<A NAME="eolPage123"></A>
<DIV ID=PGHDR39 STYLE="WIDTH: 100%; TEXT-ALIGN: LEFT">
	&nbsp;
</DIV>
</DIV>
</EFX_UNIDENTIFIED_TABLE>
<P ID=PARA39.2 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<TABLE ID=TBL6766 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR ID=TBL6766.FINROW.1>
<TD ID=TBL6766.FINROW.1.AMT.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6766.FINROW.1.TRAIL.B1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 35%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER" COLSPAN=11>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Inco
</B>
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	rporation By Reference
</B>
</FONT>
</TD>
</TR>
<TR ID=TBL6766.FINROW.2>
<TD ID=TBL6766.FINROW.2.AMT.D1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
<B>
	Exhibit
<BR>
	Number
</B>
</TD>
<TD ID=TBL6766.FINROW.2.TRAIL.D1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
<B>
	Exhibit Description
</B>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
<P ID=PARA70 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
</B>
</P>
<P STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
	Form
</B>
</P>
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.2.LEAD.D4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6766.FINROW.2.AMT.D4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; BORDER-BOTTOM: #000000 1PX SOLID" COLSPAN=2>
<P ID=PARA57 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT">
<B>
	SEC
</B>
</P>
<P ID=PARA47 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT">
<B>
	File No.
</B>
</P>
</TD>
<TD ID=TBL6766.FINROW.2.TRAIL.D4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6766.FINROW.2.LEAD.D5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE">
<B>
	&nbsp;
</B>
</TD>
<TD ID=TBL6766.FINROW.2.AMT.D5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID" COLSPAN=2>
<P ID=PARA66 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
<STRONG>
</STRONG>
</B>
</P>
<P STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT">
<STRONG>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
<B>
	Exhibit
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</B>
</STRONG>
<STRONG>
</STRONG>
</P>
</TD>
<TD ID=TBL6766.FINROW.2.TRAIL.D5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: MIDDLE; PADDING-BOTTOM: 1PX">
<B>
	&nbsp;
</B>
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM: #000000 1PX SOLID">
<P ID=PARA58 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<B>
</B>
</P>
<P STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: CENTER; MARGIN-TOP: 0PT">
<STRONG>
<B>
<B>
<B>
<B>
	Filing Date
</B>
</B>
</B>
</B>
</STRONG>
<STRONG>
</STRONG>
</P>
</TD>
</TR>
<TR ID=TBL6766.FINROW.3>
<TD ID=TBL6766.FINROW.3.AMT.1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX">
	10.33
</TD>
<TD ID=TBL6766.FINROW.3.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6659 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Modification of Contract W81XWH-15-C-0046 between the Registrant and the U.S. Army Medical Research and Materiel Command, effective August 12, 2015.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
<P ID=PARA6660 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.3.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.3.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.3.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766.FINROW.3.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.3.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.3.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.3.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.4
</TD>
<TD ID=TBL6766.FINROW.3.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6663 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/3/2015
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766.FINROW.4>
<TD ID=TBL6766.FINROW.4.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.4.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.4.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.4.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.4.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.4.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.4.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.4.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.4.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.4.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.5>
<TD ID=TBL6766.FINROW.5.AMT.1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX">
	10.34
</TD>
<TD ID=TBL6766.FINROW.5.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6665 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Modification of Contract W81XWH-15-C-0046 between the Registrant and the U.S. Army Medical Research and Materiel Command, effective September 4, 2015.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
<P ID=PARA6666 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.5.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.5.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.5.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766.FINROW.5.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.5.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.5.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.5.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.5
</TD>
<TD ID=TBL6766.FINROW.5.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6669 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/3/2015
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766.FINROW.6>
<TD ID=TBL6766.FINROW.6.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.6.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.6.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.6.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.6.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.6.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.6.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.6.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.6.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.6.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.7>
<TD ID=TBL6766.FINROW.7.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6670 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.35#
</FONT>
</P>
</TD>
<TD ID=TBL6766.FINROW.7.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6671 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Purchase and Sale Agreement between Registrant and ARPI LLC, dated as of September 18, 2015.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
<P ID=PARA6672 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.7.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.7.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.7.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766.FINROW.7.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.7.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.7.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.7.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.6
</TD>
<TD ID=TBL6766.FINROW.7.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6675 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/3/2015
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766.FINROW.8>
<TD ID=TBL6766.FINROW.8.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.8.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.8.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.8.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.8.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.8.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.8.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.8.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.8.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.8.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.9>
<TD ID=TBL6766.FINROW.9.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6676 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10.36#
</FONT>
</P>
</TD>
<TD ID=TBL6766.FINROW.9.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6677 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Subsequent Purchase and Sale Agreement between ARPI LLC (a wholly owned subsidiary of the Registrant) and PDL BioPharma, Inc., dated as of September 18, 2015.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
<P ID=PARA6678 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.9.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.9.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.9.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766.FINROW.9.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.9.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.9.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.9.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.7
</TD>
<TD ID=TBL6766.FINROW.9.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6681 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/3/2015
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766.FINROW.10>
<TD ID=TBL6766.FINROW.10.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.10.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.10.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.10.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.10.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.10.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.10.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.10.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.10.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.10.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.11>
<TD ID=TBL6766.FINROW.11.AMT.1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX">
	10.37
</TD>
<TD ID=TBL6766.FINROW.11.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6683 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Consent and Amendment No. 2 to Amended and Restated Loan and Security Agreement, dated as of December 16, 2013, and amended as of September 24, 2014, among the Registrant, Hercules Technology II, L.P. and Hercules Technology Growth Capital, Inc.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
<P ID=PARA6684 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT 1.3PT 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	10-Q
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.11.LEAD.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.11.SYMB.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.11.AMT.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	001-35068
</TD>
<TD ID=TBL6766.FINROW.11.TRAIL.4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.11.LEAD.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.11.SYMB.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.11.AMT.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-LEFT: 0PT">
	10.8
</TD>
<TD ID=TBL6766.FINROW.11.TRAIL.5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6687 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	11/3/2015
</FONT>
</P>
</TD>
</TR>
<TR ID=TBL6766.FINROW.12>
<TD ID=TBL6766.FINROW.12.AMT.B1 STYLE="MARGIN-BOTTOM: 0PX; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.12.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.12.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.12.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.12.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.12.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.12.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.12.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.12.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.12.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.13>
<TD ID=TBL6766.FINROW.13.AMT.1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX">
	21.2
</TD>
<TD ID=TBL6766.FINROW.13.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6689 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Subsidiaries of the Registrant.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.13.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.13.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.13.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.13.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.13.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.13.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.13.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.13.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.14>
<TD ID=TBL6766.FINROW.14.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: CENTER">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.14.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.14.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.14.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.14.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.14.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.14.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.14.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.14.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.14.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.15>
<TD ID=TBL6766.FINROW.15.AMT.1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX">
	23.1
</TD>
<TD ID=TBL6766.FINROW.15.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6695 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Consent of OUM &amp; Co., LLP, Independent Registered Public Accounting Firm.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.15.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.15.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.15.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.15.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.15.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.15.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.15.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.15.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.16>
<TD ID=TBL6766.FINROW.16.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.16.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.16.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.16.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.16.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.16.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.16.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.16.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.16.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.16.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.17>
<TD ID=TBL6766.FINROW.17.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	23.2
</TD>
<TD ID=TBL6766.FINROW.17.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6701 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.17.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.17.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.17.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.17.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.17.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.17.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.17.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.17.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.18>
<TD ID=TBL6766.FINROW.18.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.18.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.18.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.18.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.18.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.18.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.18.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.18.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.18.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.18.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.19>
<TD ID=TBL6766.FINROW.19.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	24.1
</TD>
<TD ID=TBL6766.FINROW.19.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6707 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Power of Attorney (included in signature page).
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.19.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.19.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.19.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.19.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.19.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.19.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.19.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.19.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.20>
<TD ID=TBL6766.FINROW.20.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.20.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.20.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.20.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.20.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.20.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.20.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.20.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.20.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.20.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.21>
<TD ID=TBL6766.FINROW.21.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	31.1
</TD>
<TD ID=TBL6766.FINROW.21.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6713 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.21.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.21.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.21.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.21.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.21.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.21.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.21.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.21.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.22>
<TD ID=TBL6766.FINROW.22.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.22.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.22.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.22.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.22.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.22.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.22.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.22.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.22.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.22.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.23>
<TD ID=TBL6766.FINROW.23.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	31.2
</TD>
<TD ID=TBL6766.FINROW.23.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6719 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.23.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.23.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.23.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.23.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.23.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.23.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.23.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.23.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.24>
<TD ID=TBL6766.FINROW.24.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.24.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.24.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.24.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.24.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.24.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.24.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.24.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.24.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.24.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.25>
<TD ID=TBL6766.FINROW.25.AMT.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	32.1
</TD>
<TD ID=TBL6766.FINROW.25.TRAIL.1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; MARGIN-LEFT: 0PT" NOWRAP>
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6725 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.25.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.25.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.25.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.25.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.25.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.25.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.25.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.25.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.26>
<TD ID=TBL6766.FINROW.26.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.26.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.26.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.26.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.26.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.26.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.26.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.26.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.26.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.26.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.27>
<TD ID=TBL6766.FINROW.27.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6730 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.INS
</FONT>
</P>
</TD>
<TD ID=TBL6766.FINROW.27.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6731 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Instance Document
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.27.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.27.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.27.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.27.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.27.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.27.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.27.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.27.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.28>
<TD ID=TBL6766.FINROW.28.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: RIGHT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.28.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.28.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.28.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.28.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.28.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.28.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.28.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.28.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.28.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.29>
<TD ID=TBL6766.FINROW.29.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6736 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.SCH
</FONT>
</P>
</TD>
<TD ID=TBL6766.FINROW.29.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6737 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Schema Document
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.29.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.29.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.29.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.29.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.29.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.29.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.29.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.29.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.30>
<TD ID=TBL6766.FINROW.30.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.30.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.30.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.30.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.30.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.30.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.30.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.30.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.30.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.30.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.31>
<TD ID=TBL6766.FINROW.31.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6742 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.CAL
</FONT>
</P>
</TD>
<TD ID=TBL6766.FINROW.31.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6743 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Calculation Linkbase Document
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.31.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.31.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.31.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.31.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.31.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.31.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.31.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.31.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.32>
<TD ID=TBL6766.FINROW.32.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.32.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.32.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.32.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.32.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.32.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.32.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.32.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.32.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.32.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.33>
<TD ID=TBL6766.FINROW.33.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6748 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.DEF
</FONT>
</P>
</TD>
<TD ID=TBL6766.FINROW.33.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6749 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Definition Linkbase Document
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.33.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.33.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.33.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.33.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.33.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.33.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.33.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.33.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.34>
<TD ID=TBL6766.FINROW.34.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.34.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.34.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.34.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.34.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.34.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.34.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.34.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.34.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.34.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.35>
<TD ID=TBL6766.FINROW.35.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6754 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.LAB
</FONT>
</P>
</TD>
<TD ID=TBL6766.FINROW.35.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6755 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Label Linkbase Document
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.35.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.35.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.35.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.35.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.35.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.35.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.35.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.35.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.36>
<TD ID=TBL6766.FINROW.36.AMT.B1 STYLE="WIDTH: 11%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.36.TRAIL.B1 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 40%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.36.LEAD.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.36.SYMB.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.36.AMT.B4 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.36.TRAIL.B4 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.36.LEAD.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.36.SYMB.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.36.AMT.B5 STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.36.TRAIL.B5 STYLE="WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
<TR ID=TBL6766.FINROW.37>
<TD ID=TBL6766.FINROW.37.AMT.D1 STYLE="MARGIN-BOTTOM: 0PX; FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 11%; VERTICAL-ALIGN: TOP; MARGIN-TOP: 0PX">
<P ID=PARA6760 STYLE="MARGIN-BOTTOM: 0PX; TEXT-ALIGN: RIGHT; MARGIN-TOP: 0PX; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	101.PRE
</FONT>
</P>
</TD>
<TD ID=TBL6766.FINROW.37.TRAIL.D1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 40%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
<P ID=PARA6761 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 3.15PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	XBRL Taxonomy Extension Presentation Linkbase Document
</FONT>
</P>
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; MARGIN-LEFT: 3.15PT">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 4%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.37.LEAD.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.37.SYMB.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.37.AMT.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.37.TRAIL.B4 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.37.LEAD.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.37.SYMB.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.37.AMT.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT">
	&nbsp;
</TD>
<TD ID=TBL6766.FINROW.37.TRAIL.B5 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 1%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
<TD STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 12%; VERTICAL-ALIGN: TOP">
	&nbsp;
</TD>
</TR>
</TABLE>
<P ID=PARA6767 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 89.6% 0PT 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<HR STYLE="BORDER-TOP: MEDIUM NONE; HEIGHT: 1PX; BORDER-RIGHT: MEDIUM NONE; WIDTH: 10.68%; BORDER-BOTTOM: MEDIUM NONE; COLOR: #000000; BORDER-LEFT: MEDIUM NONE; BACKGROUND-COLOR: #000000" ALIGN="LEFT">
</EFX_UNIDENTIFIED_TABLE>
<TABLE ID=MTAB6770 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 24PT; VERTICAL-ALIGN: TOP">
<P ID=PARA6771 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	+
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA6772 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Indicates management contract or compensatory plan.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE ID=MTAB6774 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 24PT; VERTICAL-ALIGN: TOP">
<P ID=PARA6775 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	#
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA6776 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Material in the exhibit marked with a &#8220;***&#8221; has been omitted pursuant to a request for confidential treatment filed with the SEC. Omitted portions have been filed separately with the SEC.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<TABLE ID=MTAB6778 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 24PT; VERTICAL-ALIGN: TOP">
<P ID=PARA6779 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	*
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA6780 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The certifications attached as Exhibit 32.1 accompany this Annual Report on Form 10-K pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended.
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_EXHIBIT_INDEX>
<P ID=PARA6781.1 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
	&nbsp;
</P>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage124"></A>
<A NAME="EX21-2_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
</FONT>
<P ID=PARA1 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
</P>
<P ID=PARA6783 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exhibit&nbsp;21.2
</B>
</FONT>
</P>
<P ID=PARA6784 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6785 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	SUBSIDIARIES OF THE REGISTRANT
</FONT>
</P>
<P ID=PARA6786 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6787 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
</P>
<P ID=PARA6789 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	ARPI&nbsp;LLC,
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	duly formed under the laws of the State of Delaware, a wholly-owned subsidiary
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	of AcelRx Pharmaceuticals,&nbsp;Inc.
</FONT>
</P>
<P ID=PARA6790 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6791 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage125"></A>
<A NAME="EX23-1_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
</FONT>
<P ID=PARA1 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
</P>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<P ID=PARA5 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Exhibit 23.1
</FONT>
</P>
<P ID=PARA7 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P ID=PARA6 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</P>
<P ID=PARA8 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA9 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We hereby consent to the incorporation by reference, in the Registration Statements on Form S-8 (Nos. 333-202709, 333-194634, 333-187206, 333-180334 and 333-172409) pertaining to the 2011 Equity Incentive Plan and 2011 Employee Stock Purchase Plan of AcelRx Pharmaceuticals, Inc. and in the Registration Statements on Form S-3 (Nos. 333-196089, 333-190003, 333-183237 and 333-182245) of AcelRx Pharmaceuticals, Inc. and in the related prospectuses, of our reports dated March 7, 2016, with respect to the consolidated financial statements of AcelRx Pharmaceuticals, Inc., and the effectiveness of internal control over financial reporting of AcelRx Pharmaceuticals, Inc. included in this Annual Report on Form 10-K of AcelRx Pharmaceuticals, Inc. for the year ended December&nbsp;31, 2015.
</FONT>
</P>
<P ID=PARA6800 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
	&nbsp;
</FONT>
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</P>
<P ID=PARA1 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ OUM &amp; CO. LLP
</FONT>
</P>
<P ID=PARA2 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA3 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	San Francisco, California
</FONT>
</P>
<P ID=PARA4 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 7, 2016
</FONT>
</P>
</EFX_EXPERTS_CONSENT>
</FONT>
<P ID=PARA6803 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA6804 STYLE="TEXT-ALIGN: JUSTIFY; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
<P ID=PARA6805 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage126"></A>
<A NAME="EX23-2_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23_2"></A>
</FONT>
<P ID=PARA1 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
</P>
<P ID=PARA11 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Exhibit 23.2
</FONT>
</P>
<P ID=PARA13 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT_2"></A>
<P ID=PARA12 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25; TEXT-INDENT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>
</P>
<P ID=PARA15 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA14 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	We consent to the incorporation by reference in the Registration Statements:
</FONT>
</P>
<P ID=PARA16 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB18 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 18PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA19 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1.
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA20 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Registration Statements Form S-8 No. 333-202709, 333-194634, 333-187206, 333-180334, 333-172409 pertaining to Employee Incentive Plan of AcelRx Pharmaceuticals, Inc.;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA21 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB23 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 18PT">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 18PT; VERTICAL-ALIGN: TOP">
<P ID=PARA24 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA25 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Registration Statements Form S-3 No. 333-196089, 333-190003, 333-183237, 333-182245 of AcelRx Pharmaceuticals, Inc. and in the related prospectuses;
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA26 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA27 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	of our report dated March 12, 2015, except for Note 1 and 7, as to which the date is March 7, 2016, with respect to the consolidated financial statements of AcelRx Pharmaceuticals, Inc., included in this Annual Report on Form 10-K of AcelRx Pharmaceuticals, Inc. for the year ended December 31, 2015.
</FONT>
</P>
<P ID=PARA28 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA29 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Ernst &amp; Young LLP
</FONT>
</P>
<P ID=PARA31 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Redwood City, California
</FONT>
</P>
<P ID=PARA33 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	March 7, 2016
</FONT>
</P>
</EFX_EXPERTS_CONSENT>
<P ID=PARA34 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
</FONT>
	&nbsp;
</P>
</FONT>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage127"></A>
<A NAME="EX31-1_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
</FONT>
<P ID=PARA1 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
</P>
<P ID=PARA6835 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exhibit 31.1
</B>
</FONT>
</P>
<P ID=PARA6837 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P ID=PARA6836 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CERTIFICATIONS
</B>
</FONT>
</P>
<P ID=PARA6839 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6838 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	I, Howard B. Rosen, certify that:
</FONT>
</P>
<P ID=PARA6841 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6840 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1. I have reviewed this annual report on Form 10-K of AcelRx Pharmaceuticals, Inc.;
</FONT>
</P>
<P ID=PARA6843 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6842 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</P>
<P ID=PARA6845 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6844 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT>
</P>
<P ID=PARA6847 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6846 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</FONT>
</P>
<P ID=PARA6849 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6848 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</P>
<P ID=PARA6851 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6850 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</P>
<P ID=PARA6853 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6852 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</P>
<P ID=PARA6855 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6854 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and
</FONT>
</P>
<P ID=PARA6857 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6856 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):
</FONT>
</P>
<P ID=PARA6859 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6858 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and
</FONT>
</P>
<P ID=PARA6861 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6860 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.
</FONT>
</P>
<P ID=PARA6863 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6862 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date: March&nbsp;7, 2016
</FONT>
</P>
<TABLE ID=TBL1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD VALIGN=TOP WIDTH="50%">
<P ID=PARA1.8 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH="3%">
<P ID=PARA1.9 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=BOTTOM WIDTH="35%" NOWRAP ALIGN=LEFT>
<P ID=PARA1.10 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH="12%">
<P ID=PARA1.11 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT" VALIGN=TOP WIDTH="50%" ALIGN=LEFT>
<P ID=PARA1.12 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT" VALIGN=TOP WIDTH="3%">
<P ID=PARA1.13 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
	&nbsp;
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=TOP WIDTH="35%" NOWRAP ALIGN=LEFT>
<P ID=PARA1.14 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	/s/&nbsp;Howard B. Rosen
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH="12%">
<P ID=PARA1.15 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="50%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="3%">
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH="35%">
	Howard B. Rosen
</TD>
<TD VALIGN=TOP WIDTH="12%">
	&nbsp;
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="50%">
<P ID=PARA1.16 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH="3%">
<P ID=PARA1.17 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH="35%">
<P ID=PARA1.18 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	Interim Chief Executive Officer
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH="12%">
<P ID=PARA1.19 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH="50%">
<P ID=PARA1.20 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH="3%">
<P ID=PARA1.21 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH="35%">
<P ID=PARA1.22 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	(Principal Executive Officer)
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH="12%">
<P ID=PARA1.23 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P ID=PARA6870 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage128"></A>
<A NAME="EX31-2_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
</FONT>
<P ID=PARA1 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
</P>
<P ID=PARA6871 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exhibit 31.2
</B>
</FONT>
</P>
<P ID=PARA6873 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P ID=PARA6872 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CERTIFICATIONS
</B>
</FONT>
</P>
<P ID=PARA6875 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6874 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	I, Timothy E. Morris, certify that:
</FONT>
</P>
<P ID=PARA6877 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6876 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1. I have reviewed this annual report on Form 10-K of AcelRx Pharmaceuticals, Inc.;
</FONT>
</P>
<P ID=PARA6879 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6878 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
</FONT>
</P>
<P ID=PARA6881 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6880 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
</FONT>
</P>
<P ID=PARA6883 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6882 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</FONT>
</P>
<P ID=PARA6885 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6884 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</FONT>
</P>
<P ID=PARA6887 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6886 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</FONT>
</P>
<P ID=PARA6889 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6888 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
</FONT>
</P>
<P ID=PARA6891 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6890 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and
</FONT>
</P>
<P ID=PARA6893 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6892 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):
</FONT>
</P>
<P ID=PARA6895 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6894 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and
</FONT>
</P>
<P ID=PARA6897 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6896 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT 0PT 0PT 24.45PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.
</FONT>
</P>
<P ID=PARA6899 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6898 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Date: March&nbsp;7, 2016
</FONT>
</P>
<P ID=PARA6900 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL1 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD VALIGN=TOP WIDTH=586>
<P ID=PARA1.8 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH=33>
<P ID=PARA1.9 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=BOTTOM WIDTH=409 NOWRAP ALIGN=LEFT>
<P ID=PARA1.10 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH=139>
<P ID=PARA1.11 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="TEXT-ALIGN: LEFT" VALIGN=TOP WIDTH=586 ALIGN=LEFT>
<P ID=PARA1.12 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="TEXT-ALIGN: LEFT" VALIGN=TOP WIDTH=33>
<P ID=PARA1.13 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
</FONT>
	&nbsp;
</P>
</TD>
<TD STYLE="BORDER-BOTTOM: #000000 1PX SOLID" VALIGN=TOP WIDTH=409 NOWRAP ALIGN=LEFT>
<P ID=PARA1.14 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	/s/&nbsp;Timothy E. Morris
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH=139>
<P ID=PARA1.15 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH=586>
<P ID=PARA1.16 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH=33>
<P ID=PARA1.17 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH=409>
<P ID=PARA1.18 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	Timothy E. Morris
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH=139>
<P ID=PARA1.19 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH=586>
<P ID=PARA1.20 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH=33>
<P ID=PARA1.21 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH=409>
<P ID=PARA1.22 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	Chief Financial Officer
</FONT>
</P>
</TD>
<TD VALIGN=TOP WIDTH=139>
<P ID=PARA1.23 STYLE="MARGIN-BOTTOM: 0PX; MARGIN-TOP: 0PX">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN">
	&nbsp;
</FONT>
</P>
</TD>
</TR>
<TR>
<TD VALIGN=TOP WIDTH=586>
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH=33>
	&nbsp;
</TD>
<TD VALIGN=TOP WIDTH=409>
	(Principal Financial Officer)
</TD>
<TD VALIGN=TOP WIDTH=139>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
<P ID=PARA6907 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage129"></A>
<A NAME="EX32-1_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
</FONT>
<P>
</P>
<P ID=PARA6908 STYLE="TEXT-ALIGN: RIGHT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	Exhibit 32.1
</B>
</FONT>
</P>
<P ID=PARA6910 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P ID=PARA6909 STYLE="TEXT-ALIGN: CENTER; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	CERTIFICATION
</B>
</FONT>
</P>
<P ID=PARA6912 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6911 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Howard B. Rosen, interim Chief Executive Officer of AcelRx Pharmaceuticals, Inc. (the &#8220;Company&#8221;), and Timothy E. Morris, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:
</FONT>
</P>
<P ID=PARA6914 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB6915 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT; VERTICAL-ALIGN: TOP">
<P ID=PARA6916 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	1.
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA6917 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The Company&#8217;s Annual Report on Form 10-K for the period ended December&nbsp;31, 2015, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;) fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act, and
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA6919 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=MTAB6920 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 31PT; VERTICAL-ALIGN: TOP">
<P ID=PARA6921 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	2.
</FONT>
</P>
</TD>
<TD STYLE="VERTICAL-ALIGN: TOP">
<P ID=PARA6922 STYLE="MARGIN-BOTTOM: 0PT; TEXT-ALIGN: LEFT; MARGIN-TOP: 0PT; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA6924 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6923 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
<B>
	In Witness Whereof
</B>
	, the undersigned have set their hands hereto as of the 7th day of March, 2016.
</FONT>
</P>
<P ID=PARA6925 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<TABLE ID=TBL6934 STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF; WIDTH: 100%; TEXT-INDENT: 0PX" CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR>
<TD STYLE="WIDTH: 45.7%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 6.1%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
<TD STYLE="WIDTH: 48.2%; VERTICAL-ALIGN: MIDDLE">
	&nbsp;
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 45.7%; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: #000000 1PX SOLID">
<P ID=PARA6926 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Howard B. Rosen
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 6.1%; VERTICAL-ALIGN: TOP">
<P ID=PARA6927 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 48.2%; VERTICAL-ALIGN: TOP; BORDER-BOTTOM: #000000 1PX SOLID">
<P ID=PARA6928 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	/s/ Timothy E. Morris
</FONT>
</P>
</TD>
</TR>
<TR>
<TD STYLE="WIDTH: 45.7%; VERTICAL-ALIGN: TOP">
<P ID=PARA6929 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Howard B. Rosen
</FONT>
</P>
<P ID=PARA6930 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Interim Chief Executive Officer
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 6.1%; VERTICAL-ALIGN: TOP">
<P ID=PARA6931 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</TD>
<TD STYLE="WIDTH: 48.2%; VERTICAL-ALIGN: BOTTOM">
<P ID=PARA6932 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Timothy E. Morris
</FONT>
</P>
<P ID=PARA6933 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	Chief Financial Officer
</FONT>
</P>
</TD>
</TR>
</TABLE>
<P ID=PARA6936 STYLE="MARGIN-BOTTOM: 0PT; MARGIN-TOP: 0PT">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6935 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&#8220;This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of AcelRx Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.&#8221;&nbsp;
</FONT>
</P>
</EFX_CERTIFICATION>
<P ID=PARA6937 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6938 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
<P ID=PARA6939 STYLE="TEXT-ALIGN: LEFT; MARGIN: 0PT; LINE-HEIGHT: 1.25">
<FONT STYLE="FONT-SIZE: 10PT; FONT-FAMILY: TIMES NEW ROMAN, TIMES, SERIF">
	&nbsp;
</FONT>
</P>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
